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Abstract
Mutations o f Ras and activation o f the Ras pathway are amongst the most 
common abnormalities detected in human cancer (-20%), and in myeloid neoplasia. In 
addition, excessive production o f reactive oxygen species (ROS) is a common feature of 
human malignancy and is often triggered by activation o f Ras oncogenes. ROS act as 
second messengers and can influence a variety o f cellular process including growth factor 
responses and cell survival. This study examined the contribution o f ROS production to the 
phenotype o f mutationally-activated Ras in normal human CD34+ haematopoietic 
progenitor cells. For the first time, this study demonstrated that Ras strongly upregulated 
the production o f both superoxide and hydrogen peroxide (H2O2) in these cells, through the 
stimulation o f NOX oxidase activity, without affecting the expression o f endogenous 
antioxidants or the production o f mitochondrial ROS. Ras also promoted both the survival 
and the growth factor independent proliferation o f CD34+ cells. Using oxidase inhibitors 
and antioxidants, it was found that excessive ROS production by these cells did not 
contribute to their enhanced survival; rather, this study presents the first data 
demonstrating that ROS promoted their growth factor-independent proliferation. While 
Ras-induced ROS production specifically activated the p38MAPK oxidative stress response, 
this failed to induce expression o f the cell cycle inhibitor p l6 INK4A; instead, ROS promoted 
the expression o f cyclin D1 and D3. Expression o f activated Ras in human haematopoietic 
progenitors drives hyperphosphorylation o f PKC family members, which mediates several 
phenotypes o f mutant Ras in haematopoietic cells including dysregulated development. 
This study demonstrated that endogenous H2 O2 production contributes to 
hyperphosphorylation o f PKC in this model, and that exogenous H2O2 can drive 
phosphorylation o f PKC in a similar manner. Finally, this study presents preliminary data 
obtained by kinomic PepChip analysis suggesting that endogenous ROS production driven 
by mutant Ras can influence the kinase activity o f these cells, consistent with the 
hypothesis that ROS may promote protein phosphorylation via phosphatase inhibition.
In summary, this study presents novel data showing endogenous ROS 
production makes a significant contribution to the phenotype o f human haematopoietic 
progenitor cells expressing mutant Ras and suggests that targeting ROS may be a valid 
approach in acute myeloid leukaemia therapy.
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CHAPTER 1: INTRODUCTION
1 Introduction
1 .1  N o r m a l  H a e m a t o p o i e s i s
1.1.1 Ov er v iew  of h a em a to po iesis
Haematopoiesis is the ordered process o f production and maintenance o f all 
mature blood cell types. An estimated 1012 mature blood cells are generated by the 
haematopoietic system per day; and these are responsible for critical processes in host 
maintenance including oxygen transport, innate and adaptive immunity, blood coagulation 
and tissue repair after injury. The mature blood cells that perform these functions in the 
host bear morphological and biochemical features which specialise them for then- 
respective tasks. For example, red blood cells (erythrocytes) express high levels o f 
haemoglobin, the protein responsible for oxygen and carbon dioxide transport around the 
body and their unique biconcave morphology enables them traverse the fine capillaries 
which perfuse hose tissues. Granulocytes (neutrophils, eosinophils and basophils) and 
peripheral blood monocytes (and their mature tissue-localised descendents, macrophages) 
express high levels o f  anti-microbial proteins (e.g. major basic protein expressed by 
eosinophils) and inflammatory mediators. Furthermore, phagocytic cells (neutrophils, 
monocytes and macrophages) express oxidases capable o f generating reactive oxygen 
species (ROS), which in turn contribute to the killing o f phagocytosed pathogens. 
Cytokines and chemokines secreted by innate immune cells prime a secondary, highly 
specific adaptive immune response, led by B and T lymphocytes. B lymphocytes are 
capable o f generating high levels o f  antigen-specific immunoglobulin, while T 
lymphocytes play diverse roles, both orchestrating the adaptive response (helper T cells, 
regulatory T cells) and mediating direct cytotoxicity (CD8+ T cells). Finally, thrombocytes 
(platelets) are critical for initiation o f blood coagulation cascades which limit blood loss 
after injury and lay the foundation for tissue regeneration and repair. Importantly, the 
output o f the haematopoietic system is dynamic can respond to changes in the 
environment; for example reduced oxygen at high altitude stimulates the production o f 
erythrocytes; whilst pathogenic bacteria or parasites can stimulate mobilisation and 
production o f neutrophils or eosinophils respectively. In vitro studies o f primary 
haematopoietic cells and haematopoietic cell lines, together with in vivo murine studies 
have contributed to the current model o f the haematopoietic system in mammals (discussed
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in section 1.1.2). The majority o f evidence suggests that the generation o f mature cells by 
the haematopoietic system is hierarchical, with all mature haematopoietic cells originating 
from a single cell, the pluripotent haematopoietic stem cell (HSC;Figure 1.1). HSCs 
generate mature blood cells through an ordered process o f lineage commitment, during 
which HSC progeny become increasingly restricted in their developmental potential, and 
ultimately become committed to the generation o f  a single mature cell type. The output o f 
the haematopoietic system (i.e. how many cells o f  each mature cell type are produced) are 
governed by two main mechanisms: lineage decisions are primarily dictated by the 
repertoire o f  haematopoietic transcription factors, while the proliferation, survival and 
terminal maturation o f committed progenitors is governed by the presence or absence o f 
haematopoietic growth factors. Thus, mainly through these two mechanisms, the 
haematopoietic system adjusts the number o f mature cells generated as required by the 
host.
1.1.2 M o d e l s  f o r  s t u d y i n g  n o r m a l  h a e m a t o p o i e s i s
7.1.2.1 In vitro models: ex vivo primary haematopoietic cell culture and haematopoietic
cell lines
Following the groundbreaking work by Till et al. (section 1.1.2.2), important 
experiments were performed using ex vivo bone-marrow cultures in order to discover the 
factors that governed the differentiation o f the proposed HSC (Dao, C. et al. 1977b; Dao,
C. et al. 1977a). Primary human bone marrow cells immobilised in semisolid medium (soft 
agar or methylcellulose) were cultured in the presence o f recently discovered ‘colony 
stimulating factors’ (CSFs), which were derived from cultured normal leukocytes. Since 
the cells were immobilised, the progeny o f single cells could be scored. It was observed 
that CSFs could induce the formation o f discrete mature colonies o f cells e.g. neutrophils 
or macrophages or in some cases a mixture o f both, depending on which CSF was used. 
These studies laid the ground work for our current understanding the role o f CSFs and 
other growth factors in, leading eventually to the characterisation o f the 
immunophenotypes o f the committed progenitors and HSC compartments o f mice and 
humans (section 1.1.2.2).
2
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Figure 1.1 Pathways in haematopoietic lineage commitment
Straight arrows represent steps in lineage commitment, curved arrows represent self­
renewal potential and dashed arrows represent putative lineage commitment pathways. 
Adapted from www.abdserotec.com. CFU = colony-forming unit, NK cell = natural killer 
cell
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While primary cell studies are the most relevant model for study of 
haematopoiesis, studies are often hampered by small sample sizes and difficulty in 
maintaining undifferentiated primary cells in long term culture.
Cell lines are immortalised clonal cultures o f cells that are able to replicate 
indefinitely without becoming senescent (Dao, M.A. and Nolta, J.A. 1999). In contrast to 
primary cells, cell lines provide a near unlimited amount o f cell material for investigation. 
In addition, some cell lines exhibit limited differentiation potential presenting a convenient 
means o f studying haematopoietic development. Examples o f human haematopoietic cell 
lines with myeloid differentiating potential include U937, a monocytic leukaemia cell 
derived from a patient with histiocytic lymphoma (Sundstrom, C. and Nilsson, K. 1976) 
which can be induced to undergo monocytic differentiation; and HL60 or NB4 cells which 
were both derived from patients with acute promyelocytic leukaemia (Collins, S. J. et al. 
1977; Lanotte, M. et al. 1991) which undergo granulocytic differentiation in response to 
DMSO or the vitamin A analogue all-trans retinoic acid (ATRA) (Collins, S.J. et al. 1978; 
Lanotte, M. et al. 1991). These observations ultimately led to the successful use o f ATRA 
in treatment o f APL patients (Flynn, P.J. et al. 1983). However, it should be noted that in 
addition to immortalisation, cell lines invariably harbour additional abnormalities such as 
chromosome translocations, which preclude the use o f cell lines to draw any definitive 
conclusions regarding normal haematopoiesis (Furukawa, Y. 2002). Murine 
haematopoietic cells lines have also proved useful for example, FDCP-mix, an IL-3- 
dependent multipotent cell line derived from murine bone marrow after infection with Src- 
MMLV (Spooncer, E. et al. 1986). These cells are useful in that they have a normal 
karyotype and no known molecular abnormalities and have been induced to differentiate 
into several mature cell types. Indeed, FDCP-mix cells can generate mature neutrophils 
(Heyworth, C.M. et al. 1991) and dendritic cells (Schroeder, T. et al. 2000). However, 
erythroid differentiation is incomplete (Heyworth, C.M. et al. 1995), suggesting there are 
limitations to the use o f these cells for modelling normal haematopoiesis.
1.1.2.2 In vivo models o f  haematopoiesis
Haematopoietic transplantation o f primary haematopoietic cells into murine 
recipients bypasses the difficulties associated with working with cell lines and also some o f 
the artefacts o f  ex vivo culture; as a result these studies have proved invaluable 
understanding the haematopoietic system.
Early in vivo experiments which suggested that single progenitor cells had the 
potential to generate more than one mature cell type were performed by Till et al. This
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group noticed that allotransplants o f  murine bone marrow cells appeared to form colonies 
in the spleens o f the recipients. Furthermore, there appeared to be evidence o f multi­
lineage differentiation in the colonies (Till, J.E. and McCulloch, E.A. 1961). To establish 
whether these colonies arose from single cells, murine bone marrow cells were irradiated 
prior to transplantation, which induced chromosomal aberrations that (if not fatal for the 
cell) would theoretically be detected in all members o f a colony (if that colony was derived 
from a single cell). The finding that the majority o f cells in each colony harboured the 
same chromosomal aberrations provided the first evidence that a single progenitor cell 
existed that may give rise to all mature blood cell types (Becker, A.J. et al. 1963).
Since then, assays for functional HSCs have been developed, the most stringent 
o f these being the long-term repopulation assays. These assays originally involved 
allotransplantation o f candidate HSC populations into lethally irradiated mice, which 
would die without complete rescue o f the haematopoietic system. Putative HSC 
populations are those capable o f rescuing haematopoiesis in primary, secondary and even 
tertiary irradiated recipients (Dick, J.E. 1996); a strong indication o f maximal self-renewal 
capacity -  the hallmark o f an HSC. Through the work o f John Dick’s group, murine HSCs 
were functionally purified, and this group demonstrated that a single functional HSC could 
mediate the long term haematopoietic reconstitution o f a transplant recipient (Dick, J.E. et 
al. 1985). However, xenotransplantation o f human haematopoietic cells was hindered by 
immunological rejection o f human cells even in irradiated recipients. An important step 
forward for xenotransplantation o f human haematopoietic cells was the development o f the 
beige/nude/xid (bnx) mouse (Andriole, G.L. et al. 1985). These mice have combined 
defects in T and B cell function, and the lack o f adequate adaptive immune response in 
these animals allowed the first examples o f successful xenotransplantation o f human 
haematopoietic cells (Kamel-Reid, S. and Dick, J.E. 1988).
Since the late 80’s, xenotransplantation has improved due to the development of 
mouse strains with further suppressed immune function, such as the non-obese diabetic/ 
severe combined immunodeficient (NOD/SCID) mouse, increased longevity such as the 
NOD/SCID/nude (Dick, J.E. 1996), and also ‘humanised’ mouse models which express 
human growth factors such as IL-3 by co-transplantation o f IL-3 expressing stromal cells 
(Brouard, N. et al. 1998). With the development o f flow cytometric methods including 
fluorescence activated cell-sorting (FACS), the Weissman group succeeded in 
characterising the immuno phenotype o f the major developmental stages o f the murine and 
human haematopoietic hierarchy, culminating in the report o f the immunophenotype o f 
functional murine HSCs (Spangrude, G.J. et al. 1988) and human HSCs shortly afterwards
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(Baum, C.M. et al. 1992). These findings are the basis for the current consensus on the 
haematopoietic hierarchy.
1.1.3 N o rm al  m y elo id  h a em a to po iesis
1.1.3.1 Properties o f  HSCs
As mentioned above, Weissman et al. were the first to propose the 
immunophenotype o f the murine and human HSC. A recent review stated the phenotype 
for W i n e  LT-HSCs is Lineageneg, Sca-1+, c-Kit+, Flk2neg, CD34neg, CD150+, while 
bhuman LT-HSCs are contained within the Lineage"68, CD34+, FLT3+, CD90+, 
CD45RAlo/neg compartment (Weissman, I.L. and Shizuru, J.A. 2008). Furthermore, human 
bone-marrow that is enriched for CD34+ cells shows improved engraftment after 
transplantation to myeloablated patients (Siena, S. et al. 2000). Additional 
immunophenotypic markers have been proposed for human LT-HSCs, most notably 
CD123+ (IL-3a chain) (Taussig, D.C. et al. 2005). As stated previously, the hallmark o f 
LT-HSCs is their capacity for self renewal. The factors governing the self-renewing 
properties o f LT-HSCs are poorly understood, however, recent evidence suggests that 
HOX genes play an important role in maintaining self-renewal capacity (Argiropoulos, B. 
and Humphries, R.K. 2007). HOX genes are class I homeobox genes distributed within the 
human genome in 4 discrete clusters. Each o f the human gene clusters show homology to 
the Drosophila Antennepedia and Bithorax cluster o f  homeotic genes; mutations in which 
have been shown to have spectacular effects on D. melanogaster development (Kaufman, 
T.C. 1978). Evidence that HOX genes may play a role in HSC function initially came from 
gene expression profiling o f murine HSCs showing that Hoxb4 and Hoxa9 are highly 
expressed in early progenitors but are downregulated during lineage commitment. Indeed 
over expression o f Hoxb4 in haematopoietic progenitors promoted marked expansion o f 
murine, human cell and primate models (Antonchuk, J. et al. 2001; Buske, C. et al. 2002; 
Zhang, X.B. et al. 2006), without leading to leukaemia. Hoxa9 overexpression also 
promoted o f murine HSC expansion, but with the tendency to initiate leukaemic disease 
(Thorsteinsdottir, U. et al. 2002). Interestingly, the mixed lineage leukaemia (MLL) 
protein, which is a master regulator o f HOX gene expression (Schuettengruber, B. et al.
2007), is also implicated in self-renewal (McMahon, K. A. et al. 2007), presumably through 
its influence on HOX gene expression, and is frequently targeted in chromosome
a c-Kit is the receptor for SCF, Flk2 is the murine homologue o f human Flt3, CD150 is also 
known as signalling lymphocytic activation molecule family member 1 (SLAMfl).
CD90 is also known as Thyl.
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translocations detected in acute myeloid leukaemia (AML) (De Braekeleer, M. et al. 2005). 
However, the extrinsic and intrinsic cues that govern MLL and HOX gene expression are 
not understood, neither are the mechanisms by which HOX genes promote self renewal.
In summary, LT-HSC are cells with the potential to reconstitute the entire 
haematopoietic system, their immunophenotype has been reasonably well-defined, and 
they exhibit the exclusive stem-cell ability o f long-term self renewal, which may be in part 
mediated by expression o f HOX genes.
1.1.3.2 The HSC niche
HSCs are primarily quiescent, with an estimated 3.8% in S+G2M phases o f the 
cell cycle at a given time (Kiel, M.J. and Morrison, S.J. 2008). The quiescence o f HSCs; 
together with their ability to home to the bone marrow (Kopp, H.G. et al. 2005) has been 
exploited to locate the normal resting place o f the HSCs in vivo, using label retaining cell 
(LRC) assays. As with many o f the studies described this far, studies such as LRC assays 
cannot be performed in humans for ethical reasons; therefore much o f what is known about 
the stem cell niche is based on observations from murine models. LRC assays employ 
sorted murine HSCs populations which are labelled with BrdU. This label is incorporated 
into the DNA o f replicating cells in during culture. These labelled HSCs are then 
transplanted into a lethally irradiated recipient. In quiescent cells (such as HSCs) the BrdU 
label can be retained for months, allowing tracking and localisation o f the LRCs. Using 
this approach, it has been found that the majority o f LRCs are associated with particular 
regions o f the endosteum (the cellular lining separating bone from bone marrow) located 
within the cords (narrow filament-like passages) o f the trabecular bone (Zhang, J. et al. 
2003). It is likely that these LRC populations are enriched for HSCs; however formal 
confirmation o f this is not possible since BrdU assays require that LRCs are fixed for 
analysis, which precludes assessment o f their function. LRCs are also known to associate 
with specialised endothelial cells (BMEC) o f the sinusoids, and this region has been 
proposed to act as a secondary ‘vascular’ HSC niche (Kiel, M.J. et al. 2005).
Approaches using conditional expression o f proteins which stimulate osteoblast 
growth under the control o f the type 1 collagen a  promoter (expressed by early osteoblasts) 
show that HSC numbers increase in accordance with osteoblast numbers (Calvi, L.M. et al. 
2003); and conditional ablation o f osteoblasts by targeted expression o f thymidine kinase 
and treatment with gancyclovir resulted in a depletion o f HSC numbers (Corral, D.A. et al. 
1998). These data strongly suggest that osteoblasts are an important part o f the endosteal 
niche, and govern the size o f the HSC pool, possibly through physical interaction. The
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interactions o f niche osteoblasts and HSCs are complex, but can be grouped into two main 
categories (Wilson, A. and Trumpp, A. 2006). The first are primarily adhesion interactions 
via N-cadherin and integrins such as VLA-4 and VLA-5. These interactions, together with 
binding to ECM-bound factors such as osteopontin and hyaluronic acid via CD44, promote 
the close contact o f HSC with osteoblasts encouraging a second category o f interactions to 
occur. Several o f these secondary interactions appear to mediate quiescence and survival 
signals, e.g. Ang-1 secreted by niche osteoblasts activates the Tie-2 receptor on HSCs; 
resulting in upregulation o f p21Cipl and quiescence, while SCF bound to the osteoblast 
membrane activates the c-Kit receptor on HSCs promoting survival and cell-cell adhesion. 
Furthermore, some o f these signalling interactions serve several purposes, e.g. osteopontin 
promotes HSC adhesion but also has been shown to be a negative regulator o f the HSC 
pool and c-Kit signalling not only promotes survival, but can also increase the avidity o f 
integrin adhesion, strengthening the osteoblast-HSC interaction. Overexpression o f Jagged 
(the Notch ligand) led to expansion to HSCs in vivo, suggesting the Notch signalling may 
be involved in self-renewal signals in HSCs. However, the observation that Notch 
signalling and also classical Wnt signalling are dispensable for normal haematopoiesis 
(Cobas, M. et al. 2004) suggests that (in murine haematopoiesis at least) there are other 
undiscovered factors that govern self renewal.
Whereas the above interactions appear to govern mainly adhesion and 
quiescence, the essential question o f how HSC are driven to leave the niche and undergo 
asymmetric division remains unanswered. Murine osteoblasts can respond to extrinsic 
signalling molecules such as parathyroid hormone (PTH) which induces prostaglandin E2 
(PGE2) production (Kawaguchi, H. et a l 1994; Tetradis, S. et al. 1997), and this has very 
recently been shown to augment HSC self-renewal (Frisch, B.J. et a l 2009). Although no 
definitive evidence exists at the present time, these reports support the notion that extrinsic 
or intrinsic cues could lead to alterations in the composition o f osteoblast surface 
molecules. Such a shift could represent a change from niche-derived quiescence signals to 
self-renewal or differentiation signals.
1.1.3.3 Factors governing the development o f  committed haematopoietic progenitors
Regardless o f the mechanisms which govern initiation o f HSC lineage 
commitment, it is known that differentiation o f an uncommitted HSC to a mature cell is 
characterised by a rapid loss o f self-renewal capacity, associated with downregulation o f 
transcription factors that promote self-renewal, such as Hox genes (section 1.1.3.1) and 
upregulation o f transcription factors associated with lineage commitment. Subsequently,
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the proliferation, survival and terminal maturation o f committed progenitors are largely 
governed by the presence o f  haematopoietic growth factors (Figure 1.2). Studies of 
haematopoietic differentiation in the presence o f cytokines led to the proposal that growth 
factors play an instructive role in lineage decisions (section 1 . 1 .3 .4); modulating 
haematopoietic transcription factor expression and thus deciding the fate o f developing 
progenitors and these findings form the basis o f the ‘instructive’ model o f  haematopoietic 
development. Alternatively, the stochastic model proposes that growth factor signalling 
merely provides survival and proliferation signals to committed progenitors whose lineage 
decisions are driven solely by the intrinsic cues o f  transcription factor expression. The 
evidence supporting both these models is discussed below; however most o f the evidence 
supports the stochastic model.
1.1.3.4 The role o f  growth factor signalling in haematopoietic development
Haematopoietic growth factors (or cytokines) are secreted or membrane- 
anchored glycoproteins which bind to and activate cognate receptors (Robb, L. 2007). 
During myeloid development, the most influential growth factors are FLT3L, SCF, IL-3, 
IL-6 , G-CSF, M-CSF and GM-CSF. The majority o f haematopoietic cytokine receptors fall 
into the class-I cytokine receptor family, defined by the presence o f a palindromic 
WSXSW motif and fibronectin type III domain in the extracellular portion, and conserved 
Box 1/2 domains in the cytoplasmic portion which interact with Janus kinases (JAKs). 
Several important haematopoietic growth factor receptors are members o f the receptor 
tyrosine kinase superfamily e.g. FLT3, c-KIT (SCF receptor) and M-CSFR; these receptors 
contain their own tyrosine kinase domain and therefore do not require association with 
JAKs. Finally, a few cytokines with influence in the haematopoietic system signal through 
type II cytokine receptors (e.g. IL-10 and interferons). These receptors are similar to type I 
in structure, with the exception that they lack the WSXSW motif.
Type I haematopoietic cytokine receptors are categorised by their formation o f 
either homodimers (G-CSFR, EPOR and c-Mpl which is the TPO receptor) or 
heterodimers/trimers. Heterodimeric/trimeric class I cytokine receptors are further 
classified based on their association with a common receptor subunit; either the common 
the common /3-chain (/3C) (e.g. IL-3R, GM-CSFR, IL-5R); the gpl30 chain (e.g. IL-11R) or 
the common y-chain (yc) (e.g. IL-2R, IL-4R, IL-7R). Since many o f these receptors share a 
common chain, ligand specificity is conferred by association o f the common chain with a 
specific a  subunit.
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Mature cell 
types
LT-HSC ST-HSC
B or T Lymph.
Neut. Mono.
Meg. Eryth.
Self-renewal D ifferentiation
GMP
Proliferation
Figure 1.2 The roles of transcription factors and growth factors in haematopoietic 
lineage commitment
A simplified pathway is shown from long-term (LT) and short-term (ST) HSCs, leading to 
multipotent/bipotent progenitors; common lymphoid progenitors (CLP), 
granulocyte/macrophage progenitors (GMP) and megakaryocyte/erythrocyte progenitors 
(MEP) and finally mature cell types. Progress in lineage commitment is accompanied by a 
loss in self renewal and the acquisition of morphological and biochemical features 
associated with mature cells. The lineage selection decisions are dictated by transcription 
factors (TF), and subsequently growth factors (GF) promote the proliferation of committed 
progenitors.
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Upon binding their cognate ligand, hetero- or homo-dimerisation o f these 
receptor subunits (or conformational change in the preformed homodimeric EPO-R) leads 
to activation o f JAKs bound to the Boxl/2 domains. Phosphorylation o f tyrosine residues 
on the cytoplasmic tail o f  the receptor by JAKs creates SH2 domain binding sites which 
are binding sites for several signal-transduction proteins. STATs are among the SH2- 
domain-containing proteins that are recruited, which are themselves phosphorylated by 
JAKs and dimerise. Subsequently, ST AT dimers translocate to the nucleus where they act 
as transcription factors. The formation o f binding sites for SH2 domains also results in the 
recruitment o f phosphoinositide 3-kinase (PI3K) via binding the PI3K p85 subunit, and 
She, an adapter protein which recruits GRB2 and SOS (which is a guanine-nucleotide 
exchange factor (GEF) for Ras, discussed in section 1.3.3.1). Signal transduction by the 
receptor tyrosine kinase receptors (FLT3, c-KIT and M-CSF) follows a similar course, 
with recruitment o f STATs, GRB2 and SOS to the autophosphorylated tyrosine residues.
In myeloid haematopoiesis, type I cytokine receptor and receptor tyrosine kinase activation 
generally results in proliferative drive and survival.
The suggestion that haematopoietic cytokines may direct lineage commitment 
came from evidence that treatment of GMP with M-CSF could induce monocytic 
development, while G-CSF or SCF could induce granulocyte formation (Metcalf, D. and 
Burgess, A.W. 1982). Other groups demonstrated that YL-la -deficient lymphoid 
progenitors show a block in lymphoid development, but could be stimulated to become 
myeloid cells by ectopic expression o f GM-CSFRa and treatment with GM-CSF (Iwasaki- 
Arai, J. et a l 2003). Furthermore, IL-3 dependent FDCP-mix cells expressing a chimaeric 
IL-3 receptor fused to the cytoplasmic domain o f GM-CSFR underwent 
granulocytic/monocytic differentiation in the presence o f IL-3 (Evans, C.A. et al. 1999). 
These examples appear to demonstrate a role for growth factor signalling in 
haematopoietic lineage commitment, however, transgenic studies o f murine growth factor 
genes and their receptors in murine models have revealed that the phenotype is surprisingly 
mild in most cases, and critically, lineage decisions can be made in the absence o f one or 
more o f these genes. For example, inactivating mutations o f G-CSF or the (3C chain had no 
appreciable effect on myeloid cell development (Stanley, E. et a l 1994; Robb, L. et a l 
1995). EpoR deficiency has a somewhat stronger phenotype; EpoR-null mice are 
embryonic lethal due to inadequate erythropoiesis. However, early erythroid progenitors 
are detected in these aborted embryos (Wu, H. et a l 1995). Similarly, although mice 
deficient for IL-7a are incapable for terminal lymphoid differentiation, early lymphoid 
progenitors are still detectable in these mice (Peschon, J.J. et a l 1994). Further evidence
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that growth factors do not specifically influence lineage decisions (but rather promote 
survival and proliferation) came from transgenic experiments in which the cytoplasmic tail 
o f the murine wild-type G-CSFR was replaced with that o f the murine EpoR, resulting in a 
chimaeric receptor that transduced EpoR signals in response to G-CSF. Surprisingly, 
treatment with G-CSF did not alter myeloid or erythroid progenitor frequency in these cells 
(although neutrophil function was impaired) (Semerad, C.L. et al. 1999). Finally, 
expression o f human GM-CSFR in murine EpoR null fetal liver cells was capable o f 
rescuing erythropoiesis after GM-CSF treatment (Hisakawa, H. et a l  2001).
The lack o f  a strong phenotype in some single cytokine knockout models (e.g. 
G-CSF, G-CSFR knockouts) may be due to functional redundancy o f some cytokine 
pathways, which may mask any deleterious effects o f the knockout. However, the majority 
o f evidence lends strong support for the stochastic model, and suggest that for the most 
part, cytokines promote the survival, proliferation and terminal maturation o f committed 
progenitors, but have a limited influence on lineage selection. Nevertheless, the selective 
expansion o f particular lineages by cytokine signalling represents a major control 
mechanism for the output o f the haematopoietic system. In addition to positive regulation 
in the presence o f cytokines, the haematopoietic system is subject to negative regulation by 
apoptosis in the absence o f the required cytokines. Indeed, it has long been known that Epo 
is not required for early erythroid development prior to the MEP stage. However, beyond 
this point, EPO (or TPO) is required to prevent MEP death by apoptosis (Testa, U. 2004).
1.1.3.5 Role o f  transcription factors in haematopoietic development
Much experimental evidence suggests that it is transcription factor expression 
that determines HSC fate (Rosenbauer, F. and Tenen, D.G. 2007). Indeed some o f the most 
important transcription factors necessary for myeloid lineage selection have now been 
identified. These include PU.l, GAT A binding protein-1 (GATA-1), interferon regulatory 
factor- 8  (IRF8 ) and CCAAT/enhancer binding protein (CEBP)o/e. The earliest step in 
differentiation o f HSCs is the decision to become a common myeloid or common 
lymphoid progenitor. The level o f  expression o f PU.l (Spi-1 in mice) plays a critical role 
in this decision. High levels o f  PU.l expression favours generation o f CMPs.
Subsequently, commitment to the erythroid lineage is directed by preferential expression o f 
GATA-1 in CMPs (which antagonises PU.l). Alternatively, upregulation o f CEBPa 
(instead o f GATA-1) indicates commitment to become a granulocyte/monocyte progenitor 
(GMP). Final specification o f monocytes is dictated by expression o f IRF8  in combination 
with PU.l, whereas granulocyte formation requires downregulation o f PU.l and
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upregulation o f CEBPe and growth factor independent-1 (GFI1) (Yamanaka, R. et al 
1997; Hock, H. et a l 2003). Interestingly, it is not just the presence or absence o f a 
transcription factor that is important, but its level o f expression also. Again, expression o f 
PU.l provides a good example o f this principle. Whereas high levels o f  PU.l favour CMP 
formation (described above), low (but appreciable) levels favour B-lymphoid development 
(DeKoter, R.P. and Singh, H. 2000). Critically, Spi-1 null mice show the expected block in 
monocyte development but are unable to generate competent granulocytes, whereas 
haploinsufficiency o f Spi-1 retains monocytic failure, but restores normal granulocyte 
development (Rosenbauer, F. et a l 2004). The role o f  these transcription factors in the 
lineage decisions discussed has been (in the main) determined by targeted disruption o f 
each factor in a murine model. In contrast to the milder phenotypes associated with growth 
factor deficiency, inactivation o f these transcription factors results in complete loss of the 
associated lineage. Furthermore, the effects o f transcription factor deletion are not 
restricted to lineage failure. For example CEBPa inactivation causes failure of 
granulopoiesis but also promotes expansion o f HSC populations, suggesting that CEBPa 
normally acts to negatively regulate HSC pools (Zhang, P. et a l 2004). In general ,the lack 
o f a given transcription factor results in failure to upregulate target genes required for the 
next stage o f differentiation, combined with failure to downregulate antagonistic 
transcription factors which are associated with other lineages. Alternatively, failure to 
down regulate transcription factors associated with self-renewal (e.g. HOX genes) can 
confer self-renewal capacity on committed progenitors. The importance of correctly 
regulated transcription factor activity is highlighted by the fact that abnormal transcription 
factor activity is closely associated with leukaemia. For example IFR8 -null mice are 
deficient for macrophage development, but also show a large increase in myeloid 
progenitor proliferation and develop disease closely resembling chronic myeloid leukaemia 
(CML). Reduced CEBPa expression, due to increased expression o f a dominant negative 
splice variant or loss o f the carboxy-terminal DNA binding domain, is detected in 7-9% o f 
AML cases (Rosenbauer, F. and Tenen, D.G. 2007). Finally, the most common 
abnormality associated with AML, the t(8;21) translocation leading to the expression o f the 
RUNX1-ETO fusion transcript (aka AML1-ETO), is detected in 12-15% o f AML cases 
and is believed to result in repression o f RUNX1, PU.l and CEBPoi-dependent gene 
transcription (Speck, N.A. and Gilliland, D.G. 2002). The cues that govern co-ordinated 
transcription factor expression in haematopoietic cells are unknown, and have even been 
proposed to be governed by chance (Abkowitz, J.L. et a l 1996). Nevertheless, the bulk o f
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evidence suggests that haematopoietic transcriptions factors are the most important factor 
in deciding the lineage fate o f HSCs.
1.2 M y e l o i d  l e u k a e m i a s
Leukaemias are clonal disorders o f haematopoiesis that develop as a result of 
several genetic defects in the malignant clone. Commonly, three major cell properties are 
affected by these defects, cell survival, proliferation and differentiation. Initiating events 
may not immediately lead to leukaemia, but successive genetic defects in the same cell are 
cumulative, generating a malignant clone that is unable to terminally differentiate and has 
acquired growth and survival advantages.
Myeloid neoplasias are classified at diagnosis using the current guidelines for 
classification o f myeloid neoplasms and acute leukaemia described in the 4th edition of 
WHO Classification o f Tumors o f the Hematopoietic and Lymphoid Tissues (Swerdlow, 
S.H. et al. 2008). This is an update on the 3rd edition (Jaffe, E.S. et al. 2001), which 
proposed an alternative to the French-American-British (FAB) disease classification 
system originally proposed in 1976 (Bennett, J.M. et al. 1976). Whereas the FAB system 
was based on morphological analysis and clinical features at diagnosis; the WHO 
classification also considers all available data including cytogenetic, immunophenotypic 
and molecular genetic data to assign a diagnosis. For the purposes o f diagnosis, myeloid 
cells are defined as those from the granulocytic (neutrophils, basophil, eosinophils); 
monocyte/macrophage, erythroid, megakaryocytic or mast cell lineages. Where possible, 
the myeloid lineage from which the neoplasm is most likely to have arisen is determined 
through a combination o f morphological analysis and immunophenotyping. The presence 
o f known cytogenetic and molecular abnormalities which are relevant to treatment and 
prognosis, combined with the number o f blasts detected in the peripheral blood and bone 
marrow at presentation, help to further specify the diagnosis. Broadly speaking, myeloid 
neoplasms are grouped into four main categories; myeloproliferative neoplasms (MPN, 
previously called MPD), myelodysplastic syndromes (MDS), disorders with features that 
overlap MPN and MDS (MPN/MDS), and AML. AML is diagnosed if the bone marrow or 
peripheral blood blasts exceed 20%. Cases where blasts are less than 20% may also be 
designated AML if a known cytogenetic/genetic abnormality associated with AML is 
detected (for example, the t(8;21) translocation which creates the RUNX1-ETO fusion 
gene).
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Amongst the non-AML myeloid neoplasms, MDS is characterised by refractory 
anaemia with a hyper- or normo-cellular none marrow and uni- or multi-lineage dysplasia. 
The specific form o f MDS (of which there are currently 7 described) depends on the 
morphological features on the malignant cells (e.g. the presence or absence o f  ring 
sideroblasts or the presence o f Auer rods) combined with the specific blast percentage 
(Nimer, S.D. 2008).
MPNs are characterised by an often hypercellular bone marrow or peripheral
blood with evidence o f increased proliferation o f  one lineage. Most common among these
disorders is BCR-ABL+ CML.
MDS/MPNs are a group o f  disorders which present difficulties for classification 
as either MDS o f MPN due to the presence of both lineage hyperplasia and hypoplasia. 
Amongst these disorders are chronic myelomonocytic leukaemia (CMML) and juvenile 
myelomonocytic leukaemia (JMML). CMML and JMML are closely associated with 
activating mutations in the Ras pathway (Tefferi, A. and Gilliland, D.G. 2007).
1.2.1 A cute  M yelo id  Leuk aem ia
1.2.1.1 Epidemiology, pathophysiology and pathogenesis o f  AML
AML is characterised by a rapid accumulation o f immature myeloid lineage cells 
(‘blasts’) in the bone marrow and peripheral blood o f the host, which have lost the ability 
to spontaneously differentiate and have also acquired a proliferation and/or survival 
advantage. In the UK, the incidence o f AML is 3.4 cases per 100,000 people, with a 
significant increase in incidence in persons over 60; indeed, the median age o f AML 
patients is 65 years (Milligan, D. W. et al. 2006). Development o f AML in under 18s is 
rare; instead, childhood acute lymphoblastic leukaemia (ALL; median age 3) and JMML 
(median age 1.4) are prevalent in this age group (Mitchell, C. et al. 2009; Locatelli, F. et 
al. 2005).
AML patients will often present with signs o f anaemia (lethargy, shortness of 
breath), and/or difficulty clearing infection, with excessive bleeding and predisposition to 
bruising. Patients may also suffer from abdominal discomfort due to enlarged liver and/or 
spleen (hepato- or splenomegaly). Each o f these symptoms either represents a consequence 
o f  one or more haematopoietic lineage failures or signs of organ invasion. The rapid onset 
o f  fatal symptoms in AML, such as bleeding, infection or organ infiltration usually occurs 
within 1 year o f diagnosis if not treated. This contrasts with the slow development o f 
CMLs, which is characterised by the protracted expansion o f more mature myeloid cells
15
CHAPTER 1: INTRODUCTION
over the course o f months or years, which can progress to an acute phase with more rapid 
expansion the abnormal cell population leading to similar symptoms to that o f terminal 
AML.
Aside from old-age, there are several known risk factors for developing AML; 
including exposure to environmental mutagens such as radiation and benzene, previous 
myeloid neoplasia (e.g. MDS), and prior cytotoxic chemotherapy (often for an unrelated 
cancer). AMLs resulting from previous MDS or therapy-related AMLs tend to be more 
aggressive than de novo AML (Estey, E. et a l 1997). Each o f these risk factors accelerates 
the DNA mutation rate, which presumably accelerates disease development. In some cases, 
the predisposition o f some individuals to succumb to AML development when exposed to 
environmental risk factors has been explained by the prevalence o f polymorphisms in 
foreign-toxic-substance (xenobiotic) detoxifying enzymes. Briefly, detoxification o f 
xenobiotics occurs in two phases mediated by two classes o f detoxifying enzymes. First, 
metabolic phase 1 enzymes (e.g. P450 cytochrome enzymes) transfer electrons onto the 
xenobiotic molecule generating a highly reactive intermediate, which is then primed for 
detoxification by metabolic phase 2 enzymes, e.g. glutathione-S-transferases or NADPH 
quinone oxidoreductase (NQOl) (Farquhar, M.J. and Bowen, D.T. 2003). Polymorphisms 
which confer increased phase 1 activity or decreased phase 2  activity, if not compensated 
for, can result in elevated levels o f  highly reactive intermediates, which will likely react 
with and damage most biomolecules including DNA. For example in the case o f benzene 
detoxification, a C609T polymorphism in the gene encoding NQOl (a metabolic phase 2 
enzyme) confers decreased benzene detoxification activity and is associated with an 
increased tendency to develop AML in two separate studies (Larson, R. A. et al. 1999; 
Smith, M.T. et al. 2001). Similarly, an allele (CYP1 A1*2B) which confers increased 
activity o f  CYP1 Al (a metabolic phase 1 cytochrome P450 enzyme) was not associated 
with increased tendency to develop AML overall, but was over-represented in a subset of 
AMLs with a poor risk karyotype and activating mutations in N-Ras (Bowen, D.T. et a l 
2003).
1.2.1.2 Current understanding o f  AML aetiology
It has been estimated that a human cell must (correctly) repair approximately 
10,000 DNA lesions per day to maintain the integrity o f  DNA helix under normal 
conditions (Lindahl, T. 1993). Exposure to environmental mutagens and other AML risk 
factors accelerate the DNA damage rate, and as a consequence, misrepaired (or unrepaired) 
DNA damage can lead to permanent changes (mutations) in the genetic code. Such
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mutations can accumulate in long-lived cells (such as HSCs) over time leading to an 
increased risk o f cancer development with age (DePinho, R.A. 2000).
Leukaemia development has been proposed to occur via a ‘two-hit’ process 
(Kelly, L.M. and Gilliland, D.G. 2002). This model suggests that the combination o f 
mutations o f two classes o f genes (termed class I and class II genes) can lead to AML.
Class I genes are those which transduce proliferation and survival signals while class II 
genes promote differentiation (i.e. haematopoietic transcription factors). The two-hit model 
proposes that activating mutations in class I genes (inactivation o f negative regulators e.g. 
NF1 or activation o f signal transducers such as Ras, FLT3 or c-KIT), combined with 
mutations which inactivate class II gene pathways (e.g. inactivating point mutations in 
CEBPa; or translocations involving RUNX1) may provide the necessary conditions for 
leukaemia to develop.
Although there is evidence that this model does not explain the behaviour of 
some leukaemias (Coulon, S. et al. 2007), there is strong evidence o f co-operation o f so- 
called class I and class II gene mutations in core-binding factor leukaemia; especially in 
cases involving mutations o f Ras, FLT3 and c-KIT (Schneider, F. et al. 2007; Pinheiro,
R.F. et al. 2007; Boissel, N. et al. 2006; Schnittger, S. et al. 2006) and the t(8;21) 
translocation (generating the RUNX1-ETO fusion gene). In these examples, the RUNX1 
fusion o f the haematopoietic transactivator RUNX1 is fused to the co-repressor domain o f 
ETO, resulting in suppression o f RUNX1 target gene transcription (Gardini, A. et al.
2008). The fact that loss o f RUNX1 does cause a block in differentiation is observed in 
conditional RUNX1 knockouts in mice, which show a block in lymphoid development and 
reduced platelet formation (Ichikawa, M. et al. 2004). Constitutive signalling via Ras,
FLT3 or c-KIT then provides the cooperating proliferation and survival signals, and in the 
case o f c-KIT, leads to a poorer prognosis (Schnittger, S. et al. 2006). Further support for 
the two-hit hypothesis comes from studies showing that there is a significant negative 
association between mutations o f class I genes, e.g. activating mutations o f Ras and FLT3 
(both class I genes) are rarely found together in the same patient, suggesting that co­
existent class I genes mutations do not efficiently co-operate during disease development 
(Stirewalt, D.L. et al. 2001; Bowen, D.T. etal. 2005).
Chromosomal translocations are a common feature o f myeloid leukaemias 
(Rabbitts, T.H. 1994) and provided the first prognostic indicators for AML patients 
(section 1.2.1.3). Translocations can have several consequences defined mainly by the 
features o f the genes involved in the translocation and the domains that are preserved in the 
fusion product. For example, the t(9;22) fusion generates the BCR-ABL fusion gene
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(characteristic o f CML). In this way, the kinase activity o f c-ABL is dysregulated by being 
placed under the control o f  the BCR promoter, resulting in a fusion protein with aberrant 
kinase activity. A similar example is found in some B-cell lymphomas, where BCL family 
members (which promote survival) are placed under control o f  the highly expressed 
immunoglobulin heavy-chain (IgH) genes. A final type o f chromosome translocation 
results in the inactivation o f one (or both) o f the genes involved, and this type is common 
in myeloid leukaemia, commonly involving CBP/3 (e.g. CBP/3-MYH11), p300 (e.g MOZ- 
p300) and RUNX1 (e.g. RUNX1-ETO), resulting in suppression o f their target genes. 
Abnormalities o f 1 lq23 (involving the MLL1 gene, encoding a histone-methyltransferase 
(Rabbitts, T.H. 1994)) results in increased MLL1 activity permitting aberrant transcription 
o f target genes including HOX genes (Jude, C.D. et a l 2007). In short, these abnormalities 
o f ‘class I’ genes are overwhelmingly associated with defective gene transcription, with the 
common result that haematopoietic cells are unable to correctly initiate development 
programmes.
As mentioned above, activating mutations in class I genes such as FLT3 include 
internal tandem duplications (ITDs), tyrosine kinase domain duplications (TKDs) and 
point mutations (D835Y). c-KIT is commonly mutated in exon 8  resulting in constitutive 
activation. Ras proteins may be constitutively activated due mutations most commonly in 
exons 12, 13 or 61. All o f  these events lead to activation o f pro-proliferative pathways such 
as the Raf, mitogen-activated protein kinase kinase, extracellular signal-regulated kinase 
(Raf-MEK-ERK) pathway; the JAK-STAT pathway, and survival pathways such as the 
PI3K-Akt and nuclear factor-xB (NF-kB) pathways.
The requirement for both lesions to occur in the appropriate genes within the 
same cell suggests that such a process may take time to occur; implying that the only cells 
likely to be able accumulate the necessary mutations would be long-lived cells, such as 
HSCs. Furthermore, there is evidence that some abnormalities associated with leukaemia 
can be detected in both lymphoid and myeloid lineages, indicating that the abnormality 
arose in a common precursor e.g. AML1-ETO (Miyamoto, T. et al 2000), strongly 
supporting the notion that AML arises from genetic damage sustained by HSCs. These 
observations have led to the proposal that leukaemic ‘hits’ occur at the level o f the HSC. 
Moreover, it has been proposed that myeloid leukaemia may exist in an aberrant hierarchy 
analogous to that seen in normal haematopoiesis. This notion is supported by experiments 
which show that only rare cells with an immature immunophenotype (‘leukaemic stem 
cells’ or LSCs) are capable o f reconstituting disease in an irradiated mouse (Dick, J.E. 
2005). The existence o f an LSC may explain the phenomenon o f relapse after remission is
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achieved; since it may be these LSCs are resistant to standard chemotherapy (if like normal 
HSCs they are relatively quiescent and receive survival signals from the bone marrow 
stroma). The impact o f  these genetic defects on prognosis and treatment are discussed in 
the next two sections.
1.2.1.3 Prognosis
The prognosis o f a given patient diagnosed with AML is dependent on two main 
factors. First, the likelihood that the patient will survive primary induction and 
consolidation therapy, and secondly, the probability that the disease will respond to 
treatment. The former o f these factors is adversely affected by age, but more specific 
indicators o f fitness to undergo treatment can be obtained by examining serum albumin, 
creatinine, bilirubin and excluding the presence o f ongoing infection. Patient performance 
scoring systems (such as the Zubrod scoring system (Oken, M.M. et al. 1982)) are also 
used as a measure o f the patient’s quality o f life, where 0  is perfect health and increasing 
score indicates diminishing quality o f life leading to a maximum score o f 5 (death). These 
performance scores aid in the assessment o f the urgency o f  treatment.
It is now appreciated that the latter o f  the two factors (likelihood o f response to 
treatment) is highly dependent on the cytogenetic and molecular genetic defects which are 
present at the time o f diagnosis. Early studies noted that the response o f patients to the 
standard treatment regimens was highly variable; but that cytogenetic status (the presence 
or absence o f chromosome translocations, deletions or aneuploidy) was a strong prognostic 
indicator o f clinical outcome (Estey, E. and Dohner, H. 2006). Using the cytogenetic status 
o f the patient at diagnosis, patients are stratified into three prognostic groups (favourable, 
intermediate or poor) based on their likely clinical outcome. Cases in the favourable 
cytogenetic group are predominantly the core-binding factor AMLs positive for t(8;21), 
inv(16) or t(16;16) (CBFB-MYH11) ort(15;17) (PML-RARo). The reason for the 
favourable response o f these patient to standard therapy is generally unclear, with the 
exception o f acute promyelocytic leukaemia (APL) patients (harbouring a t(15;17) 
translocation), whose improved outcome is due to specific targeting o f the molecular 
abnormality (the PML-RARa fusion protein) with ATRA (Flynn, P.J. et al. 1983). Patients 
in the intermediate prognostic group are predominantly those with normal cytogenetics 
(which represents 45% o f all patients). Also included in this group are patients with 
trisomies (e.g. +11, +21). Patients with complex cytogenetics (3 or more abnormalities) or 
inv(3)/t(3;3) are consistently assigned to the poor prognostic group. There are several other 
AML associated cytogenetic abnormalities with disputed prognostic importance, with
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disagreement mainly on whether these abnormalities confer intermediate or poor prognosis 
(Estey, E. and Dohner, H. 2006).
The prognostic value o f cytogenetic status has been verified by several large 
studies (Grimwade, D. et a l 1998; Grimwade, D. et a l 2001; Slovak, M.L. et a l 2000). 
However, there is still considerable heterogeneity in clinical outcome within each 
prognostic group. Most puzzling to early investigators was the large variation o f outcome 
in patients with no visible cytogenetic abnormalities. This observation suggested that in 
patients with normal cytogenetics, molecular genetic defects were the most likely 
determinants o f clinical outcome. Subsequently, it has been shown that molecular genetic 
defects affecting NPM1, CEBPo; MLL, EVI1, BAALC and FLT3 do have significant 
prognostic value in AML patients with normal cytogenetics. Favourable prognostic 
markers include inactivating mutations o f NPM1 and CEBPa; which are associated with 
better relapse-free and better overall survival, whilst MLL-PTD, overexpression o f EVI1, 
overexpression o f BAALC and presence o f FLT3-ITD confer a poorer prognosis (Estey, E. 
and Dohner, H. 2006). In particular, FLT3-ITD is one o f the most consistent indicators o f 
poor outcome in patients with normal cytogenetics (Kottaridis, P.D. et a l 2001; Frohling, 
S. et a l  2002; Valk, P.J. et a l 2004). Although N-Ras and K-Ras mutations are shown to 
be overrepresented in certain AML subtypes, e.g. those with t(3;5)(q21-25;q31-q35) or 
inv(16)(pl3q22) respectively (Bowen, D.T. et a l 2005), there is little evidence that Ras 
mutations have prognostic significance (section 1.3.5.2).
Studies o f co-expression o f several prognostic indicators suggest that it is 
difficult to predict which prognostic factor will be dominant, but evidence from AML 
patients with normal cytogenetics suggest that in general, poor prognostic markers are 
dominant over favourable ones. For example, the favourable effect o f  NPM1 mutation is 
nullified by the co-expression o f FLT3-ITD (Schnittger, S. et a l 2005). In addition, co­
expression o f poor prognostic markers such as FLT3-ITD and BAALC appears to have an 
additive effect (Baldus, C.D. et a l 2006). In contrast to studies o f patients with normal 
cytogenetics, the prognostic influence o f molecular abnormalities in AML patients with 
abnormal cytogenetics is less clear; however in general the cytogenetic abnormality 
appears to be dominant. However, activating mutations o f c-KIT have been shown to 
negatively affect prognosis o f  patients with favourable cytogenetics i.e. t(8 ;2 1 ) and inv(16) 
(Care, R.S. etal. 2003; Cairoli, R. et a l 2006; Schnittger, S. et a l 2006), demonstrating 
that molecular defects can have some influence on prognosis, even in core-binding factor 
AML. Table 1.1 summarises the prognostic effects o f the most common molecular
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abnormalities found in some types of AML with normal (diploid) and abnormal 
cytogenetics.
Molecular
abnormality
AML subtype Disease-free 
survival
Overall
survival
MLL PTD Diploid, trisomy 11 Shortened None
FLT-3 mutations Diploid Shortened Shortened
FLT-3 mutations APL None None
t  BAALC mRNA Diploid Shortened Shortened
CEBPa mutation Diploid Prolonged Prolonged
NPM mutation Diploid Prolonged Prolonged
WT-1 All subtypes Not reported Shortened
NRAS mutation All subtypes None None
c-KJT mutation inv( 16), t(8 ;2 1 ) Shortened Shortened
t  ERG mRNA Diploid Shortened Shortened
T EVI1 mRNA 3q26, unfavourable Shortened Shortened
Table 1.1 Prognostic influence of some common molecular abnormalities detected in 
AML
MLL PTD = mixed lineage leukaemia partial tandem duplication; FLT-3 ITD = FMS-like 
tyrosine kinase-3 internal tandem duplication; BAALC = brain and acute leukaemia 
cytoplasmic; CEBPa = CCAAT/enhancer binding protein-a; NPM = nucleophosmin; WT- 
1 = Wilms tumor-1; ERG = ETS-related gene; APL = acute promyelocytic leukaemia. 
Adapted from Ravandi et al. (Ravandi, F. et al. 2007).
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1.2.1.4 Therapy
Broadly speaking, the aim o f  any AML therapy is to induce a complete 
remission o f  the disease (less than 5% blasts in peripheral blood and marrow), followed by 
consolidation therapy to maintain the remission. How this is achieved for each patient is 
decided after consideration o f the patient’s fitness, likelihood o f imminent disease 
progression, and their genetic prognostic indications (as described in section 1 .2 .1 .3 ).
Amongst younger patients (<60 years old), standard ‘3+7’ induction regimens 
(intravenous (iv) administration o f daunorubicin (which is known to generate ROS 
production and also intercalates into DNA stalling replication) for 3 days followed by i.v. 
cytarabine (a nucleoside analogue aka ara-C) over 7 days)) results in complete remission o f 
65-75% o f patients (Estey, E. and Dohner, H. 2006). Subsequently, younger patients with 
favourable risk are currently treated with high-dose cytarabine as a consolidation therapy, 
which leads to sustained remission in 60-75% of cases. Although the same approach leads 
to lower overall survival in the intermediate prognostic groups, it is still the approach o f 
choice in the light o f evidence that autologous and allogeneic stem-cell transplants (SCTs) 
offer no significant benefit. Less than 10% o f patients in the poor risk group maintain 
remission with standard high-dose cytarabine consolidation after induction therapy. Under 
these conditions, there is evidence that allogeneic SCT may improve this dismal outcome. 
Alternatively, patients in the poor prognostic group (or those with better genetic prognoses 
but are considered unlikely to survive standard induction therapy) can opt to enrol in 
clinical trials and receive investigational therapy or choose palliative care. Perhaps 
unsurprisingly, in elderly patients (>60 years) the situation is correspondingly worse in 
each risk group, with 2 0 % o f patients surviving 2  years after diagnosis partly due to a 
higher chance o f death during standard induction regimens. As a result, the majority o f 
elderly patients are offered investigational therapy or palliative care.
In some cases where complete remission is achieved by induction therapy, the 
disease later relapses, suggesting that drug resistant clones (LSCs) remain after induction 
therapy that are capable o f re-establishing the disease (section 1.2.1.2). Indeed, it is often 
possible to detect markers o f minimum residual disease (MRD) in patients which have 
achieved remission, either through PCR-based methods (used mostly to detect fusion 
transcripts e.g. PML-RARo; (Lo, C.F. et a l 1999)) and flow cytometric methods to monitor 
the presence o f abnormal blasts by virtue o f their often aberrant surface marker expression 
(Vidriales, M.B. et a l 2003).
Several studies have examined whether clinical outcome could be improved 
using less-toxic analogues o f the mainstay drugs cytarabine (e.g. clofarabine) and
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daunorubicin (e.g. doxorubicin, idarubicin, epirubucin), as well as combination therapy 
with topoisomerase inhibitors (etoposide and mitoxantrone). However, in general these 
studies have failed to demonstrate any significant improvement in outcome (Estey, E. and 
Dohner, H. 2006). New agents are currently undergoing clinical trials; many o f  them 
targeting recently discovered molecular abnormalities, for example lestaurinib (CEP-701) 
and PKC412 are small-molecule inhibitors o f FLT3-ITD. Both these agents have 
demonstrated a clinical effect, but this effect is not sustained (Knapper, S. 2007). In 
summary, treatment o f AML remains a difficult task, especially for those younger patients 
assigned to intermediate and poor prognostic groups; and elderly patients in general.
1.3 R a s  p r o t e i n s
1.3.1 A n  o v er v iew  of the Ra s  su per fa m ily
The Ras (rat sarcoma) protein superfamily o f small GTPases currently consists 
o f ~170 described iso forms encoded by ~160 genes (in humans), grouped into 5 main 
subfamilies: Ras, Rho, Rab, Ran and Arf (Wennerberg, K. et a l 2005). Members o f this 
large protein family participate in diverse cellular functions, with members within each 
subfamily grouped together mainly on the basis o f  structural similarity. For example, 
members o f the Ras subfamily are primarily involved in proliferation and survival 
signalling; Rab and A rf subfamilies govern vesicular transport; Ran participates in 
nuclear/cytoplasmic shuttling o f RNA and protein, and Rho subfamily members are 
primarily involved in cytoskeletal remodelling. There is also evidence that Ras subfamily 
members (e.g. H-Ras and K-Ras) also play an important role in development, since 
hereditary activating mutations in Ras signalling pathways have been detected in 
congenital developmental disorders (Schubbert, S. et al. 2007). There are also several Ras 
superfamily proteins which do not appear to fall into the five main subfamilies, and may 
represent novel subfamilies, e.g. the Miro proteins which play important roles in 
mitochondrial biogenesis and homeostasis (Wennerberg, K. et a l 2005).
All Ras superfamily proteins contain a conserved G domain which is 
homologous to the GTP-binding domain found in the a  subunit ofheterotrimeric G- 
proteins (Kamoub, A.E. and Weinberg, R.A. 2008). The G domain contains several 
conserved ‘G motifs’, which form the guanine nucleotide binding pocket (phosphate- 
binding or P-loop) and also confer a weak intrinsic GTPase activity. Ras superfamily 
proteins are activated when bound to GTP, and generally inactive when bound to GDP; 
although in the case o f  Rab, Ran and Arf proteins, the GDP-bound form may also
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participate in signalling processes distinct from those o f the GTP-bound form 
(Wennerberg, K. et a l 2005). Thus Ras superfamily members all act as binary molecular 
switches, in general providing an ‘on’ or ‘o ff  signal depending on whether GTP or GDP is 
bound respectively.
X-ray crystallographic studies o f Ras proteins bound to either GDP or GTP 
show that large conformational changes are induced in the Ras protein when GDP is 
exchanged for GTP and vice-versa (Milbum, M.V. et al. 1990; Schlichting, I. et a l 1990). 
Moreover, these conformational changes are localised to two flexible loop regions which 
are termed Switch I and Switch II. Switch regions I and II are critical for Ras superfamily 
protein signalling and regulation because it is via these regions that Ras proteins make 
physical contact with their downstream effectors and also upstream regulators (Kamoub, 
A.E. and Weinberg, R.A. 2008). Accordingly, the switch regions are present in all o f  the 
Ras superfamily proteins.
By virtue o f their weak intrinsic GTPase activity, Ras proteins can hydrolyse 
bound GTP to form GDP and inorganic phosphate; thus activated Ras molecules are 
intrinsically capable o f self-limiting their activation. However, efficient GTP hydrolysis 
requires the presence GTPase activating proteins (GAPs) which greatly augment the 
intrinsic GTPase activity o f Ras proteins and thus act as negative regulators. X-ray 
crystallographic studies o f  Ras proteins complexed with GAPs e.g. neurofibromin (NF1), 
revealed that a conserved arginine finger domain within the GAP protein inserts into the 
nucleotide binding pocket on the Ras protein. This arginine residue stabilises a transition 
state during the catalytic hydrolysis o f GTP; and the lowered activation energy for this step 
o f the reaction results in (approximately) a 1000 fold increase in GTPase activity. Thus, 
GAPs promote the rapid accumulation o f GDP-bound Ras (Ahmadian, M.R. et a l 1997).
Whereas GAPs are negative regulators, the guanine nucleotide exchange factors 
(GEFs) are positive regulators o f Ras proteins. GEFs associate with inactive GDP-bound 
Ras proteins and induce a conformational change which promotes the release o f GDP. 
Since GTP is approximately 10-fold more abundant inside the cell than GDP (Kamoub, 
A.E. and Weinberg, R.A. 2008), GTP preferentially binds, and the Ras protein is activated.
In addition to GAPs and GEFs, Rho-guanine nucleotide dissociation inhibitors 
(Rho-GDIs) are a unique group o f proteins which specifically regulate Rho subfamily 
members (Sahai, E. and Marshall, C.J. 2002), including Rac. Rho-GDIs bind to and mask 
lipid groups o f Rho proteins added by post-translational modification (these modifications 
are discussed below) and thus sequester them in the cytosol. Rho proteins bound by Rho- 
GDI remain in the GDP-bound state and are therefore inactive.
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Most o f the Ras superfamily proteins require post-translational attachment o f 
lipid molecules before they are able to function. For the majority o f Ras and Rho subfamily 
proteins (which are the best studied), this modification occurs in four stages. First, the 
newly-translated Ras molecule is prenylated in the cytosol by famesyl transferase (FT) or 
geranylgeranyl transferase I, which attach either famesyl or geranylgeranyl groups 
respectively to the Cys residue within a C-terminal ‘CAAX’ motif o f the Ras protein 
(where A is an aliphatic amino acid and X is any amino acid). Second, prenylated Ras 
proteins then associate with the ER, where the C-terminal -AAX tripeptide is cleaved by 
Ras converting enzyme-1. Thirdly, the C-terminal cysteine is carboxymethylated by 
isoprenylcysteine carboxymethyltransferase-1 (Bivona, T.G. and Philips, M.R. 2003).
There is evidence that these first three steps are necessary and sufficient to activate Ras 
subfamily proteins; prenylated H-Ras and K-Ras4A oncoproteins are capable o f 
transforming murine fibroblasts without further post-translational modification (Hancock, 
J.F. et a l 1990). However, most Ras superfamily proteins undergo additional post- 
translational modifications to strengthen their association with the plasma membrane, 
sometimes referred to as the ‘second signal’. This fourth step is required for efficient 
activation o f ERKby H-Ras inXenopus oocytes (Dudler, T. and Gelb, M.H. 1996) and 
may also be required for the full spectrum o f Ras2 signalling in S. cerevisiae 
(Bhattacharya, S. et a l 1995). For H-Ras, N-Ras and K-Ras4A, this palmitoylation step 
occurs during transit through the Golgi apparatus, and involves attachment o f myristic acid 
or palmitic acid by myristoyltransferase or palmitoyltransferase (myristoylation or 
palmitoylation) o f selected cysteine residues located N-terminal to the prenylated cysteine.
Some Ras superfamily members are exceptions to the process o f post-translation 
modification described above. For example, whereas K-Ras4A undergoes the process 
described above, the closely related iso form K-Ras4B lacks the cysteine residues that are 
normally palmitoylated, and instead bears a basic poly-lysine sequence which appears to 
serve a similar role to palmitoylation in that it strengthens membrane association. Rab 
subfamily proteins do not possess a CAAX motif and are not prenylated by FT or 
geranylgeranyl transferase I, but instead encode one o f several C-terminal sequences (CC, 
CXC, CCX, CCXX, or CCXXX), which are recognised and prenylated by geranylgeranyl 
transferase II. Finally, several Ras superfamily proteins do not undergo post-translational 
modification by lipids at all, for example Ritl, Rit2 and Miro proteins can associate with 
membranes despite a lack o f prenylation, whilst Ran and Rerg lack any C-terminal motif 
containing cysteine, and do not require modification by lipids or association with 
membranes in order to function.
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1.3.2 H-R a s , K-R a s  a n d  N -R a s : fo u n d in g  m em ber s  of the Ra s  pro tein
SUPERFAMILY
H-Ras (Harvey-Ras or Ha-Ras), K-Ras (Kirsten-Ras or Ki-Ras) and N-Ras 
(neuroblastoma-Ras) proteins were discovered during the late 1970s and early 1980s, and 
are the founding members o f the Ras superfamily. They are the best-understood members 
o f the Ras superfamily, and are the principal members o f the subfamily o f  the same name, 
which (in humans) currently comprises 39 protein iso forms with molecular weights 
ranging from 20-29 KDa encoded by 36 genes (Wennerberg, K. et al. 2005). The 
endogenous wild-type genes encoding H-Ras and K-Ras proteins were identified in rats, 
mice and humans due to their homology with transforming retroviral oncogenes expressed 
by Harvey and Kirsten strains o f MSV (murine sarcoma virus) (DeFeo, D. et al. 1981;
Ellis, R.W. et al. 1982; Chang, E.H. et al. 1982). A short time later, an activated form o f a 
third Ras gene, N-Ras, was isolated from neuroblastoma cells (Shimizu, K. et al. 1983); 
two different sarcoma cell lines (Hall, A. et al. 1983) and also in the HL60 leukaemia cell 
line (Murray, M.J. et al. 1983).
H-Ras (located on human chromosome 11 pi 5.5), N-Ras (human chromosome 
1 pi 3.2), and the two known iso forms o f K-Ras (K-Ras4A and K-Ras4B, generated by 
alternative splicing o f the K-Ras gene on human chromosome 12pl2.1) show a high degree 
o f homology within the N-terminus, which contains the GTP binding G domain. In 
contrast, the C-terminal region shows considerable diversity when comparing iso forms, 
and is referred to as the hypervariable region (Figure 1.3). It is likely that differences in 
this region contributes to the differing subcellular localisation o f each different iso form 
(Bivona, T.G. and Philips, M.R. 2003). In the case o f H-Ras, N-Ras and K-Ras, the CAAX 
motif is famesylated on the conserved cysteine by FT, although N-Ras and K-Ras can be 
geranylgeranylated in the presence o f FT inhibitors (Whyte, D.B. et al. 1997).
H-Ras, N-Ras and K-Ras4A all undergo subsequent palmitoylation on one or 
two cysteine residues near the famesylation site (Figure 1.3). In addition, these proteins
9 +  • • •bind a single Mg ion, which plays a role in the guanine nucleotide-bmding interaction in 
the mature folded form.
The tertiary structure o f these proteins is globular, with a hydrophobic core 
composed o f five Qf-helices and six /3-sheets, linked together by 10 polypeptide loops. Five 
o f these loops are o f particular importance for Ras protein function; loops 1, 2, and 4 form 
the guanine nucleotide binding pocket, with loop 1 (the phosphate loop or P-loop spanning 
amino acids 10-17) forming a close association with the guanine nucleotide phosphate 
groups. The two remaining loops (3 and 5) form switch regions I and II, spanning amino
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acids 30-38 and 59-67 respectively. The conformational changes induced by GTP-binding 
in switch I and II form a distinct 3-dimensional surface on the Ras protein which are 
recognised and bound by downstream effectors o f Ras. These same switch regions are also 
the binding sites for the upstream regulators of Ras, the RasGAPs and RasGEFs, which 
recognise the conformation o f the switch regions when bound to either GTP or GDP 
respectively (section 1.3.3).
Early investigations into the biochemical basis o f  oncogenic transformation by 
Ras mutants noted that activating mutations o f the Ras protein were clustered in codons 12 
and 13 (within the P-loop) and 61 (within switch II) (Krengel, U. et a l 1990); and also that 
the intrinsic GTPase activity o f  these mutant proteins was greatly reduced when compared 
to the normal alleles, even in the presence o f GAPs (Gibbs, J.B. et a l 1984; McGrath, J.P. 
et a l 1984; Sweet, R.W. et a l 1984). Subsequent studies have revealed that amino acids at 
these positions (12, 13 and 61) play critical roles in the mechanism o f intrinsic GTP 
hydrolysis by Ras. In each Ras iso form, the 12th and 13th codons encode glycine, which is 
the only amino acid without a side chain. Therefore, any mis-sense mutation at these 
positions leads to inclusion o f  an amino acid with a side chain. The most common 
substitutions in human cancers replace glycine with valine or aspartate at these positions. 
The bulky side chains o f  these residues case a steric clash with the side chains o f catalytic 
residues during GTP hydrolysis, resulting in a drastic decrease in GTPase activity 
(Schubbert, S. et a l 2007). Thus, substitutions at codons 12 or 13 lead to an accumulation 
o f GTP-bound (and therefore activated) Ras. Codon 61 encodes a conserved glutamine 
residue which forms an important hydrogen bond with the catalytic arginine o f  GAPs 
during GAP-assisted GTP-hydrolysis (Kamoub, A.E. and Weinberg, R.A. 2008) and loss 
o f this interaction (by substitution o f the conserved glutamine) severely impairs GTP 
hydrolysis, again resulting in the accumulation o f  GTP-bound Ras.
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Figure 1.3 The primary structure of classical Ras proteins
H-Ras, N-Ras and K-Ras4A and K-Ras4B are 188-189 amino acids in length. Each of 
these iso forms has an almost identical sequence for the first 165 amino acids (spanning the 
conserved GTP-binding G-domain). Within the G-domain are the phosphate-binding P- 
loop and switch regions I and II. The switch regions are the location of dynamic 
conformational changes when GDP is exchanged for GTP, and it is the conformation of 
these switch regions that are recognised and bound by Ras upstream regulators and 
downstream effectors. The last ~20 amino acids show considerable heterogeneity and are 
referred to as the hypervariable region. Within this region, there is a conserved CAAX 
motif which is the site of Ras prenylation by prenyltransferases such as FT. The prenylated 
cysteine within this motif is highlighted in red. With the exception of K-Ras4B, Ras 
proteins also contain some additional cysteine residues which are the site(s) of 
palmitoylation (highlighted in green). K-Ras4B (the most abundant of the two K-Ras 
iso forms) has no additional cysteine residues, but instead contains a polybasic string of 
lysine residues. The net positive charges of these residues interacts with the negatively 
charged phospholipid heads in the plasma membrane thus serving a similar role to 
palmitoylation. Adapted from Karnoub, 2008 (Kamoub, A.E. and Weinberg, R.A. 2008).
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1.3.3 Ra s  sig n a l l in g  in h aem ato po ietic  cells
1.3.3.1 Upstream regulation o f  Ras activity
The principal known function o f Ras proteins is to transduce signals from the 
cytoplasmic domains o f  activated growth factor receptors to downstream effectors, 
resulting in cell cycle progression, survival and increased cell motility. H-Ras, N-Ras and 
K-Ras4B are all expressed in mammalian haematopoietic cells, although N-Ras and K- 
Ras4B are most abundant (Shen, W.P. et al. 1987), and function as common downstream 
effectors o f the majority o f haematopoietic growth factor-receptors, including FLT3-L, 
SCF, IL-3, G/GM-CSF and EPO. The sequence o f events that connect growth factor 
binding to Ras protein activation are very similar for each receptor, and ultimately result in 
the recruitment and activation o f RasGEFs (primarily son o f sevenless (SOS) proteins) 
which promote the accumulation o f activated GTP-bound Ras. This process is summarised 
in Figure 1.4.
In general, binding o f growth factors to their cognate receptors induces 
conformational changes in the cytoplasmic regions o f the receptors which drive 
phosphorylation o f tyrosine residues within the cytoplasmic tail o f  the receptor (section 
1.1.3.4). In the case o f RTKs this is an autophosphorylation event, while type I and type II 
cytokine receptors become phosphorylated after activation o f associated JAK kinases. 
Phosphorylated tyrosine residues in the cytoplasmic tail o f activated growth factor 
receptors form docking sites for proteins containing an SH2 domain. One such protein is 
the adaptor molecule GRB2, which links the activated receptor to SOS family proteins, 
which are RasGEFs. Together with additional adaptor proteins (SHC and Gab family 
proteins), this complex co-localises SOS proteins with membrane-bound Ras-GDP, which 
is then converted by SOS to the active GTP-bound form. Recruitment o f the tyrosine 
phosphatase SHP2 to the activated receptor complex (via binding to Gab) is also required 
for efficient Ras signalling. SHP2 is somewhat unusual in that, unlike most phosphatases, 
it is a positive regulator o f signalling, although the exact manner in which it promotes Ras 
activation is not understood. For example, mice with homozygous deletion o f a large 
portion o f the P tp n ll gene (encoding Shp2) die during embryogenesis due to improper 
gastrulation, and fibroblasts from these mice show decreased responsiveness to FGF and 
EGF (Matozaki, T. et al. 2009).
29
CHAPTER 1: INTRODUCTION
Growth
factor
Growth factor 
receptor Plasma membrane
ActiveInactivep) Phospho­
rs tyrosine Ras-
GDP
Ras-
GTP
GRB2 I SOSOther
Effectors
NF1 GAP
SHC Y Gab
Downstream
effectorsSHP2
Figure 1.4 Activation of Ras by growth factor receptors
The diagram depicts a typical scheme whereby Ras proteins are activated following 
binding of a growth factor (e.g. FLT3L) to its receptor. Growth factor-induced 
dimerisation of growth factor receptors results in phosphorylation of tyrosine residues in 
the cytoplasmic tail o f the receptor. Phosphotyrosine forms binding sites for proteins 
containing SH2 domains, such as GRB2, SHC, Gab and the tyrosine phosphatase SHP2. 
GRB2 is an adaptor protein which is tethered to SOS, a RasGEF, thus, recruitment of 
GRB2 and SOS to the activated receptor co-localises SOS with membrane bound Ras- 
GDP. SOS promotes binding of GTP to Ras and Ras then binds and activates its 
downstream effectors. SOS is antagonised by the RasGAPs NF1 and pl20(,AI> (labelled 
GAP) which accelerate the intrinsic GTPase activity o f Ras proteins and thus inactivate 
them. H-Ras, N-Ras and K-Ras all follow a similar route to activation, but the distinct 
subcellular localisation may restrict access of each iso form to a specific subset of effectors, 
which may result in a degree of non-redundant signalling for each isoform. Indeed, it is 
important to note that this diagram depicts activation of Ras at the plasma membrane, 
however, activation of Ras by extracellular growth factors has been reported on 
endomembranes, though the mechanism by which this occurs is poorly understood. 
Adapted from Schubbert et al. (Schubbert, S. et al. 2007).
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Conversely, mutations in SHP2 that result in constitutive activation o f the Ras 
pathway are closely associated with developmental disorders such as Noonan’s and cardio- 
facio-cutaneous (CFC) syndromes, and are also frequently detected in JMML.
Interestingly, SHP2 is sensitive to changes in cellular redox state, suggesting Ras 
activation may be influenced by ROS production (redox regulation o f phosphatases is 
discussed in section 1.4.3.2).
Activation o f Ras family proteins is antagonised by the RasGAPs NF1 and 
p l20GAP. Germline inactivating mutations ofN Fl are implicated in the congenital 
developmental disorder neurofibromatosis, where loss o f heterozygosity at the NF1 locus 
causes hyperpigmented skin lesions, development o f benign neurofibromas, and a 
predisposition to develop JMML (Schubbert, S. et al. 2007).
Ras guanine-nucleotide release proteins (RasGRPs) are a distinct family o f Ras 
GEFs that also promote Ras-GTP accumulation. They contain a Ras-binding domain 
similar to that o f  SOS, but unlike SOS, some RasGRPs appear to be regulated by 
diacylglycerol (DAG) formation by virtue o f their DAG-binding Cl domain (Johnson, J.E. 
et al. 2007), and may therefore be regulated by phospholipases in an analogous manner to 
protein kinase C (PKC) (section 1.3.3.2).
In addition to the actions o f RasGAPs and GEFs, subcellular localisation o f the 
Ras protein may also play a role in regulating Ras signalling. As discussed in section 1.3.2, 
H-Ras, N-Ras and K-Ras4B undergo a primary famesylation step, followed by 
palmitoylation (‘the second signal’) to generate mature Ras proteins. However, while the 
site o f famesylation is conserved in each iso form, the site(s) o f palmitoylation differ due to 
unique sequences in the hypervariable region upstream o f the CAAX motif. Indeed, it is 
believed that this unique ‘second signal’ contributes to the different subcellular localisation 
o f each isoform. For example, mature H-Ras and N-Ras can be detected in both the plasma 
membrane and the Golgi under normal conditions, whereas K-Ras4B (which is not 
palmitoylated) is located solely in the plasma membrane. Furthermore, within the plasma 
membrane there is a preference o f some iso forms for particular membrane microdomains; 
for example H-Ras is primarily associated with lipid-rafts, while K-Ras4B is located in the 
bulk plasma membrane. Indeed, it has been demonstrated (at least in yeast) that forced 
localisation o f S. pombe Rasl to either the ER (RaslC215S mutant) or plasma membrane 
(recombinant Rasl fused to RitC plasma membrane-targeting sequence) selectively 
blocked sexual maturation or adoption o f a normal morphology respectively (Onken, B. et 
al. 2006), suggesting that Ras signalling may have different consequences depending the 
subcellular origin o f the signal (presumably some Rasl effectors are themselves restricted
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to the ER or plasma membrane which would allow such endomembrane-specific signalling 
to occur). This subcellular localisation may offer an explanation as to how mammalian Ras 
iso forms with similar sequences can have such diverse (and in some cases) non-redundant 
functions, for example, K-Ras-null mice are not viable (Koera, K. et al. 1997), whereas N- 
Ras and/or H-Ras-null mice are viable and fertile (Esteban, L.M. et a l 2001). There is also 
evidence for cyclical depalmitoylation o f mature N-Ras and H-Ras which results in 
retraction o f these proteins from the plasma membrane and re-entry into the Golgi, where 
they may be re-palmitoylated and returned to the plasma membrane. This cycle may be 
important for regulation o f  Ras activity and access to its effectors; indeed it has been 
demonstrated in mammalian cells that endogenous Ras proteins resident in the ER and 
Golgi can respond to stimulation by EGF within minutes, and that ER-restricted H-Ras is 
capable o f activating ERK, after EGF treatment, suggesting that Ras signalling on 
endomembranes may be an important addition to signalling originating from the plasma 
membrane (Chiu, V.K. et a l  2002). However, the significance o f these mechanisms for 
Ras signalling in haematopoietic cells has not been explored.
1.3.3.2 Ras effectors and downstream signalling
After Ras has bound to GTP, switch regions I and II adopt conformations which 
form binding sites for a variety o f downstream effectors. The first o f  these to be discovered 
was Raf, a serine/threonine kinase which (like Ras) was known to be the cellular 
homologue o f a known retroviral oncogene. Raf was shown to directly bind Ras-GTP 
(Wame, P.H. et al. 1993; Zhang, X.F. et al. 1993) and was also shown to be important in 
mediating the phenotype o f mutant Ras in C. elegans (Han, M. et al. 1993). Later, Raf 
itself was shown to be mutated at a surprisingly high frequency in human cancer, 
particularly the V600E constitutively active mutant (Davies, H. et al. 2002). Binding o f 
Raf to Ras-GTP activates Raf, which resides at the start o f the first serine/threonine kinase 
cascade to be characterised, the Raf-MEK-ERK signalling pathway, the architecture o f  
which was subsequently found to be common among several kinase cascades. Activated 
ERK (a serine/threonine kinase) phosphorylates and activates several protein targets, 
notably, Elk, c-Myc, c-Jun and c-Fos transcription factors. Phosphorylation of c-Myc by 
ERK promotes heterodimerisation with Max, a c-Myc co-activator. c-Myc-Max dimers act 
as transcription factors activating several genes including the cyclin D genes (Grandori, C. 
et al. 2000). c-Myc also forms heterodimers with Miz and c-Myc-Miz dimers are 
transcriptional repressors which downregulate the transcription of several cell cycle 
inhibitor genes (Seoane, J. et al. 2002), which are discussed further in section 1.3.4.3.
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c-Jun and c-Fos heterodimerise forming the activating protein-1 (AP-1) family 
o f transcription factors, which promote cell cycle entry via direct transactivation o f the 
cyclin D1 gene (CCND1) and downregulation o f  p53, p21c,pl and p l6 INK4A, which are 
negative regulators o f the cell cycle (Shaulian, E. and Karin, M. 2002). Thus, activation o f 
the Raf-MEK-ERK pathway by Ras results in a strong drive towards proliferation.
A short time after the discovery o f  Raf as an effector o f Ras, Julian Downward 
and co-workers demonstrated that Ras-GTP also bound the catalytic subunit (pi 10) o f 
PI3K (Rodriguez-Viciana, P. et al. 1994), which confirmed a previous report by Sjolander 
et al. (Sjolander, A. et al. 1991). PI3K activation by growth factor-receptors was already 
appreciated at that time, but the placement o f Ras-GTP upstream o f PI3K activation was a 
significant step forward in the understanding o f Ras biology. PI3K kinases are 
heterodimeric lipid kinases consisting of the catalytic subunit and a regulatory subunit 
(p85), which catalyse the addition o f inorganic phosphate groups to the 3’ position o f the 
inositol ring o f phosphatidylinositol-(4,5)-diphosphate (PIP2 ) on the inner leaflet o f the 
plasma membrane, forming PI(3,4,5)P3 (PIP3). PIP3 forms a binding site at the membrane 
for proteins containing a Pleckstrin homology (PH) domain, and in general, binding o f PH 
domain-containing proteins to PIP3 co-localises them with upstream regulators and 
downstream effectors which may also be localised to the plasma membrane. One o f the 
key downstream effectors o f PI3K is Akt (aka PKB), a serine/threonine kinase which is 
recruited to the plasma membrane by binding o f its PH domain to PIP3 and is subsequently 
phosphorylated by phosphoinositide-dependent kinase-1 (PDK1) on Ser 308, and by 
mammalian target o f  rapamycin (mTOR) on Ser 473. Akt thus phosphorylated is active, 
and is an important mediator o f anti-apoptotic signalling (Osaki, M. et al. 2004). The 
substrates o f Akt are many, and include phosphorylation and inactivation o f forkhead box- 
O (FOXO) transcription factors, the pro-apoptotic protein Bad; and also activation o f IKKof 
(a positive regulator o f NF-kB signalling). Akt also contributes to cell cycle progression by 
direct phosphorylation o f p21Cipl and p27Kipl, which results in sequestration o f these 
proteins in the cytosol (Zhou, B.P. et al. 2001). Akt also phosphorylates and deactivates 
TSC2, an inhibitor o f  mTOR. mTOR plays an important role in regulating protein 
synthesis (and therefore growth), primarily by activating p70S6K, which in turn 
phosphorylates ribosomal protein S6 , which accelerates ribosomal protein translation. 
mTOR also releases eIF4E from inhibition by 4-EBP allowing eIF4E to bind to the 7- 
methyl-guanosine cap o f mRNAs and guide them to the ribosome for translation.
Opposing the activation o f Akt (and other PH domain-containing proteins) by 
PI3K are the lipid phosphatases phosphatase and tensin homologue (PTEN) and SHIP.
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These phosphatases catalyse the removal o f either the 3’ or 5’ phosphate group 
from PIP3 respectively, rendering these lipids unattractive for PH domain-binding. Loss o f 
PTEN is a common occurrence in a variety o f cancers, most notoriously in colon 
carcinomas (Goel, A. et al. 2004), resulting in hyperactive PI3K signalling and aberrant 
Akt activation.
Just a few months after Julian Downward identified PI3K as a Ras effector, a 
third Ras effector was identified, RalGDS (Hofer, F. et al. 1994), a member o f a family o f 
proteins which are now known to be GEFs for RalA and RalB. Ral proteins are small 
GTPases belonging to the Ras superfamily and follow some o f the conventions o f the other 
family members. Activated Ral (bound to GTP) plays an important role in vesicular 
trafficking mainly through its role in organising the Exocyst complex by acting directly on 
the Sec5 and Exo84 subunits o f  this hetero-octameric complex. Exocyst then orchestrates 
sorting o f proteins into exocytic vesicles and their tethering to the appropriate plasma 
membrane domains prior to excretion. In addition, Ral proteins also positively regulate 
ZONAB, a Y-box transcription factor which can promote cell cycle progression through 
transactivation o f the genes encoding cyclin D1 and PCNA (Bodemann, B.O. and White, 
M.A. 2008). In a haematopoietic context, Ral proteins have been shown to mediate the 
block in granulocytic differentiation o f murine haematopoietic cells by mutant Ras 
(Omidvar, N. et al. 2006).
Raf, PI3K and RalGDS represent the principal molecules o f the three best 
characterised Ras effector pathways, activation o f  which results in a consensus drive 
towards increased proliferation and cell survival. Additional effectors o f Ras have been 
identified, such as TIAM1 and phospholipase C-e (PLCe), which intersect with pathways 
and signalling proteins o f  interest. TIAM1 is activated by Ras-GTP and is a GEF for the 
Rac subfamily o f small GTPases. Rac proteins play important roles in cytoskeletal 
remodelling, and are therefore important components in the mechanisms that govern cell 
motility, phagocytosis and other cellular functions where movement o f the cell is required. 
Rac proteins also form a key component o f several NOX family oxidase complexes which 
are responsible for generating superoxide in phagocytic and non-phagocytic cells (Rygiel, 
T.P. et al. 2008) (section 1.4.2.1 and Figure 1.5; also see Figure 1.11).
PLCe is a relatively recent addition to the phospholipase C family, and 
represents a fourth class o f phospholipase enzymes (in addition to PLCp, PLOy and PLC8 ). 
In addition to the PLC domains (which bind the G a subunit o f activated G-proteins), PLCe 
contains two C-terminal Ras-binding domains (RA1 and RA2) similar to that found in Raf
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proteins. Indeed, Ras-GTP has been demonstrated to bind to and activate PLCe in an RA 
domain-dependent manner (Kelley, G.G. et a l 2001).
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RalGDS TIAM1
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PKC
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Figure 1.5 Important Ras effector pathways
Activation of Ras initiates several signalling pathways, including the Raf-MEK-ERK 
serine/threonine kinase cascade, the PI3K-Akt pathway, the Ral pathway and the Rac 
pathways via activation of the Rho-family GEF TIAM1. In addition, Ras activates PKC by 
activating PLCe. PLCe generates IP3, which in turn increases cytosolic Ca2+, and also 
generates DAG which binds to and activates PKC. Details o f these pathways are discussed 
in the text.
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Upon activation, PLCe (like other PLC family members) cleaves PIP3 forming 
membrane-bound DAG and releasing IP3 into the cytosol. IP3 binds to and opens IP3-gated 
Ca2+ channels in the ER, releasing Ca2+ into the cytoplasm. Meanwhile, DAG forms a 
membrane binding site for classical and novel members o f the PKC family o f serine 
threonine kinases. PKCs are a subfamily o f the AGC (protein kinase A, protein kinase G, 
protein kinase G) family o f serine/threonine kinases, o f which PDK1 is also a member.
In a haematopoietic context, PKC plays an important role in haematopoietic 
development, and mediates developmental dysregulation o f human CD34+ haematopoietic 
cells caused by activated Ras (Peam, L. et al. 2007). In addition, PKC phosphorylates 
p47phox during activation and assembly o f the NAPDH oxidase complex (section 1.4.2.1).
1.3.4 Ra s  a n d  Cell Cycle  r eg ula tio n
1.3.4.1 Overview o f  the cell cycle
The formation o f two daughter cells from one parent cell (cell division) is the 
basis for propagation o f all life on earth. In order to generate two progeny (which may be 
functionally distinct from each other and from the parent cell), a cell must accurately and 
completely replicate its genome, as well as manufacture sufficient proteins and lipids to 
construct all o f  the membranes and organelles o f the daughter cells. In mammalian 
development, early embryonic cells can accomplish this task within 2-3 hours (leaving 
time for DNA replication and mitosis only), whereas in general, adult dividing cells (e.g. 
HSCs) can complete one round o f division in approximately 24 hours, dependent on 
suitable growth conditions (Artus, J. et al. 2006).
Cell division as the mechanism o f cell propagation was first proposed by Rudolf 
Virchow and colleagues during the 19th century, as an alternative to the prevailing theories 
o f the day (Mazzarello, P. 1999). However, the mechanisms by which this process was 
orchestrated remained a mystery, until Tim Hunt and colleagues identified a family o f 
proteins in sea urchin cells that were cyclically synthesized and degraded during cell 
division in an oscillating manner (Evans, T. et al. 1983). These proteins were named 
cyclins, and subsequent work has shown that cyclins play a critical role in directing the 
ordered sequence o f events that constitute cell division, referred to as the cell cycle. The 
cell cycle is divided into four consecutive phases; Gap 1 (Gi), Synthesis (S), Gap 2 (G2) 
and Mitosis (M) (Figure 1.6). During the Gi and G2 phases, the dividing cells pause while 
proteins and organelles are synthesised for the subsequent phase; this pause also provides 
time for the cell to respond to intracellular or extracellular signals which can regulate cell
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cycle progression. During S phase, the entire genome o f the cell is replicated. Finally, 
during M phase, the genome is packaged into condensed mitotic chromosomes and the 
chromosomes are segregated equally to the far comers o f the parent cell. Subsequently, the 
parent cell physically cleaves in two, yielding two daughter cells in a process called 
cytokinesis. Some embryonic cells are an exception to this scheme in that they have 
shortened or absent Gi and G2 phases, and this lack o f Gi and G2 phases means that the 
cells have little or no time to grow (acquire mass) between divisions and hence become 
smaller with each round o f the cycle (a requirement during early embryogenesis). Cells 
may also occupy a fifth state, Go, which is a quiescent state occupied by cells that are not 
currently participating in the cell cycle. Cells in Go include those that have temporarily 
ceased dividing, as well as those which have terminally differentiated and permanently lost 
the ability to enter the cell cycle.
1.3.4.2 Cyclin-dependent kinases drive the cell cycle
During the cell cycle, the transition from one phase to the next is driven by the 
activities o f  a family o f serine/threonine kinases called cyclin dependent kinases (CDKs). 
Native CDKs are inactive due to an auto inhibitory domain which occludes the active site 
o f the catalytic domain (Alberts, B. et al. 2002). However, binding o f the CDK to its 
partner cyclin induces a conformational change in the CDK subunit which partially reveals 
the kinase domain. Thus the cyclical synthesis and degradation o f cyclin proteins observed 
by Tim Hunt and colleagues causes a corresponding cyclical oscillation in CDK kinase 
activity. As shown in Figure 1.6, several different CDK-cyclin complexes exist, and each 
phase o f the cell cycle is overseen by a single (or group o f closely related) CDK-cyclin 
complex(es); CDK4/6-cyclin D activity is required to progress through the restriction point 
in late Gi (section 1.3.4.4), CDK2-cyclin E/A are required for initiation o f and transit 
through S phase respectively, and finally CDK1-cyclin B is required for initiation of 
mitosis in M phase.
The kinase activity o f each o f these CDK-cyclin complexes waxes and wanes in 
a regular fashion; each driving the transcription o f genes required to progress to the next 
phase. For example, CDK2-cyclin E initiates replication complex firing at the start o f S 
phase by phosphorylating and inactivating cell division cycle- 6  protein, which restrains 
DNA replication by restraining the assembled origin o f replication complexes (Borlado, 
L.R. and Mendez, J. 2008).
37
CHAPTER 1: INTRODUCTION
CDK1- 
cyclin B
CDK4/6- 
cyclin D
CDK2- 
cyclin E
CDK2- 
cyclin A
Figure 1.6 Phases of the mammalian cell cycle and timepoints over which each CDK- 
cyclin complex operates
The cell cycle consists of four phases which occur in the following sequence: Gi, S, G2 , M. 
Cells may exit the cell cycle temporarily or permanently and occupy a non-cycling state 
called Go. Proliferative signals originating from Ras signal transduction pathways result in 
the upregulation of cyclin D, which promotes the activity of CDK4 and CDK6 . CDK4 and 
CDK6  phosphorylate and inactivate the restriction point (R) enforcers, the retinoblastoma 
(Rb) proteins, allowing progression through the restriction point. Initiation of S phase is 
driven by CDK2 combined with cyclin E, exit from S phase and progression through G2 is 
driven by CDK2-cyclin A. Finally, initiation of mitosis is driven by CDK1-cyclin B. The 
targeted destruction of cyclins is orchestrated by ubiquitin ligases which ensure that the 
activity of CDKs is controlled appropriately throughout the cycle.
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During G2 , CDK2-cyclin A and CDK1 -cyclin B phosphorylate nuclear lamins 
other constituents o f the nuclear cytoskeleton in preparation for disintegration o f the 
nuclear envelope prior to mitosis in M phase (Kill, I.R  and Hutchison, C.J. 1995).
Cyclins serve not only to activate CDKs but also direct their partner CDK to 
particular substrates. Additional substrate specificity may be imposed on CDKs due to 
phase-specific expression o f some substrates; therefore, the substrates which can be 
phosphorylated by a given CDK depends on which stage o f the cell cycle has been 
reached. Despite a degree o f CDK substrate specificity, there is evidence o f some 
functional redundancy among certain CDK-cyclin complexes, for example, mice lacking 
all three cyclin D1 genes die during gestation due to severe anaemia, suggesting that D- 
type cyclins are critical for HSCs to complete the cell cycle. However organogenesis in 
these embryos is generally normal, suggesting other CDKs (particularly CDK2-cyclin E) 
can perform the functions o f CDK4 and CDK6  (Kozar, K. et al. 2004).
1.3.4.3 Positive and negative regulation o f  CDKs
The activity o f CDKs is subject to several levels o f regulation (Figure 1.7; black 
detail). CDK-cyclin complexes are regulated by both activating and inhibitory 
phosphorylation events. Although CDKs are partially activated by binding a partner cyclin, 
CDKs require phosphorylation on a conserved threonine residue by CDK-activating kinase 
(CAK) to fully expose the kinase domain and reach full activity (Drapkin, R. et al. 1996).
Weel kinase acts as a negative regulator o f CDKs by phosphorylating two 
conserved residues near the catalytic domain which blocks kinase activity (Alberts, B. et 
al. 2002). These inhibitory phosphate groups can be removed by phosphatases o f the cdc25 
family (cdc25A and cdc25B). Thus CAK, Weel and cdc25 phosphatase form a CDK 
regulatory network which can be influenced by intracellular and extracellular stimuli.
In addition to regulation by phosphorylation, the availability and assembly o f 
CDKs and cyclins is controlled by the expression o f several cyclin-dependent kinase 
inhibitor (CDKI) proteins; the best understood o f these are the inhibitor o f kinase-4 (INK4) 
and p21cipl families. The INK4 protein family (p l6 INK4A, p l5 INK4B, p l 8 1NK4C and p l9 INK4D) 
share varying copy numbers o f a conserved protein-binding domain called an ankyrin 
repeat, via which members o f the INK4 family bind to CDK4 and CDK6  specifically. 
When bound to members o f the INK4 family, CDK4 and CDK6  are unable to bind to their 
partner D-type cyclins and therefore remain inactive. The p21c,pl (aka p21Wafl) family 
includes p21c,pl, p27Kipl and p57Kip2. This protein family is structurally distinct from the 
INK4 family, and contain N-terminal binding sites for both CDKs and cyclins.
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Figure 1.7 Cell cycle regulation networks and cell cycle checkpoints
The activities o f CDKs are governed by a host of positive and negative regulators which 
transmit information about the environment and conditions to the cell cycle machinery.
Not shown on the diagram is CAK, which phosphorylates and promotes activation of all 
CDKs. Several mechanisms exist to halt the cell cycle in the event of cell stress or 
damaged/unreplicated DNA. These mechanisms enforce a halt on the cell cycle at several 
defined points, known as cell cycle checkpoints. Unfavourable conditions or stress stimuli 
activate stress kinases such as p38MAPK, which engage INK4 proteins and reinforce the 
Restriction point. Later on in the cell cycle, DNA damage or unreplicated DNA can lead to 
activation of p53 and p21Cipl and inhibition of cdc25. Finally, improperly aligned 
chromosomes during mitosis send negative signals which halt M phase until the 
chromosomes are mounted on the spindle.
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Unlike INK4 proteins (which bind to CDK monomers), the p21c,pl family 
proteins main mode o f action is to bind to and inhibit assembled CDK2-cyclin E/A 
complexes. X-ray crystallography reveals that p21Cipl inhibits CDK-cyclin complexes by 
invading the substrate binding site blocking ATP and protein substrate binding (Russo,
A. A. etal. 1996).
Positive feedback loops are a common feature o f the mechanisms that govern 
cell cycle progression, and they ensure that movement from one phase to the next is an 
‘all-or-nothing event’; for example, weak or partial activation o f the mechanisms that 
perform DNA replication would have severe consequences for the dividing cell’s progeny. 
The mechanism o f CDKI degradation that is critical to cell cycle progression provides a 
good example o f this. p27Klpl is ubiquitinylated and targeted for destruction by an SCF 
(Skpl/Cullin/F-box protein) ubiquitin ligase complex, containing Skp2 and Cskl subunits 
(Bashir, T. et al. 2004). Importantly, only p27Kipl that is phosphorylated is recognised by 
the SCF complex, and this phosphorylation is performed either by Akt, or importantly, 
CDK2. Thus, once CDK2-cyclin E complexes have accumulated beyond a critical point, 
CDK2 can promote the degradation o f its own inhibitor p27Kipl, releasing more CDK2 
which inactivates more p27Kjpl and so on. This rapidly leads to activation o f all the CDK2- 
cyclin complexes in the cell, leading to robust substrate phosphorylation and cell cycle 
progression. Such positive feedback loops occur frequently throughout the cell cycle, for 
example, a similar scheme exists for CDKI-cyclin B and its inhibitor Weel kinase. When 
CDKI activity rises above a threshold, CDKI can phosphorylate and inhibit Weel and 
rapidly accumulate to promote entry into M phase.
It is o f  interest to note that, in addition to binding to and inhibiting CDK2-cyclin 
E/A complexes, p21Cipl is also capable o f binding to CDK4/6-cyclin D complexes, though 
(paradoxically) this does not inhibit CDK4/6 kinase activity (Sherr, C.J. and Roberts, J.M. 
1999; Ortega, S. et al. 2002). Rather, p21c,pl family proteins actually promote assembly o f 
CDK4/6-cyclin D complexes by virtue o f their ability to bind both o f the subunits and 
bring them into close proximity without inhibiting them, indeed active CDK4/6-cyclin D 
complexes precipitated from several mammalian cell types have been shown to also 
containp21c,pl orp27Kipl (McConnell, B.B. etal. 1999; Parry, D. etal. 1999). p21c,pl- 
assisted assembly o f CDK4/6-cyclin D complexes has been demonstrated in vitro and in 
vivo (LaBaer, J. et al. 1997). In addition, mice deficient for p21c,pl or p27Kipl (or both) 
showed decreased CDK4-cyclin D1 complex formation (Cheng, M. et al. 1999). This 
feature o f p21Cipl family proteins has the consequence that when cyclin D expression 
increases (e.g. upon Ras activation and downstream transcription o f the cyclin D1 gene),
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active CDK4/6-cyclin D complexes assemble, and sequester p21Cipl family proteins, which 
relieves CDK2-cyclin E inhibition and allows CDK2 to function. In the absence o f  cyclin 
D, p21Clpl proteins bind CDK2-cyclin E/A complexes, preventing CDK2 substrate 
phosphorylation and therefore the cell cycle is halted.
1.3.4.4 Cell cycle checkpoints
It is o f  critical importance that the cell cycle proceeds only under the correct 
conditions and at the correct time, indeed, failure to properly control cell cycle entry and 
progression is a major feature o f malignant cells. As discussed in section 1.3.4.3, there are 
several regulatory mechanisms operating in mammalian cells to control the activity o f 
CDKs and it is the active engagement o f negative regulators o f the cell cycle (in response 
to stress stimuli, DNA damage, incomplete or improper DNA replication, incomplete 
alignment o f chromosomes during mitosis or a simple lack o f proliferative signals) that 
constitutes these cell cycle checkpoints (Figure 1.7; red detail). When the proteins that 
enforce these checkpoints are activated, cell cycle progression halts. In the case o f DNA 
damage, this pause provides time for DNA damage to be repaired, and if the damage is 
irreparable, the apoptotic machinery can be activated. Alternatively, the Gi checkpoint 
(also known as the restriction point, R) restricts cell cycle progression in the absence of 
growth factor stimuli. The restriction point is particularly important because it represents 
the point o f no return, beyond which the cell becomes completely committed to completing 
a round o f cell division (provided that one o f the other checkpoints is not triggered).
The restriction point was named by Arthur Pardee in 1974, who noted that there 
was a time point during late Gi beyond which mammalian cells in culture would proceed 
to undergo cell division even if growth factors were removed. In contrast, withdrawal o f 
factors before this time point (i.e. within 3-4 hours o f completing mitosis) would result in 
growth arrest. Importantly, Pardee observed that this restriction point was defective in 
cancer cell lines (Pardee, A.B. 1974). It is now known that the restriction point checkpoint 
is enforced by the actions o f retinoblastoma (Rb) family proteins, which, in their active 
state, bind to and inhibit E2 promoter-binding factor (E2F) family transcription factors, 
preventing E2F target gene transcription by sequestering E2F and also acting as an active 
repressor o f E2F gene targets. Phosphorylation o f Rb proteins by CDK4/6-cyclin D 
complexes releases E2F from Rb and allows E2F to transactivate a large number o f genes 
including the gene encoding cyclin E, which arbitrates the GI to S transition. In the 
absence o f cyclin D expression, CDK4/6 are inactive, and the Rb checkpoint remains in 
force. Similarly, stress stimuli (such as UV exposure or exposure to excessive ROS) can
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activate p38MAPK and FOXOs, which upregulate p l 6 INK4A and p21c,pl family proteins 
respectively. These in turn inhibit CDK4/6 and CDK2-cyclin E/A complexes respectively, 
and again the Rb checkpoint is enforced.
So how is the restriction point overcome, e.g. upon receipt o f extracellular 
growth signals? The answer to this is partly through the activation o f Ras proteins. As 
mentioned in section 1.3.3.2, Ras proteins transduce signals from a variety o f growth- 
factor receptors and initiate several signalling cascades, many o f  which converge on 
regulators o f the cell cycle. Importantly, Ras activates AP-1 and c-Myc transcription 
factors which directly bind to the cyclin D 1 promoter and initiate cyclin D 1 gene 
transcription (Massague, J. 2004). Myc also directly represses CDKIs such as p21Cipl and 
p 15 INK4B (Wanzel, M. et al. 2003). Additionally, via the PI3K pathway, Ras further 
suppresses CDKI expression by Akt-mediated suppression o f FOXOs. When combined, 
these signals (driven by Ras) strongly promote activity o f  CDK4/6 leading to inactivation 
o f Rb and progression through the restriction point. DNA damage also leads to the 
enforcement o f a distinct checkpoint, which can activate at any point during cell cycle 
progression (Zhou, B.B. and Elledge, S.J. 2000). In general, the DNA damage-responsive 
kinases ATM and ATR are responsible for transmitting an alarm signal from damaged 
DNA to several downstream substrates. These include Chkl, which phosphorylates and 
inhibits cdc25 phosphatase, halting CDKI activity. In addition ATM phosphorylates and 
inhibits HDM2 (in humans) which is a ubiquitin ligase for the tumour suppressor p53 (aka 
TP53). Concurrent phosphorylation o f p53 itself by ATM leads to stabilisation and 
homodimerisation o f p53, which acts as a transcription factor to promote p21Clpl resulting 
in inhibition o f CDK2-cyclin E/A complexes, and can also co-ordinate apoptosis if DNA 
damage cannot be repaired (a process that is also orchestrated by ATM kinase). ATR 
kinase appears to arbitrate a similar but distinct checkpoint to ATM, specifically; ATR 
enforces the DNA-replication checkpoint that prevents exit from S phase in the presence o f 
unreplicated DNA or stalled replication forks. Finally, the G2 checkpoint prevents entry 
into M phase in the presence o f unresolved DNA damage, while the spindle checkpoints 
delays the start o f anaphase (chromosome segregation) until all o f the chromosomes are 
correctly aligned (Kastan, M.B. and Bartek, J. 2004). The importance of these checkpoints 
for controlling unwanted cell growth is underscored by the fact that many o f the key 
proteins that enforce these checkpoints are dysregulated in cancer. Loss o f heterozygosity 
in persons with a hereditary Rb mutation can lead to retinal carcinoma (Benedict, W.F. et 
al. 1983), whilst inactivating mutations o f p53 are amongst the most common mutations 
detected in human cancers (Levesque, A.A. and Eastman, A. 2007).
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1.3.5 Ras  o n c o g en es  in Ca n c er  a n d  AML
1.3.5.1 Ras oncogenes in human cancer
The close association o f aberrantly activated Ras proteins and cancer dates back 
to their discovery as the viral gene product responsible for transformation o f rat cells by 
murine sarcoma viruses (section 1.3.2). During these early years o f Ras research, activated 
Ras proteins were increasingly implicated in non-viral tumour formation. For example 
activated forms o f H-Ras, K-Ras and N-Ras were detected in murine tumours induced by 
topically applied carcinogens (Balmain, A. and Pragnell, I.B. 1983; Guerrero, I. etal. 
1984a) or by y-radiation (Guerrero, I. et al. 1984b); and activated H-Ras was detected in 
human bladder cancers and lung cancers (Der, C.J. et a l 1982; Parada, L.F. et al. 1982; 
Santos, E. et al. 1982). Indeed, according to recent estimates, activated Ras proteins are 
detectable in -30%  o f all human cancers (Schubbert, S. et al. 2007). In addition, mutations 
in particular Ras iso forms appear to be associated with particular cancers. K-Ras is the 
most commonly activated Ras iso form detected in a wide variety o f human cancers 
including ovarian, lung and liver cancer, but shows a particularly high incidence in 
pancreatic cancers (60% o f cases examined) and cancers o f the intestinal tract (33%). 
Activated N-Ras is prevalent in melanoma (18%) and myeloid malignancies (14%), while 
activated H-Ras is detected in cancers o f the thyroid and cervix, and 11% o f bladder 
cancers. The majority o f mutations involving activated Ras in these cancers target codons 
12, 13 and 61, the so-called ‘hot-spots’, named due to the ability o f mutations in these 
codons to promote accumulation o f Ras-GTP (section 1.3.2).
1.3.5.2 Ras oncogenes in AML
Ras oncogenes are detected in 20-40% o f AML cases (Gougopoulou, D.M. et al. 
1996) and at similar frequency in cases o f MDS, a pre-leukaemic condition (Bartram, C.R.
1992). Numerous in vitro, in vivo and clinical studies have been performed with the aim to 
understand the role o f Ras mutations in the pathogenesis o f AML.
The two-hit hypothesis o f leukaemogenesis proposes that when mutations which 
promote proliferation (e.g. activating mutations o f class I genes) co-localise with mutations 
in genes required for differentiation (class II genes), the result is generation o f a clone with 
leukaemic potential (section 1.2.1.2). Ras oncogenes primarily act as pro-proliferative class 
I genes, since they activate a variety o f pathways that lead to proliferation o f 
haematopoietic cells (section 1.3.3.2). However, in vitro studies indicate that Ras 
activation can also impact on haematopoietic differentiation and development, since
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activated Ras can bias human CD34+ cell development towards the myelomonocytic 
lineage at the expense o f erythroid and granulocytic cells in a PKC dependent manner 
(Darley, R.L. et al. 1997; Peam, L. et a l 2007). This may be in part due to the fact that 
PKC can phosphorylate the critical haematopoietic transcription factor CEBPa (a class II 
gene), leading to an alteration in CEBPa function (Behre, G. et al. 2002). Increased 
proliferation and a bias towards myeloid differentiation has also been demonstrated in 
murine haematopoietic cells expressing activated N-Ras (Shen, S.W. et al. 2004), and 
these same cells also show increased engraftment and a similar differentiation bias in vivo 
when transplanted in NOD-SCID recipient mice, however, these NOD-SCID mice did not 
develop any overt disease (although the mice were only observed for six weeks post­
transplant). Similar results were obtained from longer duration in vivo studies performed 
by Rassool and colleagues (Rassool, F.V. et al. 2007; Omidvar, N. et al. 2007). These 
studies showed that activated N-Ras expressed under the control o f the Myeloid-related 
protein- 8  (Mrp8) promoter (i.e. restricted to the haematopoietic system) induced a mild- 
myeloproliferative effect, but did not induce overt disease during a six month observation 
period. Strikingly, when mice bearing activated N-Ras mutations were crossed with mice 
overexpressing BCL-2 (generating an N-Ras/BCL-2 double transgenic), a reproducible 
disease developed with features similar to MDS or pre-AML. These data provide strong 
evidence for a two-hit model o f  leukaemogenesis in the mouse. Using a retroviral vector to 
overexpress activated Ras in murine haematopoietic progenitors, Parikh et al. have shown 
that overexpression o f oncogenic Ras alone is capable o f inducing a fatal 
myeloproliferative disease in mice, though H-Ras, N-Ras and K-Ras showed a 
progressively longer disease latency and features that ranged from closely resembling 
acute leukaemia (H-Ras) to those more closely resembling CMML (K-Ras) (Parikh, C. et 
al. 2007). In addition, it has been shown that knock-in o f oncogenic K-RasG12D into the 
normal murine K-Ras locus leads to a fatal myeloproliferative disease with 100% 
penetrance (Braun, B.S .e ta l. 2004).
Extensive efforts have also been made to establish whether in vitro and in vivo 
findings are consistent with clinical observations. These clinical studies aim to understand 
how Ras mutations contribute to leukaemogenesis in human patients, whether Ras 
mutations have any prognostic significance in AML, and whether there is evidence to 
support case for therapeutic targeting o f Ras.
Although 20-40% o f AML patients show mutations in one (or more) o f their Ras 
genes, N-Ras mutations are the most common, followed by K-Ras. In contrast, although H- 
Ras mutations in AML patients have been reported (Imamura, N. et al. 1993), they are
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generally rare in AML. There is some evidence that Ras mutations are over-represented in 
monocytic M4 and M5 AML FAB subtypes (consistent with in vitro studies showing that 
activated Ras drives monocytic differentiation) and also that Ras mutations are associated 
with particular cytogenetic subgroups, however, a consistent conclusion o f the majority o f 
clinical studies is that Ras mutations in AML do not significantly influence prognosis 
(Bowen, D.T. et a l 2005; Bacher, U. e ta l  2006; Stirewalt, D.L. e ta l  2001; Kiyoi, H. et 
a l 1999). Some studies have concluded that Ras mutations confer an improvement in 
prognosis, but this is either limited to younger patients (less than 60 years old) (Illmer, T. 
et a l  2005) or the effect was mild (Neubauer, A. et a l 1994).
So what role does Ras play in AML development and AML maintenance? This 
is a difficult question to answer, but there is evidence that Ras does contribute to the 
conversion o f MDS (considered to be a pre-AML state) to full blown AML; in a study o f 
paired samples from 70 patients with MDS who later progressed to AML, 11 acquired 
mutations in N-Ras when progressing to AML while only one patient lost an N-Ras 
mutation (Shih, L.Y. et a l 2004). In addition, when considering only MDS patients, 
another study showed that although Ras mutations were relatively rare (9% of MDS 
patients examined), these mutations were associated with a significantly decreased survival 
and increased potential to progress to AML (Paquette, R.L. et a l 1993). The strong 
correlation between acquisition o f Ras mutations and progression from MDS to AML is 
consistent with the notion that Ras mutations may compliment existing mutations in MDS 
patients leading to completion of the multi-hit model. Indeed, in AML it has been shown 
that activating mutations in Ras (or mutations that activate the Ras pathway) preferentially 
co-exist in cells with mutations in core binding factor (CBF) proteins (Goemans, B.F. et a l 
2005), while there is a significant negative correlation o f mutations in two or more 
iso forms o f Ras or mutations that affect similar pathways (Bowen, D.T. et a l 2005). 
However, whereas in MDS there is evidence for a net gain of Ras mutations upon 
progression to AML, once AML has been established there appears to be less need to 
maintain N-Ras mutations. In particular, one study examined N-Ras mutation status in 
paired samples from patients at diagnosis and also at first relapse. Amongst those patients 
whose N-Ras mutation status changed between these two time points, three patients lost an 
N-Ras mutation upon relapse compared to two patients that gained an N-Ras mutation 
upon relapse (Nakano, Y. et a l  1999). Indeed, it has been shown that there is significant 
heterogeneity in the distribution o f Ras mutations within a typical AML cell population; 
with only a minority o f  AML blasts from Ras mutation-positive patients harbouring 
detectable Ras mutations (Bowen, D.T. et a l 2005). Taken together it appears that
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activated Ras does indeed appear to act primarily as a class I gene mutation in human MDS 
and AML development (similar to in vivo findings) and may also serve this same role in 
established AML, however it appears that in overt AML the role o f Ras as a class I gene is 
interchangeable with other mutations which have a similar effect. One possible role for Ras 
proteins is to contribute to early disease progression by inducing DNA damage. Indeed, in 
vivo models have shown a strong correlation with mutant N-Ras and ROS stress in the 
murine haematopoietic system (Rassool, F.V. et a l 2007), and Ras is also over-represented 
in a subgroup patients with deficient metabolism o f toxic intermediates (Bowen, D.T. et a l 
2003). In summary, the role o f activated Ras in AML pathogenesis remains ambiguous, 
though its high frequency in AML continues to suggest that it does confer a clonal 
advantage.
1.4  R e a c t i v e  o x y g e n  s p e c i e s
1.4.1 In t r o d u c t io n  to reactive  o x y g en  species
ROS are a heterogeneous group o f inorganic molecules and free radicals derived 
from diatomic oxygen, with a wide spectrum o f lifespan and reactivity. In physiological 
systems, ROS formation begins with the univalent reduction o f oxygen to produce 
superoxide radicals, which lie at the hub o f a variety o f potential chemical reactions 
(Figure 1.8). (To avoid confusion, note that unpaired electrons themselves are often 
erroneously referred to as radicals. However, the term radical (or free radical) refers to the 
molecule or atom that bears an unpaired electron). For example, superoxide can dismutate 
(either spontaneously or by catalysis) to form hydrogen peroxide (H2 O2), a membrane 
permeable mildly pro-oxidant molecule. Further processing o f H2 O2 either through Fenton 
chemistry (section 1.4 .1.1) or by enzymatic catalysis can lead to formation o f several 
highly oxidising derivatives including hydroxyl radicals and hypochlorous acid (HOC1). 
These molecules’ high reactivity results in short half lives and broader target specificity 
than superoxide or H2O2 . For example hydroxyl radicals can abstract protons from the 
DNA backbone causing double strand breaks or can react with guanine residues forming 8 - 
oxo-guanine (an important mechanism in GC to AT transversion in the genetic code). 
Hydroxyl radicals can also initiate lipid peroxidation chain reactions leading to disruption 
o f lipid bilayers (Valko, M. et a l 2007). The toxic properties o f ROS derived from H2O2 
are harnessed by phagocytes o f the immune system, which bombard pathogens with ROS 
during phagocytosis. However, since ROS are equally toxic to host tissues, ROS 
production must be tightly regulated to avoid unwanted oxidative damage. Finally,
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although reactive nitrogen species (RNS) are not a focus of this study, they can be formed 
via reaction of nitric oxide and superoxide. The proximal RNS generated in peroxynitrite, 
which can participate in several subsequent reactions to generate various oxides of nitrogen 
(NxOy) (Valko, M. et al. 2007). Indeed, S-nitrosylation of protein cysteine residues has 
been reported to alter protein function (Leslie, N.R. 2006), although the full physiological 
significance of these modifications are unknown.
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Figure 1.8 Physiological ROS and RNS generation
Superoxide radicals are the proximal ROS from which several other ROS are derived. 
Superoxide radicals are generated mainly by the mitochondrial electron transport chain 
(ETC) and professional oxidases e.g. NOX family oxidases such as Phox (containing 
NOX2). The archetypal professional oxidase is Phox, which is expressed at high levels in 
phagocytic cells. Under normal conditions, superoxide dismutase (SOD) promotes 
conversion of superoxide to H2O2 . In an inflammatory environment, myeloperoxidase 
(MPO) activity can result in HOC1 production and also generation of singlet oxygen, which 
may be further processed into ozone in the presence of immunoglobulins. Hydroxyl 
radicals may be formed in the presence of Fe3+ ions by Fenton chemical reactions. In 
addition, superoxide may react with nitric oxide (NO) generated by nitric oxide synthase 
(NOS) to form reactive nitrogen species such as peroxynitrite. Adapted from J.D Lambeth, 
2004 (Lambeth, J.D. 2004).
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Studies demonstrating that ROS may play an important role in proliferative 
signalling (Sundaresan, M. etal. 1995; Irani, K. e ta l  1997; Sattler, M. e ta l  1999), 
together with the discovery o f  non-phagocytic homologues o f the Phox oxidase catalytic 
subunit (NOX2 aka gp91phox) in non-phagocytic cells (Lambeth, J.D. 2004), raised the 
possibility that the physiological roles o f ROS production may not be restricted to immune 
defence. Since then, the capacity o f H2O2 in particular to act as a signalling molecule has 
been well established (section 1.4.3.2). Furthermore, it appears that increased ROS 
production is a feature o f many cancers; and there is evidence o f increased oxidative stress 
in some myeloid neoplasias (e.g. MDS). Increased ROS production by cancers may serve 
to drive proliferation and also contribute to genetic instability (section 1.4.4.3), however, 
the high levels o f  oxidative stress in cancer cells may sensitise them to further oxidative 
stress induced by cytotoxic drugs, presenting a possible therapeutic strategy for their 
elimination (section 1.4.4.4).
1.4.1.1 Generation o f  hydroxyl radicals from  H 2O2 - an introduction to Fenton
chemistry
In 1894, Henry Fenton described the oxidation o f tartaric acid by H2 O2 in the 
presence o f ferrous iron (II) salts to generate a coloured product dihydroxymaleic acid 
(Fenton, H.J.H. 1894). Later Haber and Weiss suggested that hydroxyl radicals were 
formed during this reaction and could be responsible for the oxidation o f tartaric acid 
described by Fenton (Haber, F. and Weiss, J. 1932). Since then, the detailed mechanism of 
the ‘Fenton reaction’ has undergone several revisions (Koppenol, W.H. 2001), however it
94 -is agreed that during the reaction, Fe ions catalyse the degradation o f H2O2 forming 
several products, including hydroxyl radicals.
Due the variety o f side reactions that can occur in the Fenton system, it has been 
argued that it is more appropriate to speak o f Fenton chemistry rather than the Fenton 
reaction. While a detailed discussion o f Fenton chemistry is beyond the scope o f this study, 
for the purposes o f this thesis it is pertinent to mention that both physiological forms of 
iron (Fe2+ and Fe3+) can initiate Fenton chemical reactions in the presence o f endogenously 
generated H2O2 resulting in hydroxyl radical generation (Figure 1.9).
One the one hand, Fe2+ ions can react with H2O2 yielding a hydroxyl radical, 
hydroxide ion and Fe3+ (Reaction 1). Reaction o f Fe3+ with superoxide regenerates Fe2+ 
(Reaction 2), thus iron plays a catalytic role in this reaction. Superoxide radicals for 
Reaction 2 may be generated in physiological systems by the mitochondrial ETC, NOX 
oxidases or by reaction o f hydroxyl radicals with H2 O2 (Reactions 3 and 4).
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Clearly, in the presence of mitochondrial or NOX-derived superoxide 
generation, Fe3+ ions may also initiate this cycle starting with Reaction 2 generating Fe2+, 
which can participate in Reaction 1. Iron in the body is usually sequestered within storage 
proteins (such as ferritin) or bound in the haem moiety of haemoglobin in erythrocytes. 
However, since the action of iron in this reaction is catalytic, even trace amounts of free 
iron can lead to considerable hydroxyl radical generation. The mechanism of hydroxyl 
radical generation described here may also serve to partly explain the oxidative stress 
observed in patients with iron-overload (Lehmann, D. J. et al. 2006).
Fe2+ + H2O2 — Fe3+ + OH + ‘OH (1)
Fe3+ + O2 ' ' —* Fe2+ + O2 (2)
Superoxide in reaction (2) can be generated by mitochondrial ETC, NOX 
oxidases, or during reactions (3) and (4) below.
‘OH + H2 0 2 H20  + H 02‘ (3)
H 0 2* ^ 0 2-  + H+ (4)
Cupric ions may participate in a similar catalytic cycle resulting in hydroxyl 
radical formation.
Cu2+ + O2"  -*  Cu+ + O2 (5)
Cu' + H2 0 2 — Cu2+ + OH + 'OH (6)
Figure 1.9 Generation of hydroxyl radicals by Fenton chemistry
Red text indicates the reduced form of the metal ions, green indicates the oxidised form of 
the metal ions. Blue text highlights the points at which hydroxyl radicals are formed during 
the reactions.
Cupric ions (Cu2+) participate in similar reactions to those described for iron 
resulting in hydroxyl radical formation from H20 2 as shown in Reactions 5 and 6  
(Simpson, J.A. et al. 1988). As with iron, free Cu2+ ions are rarely detected under
^  I
physiological conditions; however, Cu is often bound in proteins and also to DNA 
(Lewis, C.D. and Laemmli, U.K. 1982; Sagripanti, J.L. etal. 1991), which may localise 
hydroxyl radical production at these sites in the presence of superoxide and H2 0 2.
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1.4.2 ROS HOMEOSTASIS
1.4.2.1 Production o f  ROS by NOX-family oxidases
The NOX family o f  NADPH oxidases are a family o f membrane-bound proteins 
with homology to NOX2, the founding member o f the family originally identified as the 
catalytic subunit o f Phox, the source o f ROS production in activated phagocytes (Bedard, 
K. and Krause, K.H. 2007). The enzymes o f this family (NOX1-5 and DUOX1-2) catalyse 
the transfer o f high energy electrons from NADPH to diatomic oxygen, generating 
superoxide, which leads to generation o f H2 O2 and several other reactive species as 
described in section 1.4.1.
NOX2 is a membrane-spanning protein with six transmembrane ohelices. The 
extracellular domains o f  the protein are highly glycosylated, and the intracellular portion 
contains domains for binding NADPH and FAD. NOX2 forms a mutually stabilising 
heterodimer with p22phox; forming a unit known as cytochrome bsss (Sumimoto, H. 2008). 
However, cytochrome bsss is not functional (i.e. cannot generate superoxide) until 
assembled in a complex with at least 4 other regulatory proteins, p67phox (aka NCF4), 
p47phox (aka NCF1), p40phox and the small GTPase Rac. In a resting phagocyte, p47phox 
exists in a folded, inactive conformation (by virtue o f association o f its autoinhibitory 
domain with its lipid-binding PX domain) and is bound to p67phox and p40phox in a 
heterotrimeric complex in the cytosol. Likewise, Rac is bound in an inactive state to Rho- 
GDI which promotes GTP release from Rac preventing its activation (Figure 1.10).
Upon phagocyte stimulation, p47phox is phosphorylated by conventional PKC 
iso forms (Zhao, X. et al. 2005). This causes unfolding o f the p47phox protein revealing the 
PX domain, which binds 3’-phosphosphorylated inositol lipids (such as those generated by 
activated PI3K). The interaction o f the PX domains with membrane lipids localises the 
entire heterotrimeric complex to the lipid membrane. Subsequently bis-SH3 domains on 
p47phox bind tandem pro line-rich regions on p22phox, promoting association o f the 
heterotrimeric complex with cytochrome b558. This p47phox-led model o f membrane 
localisation o f the heterotrimeric complex is based on evidence that p67phox and p40phox fail 
to associate with cytochrome b558 in the absence o f p47phox (Dusi, S. et al. 1996; Heyworth, 
P.G. et al. 1991). The close association o f p67phox with cytochrome bsss allows 
juxtaposition o f the p67phox activation domain with critical residues on NOX2 resulting in 
formation o f the catalytic core necessary for electron transfer.
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Figure 1.10 Components of Phox oxidase in the inactive state
In resting cells, the heterotrimeric complex consisting of Phox regulatory subunits p47phox, 
p67phox and p40phox resides in the cytosol. Under these conditions, p47phox exists in a folded 
state, with its bis-SH3 domains bound to the C-terminal AIR domain. p47phox is bound to 
p67phox via an interaction with the C-terminal PR domain or p47phox and the C-terminal 
SH3 domain of p67phox. p40phox is bound to the PB1 domain of p67phox. Similarly, the small 
GTPase Rac is bound to its inhibitor, Rho-GDI, which promotes dissociation of guanosine 
triphosphate (GTP) from Rac in favour of guanosine diphosphate (GDP) binding. Dotted 
lines indicate physical associations between domains. AIR = autoinhibitory region, PX = 
Phox homology domain, PB1 = Phox and Beml domain, SH3 = Src-homology-3 domain, 
PR = Proline rich region (aka PRR), TPR = tricodecapeptide repeat, AD = Activation 
domain. Adapted from J. Lambeth, 2004 (Lambeth, J.D. 2004).
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Meanwhile, activation o f Rac promotes dissociation from its negative regulator 
(Rho-GDI); and Rac-GTP also binds to the nascent oxidase complex, which is thought to 
further enhance the binding o f p67phox to NOX2 (DeCoursey, T.E. and Ligeti, E. 2005). 
There is also evidence that phosphorylation o f p67phox (possibly by PKC 5 (Zhao, X. et a l 
2005)) is required for complex activation.
The assembled complex (Phox aka NADPH oxidase) is thought to then catalyse 
the transfer o f high energy electrons from cytosolic NADPH (via an FAD molecule and 
two haem centres) to diatomic oxygen (Bedard, K. and Krause, K.H. 2007) (Figure 1.11). 
Deactivation o f  the complex is thought to be rapid; and therefore sustained NADPH 
oxidase activation may be dependent on a dynamic equilibrium o f inactivation and 
reactivation o f complexes. However, the mechanisms that govern the deactivation o f the 
complex are not fully understood (DeCoursey, T.E. and Ligeti, E. 2005).
Evidence that non-phagocytic cells could produce superoxide, even in 
individuals deficient for NOX2 (Emmendorffer, A. et a l 1993) prompted the search for 
additional members o f the NOX family. To date, there are 7 members o f the NOX family, 
NOX1-5 and the dual oxidases DUOX1 and 2; all show homology with NOX2, though 
there are distinct differences in their tissue distribution, regulation and domain structure. 
Some o f these differences are summarised in Table 1.2. For example, the first homologue 
o f NOX2 to be discovered, NOX1 (Suh, Y.A. et a l 1999), also forms a complex with 
p22phox and, similar to NOX 2, appears to also require binding o f regulatory subunits 
(NOXA1 and NOXOl) in order to be activated. However, NOX1 forms a complex with 
these regulatory proteins in resting cells, and (unlike NOX2) is constitutively active.
NOX1 activity can be augmented by PKC activity, and has also been noted to mediate 
ROS production driven by mutant Ras in some contexts (Mitsushita, J. et a l 2004; 
Shinohara, M. et a l 2007).
The inclusion o f an EF-hand (calcium-binding) domain in NOX5, and DUOX1 
and 2 suggest that these oxidases may be regulated by Ca2+ without the need for interaction 
with any regulatory subunits, including p22phox (Sumimoto, H. 2008). Indeed it has been 
shown that calcium ionophores activate NOX5 (Banfi, B. et a l 2001). DUOX oxidases 
have an additional domain not observed in the rest o f the NOX family, with homology to 
the peroxidase domain o f myeloperoxidase which suggests their ability to immediately 
catabolise the H2 O2 that they generate to form more reactive species such as hydroxyl 
radicals (Lambeth, J.D. 2004).
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Figure 1.11 The activated Phox complex
As described in the text, activation of the Phox complex in phagocytic cells requires 
association of the heterotrimeric complex ofp47phox, p67phox and p40phox, with cytochrome 
b558 in the phagosome membrane. This is initiated by phosphorylation of p47phox which 
promotes unfolding. Unfolding of p47phox allows localisation of the heterotrimeric complex 
to the lipid membrane by the association of the PX domain of p47phox with PIP3 (generated 
by PI3K). Subsequently, p47phox and p67phox associate with p22phox and NOX2 respectively, 
via the bis-SH3 domain or activation domain (AD). For the complex to be fully functional, 
Rac must also be bound. In the absence of binding to Rho-GDI, Rac binds GTP, and 
subsequently binds to p67phox via the TPR domains and also interacts with NOX2. The 
assembled, activated complex generates superoxide by transferring electrons from 
cytosolic NAPDH across the lipid membrane to diatomic oxygen. P = phosphate groups.
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Enzyme Highest level of expression Known regulatory factors
gP91phox
(NOX2)
Phagocytes P47phox, P67phox, p40phox and 
Rac
NOX1 Inducible: colon and vascular smooth 
muscle
NOXOl, NOXA1 and
p2 2 phox
NOX3 Fetal kidney Unknown
NOX4 Kidney, osteoclasts, ovary and eye; 
widespread
Unknown
NOX5 Spleen, sperm, mammary glands and 
cerebrum
Calcium
DUOX1 Thyroid, cerebellum and lungs Calcium, DUOXA1
DUOX2 Thyroid, colon, pancreatic islets and 
prostate
Calcium, DUOXA2
Table 1.2 NOX family oxidases: Tissue distribution and known regulatory factors
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DUOX enzymes are highly expressed in the thyroid, and are required for thyroid 
hormone production; inherited inactivating mutations in DUOX enzymes lead to 
congenital hypothyroidism (Moreno, J.C. et a l 2002). Finally, NOX3 and NOX4 (like 
NOX1, 2) also require association with p22phox, though their requirement for additional 
subunits for activity is unclear.
The discovery o f  non-phagocytic NOX family members raises questions about 
the physiological roles o f these proteins. For example, almost all o f  the NOX family 
members (together with most o f the regulatory proteins) have been shown to be expressed 
in human haematopoietic progenitor cells (CD34+ cells) (Piccoli, C. et al. 2007), but their 
roles in these cells are not understood. While some roles o f these oxidases have been 
elucidated (e.g. DUOX enzymes), their existence suggests that ROS production may also 
be important in physiological processes other than fighting infection. Indeed, as discussed 
in section 1.4.3.2, several roles for ROS in normal cell signalling have been proposed.
1.4.2.2 Production o f  ROS by the mitochondria
The mitochondrial electron transport chain is a multi-component sequence o f 
redox-coupled proteins expressed in the internal mitochondrial membrane (Figure 1.12, 
(Genova, M.L. et a l  2003). The proximal complex in the mitochondrial electron transport 
chain is the NADH dehydrogenase complex (aka complex I), which accepts high-energy 
electrons from NADH, an important electron donor molecule generated from pyruvate and 
fatty acids during the citric acid cycle which occurs in the mitochondrial matrix. The 
electrons are passed from NADH to complex I via a flavin mononucleotide (FMN) 
cofactor, and are circulated within complex I before being transferred to coenzyme Q (CoQ 
aka ubiquinone). Note that CoQ can also accept electrons from FADH2 or from succinate 
dehydrogenase (aka complex II). Electrons carried by CoQ are subsequently transferred (in 
this order) to the cytochrome b-ci complex (aka cytochrome c reductase or complex III), 
cytochrome c, and finally cytochrome oxidase (aka complex IV), where the electron 
transport chain terminates with the tetravalent reduction o f diatomic oxygen to two 
molecules o f water. During electron transport, the high energy o f the electrons is harnessed 
to drive active transport o f  protons into the intermembrane space forming a pH and voltage 
gradient across the inner mitochondrial membrane. The resulting proton electrochemical 
gradient induces a protein motive force which drives the re-entry o f protons to the matrix 
via ATP synthases; these protein complexes harness the energy o f protons travelling back 
into the matrix to generate ATP from ADP and inorganic phosphate. Thus, the electron 
transport chain is a critical source o f ATP generation for the cell. Studies using isolated
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mitochondria show that these organelles can generate superoxide and H2O2 in vitro 
(Murphy, M.P. 2009). In simple terms, these studies suggest that production o f superoxide 
occurs when electrons Teak’ from the transport chain before reaching the terminus.
In isolated mitochondria, electron leakage is proposed to occur primarily at 
complex I, by two main mechanisms. Which mechanism operates depends on whether the 
isolated mitochondria are operating under conditions where NADH/NAD+ ratio is high and 
ATP production is low (known as mode 1); or conditions where the C0 Q/C0 QH2 ratio is 
low, membrane potential is high and ATP production is low (known as mode 2).
The first scenario (mode 1) results in a build up o f completely reduced FMN in 
complex I, which can univalently reduce oxygen to superoxide. In the second scenario 
(mode 2) the high membrane potential encourages electrons to travel from C0 QH2 back 
through complex I in a process called reverse electron transport (RET). During RET, 
electrons travel back to the FMN site in complex I, where oxygen can accept these 
electrons forming superoxide (Chance, B. and Ho Hunger, G. 1961). Under conditions o f 
hypoxia, superoxide may also be generated at complex III (discussed in section 1.4.4.2).
Intracellular probes sensitive for mitochondrial superoxide suggest that this 
process may also occur in vivo (Mukhopadhyay, P. et al. 2007; Zimmerman, M.C. et al. 
2007), indeed, mitochondrial ROS are proposed to participate in intracellular signalling 
(Balaban, R.S. et al. 2005). However, mitochondria in vivo are thought to primarily operate 
in mode 3 (high ATP production rate), and critically, the mechanisms by which ROS are 
produced by mitochondria operating in mode 3 are not understood due to the difficulties o f 
carrying out detailed mechanistic studies on mitochondria within intact cells.
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Figure 1.12 Sources of superoxide in the mitochondrial electron transport chain
The mitochondrial electron transport chain transfers high energy electrons from NADH to 
oxygen, resulting in the reduction of oxygen to water. During electron transport, the energy 
of the electrons is harnessed to transport protons (H+) across the inner mitochondrial 
membrane into the intermembrane space. The resulting pH and electrochemical gradient 
creates an electromotive force which drives the return of H+ back in to the matrix via ATP 
synthases, which generate ATP from ADP and inorganic phosphate. Dotted red arrow 
indicates path followed by electrons within the electron transport chain. Red stars indicate 
known locations of superoxide production within the electron transport chain. NADH = 
nicotinamide adenine dinucleotide, Q = ubiquinone, Cyt c = cytochrome c.
58
CHAPTER 1: INTRODUCTION
1.4.2.3 Destruction o f  ROS by endogenous mechanisms
The potential toxicity o f ROS (especially hydroxyl radicals) demands that ROS 
production is controlled and promptly terminated when not required. Accordingly, several 
ROS catabolising enzymes and molecules are expressed by virtually all human cells for the 
purpose o f eliminating ROS. SOD is the main line o f defence against superoxide 
production, while there are several mechanisms which eliminate H2O2 , such as catalase, 
the peroxiredoxins (Prxs) and the glutathione (GSH) system.
There are three forms o f SOD expressed in mammals, cytosolic SOD1 (aka 
Cu/Zn SOD), mitochondrial SOD2 (aka Mn SOD) and extracellular SOD3 (a variant 
Cu/Zn SOD). SOD catalyses the dismutation o f superoxide forming H2 O2 , and the 
mechanism starts with the univalent reduction o f a co-ordinated active site metal ion
2 +  3~b(either Cu or Mn in Cu/Zn or Mn SOD enzymes respectively) by a first superoxide 
radical, liberating diatomic oxygen. A second molecule o f superoxide is then itself reduced 
by the metal ion regenerating the enzyme and releasing a peroxide anion, which abstracts 
protons from the solvent to form H2 O2 (Bannister, J.V. et al. 1987). Since superoxide can 
react with NO to form peroxynitrite, SOD plays an important role in suppressing 
peroxynitrite formation by converting superoxide to H2O2 . However, H2O2 breakdown can 
subsequently lead to hydroxyl radical formation (section 1.4.1.1), hence there are several 
endogenous mechanisms in place which subsequently detoxify H2 O2 generated by SOD, 
discussed below. Catalase may also serve to scavenge H2O2 generated as by products o f 
cyclo-oxygenases and lipoxygenases (Kim, C. et al. 2008).
Catalase catalyses the conversion o f H2 O2 to oxygen and water. The mechanism 
occurs by oxidation o f a first H2 O2 molecule by a haem moiety in the active site o f 
catalase, forming a cationic oxy-haem porphyrin radical and liberating a water molecule. 
This oxy-haem intermediate then oxidises a second H2O2 molecule regenerating the haem 
and releasing a second water molecule and diatomic oxygen (Kirkman, H.N. and Gaetani, 
G.F. 2007). Catalase protein in human cells is usually restricted to peroxisomes, which are 
sub-cytoplasmic organelles harbouring enzymes with a variety o f functions including 
oxidation o f long-chain fatty acids which contributes to the production o f acetyl-Co A, the 
priming molecule for the Krebs cycle (Alberts, B. et al. 2002). During this oxidation 
process, H2 O2 is produced, therefore catalase regulates H2O2 accumulation. Catalase may 
also degrade H2 O2 that diffuses into the peroxisome from the cytosol, however, H2 O2 
destruction in the cytosol is mainly achieved through the actions o f glutathione peroxidase 
as part o f the GSH system.
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GSH is a tripeptide containing a central cysteine residue, and is the most 
abundant thiol in mammalian cells, with reported concentrations approaching 10 mM 
(Komatsu, H. and Obata, F. 2003). GSH represents the main cellular defence against H2 O2 , 
oxidising H2O2 to form H2O and O2 in a reaction catalysed by glutathione peroxidase. 
During this reaction, oxidised GSH dimers (GSSG) are generated. GSH is regenerated 
from GSSG dimers by glutathione reductase in a process which uses electrons donated by 
NADPH or NADH (Ballatori, N. et a l 2009).
Finally, Prxs provide an additional line o f defence against H2O2 (Rhee, S.G. et 
al. 2005). Prxs are homodimeric cytosolic proteins containing a conserved N-terminal 
cysteine residue (Cys51 in mammalian Prx) which is sensitive to oxidation by H2O2 . There 
are three main Prx families (2-cys, atypical 2-cis and 1-cis Prxs); however the functions o f 
the 2-cys Prxs are the best understood. All 4 members o f the 2-cys Prx family (Prx I-IV) 
contain an additional cysteine residue (e.g. Cysl72 in Prx I), which (in the homodimeric 
complex) is located in close proximity to Cys51 o f the companion subunit. H2O2 reacts 
with Cys51 forming sulphenic acid (-SOH), which reacts with the sulphydryl group (-SH) 
o f Cysl72 forming an intermolecular disulphide bond (S-S). Oxidised 2-cys Prxs are 
subsequently reduced by thioredoxin and can participate in further reactions with H2 O2 , 
thus 2-cys Prxs catalytically destroy H2O2 . The mechanisms which drive the cycles o f Prx 
oxidation and regeneration are key processes which are able to regenerate oxidised 
cysteine residues in several other protein targets.
Figure 1.13 summarises two o f the major antioxidant systems (in addition to 
catalase) which are capable o f destroying H2O2 , the GSH and the Prx systems.
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Figure 1.13 Endogenous pathways which degrade H2O2
H2O2 is destroyed by several endogneous mechanisms, including the actions of glutathione 
peroxidase, and the peroxiredoxins (Prxs). (A) Glutathione peroxidase catalyses the 
reduction of H2O2 to water using GSH as an electron donor. Oxidised GSH (GSSG) is 
regenerated by glutathione reductase using electrons donated from NADPH. (B) Green 
arrows indicate oxidation and reduction cycle of 2-Cys Prxs. Reduced Prx (I), is oxidised 
forming a sulphenic acid group at Cys51 (II), and subsequently a disulphide bond forms 
(III) between Cys51 and Cysl72 (in Prxl). The disulphide bond is reduced by thioredoxin 
(Trx) which is oxidised in the process. Trx is subsequently regenerated by thioredoxin 
reductase (Trx Red.). Alternatively, Prx sulphenic acid groups (II) can be further oxidised 
by H2 O2 forming a sulphinic acid group (IV). Sulphinic acid groups in Prxl can be 
resolved by sulphiredoxin (Srx), in a reaction which requires ATP. Native Prxl is then 
regenerated by the actions of Trx Red.
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1.4.3 Ph y sio lo g ic a l  roles of ROS
1.4.3.1 Role o f  ROS production in the innate immune response
Early experiments that involved mixing bacterial preparations with dog 
leukocytes noted a sharp increase in oxygen consumption, which was attributed to an 
increase in respiration during phagocytosis (Baldridge, C.W. and Gerard, R.W. 1932). The 
notion that a ‘respiratory burst’ occurred during phagocytosis persisted until 1961, when it 
was noted that the increased oxygen consumption o f phagocytes during phagocytosis was 
accompanied by the increased ability to oxidise formate, suggestive o f oxidant production. 
Importantly, addition o f pyruvate (which stimulates respiration) did not augment formate 
oxidation, suggesting that a cellular process distinct from respiration was responsible for 
oxidant production (Iyer, G.Y.N. et al. 1961). Subsequent studies identified superoxide as 
the proximal molecule formed during phagocytosis, leading to H2O2 production formation 
via a dismutation reaction (Babior, B.M. et al. 1973). Eventually, the gene encoding the 
catalytic subunit (NOX2 aka gp91phox) o f the protein complex responsible for superoxide 
production (Phox aka NADPH oxidase) was cloned (Teahan, C. et al. 1987; Royer-Pokora,
B. etal. 1986).
The importance o f NAPDH oxidase activity during immune responses is 
highlighted in patients with chronic granulomatous disease (CGD) first described by 
Berendes et al. in 1957 (Berendes, H. et al. 1957). These patients suffer from several 
symptoms, including a strong predisposition to pyrogenic bacterial infections. Early studies 
noted that the phagocytes o f CGD patients could phagocytose pathogens as normal, but 
superoxide production was absent (Quie, P.G. et al. 1967). Later, CGD patients were 
shown to be either deficient for cytochrome bsss (the NOX2-p22phox complex) (Segal,
A.W. et al. 1978) or deficient for some regulatory subunits o f NADPH oxidase e.g. p47phox 
and p67phox (Nunoi, H. et al. 1988; Volpp, B.D. etal. 1988).
NADPH oxidase is activated in endocytic compartments (phagosomes) formed 
during phagocytosis; and the subsequent ROS production contributes to the death o f 
pathogens by two main mechanisms. The most predictable o f these is by inflicting direct 
oxidative damage on pathogen biomolecules causing loss o f homeostasis, for example, 
HOC1 (derived from H2O2 by phagocyte myeloperoxidase) has been shown to initiate lipid 
peroxidation reactions, which disrupt the microbial membrane (Nauseef, W.M. 2001).
More recently, ROS has been implicated in microbial killing by an indirect mechanism. 
Superoxide production inside the phagosome leads to an increased intra-phagosomal pH 
(primarily due to consumption o f protons during dismutation (Segal, A.W. et al. 1981))
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and increased intra-phagosomal negative charge (Schrenzel, J. et al. 1998) - because 
superoxide is negatively charged. These effects are compensated for by influx of H+ and 
K+ ions through phagosomal ion channels; and it has been proposed that the increased 
ionic strength o f the phagosome interior leads to elution o f cationic proteases from the 
microbial cell-walls and membranes resulting in accelerated degradation of the pathogen 
(Reeves, E.P. et al. 2002).
1.4.3.2 ROS signalling
As described above (section 1.4), ROS have the potential to react with and 
disrupt proteins, DNA and lipids, and these properties may be employed in the destruction 
o f pathogens by phagocytes. However, during the late 1980s and early 1990s, it was 
observed that exogenous superoxide and H2O2 appeared able to promote cell proliferation 
in a variety o f contexts. In 1988, Shibanuma et al. proposed that superoxide may act as a 
signalling ‘messenger’ after observing that superoxide drove increased proliferation o f 
human U397 histocytic leukaemia cells (Shibanuma, M. et al. 1988). Superoxide and 
H2 C>2 -driven proliferation was also observed in hamster BHK-21 and rat 208F fibroblast 
cell lines (Burdon, R.H. and Rice-Evans, C. 1989; Burdon, R.H. etal. 1989; Burdon, R.H. 
et al. 1990); and shortly afterwards in human fibroblasts and amnion cells (Murrell, G.A. et 
al. 1990; Ikebuchi, Y. et al. 1991). Subsequent studies demonstrated that ROS production 
may be an important feature o f growth factor receptor signalling; PDGF (Sundaresan, M. 
et al. 1995), EGF (Bae, Y.S. etal. 1997) and angiotensin II (Ushio-Fukai, M. et al. 1999) 
signals were all shown to be dependent on downstream H2O2 production. In addition, 
several haematopoietic growth factor signals were shown to promote ROS production and 
cell cycle progression, and blockade o f growth factor-induced ROS suppressed 
proliferation and viability (Sattler, M. et al. 1999). However, the mechanisms by which 
ROS promote proliferation are not well understood. Superoxide is also known to have the 
potential to act as a signalling molecule, indeed a seminal study by Irani et al. concluded 
that mitogenic signalling driven by mutant Ras was mediated by superoxide production 
(although H2O2 may also have contributed, (Irani, K. et al. 1997)). Furthermore, in 
prokaryotes, the superoxide-sensitive transcription factor SoxR contains iron-sulphur redox 
centres which react directly with superoxide leading to transcription o f antioxidant genes 
(D'Autreaux, B. and Toledano, M.B. 2007). However, in mammalian cell systems, most 
studies have focused on H2O2 as a potential ROS signalling molecule (Rhee, S.G. 2006). 
Indeed, in addition to proliferation, H2 O2 signalling has been implicated in diverse
63
CHAPTER 1: INTRODUCTION
processes including cell-transformation, senescence, apoptosis and extracellular matrix 
remodelling (Finkel, T. 2003; Lambeth, J.D. 2004).
H2O2 has peculiar properties which set it apart from other ROS and allow its 
function as a second messenger. First, it is uncharged and membrane permeable, allowing 
it access to all subcellular compartments. Second, its relatively low reactivity (c.f. hydroxyl 
radicals, HOC1) result in a narrower range o f target molecules than more reactive ROS, and 
third, a conserved antioxidant network exists that can efficiently eliminate H2 O2 , enabling 
prompt H2O2 signal termination (section 1.4.2.3). The best understood mechanism o f  H2O2 
signalling is via the reversible inactivation o f phosphatases. Protein tyrosine phosphatases 
(e.g. PTP1B) are well established targets for inactivation by H2O2 (den Hertog, J. et al. 
2005), but recent evidence suggests that the lipid phosphatase PTEN (Rhee, S.G. et a l 
2005) and some serine/threonine phosphatases e.g. protein phosphatase-1 and 2A (PP1 and 
PP2A) may also be susceptible to oxidative inactivation (O'Loghlen, A. et al. 2003; Rao, 
R.K. and Clayton, L.W. 2002).
Protein tyrosine phosphatases (PTPs) such as PTP1B contain a conserved 
cysteine residue within a characteristic H is-Cys-X -X -G ly-X -X -A rg-Ser/Thr motif in the 
active site. The invariant positively-charged arginine in this motif reduces the pKa o f the 
cysteine sulphydryl group to ~4 (free cysteine sulphydryl pKa ~8.5), and thus stabilises the 
thiolate form (Cys-S) o f the sulphydryl group. Therefore, at physiological pH the active 
site cysteine o f such phosphatases exists primarily in the ‘activated’ thiolate form, which is 
required for the catalytic mechanism to proceed (Jackson, M.D. and Denu, J.M. 2001). In 
contrast, most other cellular cysteine residues will preferentially exist in the less reactive 
sulphydryl form. Critically, H2O2 does not efficiently react with non-activated sulphydryl 
groups, making the thiolate in the active site o f tyrosine phosphatases (such as PTP1B) a 
preferential target o f H2O2 . The reaction o f the thiolate with H2O2 involves oxidation to 
form sulphenic acid (Cys-SOH) and water (essentially the same mechanism as described 
for Prx oxidation; section 1.4.2.3). Since the thiolate group is required for the catalytic 
mechanism to occur, the phosphatase is rendered inactive. Recent evidence suggests that 
sulphenic acid rapidly forms a cyclic sulphenamide by reacting with a nearby nitrogen 
atom in the peptide backbone (den Hertog, J. et al. 2005). Unlike the sulphenic acid, this 
cyclic sulphenamide group is resistant to further oxidation by H2O2 , and can be restored to 
the thiolate by S-glutathionylation (essentially forming a disulphide bond with GSH) and 
reduction by glutaredoxin (Gallogly, M.M. and Mieyal, J.J. 2007). This final step in the 
cycle regenerates the phosphatase activity, satisfying the condition that the effects o f H2O2 
must be reversible in order to be considered a credible second messenger.
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The lipid phosphatase PTEN is also known to be regulated by H2O2 . PTEN is a 
lipid phosphatase which catalyses the removal o f 3 ’-phospho groups from PI(3 ,4 ,5 )P3 and 
therefore directly antagonises PI3K activity (which catalyses the formation o f PI(3 ,4 ,5 )P3 
from PI(4 ,5 )P2 (Fresno Vara, J.A. et a l 2004). PTEN is reversibly inhibited by H2 O2 via a 
mechanism similar to that observed in PTPs. The catalytic Cysl24 residue o f PTEN is 
primarily in the thiolate form (similar the catalytic Cys o f PTPs), due to being surrounded 
by three positively charged amino acids. Therefore Cys 124 is susceptible to reaction with 
H2 O2 to form sulphenic acid, in a similar manner to PTPs. However, rather than forming a 
cyclic sulphenamide, sulphenic acid formed at Cys 124 reacts with nearby Cys71 to form 
an intramolecular disulphide bridge. Like the cyclic sulphenamide formed in PTPs, this 
protects PTEN from further oxidation by H2O2 . Oxidised PTEN is regenerated by 
thioredoxin (Lee, S.R. et a l 2002).
It is only very recently, that some serine/threonine phosphatases such as PP1 and 
PP2A have been included in the list o f redox-sensitive phosphatases. These phosphatases 
do not rely on an activated cysteine residue in the active site for their catalytic activity; 
however, recent studies have demonstrated that oxidation o f cysteine residues located 
outside the active site may have an allosteric effect on phosphatase activity. For example, 
PP2A has recently been shown to undergo oxidative cross-linking o f vicinal cysteine 
residues in a Cys-X-X-Cys motif located in the catalytic subunit (PP2Ac), which led to the 
ablation o f phosphatase function (Foley, T.D. et a l 2007). Furthermore, PP2A (and PP5) 
expressed in rat PC 12 cells and human SH-SY5Y neuroblastoma cells were shown to be 
inhibited by H2O2 treatment (Chen, L. et a l 2009).
Importantly, temporary inhibition o f phosphatases may be necessary for signal 
transduction. In general terms, phosphatase activities are several orders o f magnitude 
greater than kinase activities (Reth, M. 2002), suggesting that kinase activation alone may 
be insufficient to overcome the negative influence o f phosphatases. Rather, a combination 
o f increased kinase activity and phosphatase inhibition may be required for signal 
transduction. Indeed, studies using in the RAW264.7 macrophage cell line showed that 
upon stimulation with TP A and LPS (which activate NOX2), ~10% o f PTEN molecules 
were reversibly inactivated and PTEN inactivation contributed to the activation o f Akt in 
these cells (Leslie, N.R. et a l 2003). A similar but less pronounced inhibition o f PTEN 
was observed in PDGF-stimulated NIH 3T3 cells overexpressing NOX1 (Kwon, J. et a l 
2004). Importantly, oxidative inhibition o f PTEN is suppressed by antioxidants with an 
associated decreased in Akt activation (Rhee, S.G. et a l 2005). The putative role o f H2O2 
in transient inhibition o f  phosphatases for successful signal transduction could therefore
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explain why EGF, PDGF and (angiotensin II) Ang II signals are blocked by H2O2 
scavengers (Bae, Y.S. et a l 1997; Sundaresan, M. et a l 1995; Ushio-Fukai, M. et a l 
1999).
While kinases tend to receive the majority o f credit for signal transduction, it is 
clear that phosphatases are obviously vital for correct signalling and mutations in several 
phosphatases are associated with human disease. For example, activating mutations in 
SHP2 are common in JMML (Tefferi, A. and Gilliland, D.G. 2007), while constitutive 
activation o f PTP1B contributes to breast cancer progression (Tonks, N.K. and 
Muthuswamy, S.K. 2007). In contrast, inactivation o f PP2A is implicated in myeloid 
leukaemia (Neviani, P. et a l 2005; Fukukawa, C. et a l 2005). The fact that phosphatase 
dysregulation contributes to human cancers suggest that oxidative regulation of 
phosphatases by H2O2 could potentially play a role in human disease. However, the 
downstream effects o f oxidative phosphatase inhibition are likely to be highly complex and 
difficult to predict, due to the broad target specificity o f some phosphatases (e.g. PP2A), 
together with evidence that some phosphatases themselves may also be regulated by 
phosphorylation (den Hertog, J. et a l 2008).
Oxidative modification o f cysteine residues is not restricted to phosphatases. O f 
relevance to the present study, it has been shown that Ras proteins contain a conserved 
cysteine residue (Cys 118) which is located near the GTP-binding region. Cell-free studies 
have shown that oxidative modification o f this residue (either by NO or H2O2) in H-Ras 
causes increased GTP-loading (Lander, H.M. et a l 1995). Moreover, oxidative 
modification o f Ras Cysl 18 has been reported in a cardiac cell model, and interestingly, 
ablation o f oxidative modification by targeted mutation o f Cysl 18 blocks Ras activation 
and prevents downstream activation o f ERK (Pimentel, D.R. et a l 2006). This cysteine 
residue is conserved in Ras subfamily proteins (Barbacid, M. 1987), and it is possible that 
this mode o f redox regulation applies to several Ras proteins in a similar fashion. Ras 
signalling promotes NOX oxidase activation (section 1.3.3.2), therefore a positive 
feedback loop may exist which sustains Ras activity via ROS production.
Finally, it is important to note that H2O2 is membrane permeable, meaning it has 
the potential to leave the vicinity o f the generating cell and influence the biochemistry o f 
nearby neighbours in a paracrine fashion, which has implications for ROS signalling in 
densely cellular regions such as the bone marrow.
In summary, ROS (in particular H2O2) appears to influence a variety o f cell 
processes, mainly through its ability to reversibly oxidise cysteine residues within proteins.
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1.4.3.3 Role o f  ROS in self-renewal o f  HSCs
Several studies have concluded that ROS negatively regulate self renewal in 
HSCs. Therefore, to maintain HSC function, physiological ROS generation in HSCs (either 
by mitochondria or oxidases) must be controlled. One particular study showed that FoxO 
transcription factors are a functionally redundant family o f  proteins which form one 
mechanism for controlling physiological ROS production in murine HSCs (Tothova, Z. et 
a l 2007). Under normal conditions FoxO proteins are phosphorylated by Akt which 
promotes nuclear export and subsequent degradation. However, in the absence o f  Akt 
signalling or in the presence o f a cellular stress, FoxOs accumulate in the nucleus where 
they promote the transcription o f genes which promote senescence (e.g. p27Kipl, p21Cipl, 
cyclin G and cyclin B), apoptosis (Bim, Fas ligand and TRAIL) and also genes encoding 
catalase and SOD which catabolise endogenous ROS. Conditional deletion o f a single 
FoxO gene in adult mice showed no overt phenotype; however, simultaneous deletion o f 
FoxOl, Fox03, and Fox04 resulted in increased intracellular ROS, increased HSC 
proliferation and a reduction in long-term repopulating capacity (indicating a decreased 
capacity for self-renewal). Importantly, the effects o f FoxO deletion were rescued by 
introduction o f NAC into the diet o f FoxO deficient mice, strongly suggesting that tight 
regulation o f physiological ROS is a major function o f FoxOs in maintaining quiescence 
and self-renewal o f normal HSCs. Similarly, ATM-deficient mice also show excessive 
ROS production in HSCs, and show similar increase in HSC proliferation and decrease in 
self-renewal capacity to FoxO deficient mice. Again, antioxidant treatment can restore 
HSC function in ATM-deficient mice (Ito, K. et a l 2004). Furthermore excessive ROS 
production by HSCs promotes HSC migration away from the bone marrow niche 
(Hosokawa, K. et a l 2007).
To summarise, it appears that in normal HSCs, ROS rapidly accumulates in the 
absence o f antioxidant mechanisms, and this ROS accumulation forces HSCs into cell 
cycle and lineage commitment, at the expense o f self-renewal capacity. As a result, 
increased ROS production in the HSC population eventually leads to bone marrow failure. 
However, the exact mechanisms whereby ROS induce these effects are currently unknown.
1.4.4 ROS IN PATHOLOGY
In addition to playing important roles in normal physiology (section 1.4.3.3), 
ROS have long been known to play a role in some pathological conditions. Prolonged and 
excessive ROS production establishes a state known as oxidative stress manifested by
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increased DNA oxidation, lipid peroxidation, and an increase in intracellular pH (Finkel, T. 
2003). Chronic oxidative stress plays a key role in the development and maintenance of 
conditions such as atherosclerosis, rheumatoid arthritis and amyotrophic lateral sclerosis (a 
form o f motor neurone disease) (Droge, W. 2002). ROS are also thought to contribute to 
carcinogenesis.
1.4.4.1 ROS contributes to a variety o f  chronic disorders
Atherosclerosis is a chronic inflammatory condition, characterised by the 
formation o f thickened, hardened regions in the vascular wall (atherosclerotic lesions). 
Migration o f T-cells and monocytes into the vascular wall is an early step in the 
development o f these lesions. Subsequently these lesions are exacerbated by activation o f 
resident monocytes by binding to oxidised low-density lipoprotein (LDL). Monocyte 
activation leads to increased ROS and inflammatory mediator production (Alexander,
R.W. 1995). Underscoring the role o f ROS in this process, atherosclerosis-prone mice 
deficient for vitamin E (an endogenous antioxidant molecule) showed worsened 
atherosclerotic lesion formation. Moreover, vascular function was improved by treating 
atherosclerosis patients with L-2-oxo-4-thiazolidine carboxylate, a precursor o f GSH (Vita, 
J.A. etal. 1998).
Similarly, establishment o f an inappropriate inflammatory response is a major 
feature o f rheumatoid arthritis. In this case, auto-reactive T-cells and activated monocytes 
invade the synovium resulting in its gradual destruction. T cells extracted from the joints o f 
rheumatoid arthritis show evidence o f increased oxidative stress (Maurice, M.M. et al.
1997), and it has been proposed this leads to aberrant oxidative modification o f proteins 
which may maintain the auto-immune reaction (Mapp, P.I. et al. 1995).
Amyotrophic lateral sclerosis (ALS) a terminal degenerative disease 
characterised by loss o f motor neurones primarily from the spinal cord and brain stem 
resulting in a progressive loss o f motor function. Inactivating mutations o f SOD 1 (Cu/Zn 
SOD) are detected in 20% of familial ALS cases (Zimmerman, M.C. et al. 2007). It has 
been proposed that in these patients, inadequate superoxide catabolism leads to oxidative 
stress and toxicity, resulting in increased apoptosis o f motor neurones, via activation of 
caspase-1 and caspase-3 (Pasinelli, P. etal. 2000). Furthermore, mice deficient for SOD1 
have a shortened lifespan and develop symptoms similar to those seen in ALS patients (Tu, 
P.H. et al. 1996; Tu, P.H. et al. 1997).
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1.4.4.2 Cancer cells frequently overproduce ROS via the mitochondria or NOX oxidases
Elevated ROS production is a common feature o f a wide variety o f cancers 
(Pelicano, H. et al. 2004; Benhar, M. et al. 2002), including cancers o f the pancreas 
(Vaquero, E.C. et al. 2004), prostate (Khandrika, L. et al. 2009; Kumar, B. et al. 2008), 
skin (especially melanoma) (Fruehau£ J.P. and Trapp, V. 2008), lung (Tsao, S.M. et al. 
2007) and haematopoietic system e.g. CML (Sattler, M. et al. 2000; Kim, J.H. et al. 2005) 
and hairy cell leukaemia (Kamiguti, A. S. et al. 2005). Evidence o f oxidative stress has also 
been observed in chronic lymphocytic leukaemia (CLL) (Zhou, Y. et al. 2003) and MDS 
(Farquhar, M.J. and Bowen, D.T. 2003).
Investigations into the source o f excess ROS in tumour cells have implicated 
both the mitochondrial ETC and NOX oxidases. The mitochondria o f cancer cells over 
produce ROS by several mechanisms in addition to those discussed in section 1.4.2.2. For 
example, increased mitochondrial ROS may be simply be a consequence o f increased 
metabolic activity in cancer cells; resulting in a greater than normal level o f ROS 
production by the mitochondrial ETC. Indeed, studies in BCR-ABL+ CML cells indicate 
that elevated ROS generation was connected to accelerated glucose metabolism (Kim, J.H. 
et al. 2005). The mitochondria can also generate increased ROS under conditions o f 
hypoxia, a common consequence o f tumour growth. This apparent paradox is explained by 
the fact that in hypoxic mitochondria, the delayed acceptance of electrons by oxygen at the 
ETC terminus prolongs the lifetime o f ubisemiquinone radicals (usually formed transiently 
at complex III o f the mitochondrial ETC), which can participate in univalent reduction o f 
oxygen to superoxide (Fruehauf, J.P. and Meyskens, F.L., Jr. 2007). Finally, mutations in 
mitochondrial DNA are also implicated in increased ROS production. The proximity to the 
mitochondrial ETC together with the lack o f chromatin proteins mean that mitochondrial 
DNA is at an increased risk o f oxidative damage and mutation. Mutations in mitochondrial 
DNA are frequently detected in cancers (Brandon, M. et al. 2006), and mutations in genes 
encoding components o f the mitochondrial ETC can cause increased ROS (Indo, H.P. et al. 
2007). Interestingly, mitochondrial DNA mutations which induce ROS have been shown to 
confer increased metastatic potential e.g. in murine Al 1 lung carcinoma cells, and this 
increased metastatic potential can be transferred to poorly metastatic (P29) cell lines 
simply by introducing the mutant mitochondria DNA (Ishikawa, K. et al. 2008).
In some cancers, elevated ROS production is attributable to hyperactivation of 
NOX oxidases. For example, NOX1 is upregulated in gastric cancers (Tominaga, K. et al. 
2007) and in 80% o f prostate tumours (Lim, S.D. et al. 2005). NOX4 is overexpressed and 
active in pancreatic cancer (Vaquero, E.C. et al. 2004) and melanoma cells (Sander, C.S. et
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al. 2003), whilst hairy cells from hairy cell leukaemia show increased expression and 
activation o f NOX5 (Kamiguti, A.S. et a l 2005). Furthermore there is evidence that 
oncogene activation may be upstream o f NOX activation in some cancers. Specifically,
Ras oncogenes are have been associated with NOX activation in human fibroblasts (Lee, 
A.C. et al. 1999), neuroblastoma cells (Seru, R. etal. 2004) and embryonic lung cells (Liu, 
R. et al. 2001), and in a murine model o f AML (Rassool, F.V. et al. 2007). The 
mechanisms by which Ras oncogenes activate NOX are not fully understood, but it appears 
Ras oncogenes can activate NOX by activating Rac and PKC (section 1.3.3.2). Ras may 
also regulate NOX1 activity at the transcriptional level; RasG12v induced NOX1 expression 
in colon carcinoma Caco-1 cells by promoting GATA- 6  dependent transcription o f the 
NOX1 gene (Adachi, Y. et al. 2008). It is important to note that while mitochondria and 
NOX oxidases are implicated in ROS production in tumour cells, these sources o f ROS are 
not mutually exclusive and may indeed operate simultaneously within the same cell.
1.4.4.3 ROS generated by cancer cells may influence the malignant phenotype
Several studies indicate that ROS generated by cancer cells (from either the 
mitochondria or NOX oxidases) play an important role in key phenotypes o f tumour cells, 
including proliferation, angiogenesis, migration/metastasis, and survival.
ROS production is required for effective growth factor signalling and cell-cycle 
progression in normal cells (section 1.4.3.2), and it appears that some cancer cells exhibit a 
dependence on ROS production for proliferation. For example, knockdown o f NOX4 in 
melanoma cells causes rapid sequestration o f cdc25 phosphatase (which normally 
dephosphorylates and activates CDKs) by 14-3-3 proteins and subsequent cell cycle arrest 
(Yamaura, M. et al. 2009). Through both overexpression and targeted knockdown, NOX1 
has been shown to play a role in promoting proliferation o f colon cancer cells (de 
Carvalho, D.D. et al. 2008) and prostate cancer cells (Arnold, R.S. et al. 2007; Arbiser,
J.L. et al. 2002). In addition, the proliferation o f Her-2/neu-transformed rat fibroblasts 
growth is suppressed by catalase (Preston, T.J. et a l 2001), suggesting that H2O2 in 
particular may be an efficient driver o f proliferation in cancer cells. DNA damage driven 
by ROS (section 1.4.1) can also contribute to genomic instability, which may promote 
disease progression.
However, there is also evidence that ROS generation can mediate cell cycle 
arrest and senescence, especially in the context o f mutant Ras expression. For example, 
expression o f mutant Ras in primary human fibroblasts (Lee, A.C. et al. 1999; Wang, W. et 
al. 2002) or epithelial cells (Nicke, B. et a l 2005) led to a stress response and cell cycle
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arrest, which was attributed to ROS production. Reports such as these appear to conflict 
with those already discussed which propose that ROS promote proliferation, and not cell 
cycle arrest. This paradox was investigated by Dolado et al., who showed that mutant H- 
Ras expression in normal primary human fibroblasts induces a stress response resulting in 
activation ofp38MAPK and subsequent cell cycle arrest/apoptosis (Dolado, I. et a l 2007). 
However p38MAPK activation and cell cycle arrest driven by mutant Ras could be bypassed 
by co-expression o f Gstm2, an enzyme involved in GSH synthesis. Importantly, this group 
demonstrated that several ROS producing cancer cell lines have specifically silenced 
p38MAPK activation by ROS, while p38MAPK activation by UV or osmotic shock was 
normal. This important study suggests that while ROS induced by oncogenic Ras can 
promote cell cycle arrest in normal primary cells via p38MAPK, cancer cells may evolve to 
evade this response, and hence benefit from increased ROS production in terms o f 
increased proliferation.
Both mitochondrial and NOX derived ROS production are known to play a role 
in angiogenesis (the remodelling o f existing vasculature to establish blood supply to 
hypoxic/damaged tissues) and this may be due to the ability o f ROS to stabilise hypoxia- 
inducible factor - l a  (HIF-la). Under normoxic conditions, H IF -la  has an extremely short 
half-life (<5 min), due the actions o f proline hydroxlases (PHDs) which remove the 
hydroxyl groups from Pro564 and Pro402 o f HIF-la, and dehydroxylated H IF -la  is then 
bound by von Hippel-Landau factor (vHLF). Since vHLF is a recognition component for 
an E3-ubiquitin ligase, association o f H IF-la with vHLF leads to rapid proteasomal 
degradation o f H IF -la  H2 O2 generated by the mitochondria during hypoxia (1.4.2.2) 
inhibits PHDs (Fruehauf, J.P. and Meyskens, F.L., Jr. 2007), which allows accumulation o f 
H IF -la  H IF-la  then heterodimerises with HIF-1/3, and initiates the transcription o f genes 
that promote angiogenesis e.g. through VEGF production (Vaupel, P. 2004). Additionally, 
it appears that NOX derived H2O2 can augment VEGF signalling. VEGF promotes 
angiogenesis by inducing the proliferation and migration o f vascular endothelial cells via 
VEGF receptor type 2 signalling (VEGFR2 aka Flkl; a receptor tyrosine kinase). NOX- 
derived H2O2 ‘amplifies’ VEGFR2 signals by prolonging receptor phosphorylation, 
probably by inhibiting tyrosine phosphatases such as Shp-1, Shp-2 and PTP1B (Ushio- 
Fukai, M. and Nakamura, Y. 2008).
NOX-derived ROS have also been implicated in vasculogenesis; a process 
which co-operates with angiogenesis, but (unlike angiogenesis) involves the generation of 
new vasculature from endothelial progenitor cells (EPCs) derived from the bone marrow. 
Effective vasculogenesis requires that EPCs efficiently home to the ischaemic site. In a
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mouse model o f vasculogenesis, hindlimb ischaemia resulted in upregulation o f NOX2 in 
bone marrow mononuclear cells, increased ROS and increased EPC mobilisation. 
Interestingly, Nox2-deficient mice showed markedly decreased vascular recovery after 
ischaemia, reduced EPC mobilisation, and ineffective EPC homing to the ischaemic site. 
Transplantation o f Nox2-deficient bone marrow recapitulated the defect in wild type mice, 
while wild-type bone marrow could rescue the defect when transplanted in Nox2-deficient 
mice (Urao, N. et al. 2008). These studies strongly support the positive influence o f ROS 
production on angiogenesis and vasculogenesis.
There is also evidence that ROS production can contribute to metastasis in solid 
tumours (Wu, W.S. 2006; Nishikawa, M. et al. 2005). Nishikawa et al. examined the 
effects o f ROS production on metastasis using colon28 cells and B16-BL6/Luc melanoma 
cells injected intravenously into recipient mice. In both o f these studies respectively, 
catalase treatment suppressed metastatic colony formation in the liver or lungs o f recipient 
mice. Targeting the catalase enzyme to specific organs by chemical modification o f the 
catalase molecule further suppressed metastasis in those organs, suggesting that H2O2 
augments the metastatic potential o f  these cells. Similarly, Wu et al. showed that TPA- 
induced migration o f human HepG2 hepatocarcinoma cells was suppressed by a variety of 
antioxidant molecules including catalase, mannitol and NAC. In this case, it appeared that 
ROS-dependent migration o f HepG2 cells was dependent on ROS-mediated activation of 
ERK and transcription o f several integrin genes which promote migration.
The long held belief that ROS are exclusively pro-apoptotic has been challenged 
by recent evidence suggesting that ROS may participate in pro-survival signals (Groeger,
G. et al. 2009), and this may be exploited by some cancer cells. For example, targeted 
knockdown or inhibition o f NOX4 in pancreatic cancer cells induces apoptosis, suggesting 
NOX4-derived ROS promoted the survival o f these cells (Mochizuki, T. et al. 2006), 
which may be in part due to the ability o f NOX4-derived ROS to activate JAK2, an anti- 
apoptotic kinase (Lee, J.K. et al. 2007). Similarly, NOX4-derived ROS appeared to 
promote survival o f BCR-ABL* CML cells, via oxidative inhibition o f PTEN and PP2A, 
resulting in augmented PI3K-Akt signalling (Naughton, R. et al. 2009).
While the evidence presented above demonstrated that ROS can promote cancer 
cell survival, it is clear that excessive ROS can be pro-apoptotic. As discussed in section
1.4.1, excessive ROS causes widespread damage to DNA, lipids and proteins, and this can 
lead to necrotic cell death. However, it is also possible that subtle levels o f  ROS generated 
by the mitochondria may directly promote apoptosis by the intrinsic pathway. Studies in 
isolated rat mitochondria showed that mitochondrial ROS can oxidise cysteine residues of
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the adenine nucleotide translocase (ANT) component o f the mitochondrial permeability 
transition pore complex. Oxidation o f ANT promotes opening o f the pore (Costantini, P. et 
al. 2 0 0 0 ), leading loss o f mitochondrial homeostasis followed by mitochondrial rupture, 
releasing pro-apoptotic factors such as cytochrome C into the cytosol (Fruehauf, J.P. and 
Meyskens, F.L., Jr. 2007). However, it is not currently known whether this mechanism 
operates in intact cells or indeed in vivo.
It is important to note that the outcome o f ROS generation within a cell is highly 
dependent on several factors including the levels o f ROS produced, the duration o f 
production and the subcellular location. The high concentration o f  intracellular 
antioxidants in normal cells means that ROS production and signalling can potentially be 
very tightly controlled (Leslie, N.R. 2006), but in conditions where ROS production is 
augmented (or antioxidant systems are compromised), there is scope for dysregulation o f 
ROS signalling. In short, the body o f evidence strongly suggests that ROS must be 
maintained within a defined range to exert its physiological effects, and drastic increases or 
decreases in ROS are likely to lead to non-physio logical or pathophysiological conditions. 
It is also clear that ROS production is not an absolute prerequisite feature o f all tumour 
cells, indeed, there is evidence breast cancer ‘stem’ cells show consistently lower levels o f  
ROS than their normal counterparts (Diehn, M. et a l 2009). Nevertheless it is clear that 
ROS production can influence the behaviour o f a wide variety o f tumour cells that 
overproduce them.
1.4.4.4 Targeting ROS in cancer therapy
It has been proposed that the increased ROS production observed in some cancer 
cells may be exploited for therapeutic gain (Benhar, M. et a l 2002; Trachootham, D. et a l 
2009). Targeting ROS in cancer therapy can take two approaches -  the first involves 
further promotion o f ROS production in cancer cells by treating them with pro-oxidants 
(compounds which introduce exogenous ROS or promote its production), or by inhibiting 
intracellular antioxidants. Certainly, there is evidence that intracellular antioxidant pools 
(such as GSH) are augmented in cancer cells (possibly in response to increased oxidative 
stress) and that this increased antioxidant capacity may play a role in drug resistance 
(Townsend, D.M. and Tew, K.D. 2003; Townsend, D.M. et a l 2005). Indeed, it appears 
that a pro-oxidant therapeutic approach is effective in several cancer types; for example 
arsenic trioxide (AS2 O3 ) is a pro-oxidant molecule which is currently approved for 
treatment o f relapsed APL. AS2 O3 may act through inhibition o f thioredoxin function (Lu,
J. et al. 2007) and also by augmentation o f ROS produced by the mitochondrial ETC
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(Pelicano, H. et al. 2003). Phenethyl isothiocyanate (PEITC) is another pro-oxidant 
molecule which acts by depleting GSH pools, leading to elevated oxidative stress. This 
compound has shown promise in treating drug-resistant leukaemias; it was shown to be 
effective in killing fludarabine-resistant CLL cells (Trachootham, D. et a l 2008) and also- 
Gleevec resistant CML cells (Zhang, H. et al. 2008). However, in using such pro-oxidant 
approaches, it is important to note that that oxidative stress would increase in normal cells, 
which may cause increased toxicity and may also induce de novo mutations.
An alternative approach to targeting ROS is to use antioxidants to suppress the 
high levels in cancer cells; with the rationale that ROS-generating cancers may develop a 
degree o f dependence on high levels o f  ROS (apoptosis in pancreatic cancer cells after 
knockdown of NOX4 supports this notion). In addition, antioxidant treatment as an adjunct 
to standard therapies may reduce toxicity. On the other hand, several mainstay 
chemotherapeutic agents (examples) are known to depend on ROS generation for their 
cytotoxic effects; moreover, ROS depletion may suppress tumour cell proliferation, which 
potentially conflicts with the actions o f agents which specifically target proliferating cells 
(e.g. nucleoside analogues such as cytarabine). However, a recent review o f  clinical trials 
which employed antioxidants in addition to standard chemotherapy in a variety o f  cancers 
concluded that antioxidants were not antagonistic to cancer therapy, in fact several studies 
reported decreased treatment-associated toxicity, allowing an increased proportion of 
patients to complete their therapy (Block, K.I. et al. 2008).
In summary, targeting ROS in cancer therapy is an exciting approach that is 
attracting significant interest; indeed, as discussed above, many agents that target ROS are 
now in clinical trials or have been approved for use in the clinic.
1.4.5 D etection  of ROS
ROS are a chemically heterogeneous group o f molecules which are (in the main) 
moderate to strong oxidants, meaning they favour acquisition o f  electrons from donor 
molecules. However, their high reactivity makes them relatively short lived and therefore 
difficult to detect. Early studies exploited the oxidative capacity o f ROS to detect these 
species in vitro. For example, superoxide has been measured historically oxidation of 
cytochrome c and nitroblue tetrazolium (NBT) could be measured by optical spectroscopic 
methods (Tarpey, M.M. and Fridovich, I. 2001). However optical spectroscopic 
approaches suffer from a relatively low sensitivity and a narrow dynamic range, which 
limits their usefulness. In contrast, fluorescent and chemiluminescent assays offer superior 
sensitivity, and extremely large dynamic range (Wardman, P. 2007). Therefore, the present
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study employed chemiluminescence and several fluorescence-based assays for detection of 
ROS. An additional technique for studying oxygen centred radicals is electron 
paramagnetic resonance (EPR) spectroscopy. This technique (while technically 
demanding) offers the benefit o f unequivocal identification o f oxygen-centred radicals, and 
is therefore a useful tool to verify the results o f fluorescence and chemiluminescence-based 
assays.
1.4.5.1 Principles o f  fluorescence and chemiluminescence
Fluorescence occurs when an electron within a fluorochrome (a molecule that 
exhibits fluorescence) absorbs the energy o f an incident photon (becomes excited), and 
subsequently releases some o f that energy as an emitted photon. The excitable electrons 
within a fluorochrome molecule are located within a particular moiety or functional group 
o f the molecule; this region is called the fluorophore. During the first step in fluorescence, 
the excited electron is promoted from a relatively stable low-energy state (ground state) to 
an unstable (and therefore transient) excited state, for example the electron can be 
promoted to a higher energy molecular orbital (El or E2 in Figure 1.14). Within that 
higher energy orbital, the electron may occupy one o f several vibrational or rotational 
energy states (Figure 1.14). Due to the principle o f energy quantisation, an electron may 
only possess discrete energies, therefore, absorption o f an incident photon will only occur 
when the energy o f  that photon exactly matches the energy required to complete one o f the 
possible transitions (green arrows in Figure 1.14). Since the energy o f a photon is directly 
related to its frequency by Planck’s equation (E=hv, where E is the energy o f the photon, h 
is Planck’s constant, and v is the frequency of the incident photon), only photons with a 
given frequency (and therefore wavelength) are efficiently absorbed.
Since there are many possible electronic transitions in a given fluorochrome 
molecule, there is an accordingly broad range o f wavelengths that can potentially be 
absorbed resulting in a unique spectrum o f absorption for every different fluorochrome 
molecule (the absorption spectrum). However, some electronic transitions are more 
probable than others and this is reflected in the shape o f the absorption spectrum, with 
maximal absorption (absorption maxima) occurring at the wavelengths corresponding to 
the energy o f  the most probable electronic transition (Figure 1.15).
Since the electron in the excited state is unstable, conversion back to the stable 
ground state is favourable. To achieve this, the electron must release all o f the energy 
(relaxation) which was acquired from the incident photon, which can occur by several 
different processes. Some energy is lost by descending through various rotational and
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vibrational energy states (released as heat, or kinetic energy) or by internal conversion 
(transition between two high energy orbitals), until the lowest vibrational energy state 
within the Ei excited molecular orbital is reached (yellow wavy arrows in Figure 1.14). 
From this point, a transition between electronic energy levels can occur; during this 
transition energy is released by the electron in the form of a photon (fluorescence; shown 
as red arrows in Figure 1.14). Critically, since some o f the original photons energy was lost 
by non-radiative means, the energy o f the emitted photon is less than that o f the original 
photon and therefore has a longer wavelength. Again, since there are several routes that the 
relaxing electron can take in order to release its energy (and some are more probable than 
others) there is an accordingly broad range o f emitted wavelengths (the emission 
spectrum), with the most commonly emitted wavelength (the emission maxima) 
corresponding to the energy o f the most probable electronic relaxation (Figure 1.15). The 
difference in wavelength o f the excitation and emission maxima for a particular 
fluorochrome is often referred to as the Stoke’s shift, and this effect is a key factor in the 
high sensitivity o f  fluorescence-based approaches. Using a combination o f controlled 
excitation wavelengths (generated by lasers or LEDs) and optical filters, the photon 
emission by a fluorochrome can be isolated from the excitation photons, allowing 
background to be substantially reduced. Furthermore, the development o f high-voltage 
photomultiplier tubes enabled the amplification o f even weak fluorescent signals. Finally, a 
fluorescent molecule can undergo many cycles o f absorption and emission which further 
improves the sensitivity. Modem flow cytometers and laser-scanning confocal microscopes 
combine all o f  these technologies enabling the sensitive assay o f both intra- and 
extracellular targets at the sub-cellular level.
However, fluorescence-based approaches are not without their limitations. For 
example, although fluorochromes may indeed undergo several emission cycles, most 
molecules cannot do this indefinitely. The high energy associated with the excited state of 
the molecule can often promote inter- or intramolecular reactions which may destroy the 
fluorophore (photobleaching). Thus over time the fluorescence falls below that expected 
over time. Also, the Stoke’s shift for some fluorochromes is small, making it more difficult 
to separate the excitation light source from the emitted light. Similarly, care must taken 
when choosing multiple fluorochromes for use within a single assay, since the excitation 
and emission spectra o f some fluorochrome are so similar as to render them incompatible 
for simultaneous use. On the other hand, the development o f optimised fluorescent dyes 
with well-separated excitation and emission spectra, and a resistance to photobleaching 
(e.g. Alexa Fluors®), go some way to address these limitations.
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Figure 1.14 A simple electron energy level diagram highlighting the basic principles 
of fluorescence
Electrons in the stable ground state (G) may absorb the energy of incident photons if the 
photon’s energy matches the energy gap between one of the allowed electronic transitions 
(green arrows) to a higher energy orbital (Ei or E2). Within each higher energy orbital, the 
electrons may also occupy one of several rotational or vibrational energy states (labelled 0 - 
5). The excited state is transient and the electrons gradually return to the ground state via 
descent to the Ei = 0 energy level (yellow curvy arrows). Electronic transitions from here 
to within the G energy level are accompanied by a release of energy as an emitted photon. 
Since energy is lost prior to photon emission, the emitted photon has less energy (longer 
wavelength) than the incident photon. Some transitions from Ei = 0 to G are non-radiative 
(blue curvy arrows), meaning the energy is not released as a photon. Adapted from 
http://www.olympusconfocal.com.
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Figure 1.15 Examples of excitation and emission spectra
The above traces demonstrate the principles of absorption (or excitation spectra) and 
emission spectra. The green line depicts how the number of incident photons absorbed 
varies with the wavelength of those photons, and marks out a range of wavelengths over 
which absorption occurs. Similarly, the red line depicts how the number of photons emitted 
varies with wavelength, again marking out a range of wavelengths over which emission is 
detected. Note that the curves both exhibit a peak (maxima). The wavelengths at which 
these maxima occur correspond to the energies of the most probable transitions that occur 
during absorption and emission within the fluorochrome. The difference between the 
excitation and emission maxima is referred to as the Stokes’s shift (see text for an 
explanation of this phenomenon).
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Chemiluminescence is similar to fluorescence in that it describes the emission of 
photons by an electronically excited molecule or species; however it differs from 
fluorescence in that the excitation energy is supplied by a chemical reaction, rather than by 
incident photons. Detection o f chemiluminescence is achieved using similar technology to 
that used for detection o f fluorescence, with the simplification that optical filters are not 
essential, since there is no excitation light source. Since there is no significant background, 
chemiluminescent techniques exhibit an extremely high sensitivity.
1.4.5.2 Fluorescent and chemiluminescent probes fo r  ROS detection
Fluorescent probes are an iteration o f fluorochrome chemistry. Whereas 
fluorochromes will always fluoresce when exposed to electromagnetic radiation o f the 
correct wavelength, fluorescent probes are designed to fluoresce in a controlled manner 
only under specific conditions i.e. in the presence o f the probe target. Since ROS are 
predominantly oxidising agents, most o f the commonly used fluorescent probes for ROS 
detection are reduced forms o f fluorochrome molecules. The reduced form o f the probe is 
either non-fluorescent, or has a significantly different emission maxima to that o f the 
oxidised probe.
A useful example o f this principle is the commonly used probe for ROS 
detection dihydrodicholorofluoroscein diacetate (H2DCFDA), which is a reduced form of 
the green fluorescent probe dichlorofluoroscein (DCF). The reduced form (H2DCFDA) is 
non-fluorescent, since the additional hydrogen atoms in the structure disrupt the 
delocalised 7r-electron system which forms the fluorophore in DCF. The acetyl groups 
improve membrane permeability o f the probe, and are quickly cleaved by intracellular 
esterases. The deacetylated probe is less membrane permeable than the acetylated form, 
which confers a degree o f increased intracellular loading o f the probe. In the presence of 
oxidising agents, the electrons binding the two critical H atoms to the H2DCF molecule are 
lost, resulting in the formation o f the fluorescent oxidised form o f the probe (DCF).
A similar principle applies to the mechanism o f action o f the fluorescent probes 
used to detect ROS in the present study; Amplex Red and MitoSOX were used to detect 
H2O2 and mitochondrial superoxide respectively, sections 3.2.4 and 3.2.3 respectively.
In the case o f chemiluminescent probes for ROS, oxidation o f the probe 
invariably initiates a chemical reaction which results in the formation o f the electronically 
excited molecule. This study employed Diogenes, a chemiluminescent probe based on 
luminol (section 3.2.1).
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It has been noted that some commonly used probes used for ROS detection (for 
example H2 DCFDA) are rather non-specific in that they can become fluorescent in the 
presence o f several different oxidant molecules (Wardman, P. 2007). Therefore the present 
study has avoided the use o f DCF in favour o f more recently developed (and potentially 
more specific) probes. However, to verify the specificity o f  the chosen probes, this study 
has employed a variety o f  ROS scavengers and inhibitors o f ROS production, and has used 
several different assays to verify the presence o f a particular species (such as superoxide). 
Several o f  the ROS inhibitors used are exquisitely specific (for example, the enzymes 
catalase and SOD), which goes some way to compensate for any lack o f specificity o f the 
probes.
1.4.5.3 Detection o f  oxygen-centred radicals using EPR spectroscopy
Electron paramagnetic resonance (EPR) spectroscopy is a technique which can 
detect unpaired electrons (radicals) within a molecule and gain information about the local 
molecular structure by virtue o f radicals’ ability to absorb electromagnetic radiation, in an 
analogous manner to the way nuclear magnetic resonance (NMR) spectroscopy can detect 
specific nuclei. It is based on the principle that radicals can absorb X-band (9.25 GHz) 
microwave energy when placed in a strong magnetic field (-3000 Gauss).
A detailed discourse on quantum mechanics is beyond the scope o f this thesis; 
however, it is useful to consider some properties of electrons which will allow (in basic 
terms) an understanding o f  the principles o f  EPR spectroscopy. Electrons are negatively 
charged particles with a quantum mechanical property called spin (ms), which describes the 
intrinsic angular momentum o f  the electron (ms is one o f four quantum numbers that define 
each particle in quantum mechanics). While there is no precise classical analogy for this 
property, for the purposes o f this thesis it is best to consider that an electron spins about an 
internal axis; and the value given for ms relates to the number of different spin states the 
electron can occupy. In the case o f electrons, ms = !4; and this has the consequence that an 
electron can occupy two distinct spin energy states (spin-up or spin-down).
Since the electron has an intrinsic angular momentum and is charged, the 
electron has an associated magnetic moment (i.e. it has its own magnetic field and acts like 
a tiny magnet). When a strong magnetic field is applied, the electron’s own magnetic field 
interacts with the applied field; as a result the electron can adopt one o f two energy states 
(remember that ms is Vi). The electron can either align its own magnetic field with the 
applied field (which is the lower energy state) or it can anti-align with the applied field, 
which is a higher energy state. The energy difference between these two states is
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dependent on the strength o f the applied magnetic field. Importantly, electrons in the low 
energy state can be encouraged to jump to the higher energy state by irradiating them with 
microwaves. Similar to absorption o f light energy leading to fluorescence, absorption o f 
microwaves by the electrons only occurs when the energy of the incident microwaves 
exactly matches the energy gap between the two possible states. Hence, in a constant 
magnetic field, a sample can be irradiated with microwaves of varying energy resulting in 
an absorption spectrum (an EPR spectrum). The particular frequency o f microwave energy 
that the unpaired electrons will absorb is highly dependent on the properties o f the electron 
and its molecular environment. Alternatively the microwave energy can be kept constant 
and the magnetic field can be varied giving the same EPR spectrum result. Again, the 
properties o f the electron and its molecular environment define the magnetic field strength 
at which absorption will occur. It turns out that the latter method is more precise and it is 
the method used in all modem EPR instruments.
It might be expected that the EPR spectrum obtained from a single unpaired 
electron within a molecule would consist o f one absorption peak, however, EPR spectra 
are often more complex, consisting o f several separate peaks which form the EPR 
spectrum. This phenomenon occurs due to interactions between the magnetic moment o f 
the unpaired electron and the magnetic moments of nearby spin-active nuclei. These 
interactions result in additional allowed spin-energy states causing splitting o f the electron 
absorption signal into several absorption peaks. This phenomenon is known as hyperfine 
splitting or hyperfine coupling and is analogous to J-coupling observed in NMR 
spectroscopy. The spacings between the additional peaks are dependent on the properties 
o f the coupling nuclei and their distance from the unpaired electron, and are referred to as 
hyperfine coupling constants, denoted ax, where X is the element symbol o f  the nucleus 
that is causing the hyperfine splitting to occur. Hyperfine coupling constants observed in 
unidentified EPR spectra can be measured and can indicate which nuclei are proximal to 
the unpaired electron and hence provide data on the likely molecular structure o f the 
molecule.
DEPMPO is a beta-phosphorylated nitrone which stabilises short-lived radical 
molecules such as superoxide and hydroxyl radicals by reacting with them to form a 
relatively long-lived radical molecule known as a spin adduct. Each spin adduct has a 
unique EPR spectrum which enables free radical identification. Until recently, trapping and 
identifying oxygen-centred radicals (such as superoxide radicals) was often performed 
using the spin trap probe DMPO, a molecule closely related to DEMPO. However, the spin 
adduct formed by the reaction o f DMPO with superoxide (DMPO-OOH) is relatively short
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lived (half life 60 sec) due to an intramolecular elimination reaction which forms a 
molecule identical to the adduct formed when DMPO reacts with hydroxyl radicals 
(DMPO-OH). Therefore, when trapping superoxide radicals with DMPO, this phenomenon 
results in an EPR spectrum which is a superimposition of both the DMPO-OOH and 
DMPO-OH spectra, which evolves over time to that of a ‘pure’ DMPO-OH EPR spectrum.
DEPMPO offers an advantage over DMPO because rate of the intramolecular 
elimination reaction is much slower in DEPMPO, resulting in a 15 fold greater persistence 
of the DEPMPO-OOH adduct than the DMPO-OOH adduct (Frejaville, C. et al. 1995), 
enabling easier detection and identification of superoxide radicals. Importantly, DEPMPO 
itself does not contain any radicals and so does not have an EPR spectrum - EPR spectra 
are only observed from molecules derived from DEPMPO which contain a radical i.e. the 
spin adducts of DEPMPO, DEPMPO-OOH and DEPMPO-OH. The EPR spectra of the 
spin adducts formed when superoxide or hydroxyl radicals react with DEPMPO 
(DEPMPO-OOH and DEPMPO-OH respectively) have been characterised previously 
(Mojovie, M. et al. 2005; Dikalov, S. et al. 2005), therefore EPR spectroscopy using 
DEPMPO is a useful technique to verify superoxide and hydroxyl production indicated 
using other detection methods. Figure 1.16 illustrates the absorption of microwave energy 
by unpaired electrons.
N
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Figure 1.16 Absorption of microwave energy by electrons in an applied magnetic 
field
Electrons (blue circles) have an associated magnetic field (represented by North and South 
poles, N and S). In an applied magnetic field, electrons will preferentially adopt an energy 
state which aligns their intrinsic magnetic field with the applied field. However, electrons 
may also occupy a higher energy state, where the intrinsic magnetic field is anti-aligned 
with the applied field. Microwave radiation can supply the energy required for the electron 
to move to the higher energy state, in which case the microwave energy is absorbed. An 
absorption spectrum (EPR spectrum) can therefore be obtained by keeping the microwave 
energy (wavelength) constant while cycling through an increasing magnetic field.
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General Materials and Methods
2.1 M a t e r i a l s  a n d  b u f f e r  f o r m u l a t i o n s
2.1.1 M aterials
Materials in general use are listed below, grouped by manufacturer/supplier and 
listed in alphabetical order followed by synonyms in parentheses. All reagents were o f 
Analar grade and/or tissue-culture tested unless otherwise stated. Bacto-tryptone®, Bacto- 
yeast® and Ficoll-Paque® were purchased from BD Biosciences, Oxford, UK. Fetal calf 
serum (FCS) was purchased from BioSera, Ringmer, UK. Ultra-purified H2O was obtained 
using a PureLab® Ultra water purification unit manufactured by Elga LabWater, High 
Wycombe, UK. Liquid nitrogen (N2) was purchased from BOC, Guildford, UK. Tissue 
culture grade H2 O was purchased from Hameln Pharmaceuticals, Gloucester, UK.
Agarose, dithiothreitol (DTT), Hank’s Balanced Salt Solution (HBSS), penicillin, 
Phosphate Buffered Saline (D-PBS; PBS), streptomycin, Super-Optimal medium 
(Catabolite-repressing) (SOC medium) and trypsin were purchased from Invitrogen, 
Paisley, UK. Heparin was purchased from Leo Laboratories Ltd., Princes Risborough, UK. 
Tissue culture plasticware was purchased from Iwaki Biosciences, Iwaki, Japan and Nunc, 
Roskilde, Denmark. Human Fms-like tyrosine kinase-3 ligand (FLT3L), human 
Granulocyte(G) colony-stimulating factor(CSF), human Granulocyte-Macrophage(GM)- 
CSF, human interleukin(IL)-3, human IL-6 , human stem cell factor (SCF), murine GM- 
CSF (mGM-CSF), murine IL-3 (mIL-3) and murine SCF (mSCF) were purchased from 
Peprotech, London, UK. Complete mini EDTA-free protease inhibitor tablets and human 
transferrin were purchased from Roche, Welwyn Garden City, UK. Gentamycin 
(Cidomycin®) was purchased from Sanofi-Aventis, Guildford, UK. Phosphatase Inhibitor 
Cocktail for Western blotting was purchased from Santa Cruz Biotechnology, CA, USA. 
Ampicillin, apocynin (4’-Hydroxy-3'-methoxyacetophenone; acetovanillone), Bradford’s 
Reagent, bovine serum albumin fraction V (BSA), calcium chloride (CaCh), catalase, 
chloroquine (N'-(7-chloroquinolin-4-yl)-N,N-diethyl-pentane-1,4-diamine), 
diphenyleneiodonium (DPI), Dulbecco’s Modified Eagle’s Medium (DMEM), 
deoxyribonuclease I (DNAse I), ethylenediamine-tetraacetic acid (EDTA), ethylene glycol- 
bis(2 -aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA), ethanoic acid, ethanol, Qf-D-
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glucose, glucose oxidase (GOX), glycerol, hydrochloric acid (HC1), hypoxanthine (6 - 
hydroxypurine), Iscove’s Modified Dulbecco’s Medium (IMDM), L-glutamine, 
magnesium chloride (MgCh), magnesium sulphate (MgS0 4 ), mercaptoethanol ((3- 
mercaptoethanol), methanol, N-acetyl cysteine (NAC), polybrene, Ponceau S Reagent, 
potassium chloride (KC1), potassium dihydrogen phosphate (KH2 PO4 ), rotenone, Roswell 
Park Memorial Institute 1640 culture medium (RPMI 1640), sodium chloride (NaCl), 
sodium hydroxide (NaOH), sodium orthovanadate (Na3VC>4), sodium phosphate 
(Na2 HP0 4 ), SOD1 (bovine Cu/Zn SOD), tempol (4-Hydroxy-2,2,6,6-tetramethylpiperidine 
l-oxyl), TPA (12-O-tetradecanoylphorbo 1-13-acetate; aka phorbol 12-myristate 13-acetate 
(PMA)), Tris (tris(hydroxymethyl)aminomethane), Triton X-100 (4 -(l,1,3,3- 
tetramethylbutyl)phenyl-polyethylene glycol), Tween-20 (polyethylene glycol sorbitan 
monolaurate) and xanthine oxidase were purchased from Sigma-Aldrich, Poole, UK. 
Retronectin was purchased from Takara, Shiga, Japan.
2 .1 .2  Fo r m u la tio n  of buffers a n d  so lutio ns
Formulations o f buffers that are not defined in the text are given below in 
alphabetical order. Where appropriate, solutions were autoclaved for 20 min at 15 lb/sq.in 
after preparation, but before addition o f labile substances, such as antibiotics. Where 
autoclaving was inappropriate, solutions were passed through a 0.45 pm sterile filter. All 
solutions are aqueous unless otherwise stated.
Diogenes buffer (section 3.2.1.1): 4.6 mM KH2 PO4 , 8.0 mM Na2 HPC>4 , 130.0 
mM NaCl, 4.4 mM KC1, 5.5 mM glucose, 0.5 mM MgCl2, 0.5 mM CaCl2, 0.1% BSA, 
dissolved in dH2 0 , pH 7.4. Krebs-Ringer phosphate-glucose buffer (KRPG) (section
3.2.4.2): 145 mM NaCl, 5.7 mM NaH2P 0 4, 4.9 mM KC1, 0.5 mM CaCl2, 1.2 mM M gS04,
5.5 mM glucose, dissolved in dH2 0 , pH 7.4. Lysis buffer (section 2.5.1): 10 mM HEPES- 
KOH, 10 mM betamercaptoethanol, ImM magnesium acetate, 0.5 mM EDTA, 0.5 mM 
EGTA, 0.25 M sucrose, 1 mM Na3VC>4 , 1 complete protease inhibitor tablet per 10 ml, 
dissolved in dH2 0 , pH 7.2. Magnetic activated cell sorting (MACS) buffer (section
2.3.2): PBS containing 0.5% BSA, 5 mM MgCL, dissolved in dH2 0 , 0.45pm filtered, 
degassed under negative pressure for 30 min. PepChip activation mix (section 5.2.2.2): 2 
mCi/ml y-33P-ATP, 50% glycerol, 5 mM DTT, 50 mM MgCL, 50 mM MnCL, 250 pg/ml 
polyethylene glycol 8000, 250 pg/ml BSA. PepChip lysate dilution buffer (section
5.2.2.2): 50 mM HEPES-KOH (pH 7.5), 10 mM MgCl2, 10 mM MnCl2, one complete 
protease inhibitor cocktail tablet per 10 ml. Ponceau S (section 2.5.3): 1.3 mM Ponceau S, 
dissolved in 0.83 M ethanoic acid. Selective Luria-Bertani (LB) broth (section 2.4.2):
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lOg Bacto-Tryptone, 5g Bacto-yeast extract, lOgNaCl dissolved in 1 L dH2 0 , pH 7. 50 
pg/ml ampicillin added just before use. Selective LB agar (section 2.4.2): As selective LB 
broth with addition o f 15 g/L agarose. 50 pg/ml ampicillin added just before use. Staining 
buffer for flow cytometry (section 2.6): PBS containing 1% BSA, 3.1 mM NaN3, 
dissolved in dH2 0 . Tris-buffered saline (TBS) (section 2.5.1): 1 M Tris-HCl, 130.0 mM 
NaCl, dissolved in dH20 , pH 7.6. TBS-Tween-20 (TBS-T) (section 2.5.3): TBS 
containing 0.1% Tween-20. Tris-EDTA (TE) buffer (section 2.4.5): 10 mM Tris-HCl, 1 
mM EDTA, pH 7.5.
2 .2  C e l l  c u l t u r e  a n d  c r y o p r e s e r v a t i o n
2.2.1 Cr y o pr eser v a tio n  a n d  th aw ing  of cell sam ples
Cell suspension (500 pi in appropriate growth medium) was mixed with 500pl
o f IMDM containing 30% FCS and 20% DMSO. Samples were transferred to 1.8 ml vials
and immediately placed in a controlled refrigeration container (using 1 0 0 % isopropanol as 
the thermal interface) which had been equilibrated to room temperature before use. 
Controlled refrigeration containers were then immediately placed in a -80°C freezer until 
samples had equilibrated. For long term storage, frozen samples were transferred to liquid 
N2 storage.
Cryopreserved primary cells were recovered by rapid defrosting in a 37°C water 
bath in the presence o f 900 pi 0.45pm-filtered FCS and 200 pg sterile DNAse I. 
Cryoprotectant was slowly diluted by dropwise addition o f an equal volume o f MACS 
buffer over 3 min. This addition o f an equal volume over 3 min was performed twice more, 
and primary cells were then recovered by centrifugation at 180 g for 1 0  min and 
resuspended in growth medium (section 2.2.3) and allowed to recover for 16-24 h in a 5% 
CO2 humidified atmosphere at 37°C.
Cryopreserved cell lines were recovered by rapid defrosting in a 37°C waterbath 
followed by dropwise addition o f 5 ml growth medium (section 2.2.3). Cell lines were then 
recovered by centrifugation at 180 g for 5 min and resuspended in growth medium and 
allowed to recover for 16-24 h at 37°C in a 5% CO2 humidified atmosphere at 37°C.
2.2.2 D eterm in atio n  of cell c o u n t
Cellularity o f cultures was determined using a glass haemocytometer with 
counting chambers delineated with improved Neubauer ruling (Hawksley, Brighton, UK). 
Briefly, 8  pi was removed from cell suspension with a known total volume and placed into
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a counting chamber. The haemocytometer is etched with ruled lines marking a counting 
space which has a known volume (0.9 pi). This volume is subdivided by ruled lines into 9 
cuboids equivalent to 100 nl each. The cellularity o f the sample in cells/ml is given by the 
average number o f cells per cuboid multiplied by lxlO4.
2 .2 .3  Cultu re  of pr im a r y  a n d  t ra nsfo rm ed  cell lines
All cell lines listed below were obtained from ATCC (Teddington, UK) unless 
otherwise stated, and cultured at 37°C in a humidified 5% CO2 atmosphere in RPMI 1640 
containing 10% FCS and 20pg/ml gentamycin, unless otherwise stated. Cell lines were 
certified mycoplasma free by the supplier. Cells beyond passage 15 from receipt were 
discarded. For primary cell cultures, the age o f the culture is quoted in days since isolation. 
Normal human primary CD34+ haematopoietic cells were isolated as described in section
2.3.2.; primary murine Sca-1+ haematopoietic cells were isolated as described in section 
3.2.5.
2.2.3.1 Culture o f  primary human CD34+ haematopoietic progenitor cells
Transduced human CD34+ cells were cultured at 37°C in a humidified 5% CO2 
atmosphere 37°C and were maintained at 2-4x105 cells/ml in supplemented IMDM (section
2.3.2) containing 5 ng/ml human(hu)IL-3, huG-CSF and huGM-CSF and 20 ng/ml huSCF, 
unless otherwise stated. In all cases, media were renewed as necessary or once a week.
2.2.3.2 Culture o f  primary murine Sca-1+ haematopoietic progenitor cells
Transduced murine Sca-1+ cells were cultured under the same conditions as 
human CD34+ cells (section 2.2.3.1); in supplemented IMDM (section 2.3.2) containing 5 
ng/ml murine(mu)IL-3, huG-CSF and muGM-CSF and 20 ng/ml muSCF, unless otherwise 
stated. In all cases, media were renewed as necessary or once a week.
2.2.3.3 Mono-Mac 6 cells
Mono-Mac 6  (MM6 ) cells are a human acute monocytic leukaemia cell line 
established from the peripheral blood o f a 64-year-old man with relapsed acute monocytic 
leukaemia (AML FAB M5) in 1985 following myeloid metaplasia (Ziegler-Heitbrock,
H.W. et al. 1988). They have previously been used as a model o f human monocytes 
capable o f producing superoxide upon stimulation with lipopolysaccharide (LPS aka
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endotoxin) or TPA (Tonks, A.J. et al. 2003). MM6  cells were maintained at 0.3-1.0x106 
cells/ml, and were subcultured 1 : 2  with fresh medium as necessary or every 60 h.
2.2.3.4 HL60 cells
HL60 cells are a promyelocytic cell line derived in 1977 by leukapheresis from a 
36-year-old patient with acute promyelocytic leukaemia (Collins, S.J. et al. 1978). HL60 
cells were maintained at 2-5x105 cells/ml to minimise spontaneous differentiation and were 
subcultured 1:2 with fresh medium as necessary or every 24-36 h.
2.2.3.5 PLB-985 cells
PLB-985 cells are a subclone o f HL60 cells (section 2.2.3.4) and can be induced 
to differentiate in a similar way to HL60 cells when treated with certain agents (Neildez- 
Nguyen, T.M. et al. 1998). PLB-985 cells and a PLB-985 subline deficient for NOX2 
expression (PLB-985 NOX2' ')were obtained from Mary Dinuaer, Department o f Medical 
and Molecular Genetics, Indiana University, USA. PLB-985 cells express the Phox 
complex and can produce superoxide when treated with TPA (section 3.3.2.2), while PLB- 
985 NOX27' cells cannot produce superoxide via Phox (Zhen, L. et al. 1993). PLB-985 
cells were maintained at 2-5x105 cells/ml and were subcultured 1:2 with fresh medium as 
necessary or every 36 h.
2.2.3.6 HeLa cells
HeLa cells are an adherent cell line derived from cervical cancer cells cultured 
from a 31 year old patient in 1951 (Masters, J.R. 2002). HeLa cells were cultured in 
DMEM containing 10% FCS and 20pg/ml gentamycin. Confluent cultures were detached 
from cell culture plasticware by incubation with 1 ml 500pg/ml trypsin solution containing
0.53mM EDTA (per 25 cm2 vessel surface area) for 3 min. Trypsin was neutralised with 5 
ml warm growth medium and cells were disaggregated by pipetting. Cells were centrifuged 
for 180 g for 5 min and resuspended in fresh growth medium. Cells were subcultured 1:4 
as necessary or every 72 h.
2.2.3.7 Phoenix virus-packaging cells
Phoenix retroviral-packaging cells, which are derived from HEK 293T cells 
(Kinsella, T.M. and Nolan, G.P. 1996), were obtained from Garry Nolan (Dept, o f 
Microbiology and Immunology, Stanford University, MA) and cultured in DMEM
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containing 10% FCS and 20pg/ml gentamycin. Confluent cultures were detached from cell 
culture plasticware as for HeLa cells (section 2.2.3.6 ). Cells were subcultured 1:3 as 
necessary or every 36 h.
2.3 I s o l a t i o n  o f  n o r m a l  h u m a n  CD34+ h a e m a t o p o i e t i c
PROGENITOR CELLS FROM HUMAN CORD BLOOD
2.3.1 Iso latio n  of h u m a n  m o n o n u c lea r  cells from  w hole co rd  blo od
Human cord blood was obtained from healthy frill-term pregnancies at the 
Maternity Unit, University Hospital Wales, Cardiff, UK. These were obtained with 
informed consent and with approval from the South East Wales Research Ethics 
Committee performed in accordance with the 1964 Declaration o f Helsinki. Cord blood 
samples were aseptically collected into tubes containing 500 pi heparin (1000 Ua/ml) and 
mononuclear cells were immediately isolated by density centrifugation over Ficoll- 
Paque®. Briefly, cord blood was diluted with an equal volume o f Hank’s balanced salt 
solution (HBSS) containing 25 mM HEPES, 100 pg/ml gentamycin and 1 U/ml heparin. 
Diluted blood (7 ml) was layered onto Ficoll-Paque® (5 ml) and centrifuged at 400 g for 
40 min (brake disengaged). A distinct layer o f mononuclear cells formed at the plasma- 
Ficoll interface; this layer was recovered and initially washed with RPMI 1640 containing 
5% FCS and 1 U/ml heparin. The washed mononuclear cells were recovered by 
centrifugation at 200 g for 10 min (brake disengaged) and were further washed in RPMI 
1640 containing 10% FCS until platelet contamination had been removed, verified by 
microscopic inspection in a haemocytometer chamber. Mononuclear cells were counted 
using a haemocytometer (section 2 .2 .2 ) and stored under liquid N2 (section 2 .2 .1 ).
2 .3 .2  Iso latio n  of h u m a n  CD34+ h aem atopoietic  cells from  total
MONONUCLEAR CELLS
Human CD34+ haematopoietic progenitor cells were isolated from total 
mononuclear cells by positive selection using the miniMACS® CD34+ Progenitor Cell 
Isolation Kit (Miltenyi Bio tec, Bisley, UK) according to the manufacturer’s instructions. 
Briefly, cryopreserved mononuclear cells prepared as above were thawed (section 2.2.1) 
and resuspended in MACS buffer (section 2.1.2) at 6.5x108 cells/ml. The cells were then
a U equates to one international unit (IU) of heparin, currently equivalent to the activity 
contained in 0.0077 mg of the Second International Standard for heparin (Bangham, D.R. and Mussett, M.V. 
1959).
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incubated for 15 min at 4°C with 50 jul anti-CD34 antibody (clone QBEND/10) per 108 
cells in the presence o f an FcR blocking agent and were subsequently washed with 5 ml 
MACS buffer by centrifugation at 180 g for 5 min. Washed mononuclear cells were then 
incubated at 4°C with magnetic anti-Fc microbeads followed by washing as above. 
Magnetically-labelled CD34+ cells were isolated from total mononuclear cells by passing 
the labelled cells through an MS+ separation column. CD34+ cells were then eluted from 
the column in the absence o f a magnetic field by rinsing the column with 1 ml MACS 
buffer. A small sample o f isolated CD34+ cells (~ lx l04) was stained with anti-human 
CD34 antibody conjugated to R-phycoerythrin (PE) (BD Biosciences), and analysed by 
flow cytometry (section 2.6) to check for purity. Freshly isolated CD34+ cells were 
cultured in supplemented IMDM (IMDM containing 1% BSA fraction V, 20% FCS, 45 
pM beta-mercaptoethanol, 360 pg/ml 30% iron-saturated human transferrin, 100 Ua/ml 
penicillin, lOOpg/ml streptomycin) containing 50 ng/ml huIL-3, huSCF, huFLT3L and 25 
ng/ml huIL-6, huG-CSF and huGM-CSF.
2.4 G e n e r a t i o n  o f  h u m a n  CD34+ h a e m a t o p o i e t i c
PROGENITOR CELLS EXPRESSING H -R A S G12V OR N -R A S G12D
Retroviral transduction presents an extremely effective method o f gene transfer 
to haematopoietic cells. The retroviral infection process involves reverse transcription o f 
the RNA viral genome to DNA and integration o f the viral DNA into the host genome 
(Buchschacher, G.L., Jr. 2001). This method offers the major advantage o f stable gene 
expression, which is maintained in the progeny o f transduced cells as opposed to transient 
gene transfer methods based on DNA transfection, such as calcium phosphate transfection, 
electroporation and liposomal gene transfer. The PINCO amphotrophic retroviral vector 
has previously been shown to effectively deliver genetic material to a variety o f cell types 
including enriched haematopoietic progenitor cells (Grignani, F. et a l 1998) and has been 
engineered to produce extremely high titres when produced in Phoenix virus-packaging 
cells (Pear, W.S. et a l 1993). Finally, the use o f a GFP reporter gene instead o f a drug 
resistance gene eliminates drug-selection regimes and drug-associated artifacts, and 
enables simple measurement o f transduction efficiency by flow cytometry.
Amphotrophic retroviral particles harvested from transfected Phoenix cells have 
a similar structure to MMLV virions, since both are constructed from proteins encoded by
a U equates to one international unit (IU) o f crystalline penicillin G, equivalent to the activity of 
0.5988 pg o f the current International Standard for penicillin.
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the MMLV gag, pol and modified env genes, driven by the MMLV LTR promoter 
sequences. The similarity in virion structure means that recombinant PINCO retroviruses 
infect cells and integrate as proviral DNA into the host genome in an analogous manner to 
MMLV. An important difference is that PINCO derived retroviruses are replication 
deficient, because they do not carry RNA encoding gag, pol or env. Instead, they carry 
recombinant RNA, engineered to contain the MMLV RNA packaging signal sequence (VP). 
This sequence is recognised by viral proteins which package that RNA molecule into a 
virion.
2.4.1 Gener atio n  of r e c o m b in a n t  PINCO pla sm id  DNA e n c o d in g  H-
Ra s g,2v , N -R a sg12D or  control
Ectopic expression o f H-RasG12v or N-RasG12D in normal human CD34+ 
haematopoietic cells was achieved using the PINCO retroviral expression vector (Grignani, 
F. et a l  1998) (Figure 2.1). This vector expresses green fluorescent protein (GFP) as a 
reporter gene. In addition, a modified PINCO vector was produced which expressed the 
reporter gene DsRed. The use of these plasmids allowed the identification o f transduced 
cells by flow cytometry.
Full length cDNA encoding H-Ras was provided by Julian Downward, 
CRUK London Research Institute, UK and cDNA encoding N-RasG12D was provided by 
Alan Hall, University College of London, UK. Control vectors received a non-translated 
DNA stuffer fragment (1.2Kb). The presence o f the stuffer fragment prevented excessive 
expression o f the reporter gene in control cells. This resulted in a similar level o f reporter 
gene expression in all transduced cells. cDNA sequence information is found in Appendix
1. Directional subcloning o f full length cDNAs into the original and modified PINCO 
plasmid was performed previously (Peam, L. et a l 2007; Peam, L. 2008). The presence o f 
the expected inserts in the recombinant PINCO plasmid was verified by agarose gel 
electrophoresis and by direct sequencing (section 2.4.5).
90
CHAPTER 2: GENERAL MATERIALS AND METHODS
PINCO
D sR ed
3'LTR
EBNA1
PGKJ PURO
B
5’ LTR
I
> 1
CMV
+2 kb
Reporter
Gene
+2.7kb
Start of 5’ LTR V BamUl EcoRl
0 kb +0.6Kb +1.8kb +1.9kb
MCS
(not to scale)
Figure 2.1 A limited restriction enzyme map of the PINCO retroviral vector plasmid
(A) The retroviral vector PINCO was used to generate retrovirus encoding H-RasG,2v and 
N-Rasc,l2D. The map shows locations of restriction enzyme recognition sequences and the 
location of major sequences o f interest. Adapted from Grignani, 1998 (Grignani, F. et al.
1998). (B) Diagram represents short section of PINCO plasmid containing multiple cloning 
site (MCS) and flanking sequences of interest. Distances in kilobases (kb) represent 
distance from start of the 5’ LTR sequence to the start of sequences indicated in the 
original PINCO plasmid. Restriction enzyme digestion at the MCS enabled insertion of H- 
RasG12v, N-Ras° 2 0  or control cDNAs as described in section 2.4.1. oriP = EBV origin of 
replication, EBNA1 = EBV EBNA1 gene involved in episomal maintenance, PURO = 
Puromycin resistance gene under control of PGK-1 promoter, pUC = pUC prokaryotic 
control sequence, Amp = Ampicillin resistance gene, LTR = MMLV Long Terminal 
Repeats, T = retroviral RNA packaging signal sequence, CMV = cytomegalovirus 
promoter, GFP = Enhanced green fluorescent protein gene, DsRed = red fluorescent 
protein gene
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2.4.2 T r a n s fo r m a t io n  o f  c o m p e te n t  E s c h e r i c h i a  c o l i  w ith  r e c o m b in a n t
PINCO PLASMID DNA
In order to generate sufficient plasmid DNA for subsequent transfection o f virus- 
packaging cells, plasmid DNA was amplified in Escherichia coli (E.coli). Recombinant 
PINCO plasmid DNA (2.5 pg) was added to one freshly thawed vial o f  competent E.coli 
(One Shot TOP 10®, Invitrogen) followed by gentle tapping to mix.
Following incubation on ice for 30 min, the cells were subjected to heat shock 
(42°C for 30 sec), then returned to ice and allowed to recover on a rotary shaker (225 rpm) 
for 1 h at 37°C in the presence o f SOC medium. During the recovery period, selective 
Luria-Bertani (LB) agar plates were prepared by melting LB agar which was allowed to 
cool to 42°C before adding 50 pg/ml ampicillin. Selective LB agar (30 ml) was poured into 
90 mm petri dishes and allowed to cool in a sterile environment. After the recovery period, 
100 pi o f transformed E. coli suspension was spread on selective LB agar plates using a 
sterile loop and incubated for 16 h at 37°C. Single colonies were harvested and used to 
inoculate 5 ml selective LB broth cultures containing 50 pg/ml ampicillin (added just 
before use) which were incubated for 8 h at 37°C on a rotary shaker as above. These 
‘starter’ cultures were diluted in selective LB broth (300 pi starter culture in 150 ml broth) 
and incubated for 16 h at 37°C on a rotary shaker as above. DNA was purified from these 
bacterial cultures as described in section 2.4.3. Purified DNA was used for transfection of 
Phoenix cells (for transfection method section 2.4.6, for cell line information see section 
2.2.3.7). Additional starter cultures were used to prepare bacterial glycerols (section 2.4.4), 
and to verily successful transformation (section 2.4.5).
2.4.3 Iso latio n  a n d  q u an titatio n  of am plified  r ec o m bin a n t  PINCO
PLASMID DNA
Transformed E.coli which had been incubated in 150 ml selective LB broth for 
16 h at 37°C with on a rotary shaker were collected by centrifugation at 6,000 g for 15 min, 
and high-purity plasmid DNA was obtained using the HiSpeed Midi-Prep DNA isolation 
kit (Qiagen, Crawley, UK) according to the manufacturer’s instructions. This kit is based 
on the principle o f preferential renaturation o f plasmid DNA after alkaline lysis. Purified 
DNA was quantitated using a NanoDrop spectrophotometer (Thermo Fisher Scientific, 
Loughborough, UK) according to the manufacturer’s instructions. The purity o f DNA was 
confirmed by A260/A280 which was 1.8±0.1. Insert integrity was also checked by restriction 
enzyme digestion (section 2.4.5).
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2.4.4 C r y o p r e s e r v a t io n  a n d  th a w in g  o f  t r a n s fo r m e d  E . c o l i
For long term storage o f transformed E. coli, 850 pi o f LB broth cell suspension 
was mixed with 150 pi glycerol and stored at -80°C. Cryopreserved E.coli were recovered 
from storage by streaking selective LB agar plates with a sterile loop dipped into partially 
thawed storage mixture. Selective plates were then incubated for 16 h at 37°C in a dry 
incubator. Single colonies were harvested and expanded in selective LB broth as above 
(section 2.4.2).
2.4.5 Rec o m b in a n t  PINCO pla sm id  DNA ver ifica tio n
To verify the insertion o f H-RasG12v or N-RasG12D or control cDNAs into the 
PINCO plasmid and to verify successful transformation oiE . coli, 5pg PINCO plasmid 
DNA isolated as above was incubated with 50 U EcoRl and BamHl in IX EcoRl buffer 
(all from NEB, Hitchin, UK) for 1 h at 37°C in a water bath. Restriction enzymes and other 
contaminants were removed by passing DNA sample through a QIAquick Spin Column 
(Qiagen) according to the manufacturer’s instructions and eluted DNA was resuspended in 
TE buffer at 50 pg/ml. An agarose gel was prepared by creating a 1% agarose solution in 
TE buffer containing 500 pg/ml ethidium bromide and allowing gel to solidify in a flat-bed 
electrophoresis tank. DNA samples for loading contained 500 ng DNA, 0.34 M glycerol, 
200 pM bromophenol blue and 120 pM xylene cyanol and 20 pi o f sample was loaded per 
lane. Samples were electrophoresed in TE buffer at 80V for 20 min and DNA was 
visualised by UV transillumination using a LAS-3000 digital imaging device (Fujifilm UK 
Ltd., Bedford, UK). The size o f DNA fragments or plasmids was estimated using a 1 Kb 
DNA Ladder (NEB), which was run in parallel with samples. Digital images were 
processed and analysed using AIDA Image Analyzer v4.19 (Fujifilm UK). The 
degradation o f DNA restriction enzyme digestion was compared to expected restriction 
mapping (Figure 2.2A).
The insertion o f the cDNAs into the plasmids was also verified by direct 
sequencing. Sequencing was performed using the BigDye® Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems, Warrington, UK) according to the manufacturer’s 
instructions. This kit provides sequence data based on the principle o f dye-labelled 
dideoxynucleotide terminators first described by Fred Sanger (Sanger, F. and Coulson,
A.R. 1975). Briefly, a sequencing reaction mixture was prepared containing 8 pi o f Ready 
Reaction Mix (containing DNA polymerase, dNTPs and dye-labelled ddNTPs), 10 ng o f 
DNA template (PINCO plasmid) and 3.2 pmol primer in a final volume o f 20 pi o f IX
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BigDye® sequencing buffer. The primers were designed to anneal at PINCO-specific 
sequences 5’ and 3’ o f the MCS respectively (Figure 2.2B). Forward primer sequence was 
5’-TAG AAC CTC GCT GGA AAG GA-3’, reverse primer sequence was 5’-TTA TGT 
AAC GCG GAA CTC CA-3\
Primers were obtained from Euro fins MWG Operon, London, UK. Sequencing 
reactions containing either forward or reverse primers were carried out in a GeneAmp® 
9700 thermal cycler with initial denaturation stage of 96°C for lmin followed by 25 cycles 
of: denaturation at 96°C for 10 sec then annealing at 50°C for 5 sec then extension at 60°C 
for 4 min. Reaction was cooled to 4°C after 25 cycles and held. Sequencing reactions (20 
pi) were passed through a DyeEx 2.0 spin column (Qiagen) and centrifuged at 750 g for 3 
min in order to remove contaminating polymerase and unincorporated dNTPs and ddNTPs. 
Samples were then sequenced using an ABI Prism® 3130x1 Genetic Analyser (Applied 
Biosystems) performed by staff at Core Biotechnology Services (CBS), School o f 
Medicine, Cardiff University, and analysed using SeqMan® II v5.07 (DNAStar Inc., 
Madison, WI).
2.4.6 Tr a n sfec tio n  of Ph o enix  v ir u s -pack ag ing  cell line
PINCO plasmid DNA harvested from transformed E.coli was used to transfect 
Phoenix virus-packaging cells in order to produce recombinant retrovirus. An aqueous 
plasmid DNA solution (450 pi) containing 10-45 pg plasmid DNA and 250 mM CaCL was 
added dropwise to 450 pi o f 2X HEPES-buffered saline (HBS). During the dropwise 
addition, the HBS was bubbled using an automatic pipette, which encouraged a DNA- 
CaCL precipitate to form. The DNA precipitate was allowed to sit undisturbed for 20 min. 
Phoenix virus-packaging cells (see 2.23.1) in logarithmic growth phase at either 60-70% 
confluence (H-RasG12v and N-RasG12D) or 30-40% confluence (control) were incubated 
with 25 pM chloroquine for 5 min at 37°C prior to addition o f the DNA-CaCL precipitate. 
Retrovirus-containing medium (RCM) was harvested 48 and 72 h post-transfection with a 
medium change (8 ml) being made 16 h prior to harvesting. RCM was centrifuged in 
sealed centrifuge buckets at 180 g for 10 min and aliquoted in 1 ml freezing vials before 
snap freezing in liquid nitrogen. RCM was stored at -80°C.
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Figure 2.2 Recombinant PINCO plasmid DNA verification by direct sequencing and 
restriction enzyme digestion
(A) Recombinant PINCO plasmid DNA obtained from ligation reactions was digested with 
restriction enzymes EcoRl and BamHl, electrophoresed, and visualised by UV 
transillumination of ethidium bromide-stained DNA. The figure shows results of digestion 
of PINCO plasmid with H-RasG12v cDNA insert. As expected, a 600bp fragment was 
detected, as well as a ~ 1 2 Kb bands corresponding to the digested and native plasmids. T = 
retroviral RNA packaging signal. (B) Limited sequence map depicting region of PINCO 
plasmid flanked by 5’ and 3’ LTR sequences (red arrows). Location ofiscoRI and BamUl 
recognition sites are labelled, and the annealing sites of forward and reverse primers used 
to confirm cDNA insertion by sequencing are also labelled (heavy black arrows).
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2.4.7 Retr o v ir a l  tr a n sd u c tio n  of no r m a l  h u m a n  CD34+ progenitor
CELLS
Normal human haematopoietic CD34+ progenitor cells obtained from neonatal 
cord blood (section 2.2) were cultured overnight in supplemented IMDM containing 
growth factors as described in section 2.3.2, which promoted cell-cycle entry, a necessary 
condition for successful retroviral transduction. CD34+ progenitor cells were transduced
p i ^ y  m n
with retrovirus encoding H-Ras , N-Ras or control (section 2.4.6) using an 
optimised force pre-loading method (Tonks, A. et a l 2005b) with minor modifications. For 
mock gene transductions, RCM was supplanted with conditioned growth medium from 
untransfected Phoenix cells. Non-treated tissue culture plates were coated with 100 pl/cm 
o f 100 pg/ml reconstituted Retronectin® for two hours at room temperature. Retronectin 
solution was removed and immediately replaced with PBS containing 1% BSA and 
incubated at room temperature for 30 min. During this incubation, 1 ml o f RCM was 
treated with 320 pg/ml polybrene and incubated at 37°C for 20 min. PBS containing 1% 
BSA was then removed from the tissue culture wells and immediately replaced with 
polybrene-treated RCM. These tissue culture plates were centrifuged at 2000 g for 120 min 
after which, the supernatant was removed and immediately replaced by 1 ml o f RPMI 1640 
containing 10% FCS (pre-warmed to 37°C) and plates were incubated for 5 min at room 
temperature. This RPMI 1640 wash was then removed and immediately replaced with 500 
pi o f supplemented IMDM medium (section 2.3.2) containing 1x10s CD34+ cells. Cell 
cultures were then incubated for 16 h at 37°C in a humidified 5% CO2 atmosphere. The 
following day, the infection process was repeated by aspirating the CD34+ cells, re-coating 
the well with virus as above and returning the cells to the virus coated well followed by a 
further 16 h at 37°C in a humidified 5% CO2 atmosphere. On day 3 post-isolation, cell 
transduction frequency was assessed by flow cytometry to detect GFP or DsRed expression 
(section 2.6) and either cryopreserved (section 2.2.1) or continued in culture (section 
2.2.3.1) for determination o f experimental endpoints.
2 .5  W e s t e r n  b l o t t i n g
2.5.1 Cell  ly sis  a n d  protein  prepara tio n
Cells were harvested and counted and centrifuged at 180 g for 5 min. The 
supernatant was removed and the cell pellet was washed twice in ice-cold 10 ml TBS 
followed by centrifugation and removal o f supernatant as above. To ensure full cell
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fragmentation, the washed cell pellet was then flash frozen in liquid N2 and stored at -80°C 
until ready for processing unless otherwise stated. Volumes o f protein extracts were 
recorded during extraction to enable total protein quantitation.
2.5.1.1 Preparation o f  whole-cell protein extracts
Flash frozen cell pellets were thawed on ice with gentle tapping in the presence 
o f 10 pg DNAse I per lxlO6 cells (minimum 10 pg). Thawed cells were resuspended in a 
minimum o f 50 pi ice-cold lysis buffer containing 1% Triton X-100 per lxlO6 cells 
(section 2.1.2) and incubated on ice for 30 min with occasional vortexing to promote 
protein solubilisation. Detergent-insoluble material was sedimented by centrifugation at 
16,000 g for 5 min at 4°C and supernatants were recovered to fresh tubes and protein 
concentration was determined (section 2.5.2). Protein extracts were stored at -80°C.
2.5.1.2 Preparation o f  cytosol-membrane fractionated protein extracts
Flash frozen cell pellets were thawed on ice with gentle tapping in the presence 
o f 4 pg DNAse I per lxlO5 cells (minimum 10 pg). Thawed cells were resuspended in 20 
pi ice-cold lysis buffer (no detergent) per lxlO5 cells (minimum volume 50pl). A 
maximum o f 100 pi o f this cell suspension was transferred to a fresh tube and was flash 
frozen in liquid N2 followed by rapid thawing in a 37°C water bath, taking care to maintain 
the sample at 0°C or below. This freeze-thaw cycle was repeated followed by 
centrifugation o f the sample at 16,000 g for 1 h at 4°C. The supernatant (containing 
cytosolic proteins) was carefully removed and stored in a fresh tube on ice and the pellet 
(membrane fragments) was resuspended in 25 pi ice-cold lysis buffer containing 1% Triton 
X-l 00. The resuspended pellet was incubated on ice for 30 min with occasional vortexing 
followed by centrifugation at 16,000 g for 15 min at 4°C. The supernatant (containing 
soluble membrane associated proteins) was transferred to a fresh tube and both fractions 
were stored at -80°C.
2.5.1.3 Preparation o f  cytosol/membrane-nucleus fractionated protein extracts
Cells were washed in TBS as in section 2.5.1 and transferred into fresh tubes. 
Separate protein extracts containing enriched cytosol, membrane and nuclear proteins were 
obtained using a Cellular Fractionation Kit (Perkin Elmer, Waltham, MA) according to the 
manufacturer’s instructions. Briefly, cells were washed in 2 ml Wash Buffer by 
centrifugation at 300 g for 10 min. Washed cells were resuspended in 500 pi ice-cold
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Cytosol Protein Buffer containing 2.5 pi Protease Inhibitor solution per 3x106 cells and 
incubated on ice for 10 min on a rotary shaker. Detergent-insoluble material was 
sedimented by centrifugation at 1000 g for 10 min at 4°C, and the supernatant (containing 
cytosol proteins) was stored in a fresh tube at 4°C. The detergent-insoluble pellet was 
resuspended in 500 pi ice-cold Membrane/Organelle Protein buffer containing 2.5 pi 
Protease Inhibitor solution per 3x106 cells and incubated on ice for 30 min on a rotary 
shaker. Detergent-insoluble material was sedimented by centrifugation at 5500 g for 10 
min at 4°C and the supernatant (containing membrane and organelle proteins) was added to 
the tube containing the cytosol proteins and the mixed protein extract containing cytosol, 
membrane and organelle proteins was stored at -80°C. The detergent-insoluble pellet was 
resuspended in 500 pi ice-cold Nuclear Protein buffer containing 5 pi Protease Inhibitor 
and 1.5 pi Nuclease solution per 3x106 cells and incubated on ice for 10 min on a rotary 
shaker. Detergent-insoluble material was sedimented by centrifugation at 6800 g for 10 
min at 4°C and the supernatant (containing nuclear proteins) was transferred to a fresh tube 
and stored at -80°C. Nuclear protein extracts were concentrated into a 100 pi volume using 
a Microcon YM-3 Ultracentrifuge filter (Millipore, Watford, UK). Nuclear extract (500 pi) 
was added to a YM-3 filter unit assembly and the unit was centrifuged at 12,000 g for 50 
min. Protein concentrate was recovered by inverting the filter unit and placing into a clean 
tube and centrifuging at 180 g for 5 min.
2.5.2 Protein  q u a n tita tio n
Protein concentration in the protein extracts obtained above were determined 
using Bradford’s reagent (Sigma-Aldrich; based on Coomassie Blue G-250 dye (Bradford, 
M.M. 1976)). Bradford’s reagent was diluted with an equal volume o f water to create 
sufficient diluted reagent (190 pi per test well). Protein extracts were diluted a minimum of 
10 fold and 10 pi o f  diluted extract was mixed in a 96-well plate with 190 pi diluted 
Bradford’s reagent in duplicate and absorbance at 590 nm was measured using a 
spectrophotometer. BSA standard solutions were assayed in duplicate alongside protein 
extract samples to create a standard curve, which enabled calculation o f protein extract 
concentration.
In the case o f fractionated protein extracts obtained from the Cellular 
Fractionation Kit, where the formulation o f the buffers are proprietary, the DC Protein 
Assay (BioRad, Hemel Hempstead, UK) was used to quantitate protein concentration 
according to the manufacturer’s instructions. The DC Protein Assay is based on a modified 
Lowry method (Lowry, O.H. et al. 1951), and is less sensitive to detergent contamination
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than Bradford’s method and the original Lowry method, but is also less sensitive to protein 
and therefore requires the use o f undiluted protein extract for the assay. Briefly, 20 pi 
reagent S was mixed with each 1 ml o f reagent A required (25 pi o f mixed reagent per 
sample well). Mixed reagent (25 pi) was mixed with 5 pi cell lysate and 200 pi o f reagent 
B was added. Samples were incubated at room temperature for 15 min before reading 
absorbance at 750 nm.
2.5.3 Pro tein  electro ph o resis a n d  electroblotting
Protein electrophoresis and electroblotting was performed using the NuPAGE® 
X-Cell II® electrophoresis and electroblotting system. These, and all consumables required 
for the procedure including gels, buffers and membranes were manufactured by Invitrogen.
Prior to gel electrophoresis, protein extracts were incubated for 10 min at 70°C 
in the presence o f IX LDS sample buffer and 50 mM DTT to promote denaturation o f 
proteins and reduction o f disulphide bonds. The final concentration o f protein in the 
denatured extract was controlled to ensure an equal mass o f protein was loaded in all lanes 
(determined by the sample with the lowest protein concentration).
Sub cellular protein fractions were loaded in a mass ratio that reflected their 
contribution to the total cellular protein. This ratio was given by: 1 -s- (sub cellular fraction 
protein mass yield total protein mass yield). This method enabled sub cellular fractions 
to be loaded in ‘cell equivalents’. Denatured protein samples (0.5-10 pg protein per lane, 
depending on the experiment) were loaded onto a 4-12% Bis-Tris HC1 polyacrylamide gel 
and electrophoresis was performed at 200 V for 50 min in the X-Cell II® Mini-Cell in the 
presence o f MOPS-SDS running buffer unless otherwise stated. Electrophoresed proteins 
were then electroblotted from the electrophoresis gel onto nitrocellulose membranes using 
the X-Cell II® Blot Module. Briefly, gels were extracted from their cassettes and placed 
into a stack consisting o f 2 spacer sponges, the gel and membrane (with membrane closest 
to the positive electrode) sandwiched between blotting paper and 3 further spacer sponges. 
The module was then placed in the X-Cell II® Mini-Cell and filled with transfer buffer 
containing IX NuPAGE® Transfer buffer and 10% methanol. Proteins were then 
electroblotted at 30 V for 1 h. Following electroblotting, membranes were washed twice 
with 10 ml o f dH20 for 5 min at room temperature. Electroblotted membranes were 
incubated with Ponceau S solution (section 2.1.2) for 30 sec to visualise transferred protein 
and check for equal protein loading. When required this also enabled membrane cutting 
between lanes. Following two further washes with dH20 as above, membranes were 
incubated with 10 ml TBS-T containing 5% membrane blocking agent (provided as part o f
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the ECL Advance® Western Blotting Detection Kit, GE Healthcare, Amersham, UK, 
section 2.5.4) for 1 h at room temperature. Blocked membranes were rinsed thrice with 10 
ml TBS-T, followed by one 15 min wash and three subsequent 5 min washes all with 10 ml 
TBS-T.
2.5.4 IMMUNOBLOTTING
Blocked membranes were incubated for 16 h at 4°C in the presence of diluted 
primary antibody(ies) in TBS-T containing 5% blocking agent and diluted (lxlO4 fold) 
Phosphatase Inhibitor Cocktail (Santa Cruz). Optimum dilution o f previously untested 
primary antibody was determined empirically. Details o f particular antibodies used will be 
given in the appropriate section of Results. For estimation o f molecular weight o f proteins, 
outer lanes o f gels were loaded with 10 pi o f IX LDS buffer containing a 20 fold dilution 
o f MagicMark XP® Protein Standard (Invitrogen). To check for equal loading, membranes 
were incubated overnight at 4°C with one o f the following antibodies: 20 ng/ml anti- 
GAPDH (Santa Cruz), 10 ng/ml anti-/3-actin (Abeam, Cambridge, UK) or 10 ng/ml anti-a 
tubulin (Calbiochem, Nottingham, UK). Following primary stage antibody binding, 
membranes were rinsed thrice, washed once for 15 min and thrice for 5 min as above. 
Washed membranes were then incubated with diluted (5x104 fold) HRP-conjugated anti­
mouse or anti-rabbit secondary antibody (GE Healthcare) in TBS-T containing 2% 
membrane blocking agent for 1 h at room temperature. Finally, membranes were rinsed 
thrice, washed once for 15 min and thrice for 5 min as above.
Electroblotted proteins labelled with primary and secondary antibodies were 
visualised using ECL Advance® Western Blotting Detection Kit (GE Healthcare).
Immunolabelled membranes were drained of excess wash buffer and incubated under low 
light for 5 min at room temperature with reconstituted ECL Advance®, a substrate o f HRP 
which becomes chemiluminescent once cleaved. Following incubation, excess ECL 
Advance® solution was decanted and excess solution was removed from edge using 
blotting paper. Membranes were placed between two sheets of clean acetate and a LAS- 
3000 digital imaging device (Fujifilm UK) was used to detect ECL Advance® 
chemiluminescence. Digital images were processed and analysed using AIDA Image 
Analyzer v4.19 (Fujifilm UK).
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2 .6  F l o w  c y t o m e t r i c  a n a l y s i s
Cells to be analysed by flow cytometry were first recovered from growth 
medium by centrifugation at 180 g for 5 min and then washed by resuspension in 1 ml 
staining buffer (section 2.1.2) per lxlO6 cells unless otherwise stated. Following 
centrifugation as above, washed cells were resuspended in 25 pi staining buffer (unless 
otherwise stated) and incubated with primary stage antibodies or reagents according to the 
experimental protocols described in the appropriate section o f Results. Subsequent staining 
stages (secondary, tertiary, etc) were separated by a wash step involving resuspension in 
200pl staining buffer followed by centrifugation and resuspension in 25 pi o f staining 
buffer unless otherwise stated. In the case o f conjugated antibodies, background 
fluorescence was established by isotype- and manufacturer-matched irrelevant control 
antibodies conjugated to the same fluorochromes. In the case of flow cytometric 
measurement o f reporter gene expression, the autofluorescence o f mock-infected cultures 
defined the threshold for GFP or DsRed positivity, with the threshold for positive staining 
was set to 95% o f background fluorescence. Before acquisition, samples to be analysed 
were resuspended in a maximum of 50 pi FACSflow unless otherwise stated. Data were 
acquired using a FACSCalibur flow cytometer (BD Biosciences) and a minimum o f 10,000 
events were collected (unless otherwise stated) and analysed using FCS Express v3 (De 
Novo Software, Los Angeles, CA). Debris was excluded from analysis using forward and 
side scatter characteristics.
In some experiments, allophycocyanin(APC)-conjugated microbeads (BD 
Biosciences) were used to control for cell recovery as follows. A consistent number o f 
microbeads was introduced into each sample by adding 50 pi microbead suspension per 
well. Control microbead samples (50 pi microbead suspension alone in triplicate) were 
also prepared. After sample acquisition, microbeads were gated in the basis o f APC 
fluorescence and forward and side scatter characteristics and counted using FCS Express. 
Microbead data was used to calculate a correction factor for each sample; Correction factor 
= (Mean number o f beads in microbead controls -s- number o f beads in sample).
2 .7  S t a t i s t i c a l  a n a l y s e s
Significance o f difference was determined using one-way ANOVA with Tukey’s 
Honestly Significant Differences Test, Mann-Whitney Test or Student’s T-test using 
Minitab vl3.0 (Minitab Ltd., Coventry, UK).
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3 Examination of ROS production by human CD34+ haematopoietic 
cells
Activating Ras mutations are detected in 15-25% of AML cases (Bowen, D.T. et 
a l 2005) and are strongly associated with increased ROS production in human cell lines 
and cancer models (Liu, R. et a l 2001; Seru, R. et a l 2004; Lee, A.C. et a l 1999), and in 
animal models o f leukaemia (Rassool, F.V. et a l 2007; Sallmyr, A. et a l 2008) (section 
1.4.4). However, it is not currently known whether these mutations lead to increased ROS 
production in human primary haematopoietic cells.
It is generally accepted that most genetic lesions leading to leukaemia are 
sustained by early haematopoietic progenitor cells including, but not limited to, CD34+ 
cells (Blair, A. and Pamphilon, D.H. 2003). Therefore using a model system based on 
normal human CD34+ haematopoietic progenitor cells, this chapter examined the impact o f 
Ras mutant expression (H-RasG12v or N-RasG12D) on the capacity o f CD34+ cells to 
produce ROS. Recently, ROS have been implicated in cell signalling in a variety of normal 
tissues including haematopoietic cells (section 1.4.3.2). The fact that many cancers 
overproduce ROS suggests that the signalling functions o f ROS may be dysregulated in 
cancer cells. However, the high reactivity and short life-span o f most ROS presents 
challenges for the detection and quantitation o f ROS in physiological systems. This study 
used several assays to detect superoxide and H2O2 . To detect superoxide, Diogenes and 
EPR spectroscopy using the spin trap probe DEMPO were used, whilst H2 O2 was detected 
using Amplex Red (section 1.4.5). The use o f several techniques in parallel served to 
overcome some of the limitations of the techniques by providing corroborating evidence. 
Production o f ROS was assayed at several timepoints during cell culture, from day 3 
(immediately following isolation) up to day 14. During this period, primary haematopoietic 
cells (which are predominantly CD34+ progenitor cells at day 3) undergo morphological 
and phenotypic changes which accompany myeloid lineage commitment and maturation. 
By day 7 o f culture, CD34+ cells are scarce, and mature neutrophils, and macrophages are 
visible. These cells are professional ROS producing cells which must be considered when 
evaluating the results.
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3.1  A im s
To investigate the effects o f activated Ras expression on ROS production by 
primary human CD34+ haematopoietic cells, this Chapter aims to:
• Optimise and validate assays for the detection o f ROS. This will provide 
important assay conditions for the detection o f superoxide and H2 O2 in human 
CD34+ haematopoeitic progenitor cells.
• Determine whether activated Ras can induce ROS production in human CD34+ 
haematopoietic progenitor cells and to identify the specific ROS produced.
• Determine the source o f ROS production in these cells. This will be achieved 
using organelle specific ROS probes in combination with appropriate ROS 
inhibitors.
3 .2  M a t e r i a l s  a n d  M e t h o d s
3.2.1 D etectio n  of su per o x ide  u sin g  D iogenes
In order to detect superoxide radicals, the chemiluminescent probe Diogenes 
(National Diagnostics, Atlanta, GA) was used. The following sections give an overview of 
the mechanism by which Diogenes detects superoxide. This is followed by a description of 
the validation o f Diogenes as a sensitive probe for superoxide; optimisation o f Diogenes 
assay conditions and the use o f optimised conditions for measurement o f superoxide 
production by transduced human CD34+ haematopoietic progenitor cells. Diogenes reagent 
was reconstituted in dH2 0  according to the manufacturer’s instructions, and aliquots were 
flash frozen and stored in liquid N2 .
3.2.1.1 Principles o f  superoxide detection by Diogenes
The Diogenes probes consists o f two components; luminol, which reacts with 
superoxide to form an electronically excited product, which subsequently returns to a 
stable unexcited state; releasing a photon. The second component is a proprietary enhancer 
which is stimulated by photons emitted by luminol to emit several additional photons.
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Thus the enhancer amplifies luminol chemiluminescence, offering an increased 
sensitivity over luminol alone. Several reaction steps are necessary for luminol to generate 
photons in the presence o f superoxide. These reactions are shown in Figure 3.1.
3.2.1.2 Determination o f  sensitivity and specificity o f Diogenes to superoxide radicals
and H 2 O2
To confirm the specificity o f Diogenes for superoxide, Diogenes was exposed to 
superoxide radicals generated using a cell-free system. Since superoxide radicals can 
dismutate to form H2O2 , the sensitivity o f Diogenes to H2O2 was also determined.
Superoxide radicals were generated as a by product o f the oxidation of 
hypo xanthine (HX) by xanthine oxidase (Roubaud, V. et al. 1997). HX was dissolved in 
0.1 M NaOH to create a 40 mM stock HX solution. HX working solutions were created by 
diluting HX stock in Diogenes buffer (section 2.1.2) to 1.3 fold greater than the final HX 
concentration (0 to 1.8 mM HX) to allow for addition of Diogenes. Working solutions (150 
pi) were added to a white FluoroNunc Maxisorp 96 well plate (Thermo Fisher Scientific) 
followed by 50 pi o f  reconstituted Diogenes reagent. To initiate superoxide production, 50 
mU o f xanthine oxidase dissolved in 5 pi Diogenes buffer was added to each well, and 
time-resolved chemiluminescence was measured using a Dynex MLX Luminometer 
(Dynex Technologies Ltd., Worthing, UK). All reaction volumes contained 0.1 mM DTPA 
as a chelating agent to suppress unwanted metal ion-catalysed side-reactions such as the 
Fenton reaction (section 1.4.1.1).
To test whether Diogenes was reactive with H2O2 , stock H2O2 (8.8 M) was 
diluted in Diogenes buffer to 1.3 fold greater than the final H2O2 concentration, to account 
for Diogenes addition. Diluted H2O2 (150 pi) was added to a 96-well plate followed by 
addition o f 50 pi reconstituted Diogenes and measurement of time-resolved 
chemiluminescence as above.
3.2.1.3 Ability o f Diogenes to detect superoxide generated by PLB-985 cells stimulated 
with TPA
PLB-985 cells are a promyelocytic cell line and are a subclone o f HL60 cells 
(section 2.2.3.5). PLB-985 cells produce superoxide when treated with 12-0- 
Tetradecanoylphorbol-13-acetate (TPA).
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Figure 3.1 Generation of photons by Diogenes in the presence of superoxide
Luminol is an acylhydrazide which undergo simple ionisation to form the luminol anion as 
shown in (A). The luminol anion may then be oxidised to form a luminol radical (B), and 
this luminol radical can then react with superoxide to form an unstable endoperoxide (C). 
The endoperoxide rapidly decomposes to form nitrogen gas and an excited aminopthallate 
(D), which returns to the ground state releasing a photon (hv) (E). The emitted photon then 
stimulates the Diogenes enhancer to release several more photons (E), providing a means 
o f amplification o f the luminol chemiluminescent signal. Adapted from Faulkner, 1993 
(Faulkner, K. and Fridovich, I. 1993).
105
CHAPTER 3: CHARACTERISATION OF ROS PRODUCTION
TPA is a phorbol ester which activates PKC iso forms and results in downstream 
activation o f Phox, a member o f the NOX family o f oxidases (Lambeth, J.D. 2004). As a 
negative control, a subline o f PLB-985 cells deficient for NOX2 expression (PLB-985 
NOX2'~ cells) were used. Without NOX2, these cells cannot produce superoxide via Phox 
(Zhen, L. et al. 1993).
To confirm whether Diogenes was able to detect superoxide production by PLB- 
985 cells stimulated with TPA, both PLB-985 and PLB-985 NOX2'7' cells (1.5xl05 per 
well) were washed twice by centrifugation (as above) in 10 ml PBS and resuspended in 
Diogenes buffer at lxlO6 cells/ml. Cell suspension (150 pi; 1.5xl05 cells) was added to a 
FluoroNunc Maxisorp 96 well plate in triplicate and reconstituted Diogenes reagent (50 pi) 
was added to the cell suspension followed by either 1 pi o f 200 pM TPA dissolved in 
DMSO or 1 pi DMSO alone. Time-resolved chemiluminescence was measured as above.
3.2.1.4 Optimisation o f detection o f  superoxide production by transduced CD34+
haematopoietic progenitor cells
The optimum conditions for detection o f superoxide by Diogenes were 
determined by varying the concentration o f Diogenes reagent and the number o f cells used 
in the assay.
To determine optimum cell numbers for the Diogenes assay, transduced CD34+
p  1 9 V  .
cells expressing H-Ras or controls (day 8) were recovered from growth medium by 
centrifugation at 180 g for 5 min. Cells were washed twice in 10 ml PBS by centrifugation 
as above, and the washed cell pellet was resuspended in Diogenes buffer at 0.1-3xl06 
cells/ml. Cell suspension (150 pi; 0.15-4.5xl05 cells) was added in triplicate to white 
FluoroNunc Maxisorp 96 well plates followed by 50 pi reconstituted Diogenes reagent.
The effect o f changing Diogenes concentration was also examined. Transduced 
CD34+ cells were resuspended in Diogenes buffer at 0.75x106 cells/ml, and 100 pi o f cell 
suspension (7.5x104 cells) was added in triplicate to a white FluoroNunc Maxisorp 96 well 
plate followed by either 50pl reconstituted Diogenes reagent and 50 pi Diogenes buffer or 
100 pi reconstituted Diogenes reagent alone; to create a final reaction volume o f 200 pi. 
Time-resolved chemiluminescence was then measured as above.
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3.2.1.5 Measurement o f  superoxide production by transduced CD34+ haematopoietic 
progenitor cells using optimised conditions
Transduced CD34+ cells expressing H-RasG12v, N-RasG12D or control (day 3 to 
14) were washed twice in 10 ml PBS by centrifugation at 180 g for 5 min and resuspended 
in Diogenes buffer at lxlO6 cells/ml. Cell suspension (150 pi) was assayed in triplicate in 
white FluoroNunc Maxisorp 96 well plates. Reconstituted Diogenes (50 pi) was 
immediately added and chemiluminescence was recorded as above. Some experiments 
were performed in the presence o f one o f the following reagents: 5 pg/ml SOD; 1 pM 
TPA; 50 pM diphenyleneiodonium (DPI) or 1 mM apocynin (NOX family oxidase 
inhibitors); 5 pM rotenone (an inhibitor o f the mitochondrial electron transport chain); 100 
pg/ml purified catalase (40,000-60,000 Ua/mg protein), all purchased from Sigma-Aldrich.
3.2.1.6 Measurement o f  superoxide produced by stimulated primary peripheral blood 
monocytes
In order to compare the level o f  constitutive superoxide production o f transduced 
CD34+ cells to that o f the phagocytic oxidative burst, normal human peripheral blood 
monocytes were isolated from healthy donors as follows. Freshly isolated (less than 8 h) 
venous peripheral blood was diluted 2 fold with sterile PBS and 35 ml diluted blood was 
layered onto 15 ml Ficoll-Paque®, after which total mononuclear cells were isolated from 
the diluted blood by density centrifugation as described in section 2.3.1.
CD14+ peripheral blood monocytes were isolated from total mononuclear cells 
by depletion o f cells expressing non-monocytic markers using the miniMACS® Monocyte 
isolation kit according to the manufacturer’s instructions. Briefly, mononuclear cells were
o
resuspended in MACS buffer (section 2.1.2) at 3x10 cells/ml. The cells were then 
incubated for 15 min at 4°C with 10 pi biotinylated antibody cocktail (containing 
biotinylated antibodies raised against CD3, CD7, CD16, CD19, CD56, CD123 and 
glycophorin A) per 108 cells in the presence o f an FcR blocking agent. Following 
incubation, an additional 30 pi o f MACS buffer was added per 108 cells followed by
o
incubation for 15 min at 4°C with 20 pi o f anti-biotin microbeads per 10 cells.
Labelled cells were washed with 5 ml MACS buffer and recovered by 
centrifugation at 180 g for 5 min. Washed cells were passed through an MS+ separation 
column and unlabelled cells were collected in the column effluent. To maximise CD14+
a One unit (U) will decompose 1.0 pinole of H2O2 per min at pH 7.0 at 25 °C, while the H2O2 
concentration fells from 10.3 to 9.2 mM, measured by the rate o f decrease o f A240.
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cell enrichment, column effluent was passed through a second MS+ column and the 
effluent obtained was centrifuged at 180 g for 5 min. The supernatant was removed and the 
cell pellet was resuspended in RPMI 1640 containing 10% FCS, 100 IU/ml penicillin and 
lOOpg/ml streptomycin and incubated at 37°C in humidified 5% CO2 atmosphere. A small 
sample o f isolated effluent cells (~ lx l0 4) was stained with anti-human CD 14 antibody 
conjugated to FITC (Dako Cytomation, Ely, UK), and analysed by flow cytometry (section 
2.6) to check for CD14 positivity. Isolated peripheral blood monocytes were assayed using 
optimised Diogenes conditions as described in section 3.2.1.5. Immediately before 
measuring time-resolved chemiluminescence, monocytes were stimulated with 250 pg/ml 
opsonised zymosan. Opsonised zymosan was prepared as previously described (Tonks, A. 
et al. 2005a).
3.2.1.7 Calculation o f  total superoxide production measured using Diogenes
Diogenes chemiluminescence traces were plotted as a curve with the light 
emission rate (measured in relative light units (RLU) per min) on the y axis and time (min) 
on the x axis (some examples of the curves obtained are shown in Figure 3.7). Using the 
curves generated during each assay, the total light emission for each assay was determined 
by finding the area under the curve using the trapezium rule, equivalent to the total light 
emission (given in RLU). This RLU value was used as a measure o f total superoxide 
production during the assay.
3.2.2 D etection  of su per o x ide  a n io n  pro ductio n  b y  h u m a n  CD34+
PROGENITOR CELLS USING EPR
To confirm the production o f superoxide detected by Diogenes 
chemiluminescence, EPR spectroscopy was performed. EPR spectroscopy is a technique 
which can detect the presence of unpaired electrons using spin-trap probes (section 
1.4.5.3). This is o f relevance to ROS detection because several important ROS are radicals 
(section 1.4.1).
The spin-trap probe 5-(diethoxyphosphoryl)-5-methyl-l-pyrroline-N-oxide 
(DEPMPO) (Axxora, Nottingham, UK) was used to capture and detect radical species 
generated by transduced cells. Transduced CD34+ cells were washed by centrifugation at 
180 g for 5 min in 10 ml PBS and resuspended at lxlO7 cells/ml in Diogenes buffer. Cell 
suspension (150 pi) was placed in a quartz cuvette in the presence o f 60 mM DEPMPO 
prior to detection o f EPR spectra. EPR spectra were detected in ten scans o f 60 sec at 37°C
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using a Varian 104 EPR spectrometer (Varian Inc., Palo Alto, CA) using X-band 
microwave radiation (9.5GHz). Typical recording conditions were field centre: 3378 Gauss 
(G), gain: 2x105, modulation amplitude: 2.0, time constant: 0.25, microwave power: 10 
mW, field range: 160 G. A similar xanthine oxidase system to that used in Diogenes 
experiments was used as a positive control for superoxide detection. Background was 
established using DEPMPO probe alone. EPR spectral data was recorded and analysed 
using ‘in-house’ software developed at the Wales Heart Research Institute (WHRI),
Cardiff University, UK. This study gratefully acknowledges the expert assistance o f Dr P. 
E. James (WHRI, Cardiff University, UK) in operation o f the Varian 104 EPR 
spectrophotometer.
3.2.3 D etection  of m ito ch o n drial  ROS pro duc tio n  u sin g  M ito SOX
Superoxide can be produced via the NOX family o f oxidases (Lambeth, J.D. 
2004) or via the mitochondrial electron transport chain (Murphy, M.P. 2009). In order to 
determine whether mutant Ras increased superoxide production in CD34+ cells via the 
ETC, mitochondria-specific superoxide was measured using MitoSOX (Invitrogen). 
Transduced CD34+ cells (day 5 to 7; 2.5x104 per test) were washed twice by centrifugation 
at 180 g for 5 min in 10 ml warm PBS and resuspended in 25 pi PBS followed by 
incubation with 5 pM MitoSOX for 15 min at 37°C. Cells were washed by centrifugation 
at 180 g for 5 min with 1 ml FACSflow (BD Biosciences) and were resuspended in 50 pi 
FACS flow prior to flow cytometric analysis (section 2.6). For some experiments, cells 
were incubated for 15 min at 37°C prior to MitoSOX treatment with either 50 pM rotenone 
(Sigma-Aldrich) as a positive control or 5 pM Iron (III) 5, 10, 15, 20-tetrakis-4- 
carboxyphenyl porphyrin (FeTCPP), (Frontier Scientific Inc., Logan, UT) as a negative 
control. Rotenone is a mitochondrial poison which inhibits mitochondrial ETC complex I 
(Grivennikova, V.G. and Vinogradov, A.D. 2006), and can lead to increased superoxide 
production (Indo, H.P. et al. 2007). FeTCPP is a membrane-permeable SOD mimetic (Wu, 
A.S. etal. 2003).
3.2.4 D etection  of H20 2 u sin g  A m plex  Red
3.2.4.1 Principle o f  H2 O2 detection by A mplex Red
The Amplex Red probe is a substituted phenoxazine molecule which is not 
fluorescent. The probe can be oxidised by H20 2 in the presence o f horseradish peroxidase
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(HRP) to form a red-fluorescent product, resurofin, with an excitation maximum o f  571 nm 
and an emission maximum o f 585 nm (Figure 3.2).
N'
COCH3
10-acetyl-3,7-dihydro xyphenoxazine 
(Amplex Red)
H20 2
+
HRP
Resurofin
Figure 3.2 Oxidation of Amplex Red by H2O2 in the presence of HRP to form 
resurofin
3.2.4.2 Detection o f  H 2 O2 production by human CD34+ progenitor cells using Amplex
Red
Superoxide can dismutate to H2O2 spontaneously or via a reaction catalysed by 
SOD (Bannister, J.V. et al. 1987). In order to detect H2O2, the H202-sensitive fluorescent 
probe Amplex Red (Invitrogen), was prepared according to the manufacturer’s 
instructions. Briefly, Amplex Red working solution was prepared, containing 100 pM 
Amplex Red reagent, 0.2 Ua/ml horseradish peroxidase (HRP) dissolved in Krebs-Ringer 
phosphate-glucose buffer (KRPG buffer; section 2.1.2). Transduced CD34+cells (day 4 to 
5; 2x105 per test) were resuspended at lxlO6 cells/ml in KRPG buffer for 4 h at 37°C. 
Subsequently the cell suspension was centrifuged at 180 g for 5 min and the conditioned 
medium was harvested by aspiration. Conditioned medium (50 pi) was added in triplicate 
to a 96-well fluorescent assay plate (Thermo Fisher Scientific) and the reaction was 
initiated by adding 50 pi o f Amplex Red working solution prepared above. Amplex Red 
fluorescence development was recorded for 15 min at 37°C using a FluoStar® Optima 
instrument (BMG Labtech, Aylesbury, UK) using excitation wavelength o f 540 nm and a 
590 nm emission filter. A H2O2 standard curve was included in each experiment to 
determine H2O2 concentration in conditioned medium. To prepare the H2 O2 standard 
curve, H2O2 (0-20 pM) was diluted in 50 pi KRPG buffer and added to a 96-well 
fluorescent assay plate followed by 50 pi Amplex Red working solution. After dilution
a One unit (U) will form 1 mg purpurogallin from pyrogallol in 20 sec at pH 6.0 at 20 °C.
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with 50 pi Amplex Red working solution, the final concentration o f H2O2 standards were 
0-10 pM.
3.2.5 Me a su r e m e n t  of su per o x id e  pro ductio n  in  prim ar y  m urine  Sc a -1+
HAEMATOPOIETIC CELLS EXPRESSING N-RASG12D
In order to determine the contribution o f NOX2 to ROS production promoted by 
activated Ras, N-RasG12D was expressed in bone marrow-derived Sca-1+ cells obtained 
from either wild-type or NOX2 deficient mice (generated previously (Pollock, J.D. et al. 
1995)). Wild-type or NOX2 ' C57BL/6 male littermates (16 weeks old); killed by cervical 
dislocation were kindly donated by Professor A. Shah, King’s College Hospital, London. 
Deceased mice were immersed in 70% ethanol and both femurs and tibiae were excised 
aseptically. Muscle and ligament tissue was removed from the bones, and the ends o f  the 
bones were cut off using a sterile scalpel. The bone-channels were flushed thrice with 
RPMI using a 26 G needle into a 30 mm petri dish containing 10 ml RPMI. Bone-marrow 
derived cells were collected by centrifugation at 180 g for 10 min and Sca-1+ cells were 
positively selected using a Sca-1+ cell isolation kit (Miltenyi Biotec) according to the 
manufacturer’s instructions. Total bone marrow cells were resuspended in MACS buffer 
(section 2.1.2) at 6.5x108 cells/ml. The cells were then incubated for 15 min at 4°C with 50
Q
pl anti-Sca-1 antibody conjugated to PE (clone D7) per 10 cells in the presence o f an FcR 
blocking agent and were subsequently washed with 5 ml MACS buffer by centrifugation at 
180 g for 5 min. Washed bone marrow cells were then incubated at 4°C with magnetic 
anti-PE microbeads followed by washing as above. Magnetically-labelled Sca-1+ cells 
were isolated by passing the labelled cells through an MS+ separation column. Sca-1+ cells 
were then eluted from the column in the absence of a magnetic field by rinsing the column 
with 1 ml MACS buffer. Freshly isolated CD34+ cells were cultured in supplemented 
IMDM (as described in section 2.3.2) containing 50 ng/ml muIL-3, muSCF, huFLT3L and 
25 ng/ml huIL-6, huG-CSF and muGM-CSF.
Isolated Sca-1+ cells were then transduced with N-RasG12D or control using the 
PINCO vector as described in section 2.4.7. Following transduction (day 3), isolated Sca- 
1+ cells were recovered from growth medium by centrifugation at 180g for 5 min and 
cultured as described in section 2.2.3.2. A small sample o f isolated Sca-1+ cells (~ lx l0 4) 
was stained with anti-Sca-1 antibody conjugated to PE, and analysed by flow cytometry as 
described in section 2.6 to check for purity. Superoxide production by transduced Sca-1+ 
cells was assayed on day 6 o f culture using Diogenes, as described in section 3.2.1.5.
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3 .3  R e s u l t s
3.3.1 E c to p ic  e x p r e s s io n  o f  m u ta n t  H -R a sg12v a n d  N -R a sg12D in  n o r m a l  
HUMAN CD34+ HAEMATOPOIETIC PROGENITOR CELLS
This study used a primary human CD34+ haematopoietic cell model to 
investigate the effect o f mutant Ras expression on ROS production. Human CD34+ 
haematopoietic cells were positively selected from cord-blood mononuclear cells and
• C I O V
ectopic expression o f H-Ras or N-Ras in these cells was achieved by retroviral 
transduction using the PINCO expression vector (which encodes GFP as a reporter gene). 
Control cells expressed GFP alone. Transduced human CD34+cells were analysed for GFP 
expression by flow cytometry 24 h after retroviral transduction (section 2.4.7). Figure 3.3A 
shows that 70±7% of controls expressed GFP whereas H-RasG12v and N-RasG12D had a 
transduction frequency o f 57±6% and 58±7% respectively. To ensure that the transduced 
cell populations were still enriched for CD34 expression, flow cytometric analysis was 
performed immediately after retroviral transduction. These experiments demonstrated that 
control and Ras-transduced cells were predominantly CD34+ (Figure 3.3B and C; see also 
Appendix 2).
Expression o f GFP is an indirect measure o f transgene expression; therefore 
Western blotting was performed to confirm the expression o f H-RasG12v or N-RasG12D. 
CD34+ H-RasG,2v cells expressed ~5 fold increase in total Ras protein compared with
C* 1 ?Vcontrols and expression o f Ras mutant protein was detected in these cells. As expected, 
mutant Ras protein was not expressed in CD34+ control cells (Figure 3.3D). CD34+ N- 
Ras cells showed similar results (data not shown).
3 .3 .2  D iogenes c a n  detect  su per o x id e  g enera ted  by  h u m a n  CD34+
HAEMATOPOIETIC PROGENITOR CELLS
3.3.2.1 Diogenes is a sensitive and specific probe fo r  superoxide
To detect superoxide production in transduced CD34+ cells, the 
chemiluminescent probe Diogenes was used. Diogenes reagent consists o f luminol and a 
proprietary activator which amplifies luminol chemiluminescence providing greater 
sensitivity to low levels o f  superoxide.
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Figure 3.3 Expression of mutant Ras in normal human CD34+ haematopoietic 
progenitor cells
(A) Transduced human CD34+ haematopoietic progenitor cells were analysed for GFP 
positivity (filled histograms) on day 3 post transduction. GFP+ threshold was defined by 
auto fluorescence (open histograms) of mock-transduced cells, and typical percentages of 
viable GFP+ cells are shown for i) CD34+ control cells, ii) CD34+ H-RasGUV cells and iii) 
CD34+ N-RasGI2D cells. Data indicates mean GFP+ frequency ± 1 S.D. (n=6 ). (B) 
Transduced CD34+ cells were labelled with 5 pg/ml anti-CD34 antibody conjugated to PE 
or isotype matched control antibody (PE conjugate) (both from BD Biosciences) for 30 
min at 4°C, and analysed by flow cytometry as described in section 2.6. Figure shows 
typical histogram, depicting CD34 antigen expression by CD34+ control cells on day 3 
post-isolation. (C) Mean CD34+ cell frequencies for transduced cultures on day 3. Bar 
chart represents mean plus 1 S.D. (n >2). (D) Whole-cell protein extracts of 3x105 CD34+ 
control and CD34+ H-RasGI2v cells (day 4) were prepared as described in section 2.5.1.1, 
and Western blot analysis was performed as described in section 2.4.7, using 170 ng/ml 
anti-pan Ras antibody (Cell Signaling, Danvers, MA) or 100 ng/ml anti-pan RasVI2  
antibody (clone DWP; Calbiochem). 20 ng/ml GAPDH (Santa Cruz) was used as a loading 
control.
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To establish the specificity of Diogenes for superoxide, the response of 
Diogenes was assayed using a cell-free system consisting o f xanthine oxidase and its 
substrate HX. Xanthine oxidase generates superoxide and uric acid during catabolism o f 
HX and has previously been used to generate superoxide anions (Roubaud, V. et al 1997). 
In the presence o f xanthine oxidase, Diogenes chemiluminescence increased linearly with 
0.1-1.5 mM HX (Figure 3.4A). No chemiluminescence was detected in the absence o f HX 
or when experiments were carried out in the presence o f 5 pg/ml SOD (Figure 3.4B). 
Furthermore, no chemiluminescence was observed when Diogenes was assayed against 
0.1-5 mM H2O2 (Figure 3.4C). Taken together these data suggest that Diogenes can detect 
superoxide generated using a cell-free system but is not sensitive to H2O2 .
3.3.2.2 Detection o f  superoxide produced by PLB-985 cells stimulated with TPA using
Diogenes
The data above suggested that Diogenes is a probe suitable for detection o f 
superoxide generated by cell-free systems. To determine whether Diogenes was also able 
to detect superoxide production by live cells, a promyelocytic cell line model (PLB-985 
cells) was used as a source of superoxide. As a negative control, a subline of PLB-985 cells 
deficient for NOX2 (also known as gp91phox) expression was used (PLB-985 NOX2' ' 
cells), which were previously generated from PLB-985 cells by gene-targeting (Zhen, L. et 
al. 1993). To confirm that PLB-985 cells express NOX2, while PLB-985 NOX2A cells do 
not, NOX2 expression was measured by flow cytometric analysis. Figure 3.5A shows that 
NOX2 expression was observed in PLB-985 cells, but not in PLB-985 NOX2'A cells.
To determine whether Diogenes was able to detect superoxide production in 
vitro, PLB-985 cells and PLB-985 NOX2'7' cells were incubated with Diogenes in the 
presence or absence o f TPA (a phorbol ester which is a potent activator PKC and NOX 
family oxidases, including Phox containing the catalytic subunit NOX2 (Sumimoto, H. 
2008)). Unstimulated PLB-985 cells did not produce detectable superoxide, however, 
when stimulated with TPA, a ~30 fold increase in Diogenes chemiluminescence was 
observed. As expected PLB-985 NOX2'7' cells gave no detectable Diogenes 
chemiluminescence under these conditions (Figure 3.5B). These data show that Diogenes 
is able to detect NOX2-derived superoxide from live cells, and suggest that in PLB-985 
cells, NOX2 is the major contributor to TPA induced superoxide production.
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Figure 3.4 Diogenes chemiluminescence in the presence of xanthine oxidase and 
hypoxanthine or H2O 2
(A) Diogenes was incubated with 50 mU xanthine oxidase in the presence of 0-1.5 mM 
HX and time-resolved chemiluminescence was recorded over 50 min (n=3). (B) Some 
experiments were carried out in the presence of 5 pg/ml SOD (n=3). (C) Diogenes was 
incubated with 0.1-5 mM H2O2 and time-resolved chemiluminescence was recorded over 
50 min (n=4). Data depicts mean total RLU detected ±1 S.D. RLU values represent total 
superoxide output during the assay calculated as described in section 3.2.1.7. A linear 
regression line has been fitted to the scatter data. RLU = relative light units
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Figure 3.5 Detection of superoxide produced by PLB-985 cells stimulated with TPA
(A) Representative flow cytometric histograms of NOX2 expression by i) PLB-985 and ii) 
PLB-985 NOX2' '  cells. NOX 2 expression was analysed by flow cytometry as described 
in section 2.6, using 5 pg/ml mouse IgGi anti-NOX2 unconjugated primary antibody 
raised against an external epitope of NOX2 (clone 7D5; Caltag Medsystems, 
Buckinghamshire, UK). To determine background fluorescence, some samples were 
incubated with 5 pg/ml manufacturer- and isotype-matched unconjugated control antibody. 
Primary antibody was detected incubation for 15 min at 4°C with 5 pg/ml rat-anti mouse 
IgGi-PE secondary antibody (BD Biosciences). (B) PLB-985 and PLB-985 NOX2'7' cells 
were treated with either 1 pM TPA or vehicle control (1% DMSO). Diogenes 
chemiluminescence was measured over 100 min. Data represents mean plus 1 S.D. RLU 
values represent total superoxide output during the assay calculated as described in section 
3.2.1.7. RLU = relative light units.
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3.3.2.3 Optimisation o f  Diogenes in vitro assay conditions
Prior to this study, it was not known whether human CD34+ haematopoietic cells 
could produce superoxide, neither was it known whether expression o f activated Ras 
would have an effect on superoxide production. Therefore, optimum conditions for 
detection o f superoxide production by human CD34+ cells using Diogenes were established 
by variation o f the CD34+ cell number used per well and varying the final concentration of 
Diogenes in the reaction volume.
Diogenes chemiluminescence was observed in a cell-density dependent manner 
across the entire range tested in both unstimulated CD34+ control cells and CD34+ H- 
RasG12v cells (Figure 3.6A). In addition, CD34+ H-RasG12v cells exhibited a significant 7- 
fold increase CP<0.05) in superoxide production compared with controls during the assay.
These data suggest that Diogenes assays should be performed using the 
maximum number o f cells available. Given that transduced CD34+ cell numbers are often 
limited, 1.5x10s cells per well was selected as an achievable number o f cells for future 
experiments. In addition, these preliminary data suggest that CD34+ H-RasG12v cells 
constitutively produce more superoxide than controls. This observation was investigated 
further in section 3.3.2.4.
3.3.2.4 Expression o f  mutant Ras in human CD34+ cells increases superoxide
production
Using the optimised conditions for Diogenes assays established in section 
3.3.2.3, superoxide production in transduced human CD34+ haematopoietic progenitor 
cells was examined immediately after transduction and on subsequent days in culture. In 
early cultures (days 3 to 5), a low level o f constitutive superoxide production was observed 
in control cells, which was strongly augmented by activated Ras (Figure 3.7A). As shown
G12 Vin Figure 3.7B, superoxide induction was typically most efficient with H-Ras , which
G120showed a significant ~4 fold increase compared with controls, while N-Ras showed a 
similar trend (~2 fold increase in superoxide compared with controls). The presence of 
SOD quenched Diogenes chemiluminescence, whilst treatment with catalase (which 
decomposes H2 O2 but not superoxide) did not, confirming the specificity o f the probe and 
confirming superoxide as the major detectable source o f ROS in this assay (Figure 3.7C).
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Figure 3.6 Determination of optimal cell number and volume of Diogenes reagent for 
Diogenes assays
CD34+ control and CD34+ H-RasGI2v cells (0.1-1.5x105) were incubated with 50 pi 
Diogenes reagent and Diogenes chemiluminescence was measured over 100 min. Data 
represents mean plus 1 S.D. RLU values represent total superoxide output during the assay 
calculated as described in section 3.2.1.7. Statistical significance was calculated by Mann- 
Whitney Test (n=4); *P<0.05. RLU = relative light units
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Figure 3.7 Detection of superoxide production by transduced CD34+ cells using 
Diogenes
(A) i) Representative chemiluminescence traces of superoxide production by CD34+ 
control, CD34+ H-RasG12v and CD34+ N-RasG,2D cells measured using Diogenes, ii) SOD 
was added to some replicates at 50 min, indicated by arrow. (B) Summary of fold increase 
of total light emission due to expression of activated Ras over controls during early 
hematopoietic development. (C) Using Diogenes, superoxide production in CD34+ H- 
RasGI2v cells was measured in the constant presence of 5 pg/ml SOD or 100 pg/ml catalase 
(n=3). Bar chart represents mean plus 1 S.D. Statistical significance was calculated by 
Mann-Whitney Test or ANOVA using Tukey’s Honestly Significant Differences; *P<0.05; 
t P < 0 . 0 0 1 .
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To establish whether this increased superoxide production was sustained during
p 19 v
subsequent culture, superoxide induction by H-Ras was measured on days 5 to 14 of 
culture. Superoxide production remained significantly elevated during culture; inducing a 
maximal ~7-fold increase in superoxide production by day 9. (Figure 3.8).
3.3.2.5 Ras upregulates ROS production by activation o f NOX family oxidases
ROS can be generated by several mechanisms, the major sources being oxidase 
activity (e.g. NOX family) or via the mitochondrial electron transport chain (Finkel, T. 
2003). To determine whether NOX enzymes were responsible for the over-production of 
superoxide, this study focused on the effects o f the NOX oxidase inhibitors DPI and
I 1
apocynin on superoxide production by CD34 H-Ras cells, since these cells produce 
the most ROS and were therefore likely to display the strongest phenotype. In the presence 
o f these inhibitors, superoxide production was completely blocked in both CD34+ H- 
RasG12v cells and control cells, as determined by Diogenes assay, whereas the 
mitochondrial poison rotenone had no effect (Figure 3.9A).
To establish whether mutant Ras altered the capacity o f CD34+ cells to produce 
superoxide, CD34+ control and CD34+ H-RasG12v cells were stimulated with the potent 
PKC activator, TPA. Both CD34+ control and CD34+ H-RasG12v cells responded to TPA 
stimulation with a 58 fold and 33 fold respective increase in superoxide production when 
compared to unstimulated cells. However, CD34+ H-RasG12v cells maximal superoxide 
output was significantly (~1.5 fold) greater than CD34+ control maximal superoxide output 
(F><0.01; Figure 3.9B).
Taken together these data show that normal CD34+ cells constitutively produce 
superoxide and that mutant Ras induces a significant increase in superoxide production and 
also increases the maximal superoxide output. These data also suggest NOX family
+ G 12Voxidases are the major source o f increased superoxide production in CD34 H-Ras 
cells, whilst mitochondrial production does not significantly contribute to Diogenes 
chemiluminescence.
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Figure 3.8 Summary of superoxide production by transduced CD34+ cells during 
culture
Superoxide production by control and H-Ras(,l2v-transdued cells was measured using 
Diogenes through early haematopoietic development. Data represent fold increase of total 
light emission of H-RasG12v-transduced cells over control cells; where control cell output is 
represented by dotted line. Data represents mean plus 1 S.D. (n >3). Statistical 
significance was calculated using the Mann-Whitney Test, * /><0.05.
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Figure 3.9 Effect of NOX inhibitors, ROS scavengers, and rotenone on superoxide 
production by transduced CD34+ cells
(A) Using Diogenes, superoxide production in CD34+ H-RasG12v transduced cells was 
measured in the presence of 50 pM DPI or 50 pM apocynin (NOX inhibitors) or 5 pM 
rotenone (inhibitor of mitochondrial electron transport chain) (n=3). (B) Using Diogenes, 
superoxide production in CD34+ control and CD34+ H-RasGI2v cells was measured in the 
presence of either 1 pM TPA or DMSO control. Data represents mean plus 1 S D. RLU 
values represent total superoxide output during the assay calculated as described in section 
3.2.1.7. Statistical significance was calculated using ANOVA using Tukey’s Honestly 
Significant Differences, *P<0.05, **/><0.01, *tP<0.001. RLU = relative light units
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3.3.2.6 Comparison o f  superoxide production by transduced CD 3 4+cells to stimulated
primary monocytes
Superoxide production is commonly associated with the phagocytic oxidative 
burst produced by phagocytes o f the innate immune system such as neutrophils, monocytes 
and tissue macrophages (Bedard, K. and Krause, K.H. 2007). To compare the levels of 
superoxide produced by transduced human CD34+ cells to those produced by a phagocyte 
oxidative burst, normal primary monocytes were isolated from healthy donor’s peripheral 
blood and stimulated with zymosan (an extract o f yeast cell-wall) which had been 
opsonised with complement by heating with human serum (Tonks, A. et a l  2005a). The 
superoxide output from these cells was monitored using Diogenes alongside unstimulated 
control and H-RasG12v-expressing cells. Figure 3.10 shows that constitutive superoxide 
production by CD34+ H-RasG12v-expressing cells is 11% of the superoxide generated by 
stimulated monocytes, whilst control cells constitutively produce 2% o f the superoxide 
generated by stimulated monocytes.
3.3 .3  D e t e c t io n  o f  su p e r o x id e  a n io n  p r o d u c t io n  b y  h u m an  CD34+ 
PROGENITOR CELLS USING EPR
3.3.3.1 Principles o f  EPR spectroscopy
Superoxide production by Ras mutants was confirmed using EPR spin trapping 
with DEPMPO. DEPMPO is a beta-phosphorylated nitrone which stabilises short-lived 
radicals such as superoxide by reacting with them forming a relatively long-lived radical 
molecule known as a spin adduct. Each spin adduct has a unique EPR absorption spectrum 
which enables free radical identification (Bacic, G. et a l 2008). For a more detailed 
explanation, see section 1.4.5.3.
3.3.3.2 EPR spectroscopy confirms the presence o f  superoxide radicals and also 
indicates the presence o f  hydroxyl radicals
EPR spectroscopy was used to detect DEMPO spin adducts formed in the 
presence o f CD34+ control and CD34+ H-RasG12v cells. While no spectra were obtained 
from CD34+ control cells, an EPR spectrum was detected from DEPMPO-treated 
CD34+ H-RasGI2v cells.
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Figure 3.10 Comparison of superoxide production of transduced CD34+ cells with the 
oxidative burst of activated peripheral blood monocytes
Normal human monocytes were isolated from peripheral blood and stimulated with 250 
pg/ml opsonised zymosan as previously described (Tonks, A. et al. 2005a). Superoxide 
production was measured using Diogenes and compared with typical constitutive 
superoxide output from control and H-RasG,2v cultures (day 7).
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This spectrum appeared to be a superimposition o f two separate EPR spectra.
The first EPR spectrum exhibited hyperfine splitting with hyperfine coupling constants 
typical o f the EPR spectrum o f the DEPMPO-OOH adduct (aN=13.1 Gauss (G), an^=l 1.3 
G) formed by trapping superoxide. The second spectrum was more intense than the first, 
and was typical o f  the DEPMPO-OH adduct (hyperfine coupling constants aN=14.0 G, 
an£=13.0 G), which is formed by trapping hydroxyl radicals or by slow conversion from 
the DEPMPO-OOH adduct (Figure 3.11 A).
As a positive superoxide control, DEPMPO was incubated with xanthine oxidase 
and HX under the same conditions as those used in the cell-free assays above. A very 
similar EPR spectrum to that obtained from cell assays was observed, indicating both the 
presence o f superoxide radicals and hydroxyl radicals (Figure 3.1 IB).
These data indicate that superoxide radicals are produced by CD34+ H-RasG12v 
cells and that hydroxyl radicals are also present. No EPR spectra were obtained from 
CD34+ control cells, suggesting the levels o f  superoxide (and possibly hydroxyl radicals) 
from these cells falls below the sensitivity o f this assay.
3.3.4 E x a m i n a t i o n  o f  m i t o c h o n d r i a l  ROS p r o d u c t i o n
3.3.4.1 Optimisation o f MitoSOX assay
Experiments using Diogenes to detect superoxide produced by CD34+ control 
and CD34+ H-RasG,2v cells in the presence o f NOX inhibitors suggested that NOX family 
oxidases are the main source o f superoxide in this study. However, mitochondria can also 
produce superoxide (Murphy, M.P. 2009) and have been previously implicated in ROS 
production induced by expression o f mutant Ras (Kim, J.H. et a l 2005).
To assess the effects o f mutant Ras on mitochondrial superoxide production, a 
flow cytometric assay using the red-fluorescent mitochondrial superoxide-sensitive probe 
MitoSOX was used. Flow cytometry was chosen over fluorescence microscopy because 
the former lends itself to simpler quantitation of fluorescence intensity and enables 
simultaneous analysis o f additional parameters such as cell-surface marker expression and 
cell viability. To determine the optimum MitoSOX concentration for future assays, CD34+ 
control cells were labelled with 1-5 pM MitoSOX reagent and analysed by flow cytometry. 
Figure 3.12A shows that 5 pM MitoSOX gave the most intense fluorescence, therefore 5 
pM MitoSOX was used in subsequent experiments.
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Figure 3.11 Detection of superoxide and hydroxyl radicals using EPR spectroscopy
CD34+ control, CD34+ H-Rasc,l2v cells and xanthine oxidase in the presence of HX were 
incubated with the spin-trap probe DEPMPO. Data shows representative EPR signals 
detected from (A) CD34+ control, (B) CD34+ H-RasG12v cells and (C) xanthine oxidase 
and HX. Scans shown are representative of 5 independent experiments, x and y axes in all 
traces are shown on the same scale, o denotes DEPMPO-OOH adduct peaks, •  denotes 
DEPMPO-OH adduct peaks.
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Figure 3.12 Optimisation of MitoSOX assay conditions using CD34+ control cells
Flow cytometric histograms representing MitoSOX fluorescence in CD34+ control cells 
(day 7). MitoSOX fluorescence was analysed by flow cytometry as described in section 
2.6. (A) CD34+ control cells were incubated with (1) vehicle control or (2) 1 jliM, (3) 2.5 
pM or (4) 5 pM MitoSOX reagent. (B) CD34+ control cells were labelled with either (1) 
vehicle control or (2) 5 pM MitoSOX reagent alone; or pre-incubated with either (3) 5 pM 
FeTCPP (a SOD mimetic) or (4) 50 pM rotenone (a mitochondrial poison) prior to 
labelling with 5 pM MitoSOX.
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In order to determine whether MitoSOX detected changes in superoxide levels in 
the mitochondria, CD34+ control cells were labelled with MitoSOX under the optimised 
conditions determined above in the presence o f either FeTCPP, a superoxide scavenging 
molecule (Wu, A.S. et al. 2003) which would be expected to decrease MitoSOX 
fluorescence, or rotenone, an inhibitor o f the mitochondrial electron transport chain which 
can cause an increase in mitochondrial superoxide (Pelicano, H. et al. 2003). As expected, 
peak channel MitoSOX fluorescence was reduced substantially (~ 4 fold) by treatment 
with FeTCPP, while rotenone treatment caused a ~ 2 fold increase in peak channel 
MitoSOX fluorescence (Figure 3.12B).
Taken together these data suggest that MitoSOX can be assayed easily by flow 
cytometry and also that MitoSOX is sensitive to changes in mitochondrial superoxide 
levels.
3.3.4.2 Mitochondria do not appear to contribute to superoxide overproduction in
CD34* H-RasGI2v cells
Using the optimised MitoSOX labelling protocol devised above, we compared 
the level o f MitoSOX fluorescence in CD34+ control and CD34+H-RasG12v cells. No 
significant differences in mitochondrial ROS were observed in CD34+H-RasG12v cells 
compared to controls (Figure 3.13A). As expected the negative and positive controls 
(FeTCPP and rotenone) decreased and increased mitochondrial superoxide detection 
respectively. However, FeTCPP and rotenone induced a similar effect in control and 
CD34+H-RasG,2v cultures, causing a consistent decrease or increase in MitoSOX 
fluorescence respectively (Figure 3.13B). These data suggested that the source of excess 
superoxide production detected by Diogenes and EPR spectroscopy did not arise from the 
mitochondria.
3.3.5 D e t e c t io n  o f  H20 2 p r o d u c t io n  b y  t r a n s d u c e d  h u m a n  CD34+
HAEMATOPOIETIC PROGENITOR CELLS USING AMPLEX RED
3.3.5.1 Mutant Ras promotes H2O2 production in transduced CD34+ cells
The data presented thus far strongly indicates that transduced CD34+ cells 
constitutively produce superoxide, with CD34+ H-RasG12v cells and CD34+N-RasG12D cells 
producing 5 fold more and 3 fold more superoxide than controls respectively.
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Figure 3.13 Examination of mitochondrial superoxide production in transduced 
CD34+ cells using MitoSOX
Flow cytometric histograms representing MitoSOX fluorescence in CD34+ control and 
CD34+ H-RasGI2v cells (day 5). MitoSOX fluorescence was analysed by flow cytometry as 
described in section 2.6. (A) Transduced CD34+ cells were incubated with (1) vehicle 
control or (2) 5 pM MitoSOX. (B) Transduced CD34+ cells were incubated with (1) 
vehicle control or (2) 5 pM MitoSOX alone (position of peak channel fluorescence of 
MitoSOX alone is marked with an arrow for comparison). Some samples were pre­
incubated with (3) 5 pM FeTCPP or (4) 50 pM rotenone prior to labelling with 5 pM 
MitoSOX. (C) i) Percentage of cells exhibiting positive MitoSOX staining. A PBS control 
was used to define positive threshold (n=3). ii) Mean MitoSOX fluorescence in MitoSOX+ 
population (n=3). Data represents mean plus 1 S D. Statistical significance was calculated 
using the Mann-Whitney test.
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However, it is H2 O2 that has been implicated as a second messenger rather than 
superoxide (section 1.4.3.2). H2 O2 can be generated from superoxide via a dismutation 
reaction (Bedard, K. and Krause, K.H. 2007) or by the action of SOD (Bannister, J.V. et al. 
1987) therefore it is conceivable that excessive superoxide production may lead to a 
subsequent increase in local H2 O2 .
Transduced CD34+ cells were incubated at a fixed cell density (4x105 cells/ml) 
in KRPG buffer and H2 O2 released into the buffer medium was assayed using the H2 O2 - 
sensitive fluorescent probe, Amplex Red. CD34+H-RasG12v cells showed significantly 
higher rates of H2 O2 production compared to controls (P<0.05), while CD34+N-RasGI2D 
cells showed a similar trend (Figure 3.14).
CD34 CD34 CD34+
Control N-RasG12D H-RasG12v
Figure 3.14 Measurement of H2O2 production by transduced CD34+ cells using 
Amplex Red
Transduced CD34+ cells (2x105) were incubated in KRPG buffer for 4 h and H2O2 
concentration in the conditioned buffer was measured using Amplex Red (n=3). Amplex 
Red fluorescence was converted to H2O2 concentration using a H2 O2 standard curve. Data 
represents mean plus 1 S.D. Statistical significance was calculated using the Student’s T 
Test, */><0.05.
130
CHAPTER 3: CHARACTERISATION OF ROS PRODUCTION
3.3.6 A c t iv a t e d  NOX2 is t h e  m a j o r  s o u r c e  o f  ROS p r o d u c t io n  in
PRIMITIVE HUMAN AND MURINE HAEMATOPOIETIC CELLS
G12 V3.3.6.1 H-Ras promotes expression o f  NOX2 and membrane translocation o f  NOX2-
regulatory subunits
Taken together, the data presented above (sections 3.3.2.4, 3.3.2.5 and 3.3.4.2) 
suggest that NOX oxidases are the major contributor to superoxide and H2O2 production in 
mutant Ras transduced CD34+ cells, while the mitochondria do not significantly contribute.
The most likely member o f the NOX oxidase family responsible for ROS 
production in haematopoietic cells is the trans-membrane multi-component enzyme 
complex, Phox. This enzyme consists o f a membrane-bound catalytic complex NOX2 and 
cytosolic regulatory and organiser components (p47phox, p40phox, p67phox and Rac) which 
assemble to form a complete complex at the membrane upon activation.(Bedard, K. and 
Krause, K.H. 2007) To determine whether Phox could be the source o f excess ROS 
production in these cells, the expression and localisation o f Phox components was 
investigated. Flow cytometric analysis showed expression o f the Phox catalytic subunit 
(NOX2) in both CD34+ control and CD34+H-RasG12v cells, however, the proportion of 
cells expressing NOX2 was ~2-fold greater in CD34+H-RasG12v cells compared to controls 
(Figure 3.15A) (P>0.05). In addition, Figure 3.15B shows that H-RasG12v also promoted 
the membrane translocation/expression o f the Phox activators p67phox and p40phox. Subtle 
membrane translocation o f Rac was also detected together with very faint evidence o f 
p47phox membrane translocation.
Despite our inability to detect large amounts of p47phox membrane translocation,
c* \'y\/the majority o f evidence suggests that H-Ras promotes ROS production by increasing 
Phox expression and activity in human CD34+ cells.
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Figure 3.15 The Phox NADPH oxidase is dysregulated in CD34+ H-RasG,2v cells
(A) Transduced CD34+ cells (day 5; 2.5x104 per test) were labelled with 5 gg/ml mouse 
IgGi anti-NOX2 antibody (clone 7D5; Caltag Medsystems) or an appropriate isotype- 
matched control antibody, followed by incubation with 5 pg/ml rat anti-mouse IgGi 
antibody conjugated to PE (BD Biosciences) as described in legend to Figure 3.5; and 
analysed by flow cytometry as described in section 2.6. i) Typical histogram showing anti- 
NOX2-PE fluorescence, ii) Data represents percentage of fluorescent cells after incubation 
with anti-NOX2-PE. Isotype control antibody was used to define positive threshold (n=5).
(B) Cytosol/membrane fractionated protein extracts were prepared from 3x105 CD34+ 
control and CD34+ H-RasGI2v cells (day 3) as described in section 2.5.1.2, and analysed by 
Western blot (section 2.4.7), using 50 ng/ml anti-p67phox (clone H-300), 400 ng/ml anti- 
p47phox (A-7) or 80 ng/ml anti-p40phox (D-8 ) (all from Santa Cruz) or 80 ng/ml anti-pan 
Rac (Cell Signaling). 10 ng/ml anti-Qf-tubulin (DMA1; Calbiochem) was used as a loading 
control and cytosolic marker. 250 ng/ml anti-CD45 (clone 69, BD Biosciences) was used a 
membrane marker. Data represent mean plus 1 S D. Statistical significance was calculated 
using the Mann-Whitney Test, *P<0.05. C = cytosolic fraction, M = membrane fraction.
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3.3.6.2 N-RasGI2D augments ROS production in wild-type murine Sca-1+ haematopoietic
cells, but not in those deficient fo r  Nox2
The data presented in section 3.3.6.1, suggested that increased NOX2 activity is 
responsible for ROS production in haematopoietic cells expressing activated Ras. In order 
to independently assess the contribution o f Nox2 to Ras-induced ROS production, N- 
RasG12D was expressed in either wild-type murine Sca-1+ haematopoietic progenitor cells 
or analogous cells from mice deficient for Nox2 (generated previously using gene- 
targeting (Pollock, J.D. et al. 1995)); isolated cells were >65% Sca-1+ (Figure 3.16A). 
Retroviral transduction o f these cells was relatively inefficient in comparison to human 
CD34+ transductions with a mean gene transduction efficiency o f 50% GFP+ in control 
cultures and 20% GFP+ in N-RasG12D cultures (Figure 3.16B).
Following retroviral transduction, superoxide production was assayed using 
Diogenes. As shown in Figure 3.16C, expression ofN-RasG12D in wild type Sca-1+ cells 
caused a 1.5 fold increase in constitutive superoxide production when compared with 
controls. However, no superoxide production was detected in Sca-1+ cells deficient for 
Nox2, regardless ofN-RasG12D expression. ROS induction in murine Sca-1+ cells 
expressing N-RasG12D was less efficient than in human CD34+ cells compared to controls 
(section 3.3.2.4). This may be due to context-dependent differences, or more likely the low 
transduction efficiency achieved in Sca-1+ cells compared with CD34+ cells.
These data suggest that NOX2 plays a major dominant role in superoxide 
generation in normal haematopoietic cells, and furthermore that (at least in murine 
haematopoietic progenitors) Nox2 is the major source of increased ROS production due to 
expression o f mutant Ras.
3.3.7 H -R a s g12V d o e s  n o t  a l t e r  t h e  e x p r e s s io n  o f  e n d o g e n o u s
ANTIOXIDANTS
Aberrant Ras signalling affects transcription o f a variety o f genes (Chang, F. et 
al. 2003) and could potentially perturb the expression o f endogenous antioxidant molecules 
resulting in an apparent increase in ROS production. In order to examine the expression of 
common endogenous antioxidants in CD34+H-RasG12v cells, Western blot analysis was 
performed for catalase, Prxl or Cu/Zn SOD (SOD1) expression.
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Figure 3.16 Superoxide production by wild type and Nox2-deficient primary murine 
Sca-1+ haematopoietic cells expressing N-RasG12D
Sca-1+ cells derived from bone marrow of either wild-type or Nox2-deficient mice were 
transduced with N-RasG12D or control. (A) Flow cytometric histograms depicting Sca-1 
expression in transduced murine bone-marrow derived cells. Transduced cells (day 3;
2.5x104 per test) were labelled by incubating with rat IgG2a anti-Sca-1 antibody conjugated 
to PE (clone D7; Miltenyi Biotec) or isotype-matched control antibody conjugated to PE 
(BD Biosciences) for 15 min at 4°C and analysed by flow cytometry as described in 
section 2.6. (B) Bivariate flow cytometric plots depicting GFP fluorescence in transduced 
Sca-1+ cells (day 3). (C) Superoxide production by transduced Sca-1+ cells was assayed on 
day 6  using Diogenes. Bar chart represents total superoxide production during the assay. 
Data represents mean ± 1 S.D. RLU values represent total superoxide output during the 
assay calculated as described in section 3.2.1.7. RLU = relative light units.
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There was no difference in the expression levels of these intracellular 
antioxidants in CD34+H-RasG12v cells compared with controls (Figure 3.17).
These data suggest the observed increase in ROS production in CD34+ cells 
expressing mutant Ras is unlikely to be due to decreased antioxidant expression. Instead, 
when considered with the rest of the data presented in this chapter, it is more likely that 
increased expression and activation of the Phox oxidase complex is responsible.
CD34+ CD34+
Control H-RasG12V
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Figure 3.17 Determination of endogenous antioxidant expression in CD34+ control 
and CD34+ H-RasGI2v cells
Whole-cell protein extracts o f 3x105 transduced human CD34+ cells (day 6) were prepared 
as described in section 2.5.1.1, and Western blot analysis was performed as described in 
section 2.4.7, using 5 pg/ml anti-catalase (Abeam), 80 ng/ml anti-Prxl (Lab Frontier, 
Korea) or 300 ng/ml anti-SODl (Cell Signaling). 20 ng/ml anti-GAPDH (Santa Cruz) was 
used as a loading control.
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3 .4  D i s c u s s i o n
Using several validated ROS-sensitive probes, this study detected constitutive 
production o f superoxide and its derivative H2O2 in normal human CD34+ haematopoietic 
progenitor cells. Furthermore this study demonstrated for the first time that ectopic 
expression o f a either H-RasG12v or N-RasG12D in human CD34+ haematopoietic progenitor 
cells induces a significant ~4 fold or ~2 fold increase in constitutive superoxide production 
respectively; with a concomitant ~3 fold or ~2 fold increase in H2O2 production rate 
respectively.
The instability o f ROS complicates their detection, therefore this study 
employed cell-free assays and cell lines to establish the sensitivity and specificity o f the 
probes used. These assays demonstrated that Diogenes was sensitive to enzymatically 
generated superoxide as well as superoxide generated by stimulated HL60 cells. Amplex 
Red was shown to be sensitive to very low levels o f H2O2 , verified by addition o f catalase, 
which is an exquisitely specific inhibitor o f H2O2 .
It is important to emphasize that normal CD34+ cells constitutively produced 
ROS in this study albeit at a comparable low level. This study’s findings are consistent 
with a previous study by Piccoli et a l , in which constitutive expression o f ROS in normal 
human CD34+ haematopoietic cells was reported using the intracellular probe DCF for 
H2O2 (Piccoli, C. et al. 2007). The exact role o f the constitutive ROS production by normal 
CD34+ cells is unknown. However, ROS are known to play an important role in 
haematopoietic growth factor signal transduction (Sattler, M. et a l 1999; Sundaresan, M. 
et a l 1995) angiogenesis and cell cycle progression (Blanchetot, C. and Boonstra, J. 2008). 
At the other end o f the ROS spectrum, excessive ROS is closely associated with growth 
arrest (Dolado, I. et a l 2007), suggesting that for efficient intracellular function, ROS need 
to be maintained within a finite range. Indeed, it appears some important transduction 
pathways require transient inhibition o f phosphatases by H2O2 to allow efficient signal 
propagation (Rhee, S.G. 2006). In light o f the wide range o f roles for ROS in normal 
cellular function, it may be that constitutive low levels o f ROS production in CD34+ cells 
represents normal homeostasis. However, more research is needed to determine whether 
this is the case (explored further in Chapter 6).
This is the first study to report Ras-induced ROS production in normal human 
primary CD34+ haematopoietic cells. Specifically, it appears that Ras augments the low 
constitutive ROS production seen in normal CD34+ cells. Ras-induced ROS production has 
been previously demonstrated in a variety o f human cell types including embryonic lung
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cells (Liu, R. et a l 2001), keratinocytes (Yang, J.Q. et a l 1999) and neuroblastoma cells 
(Seru, R. et a l 2004) and also in transformed murine cell models (Irani, K. et a l 1997; 
Santillo, M. et a l 2001; Dolado, I. et a l 2007; Mitsushita, J. et a l 2004). In the case of 
primary human cells, primary human fibroblasts expressing mutant Ras also produced 
ROS (Wu, C. et a l 2004; Lee, A.C. et a l 1999). Furthermore, a murine study investigating 
leukaemic disease in transgenic mice overexpressing human BCL-2 or N-RasG12D (or both 
simultaneously) in the myeloid compartment has suggested that Ras-induced ROS 
contributes to genetic instability, which is a key factor in disease progression. Expression
p 1 on
o f BCL-2 or N-Ras in myeloid cells under the expression o f the myeloid MRP8
promoter caused increased ROS production in both Sca-1+ common myeloid progenitor 
cells and committed M acl+ myeloid progenitors, resulting in single-stranded and double 
stranded DNA breaks. While N-RasG12D single transgenic mice exhibited only mild 
haematological abnormalities, double transgenic mice exhibited greater ROS production
p 1 or\
than N-Ras alone (attributed to BCL-2 enabling the survival o f clones expressing
p |
higher levels o f  N-Ras ), and these mice developed haematological disease resembling
human AML within 6 months (Rassool, F.V. et a l 2007).
EPR spectroscopy was used to confirm the presence o f superoxide radicals 
suggested by Diogenes assays. However, EPR could not detect ROS production by control 
cells (presumably the low level o f superoxide production fell below the sensitivity o f the 
assay) but did detect superoxide production by CD34 H-Ras cells. In addition to 
superoxide radicals, EPR spectroscopy experiments also detected hydroxyl radicals. While 
the exact source o f hydroxyl radicals in this study are unknown, formation o f these radicals 
can occur downstream o f superoxide production. First, superoxide dismutates to form 
H2O2 ; a reaction which could be catalysed by extracellular SOD3 expression in these cells 
(Piccoli, C. et a l 2007). Hydroxyl radicals can then form from H2O2 via Fenton chemistry,
3+ 2+a class of radical reactions which can be catalysed by metal ions such as Fe or Cu in the 
Haber-Weiss reaction (Simpson, J.A. et a l 1988). Alternatively, cellular peroxidases can 
catalyse the symmetric breakdown o f the H2O2 molecule resulting in hydroxyl radical 
formation, though these are not normally expected to be expressed in haematopoietic 
progenitors. It is important to note that Diogenes (which is based on luminol) is unable to 
distinguish between superoxide and highly reactive hydroxyl radicals (Wardman, P. 2007); 
therefore the chemiluminescence detected using this probe is likely to be an indication of 
both species. The fact that SOD quenched chemiluminescence in Diogenes experiments 
suggests that production o f hydroxyl radicals is indeed downstream o f superoxide 
production in this model, and may progress via a Haber-Weiss mechanism catalysed by
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trace transition metal ion impurities in the buffer (Wardman, P. 2007). Hydroxyl radicals 
are highly reactive and participate in destructive reactions with lipid membranes (which 
can result in the initiation o f lipid peroxidation chain reactions) and oxidative inactivation 
of proteins (Valko, M. et al. 2007). Hydroxyl radicals can further react with endogenous 
NO to form peroxynitrite, a molecule with similar destructive properties; therefore, 
downstream production o f hydroxyl radicals is likely to be the primary source o f toxicity 
due to superoxide generation production in this model.
P 19V
Interestingly, the present study consistently observed that H-Ras is more 
efficient than N-RasG12D at driving both superoxide and H2 O2 production in human CD34+ 
cells. Given that H-Ras and N-Ras were not differentially expressed in our model 
system, this effect may be attributable to the reported iso form-specific signalling 
preferences o f H-RasG12v and N-RasG12D (Omerovic, J. et al. 2007). In particular, H- 
RasG12v is reported to be a more effective activator of the Rac pathway (important in 
NOX2 activation) than other Ras isoforms (Shin, I. et al. 2005; Oliva, J.L. et al. 2004). It is 
also known that the specific amino acid substitution has an influence on the strength o f the 
phenotype observed, even when comparing mutants o f the same Ras iso form mutated at 
the same residue position, and this could potentially contribute to the difference between 
the two mutant isoforms used herein. In particular, a valine substitution at position 12 in H- 
Ras promotes foci formation in NIH 3T3 cells to a greater extent than an aspartate 
substitution at the same position (Seeburg, P.H. et al. 1984).
This study also sought to establish the source of ROS production in this model. 
ROS can be produced via oxidase activity (e.g. NOX family) or via the mitochondrial 
electron transport chain (Bedard, K. and Krause, K.H. 2007). This study found no evidence 
o f altered mitochondrial superoxide production as a result o f mutant Ras expression. 
Rather, the results o f experiments conducted in the presence o f a variety o f inhibitors and 
ROS scavengers suggested that NOX family oxidases were the major source for ROS 
production detected in our assays supporting the conclusions o f (Piccoli, C. et al. 2007). It 
is important to note that the methods used to detect superoxide in the present study are not 
capable o f distinguishing ROS production by differing NOX isoforms. However, 
experiments showing that NOX2 (the catalytic subunit o f Phox) appeared to be both
_l_ t G12V
overexpressed and localised with activating subunits in CD34 cell expressing H-Ras ; 
together with evidence that NOX2 appears to be the exclusive source o f ROS (detectable 
by Diogenes) in murine Sca-1+ cells, suggested that NOX2 is the most probable source of 
superoxide production.
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In haematopoietic cells, NOX2 appears to be indispensible for superoxide 
production, since both Nox2-deficient primary murine Sca-1+ cells and NOX2-deficient 
PLB-985 cells produced no superoxide (detectable by Diogenes) either constitutively or 
after stimulation with TPA. Furthermore, in those studies where the source o f Ras-induced 
ROS production was investigated, ROS production was primarily ascribed to NOX2 (Seru, 
R. et a l 2004; Yang, J.Q. etal. 1999; Santillo, M. et a l 2001). Although involvement of 
NOX1 has been reported (Mitsushita, J. et a l 2004), this appears to be in the minority. The 
significance ofNOXl and NOX2 being the primary sources o f Ras-induced ROS (as 
opposed to other NOX family members) is unclear, however, the predisposition o f mutant 
Ras to activate NOX1 and NOX2 may stem from its ability to activate Rac (Schubbert, S. 
et a l 2007), which contributes to activation o f these oxidases, while Rac appears to be 
dispensable for activation o f other NOX family members (Bedard, K. and Krause, K.H. 
2007).
Western blot analysis o f Phox components revealed that H-RasG12v induced 
NOX2 and p67phox expression compared with controls, while the total expression o f the 
other Phox regulatory subunits remained largely unchanged (Figure 3.15). Expression o f 
NOX2, p47phox, p67phox and p40phox genes during normal myeloid haematopoietic 
development is co-ordinated by the myeloid-specifying transcription factor PU.l (Li, S.L. 
et a l 2002; Li, S.L. et a l 1997; Suzuki, S. et a l 1998; Gauss, K.A. et a l 2002).Given that 
mutant Ras can accelerate monocyte development (Peam, L. et a l 2007), it is possible that 
Ras acts via PU. 1 to drive monocytic differentiation and simultaneously dysregulates Phox 
component expression, however, western blot analysis o f PU.l expression in these cells 
would be required to confirm this. In the present study, a subset o f Phox complex genes 
(p47phox, p40phox and Rac) were not upregulated by H-RasG12v expression. The mechanism 
o f selective upregulation o f Phox components was not explored, however, it is known that 
Phox component regulation is regulated by the expression o f several co-operating 
transcription factors, such as PU.l and AP-1 (Gauss, K.A. et a l 2002; Li, S.L. et a l 2001), 
or PU.l and IRF1, ICSBP and CBP (Kautz, B. et a l 2001), and it may be that suboptimal 
combination o f transcriptions factors such as these may result in inefficient upregulation of 
some Phox subunits. Alternatively it could be that the Phox complex partially dissociates 
during protein extract processing, leaving only a remnant o f the complex at the membrane. 
Indeed, it is proposed that phosphorylated p47phox directs and drives p67phox membrane 
association (section 1.4.2.1), therefore large amounts o f membrane-bound p67phox implies 
that p47phox must also have been present at some point. Techniques such as confocal laser 
scanning microscopy (CLSM; which allow visualisation o f the interior o f intact cells) may
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serve to clarify whether p47phox is also translocated to the membrane with p67phox in H- 
RasG12v cells. Despite the fact that p47phox, p40phox and Rac appear to be unchanged in
■b G12V •CD34 H-Ras cells compared with controls, we nevertheless saw increased ROS 
production, suggesting that the composition o f Phox subunits in Ras cells was sufficient to 
confer an advantage in ROS production.
Finally, cellular ROS production is balanced by the actions o f endogenous 
antioxidants. Previously, it has been shown that an apparent increase in ROS production to 
due to mutant Ras expression in transformed human and rat fibroblasts could be attributed 
to a decrease in activity o f Prxs, leading to an increase in intracellular ROS (Kopnin, P.B. 
et a l 2007). Also, a study investigating expression o f endogenous antioxidants in cells 
from the bone marrow o f AML and MDS patients concluded that there was evidence of 
increased antioxidant expression in malignant cells compared with controls, suggesting 
that these cells were subject to oxidative stress (Bowen, D. et a l 2003). Lastly, although 
the expression o f FOXO proteins was not examined in detail (see Appendix 3), activated 
Ras would be expected to suppress FOXO activity (and therefore SOD and catalase 
expression) via activation o f Akt (Tothova, Z. et a l 2007). However, in the present study, 
activated Ras expression did not affect levels of SOD 1, catalase or Prxl, suggesting that 
altered antioxidant expression was unlikely to account for the increased ROS detected; 
rather, overactivity o f NOX2 appeared to be the source o f elevated ROS.
In the case o f the first study by Kopnin et a l , the differences observed here are 
likely to be due to context-dependent expression and activity o f sestrins, but this could 
potentially be verified by RT-PCR or Western blot analysis. The differing conclusion 
drawn in the present study compared with that o f Bowen et a l is most likely to be due to 
the short experimental time-frames used. CD34+ cells assays were generally conducted 
within 7 days, whereas malignant cells derived from patients are likely to have been 
subject to oxidative stress for much longer, and therefore had a longer period within which 
to upregulate antioxidant defences. Finally, Western blot analysis o f  FOXO proteins in
I i ^
CD34 H-Ras cells may reveal why SOD and catalase expression remain unchanged 
compared with controls. Finally, although GSH levels were not assayed in the present 
study, deficiencies in GSH homeostasis can also lead to oxidative stress, and it is possible 
that depletion or disruption o f the GSH system could contribute to the increased ROS 
production by CD34+ cells expressing activated Ras, indeed targeted disruption o f GSH 
production is an emerging concept in cancer therapy (section 1.4.2.3).
In summary, these experiments suggest that activated Ras alone is capable o f 
inducing NOX2 activation in primary CD34+ cells, while mitochondrial ROS production is
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not significantly affected. Furthermore, NOX2 activation appears to promote the 
generation o f superoxide and also downstream ROS including H2O2 and hydroxyl radicals. 
However, it is not known whether this excessive production o f ROS plays a role in the 
phenotype o f haematopoietic cells expressing activated Ras. This is dealt with in the next 
chapter.
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Effect of ROS on the phenotype 
of CD34+ haematopoietic 
progenitor cells expressing 
mutant Ras
One o f the best studied roles o f Ras proteins is in signal transduction o f growth- 
factor receptor signals, resulting in activation o f three main signalling pathways, the PI3K 
pathway, the MAPK pathway and the Ral pathway (section 1.3.3.2). Normal Ras signalling 
leads to increased cell survival, cell cycle entry/proliferation cell motility and 
differentiation (Alvarado, Y. and Giles, F.J. 2007). Constitutive Ras activity can contribute 
to the increased proliferative drive in cancer cells (section 1.3.5), but can also trigger a 
cellular senescence program mediated by activation of p53 and/or cell cycle inhibitor 
molecules such as p l6 INK4aand p21c,pl which directly opposes this (Malumbres, M. et a l 
2000; Kwong, J. et a l 2009). Furthermore, the strength and duration of Ras signalling may 
influence which outcome prevails (Deng, Q. et a l 2004; Dorrell, C. et a l 2004). However, 
it is not currently known whether expression o f activated Ras influences survival o f human 
CD34+ haematopoietic cells and whether any observed effects are mediated via ROS 
production. In addition, there is no data available regarding the effect of activated Ras 
and/or ROS production on the proliferation o f human CD34+ haematopoietic cells.
Normal CD34+ haematopoietic cells require the presence o f several 
haematopoietic growth factors in order to avoid growth arrest and subsequent apoptosis.
p i ^ \ 7  1 O IY
This study ectopically expressed H-Ras and N-Ras in normal human 
haematopoietic CD34+ cells to determine whether activated Ras could rescue CD34+ cells 
from apoptosis due to growth-factor and serum withdrawal. In addition, CD34+ cells 
expressing mutant Ras were treated with antioxidants and ROS scavengers to determine 
whether ROS production influences the phenotype elicited by activated Ras.
This study used annexin V conjugated to Cy5 (which fluoresces in the far red 
region o f the EM spectrum) to detect apoptotic cells by flow cytometry. Flow cytometric 
analysis offers the additional advantage of accurate counting o f cells using APC 
conjugated to microbeads to control for cell recovery and also allows for detection of 
additional parameters (e.g. CD34 expression) in the remaining flow cytometer fluorescence 
channel (FL2).
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This study also investigated the effect o f Ras on the proliferation o f normal 
human CD34+ haematopoietic cells. When incubated in serum-replete medium without 
growth factors (note that survival experiments were carried out in medium without serum), 
normal CD34+ cells show less tendency to undergo apoptosis and instead tend to enter a 
state o f quiescence. This study investigated whether activated Ras can drive CD34+ cells to 
proliferate under conditions which would normally cause quiescence, and whether 
antioxidants and ROS scavengers can interfere with proliferation driven by activated Ras.
In addition, cell cycle analysis was performed, to determine whether mutant Ras affects the 
proportion o f cells in Go or S+G2M phase o f the cell cycle.
4.1 A im s
In order to understand to role o f ROS production in the phenotype o f human 
CD34+ haematopoietic cells expressing activated Ras, this Chapter aims to:
• Determine the effect o f activated Ras on growth factor-independent survival of 
human CD34+ haematopoeitic cells using a model system, in the presence and 
absence o f ROS, using ROS inhibitors.
• Determine whether activated Ras affects the proliferation o f these cells in the 
absence o f growth factors, and whether ROS production is repsonsible for any o f 
the effects observed, again using ROS inhibitors and antioxidants.
4 .2  M e t h o d s
4.2.1 D e t e r m in a t io n  o f  s u r v iv a l  o f  t r a n s d u c e d  CD34+ h a e m a t o p o ie t ic  
c e l l s
4.2.1.1 Validation o f cell survival assay using annexin V-CyS and 7-AAD to detect 
apoptosis in normal human CD34+ haematopoietic cells
Previous research suggests that expression o f activated Ras confers resistance to 
apoptosis due to growth factor withdrawal, for example in the murine BaF3 cell line 
(Fukuda, S. and Pelus, L.M. 2004), but it is not currently known whether expression of 
activated Ras has a similar effect in normal human CD34+ cells. Therefore, a key 
requirement for this study was the development o f a sensitive assay to detect apoptotic 
cells in response to stress. Phosphatidylserine (PS) is plasma-membrane phospholipid
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which is maintained on the inner leaflet o f the membrane under normal conditions by the 
enzymatic action o f flippases (van Engeland, M. et a l 1998). Under conditions of cellular 
stress, PS begins to appear on the outer leaflet o f the plasma membrane, and this 
phenomenon is generally considered as a marker of early to intermediate stages of 
apoptosis (Boersma, H.H. et al. 2005). Annexin V (also known as annexin A5) is a 
member o f the annexin protein family with a high avidity for PS (van Engeland, M. et a l 
1998). Fluorochrome conjugates o f annexin V have been developed in order to detect PS 
expression on the surface o f cells by flow cytometry. Late stage apoptosis/necrosis are 
characterised by loss o f homeostasis and subsequent loss o f membrane integrity (Wyllie, 
A.H. 1997). The membrane-impermeable molecule 7-aminoactinomycin D (7-AAD) can 
enter cells with compromised plasma membranes and intercalates with DNA (Schmid, I. et 
a l 1992) forming fluorescent DNA/7-AAD complexes that are easily detected by flow 
cytometry.
To detect apoptosis in transduced CD34+ cells, an assay was devised using 
annexin V conjugated to Cy5 (BioVision, Mountain View, CA, USA) and 7-AAD (Sigma- 
Aldrich). To confirm that this assay could detect apoptotic cells, normal human CD34+ 
cells (day 3) were recovered from growth medium by centrifugation at 180 g for 5 min. All 
traces of growth factors and serum remnants (which would interfere with the survival 
assay), were removed by washing the cell pellets twice by centrifugation at 180 g for 10 
min in 25 ml Hanks Balanced Salt Solution (HBSS; Invitrogen). To induce apoptosis, 
washed CD34+ cells (lxlO 4) were incubated in 96U-well microplates (Thermo Fisher 
Scientific) in duplicate for 24 h in 150 pi IMDM without supplements, serum or growth 
factors at 37°C in a 5% CO2 humidified atmosphere. Following incubation, remaining cells 
were transferred to 96V-well microplates (Thermo Fisher Scientific) and collected by 
centrifugation at 180 g for 5 min. Cell pellets were washed by centrifugation (180 g for 5 
min) in 200 pi staining buffer (section 2.1.2) followed by a further wash by centrifugation 
in 200 pi annexin V binding buffer (Bender Medsystems, Vienna, Austria) containing 1 
pg/ml 7-AAD. Finally, washed cells were resuspended in 25 pi annexin V binding buffer 
containing 1 pg/ml 7-AAD and 100 fold dilution o f annexin V-Cy5 conjugate. Annexin V- 
Cy5 and 7-AAD enabled discrimination o f apoptotic and viable cells. The percentage of 
recovered cells that were viable (annexin Vneg and 7-AADneg) was determined by flow 
cytometry (section 2.6).
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4.2.1.2 Detection o f  apoptosis in transduced human CD34+ haematopoietic cells
deprived o f  growth factors and serum
To determine whether activated Ras promotes growth factor-independent 
survival in human CD34+ haematopoietic cells, a modified version of the protocol 
described in section 4.2.1.1 was used. Briefly, transduced CD34+ cells (day 3) were 
recovered from growth medium by centrifugation at 180 g for 5 min. Cells (0.1-3xl05) 
were washed with HBSS, resuspended in 150 pi IMDM without supplements, serum or 
growth factors and incubated in a 96-U well or 96-Flat well plate at 37°C in a 5% CO2 
humidified atmosphere as described in section 4.2.1.1. However, the incubation period was 
increased from 24 h to 48 h to maximise any survival differential between CD34+ control 
and CD34+ H-RasG12v cells. Some experiments were carried out in the presence of either 
50-500 pg/ml catalase, 0.015-1.5 pM DPI, 0.015-1.5 pM apocynin, 0.075-75 pM NAC or 
10-50 pU7ml GOX. Where applicable, the concentration of H2O2 generated by GOX 
treatment was monitored using Amplex Red. After incubation, remaining cells were 
washed with staining buffer and labelled with 7-AAD and annexin V-Cy5; and the 
percentage o f viable cells was determined by flow cytometry as in section 4.2.1.1.
4.2.1.3 Measurement o f  survival o f  normal human CD34+ haematopoietic cells co-
_l_ G12Vcultured with CD34 haematopoietic cells expressing H-Ras
To determine whether increased cell survival observed in CD34+ H-RasG12v cells 
was transferable to CD34+ control cells, a co-culture system was used. CD34+ control cells 
expressing GFP were co-cultured with an increasing proportion o f CD34+ H-RasGI2v cells 
expressing DsRed. These DsRed-expressing cells were generated by subcloning the DsRed
p i ^ \ /
gene into the PINCO-H-Ras plasmid in place of the GFP gene. The recombinant 
PINCO-DsRed-H-RasG12V plasmid was used to generate retrovirus as described in section
2.4.6 and transduction efficiency was measured by flow cytometry. The use o f GFP and 
DsRed reporter genes enabled independent analysis of both cell populations in mixed 
culture by flow cytometry.
CD34+ control (expressing GFP) and CD34+ H-RasG12v cells (expressing 
DsRed) were recovered from growth medium and washed twice in HBSS as described in 
section 4.2.1.1. Co-cultures containing a fixed total number o f cells (lxlO4) were prepared 
by resuspending 0 .3-lx l04 CD34+ control cells in a fixed volume (150 pi) of IMDM
a One unit (U) will oxidize 1.0 pinole o f /3-D-glucose to D-gluconolactone and H2O2 per min at 
pH 5.1 at 35 °C, equivalent to an 0 2 uptake of 22.4 pi per min.
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without supplements, serum or growth factors in the presence of CD34+ H-RasG12v cells. 
Co-cultured cells were incubated for 48 h at 37°C in a 5% CO2 humidified atmosphere. 
After incubation, remaining cells were washed with staining buffer and labelled with 7- 
AAD and annexin V-Cy5 and the percentage o f GFP+ viable cells was determined by flow 
cytometry as in section 4.2.1.1.
4.2.2 Ex a m in a t io n  of pro liferatio n , cell cycle pro g r essio n  a n d  status
OF CELL CYCLE CONTROL PROTEINS IN TRANSDUCED HUMAN CD34+
HAEMATOPOIETIC CELLS
4.2.2.1 Determination o f  proliferation o f  transduced CD34+ cells
To determine whether activated Ras promotes proliferation in the absence of 
growth factors, a protocol similar to that described in section 4.2.1.2 was used, with slight 
modifications.
CD34+ control, CD34+ N-RasG12D and CD34+ H-RasG12v cells (day 3) were 
recovered from growth medium by centrifugation at 180 g for 5 min. Transduced CD34+ 
cells (lxlO4) were then washed with HBSS and incubated for 48 h at 37°C in a 5% CO2 
humidified atmosphere as described in section 4.2.1.2, with the exception that the cells 
were resuspended in 150 pi serum-replete, supplemented IMDM without growth factors 
(as opposed to IMDM without supplements, serum or growth factors used in survival 
experiments described in section 4.2.1). Some experiments were carried out in the presence 
o f either 10-500 nM DPI, 50-100 pg/ml catalase or 0.05-100 pM NAC. After incubation, 
remaining cells were washed with staining buffer and labelled with 7-AAD and annexin V- 
Cy5 as described in section 4.2.1.1, and the absolute number o f viable cells was counted by 
flow cytometry; using APC microbeads to control for recovery (APC microbead correction 
method is described in section 2.6).
4.2.2.2 Cell cycle analysis o f  transduced human CD34+ cells
To verify that expression o f mutant Ras caused human CD34+ haematopoietic 
cells to enter the cell cycle, propidium iodide (PI) was used to label intracellular DNA and 
DNA content was analysed by flow cytometry.
CD34+ control, CD34+ N-RasGI2D or CD34+ H-RasGI2V cells (day 5) were 
incubated in supplemented IMDM (formulation given in section 2.2.3.1) without growth 
factors at 4x105 cells/ml for 16 h at 37°C in a 5% CO2 humidified atmosphere. Growth 
factors were withheld to minimise cell-cycle entry due to growth factor signalling. After
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incubation, lxlO5 cells were washed with 15 ml PBS by centrifugation at 180 g for 10 min 
and the cell pellet was resuspended in 300 pi PBS and incubated on ice for 5 min. Ice-cold 
ethanol (700 pi) was then added to the cell suspension and the mixture was incubated on 
ice for 30 min followed by incubation at -20°C for 16 h. After incubation, 10 ml PBS was 
added to the cell suspension, followed by centrifugation at 300 g for 10 min. The pellet 
was resuspended in 50 pi PBS containing 40 pg/ml PI and 0.1 mg/ml DNAse-free RNAse 
(Sigma-Aldrich) and incubated for 30 min at 37°C. Pi-labelled cells were analysed by flow 
cytometry as described in section 2.6. The threshold for inclusion o f apoptotic bodies was 
set at 25% o f the fluorescence peak representing cells in Go. The proportion o f cells in Go 
and S+G2/M was determined using Cylchred vl.O (T. Hoy, Cardiff University, UK).
4.2 .3  D eterm ination  of c o lo n y -form ation  capacity  a n d  m orphology  in
TRANSDUCED HUMAN CD34+ CELLS
CD34+ control and CD34+ N-RasG12D cells (day 4) were recovered from growth 
medium by centrifugation at 180 g for 5 min, and incubated for 48 h in fresh growth 
medium at 2x105 cells/ml containing 0.2-1 pM DPI or vehicle control. After incubation, 
the CD34+ progenitor frequency (method described in legend), cellular morphology and 
number o f colony-forming cells was examined. For morphological assessment, 3.5x104 
cells were loaded onto a glass slide (Thermo Fisher Scientific) by centrifugation at 60 g for 
5 min using a Cytospin 3 cytocentrifuge (Thermo Fisher Scientific), stained with May- 
Griinwald-Giemsa using a Pentra DX 120 SPS analyser (Horiba ABX, Northampton, UK) 
and mounted using DPX mountant (Sigma-Aldrich). Digital photomicrography was 
performed using a Diaplan microscope with a 40x/0.65 objective lens (Leica, Cambridge, 
UK) and an Optronics MicroFire digital camera (Optronics, Goleta, CA). Images were 
acquired using MicroFire v l.l  software (Optronics).
Colony-forming cell frequency was determined using a limiting dilution colony 
assay. Transduced cells incubated with DPI or vehicle control (as described in this section) 
were resuspended in fresh growth medium and seeded in 96-well plates in triplicate at a 
limiting dilution o f 1.5 cells/well. After 7 days, colonies with >50 cells were scored.
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4 .3  R e s u l t s
4.3.1 The role of ROS in su r v iv a l  of h u m a n  CD34+ haem atopoietic  cells
4.3.1.1 Optimisation o f  survival assay using annexin V-Cy5 and 7-AAD
To assess the role o f ROS production in the survival o f transduced human 
CD34+ haematopoietic cells expressing mutant Ras, a suitable method for discrimination of 
apoptotic and viable cells was required. To this end, a protocol was devised using annexin 
V-Cy5 binding and internalisation o f 7-AAD to exclude apoptotic cells from the analysis.
To verify that these reagents were able to detect apoptosis in transduced CD34+ 
cells, normal CD34+ were cells labelled with annexin V-Cy5 and 7-AAD both before and 
after growth factor and serum deprivation for 24 h. As shown in Figure 4.1, normal CD34+ 
cells were 98% viable (annexin Vneg and 7-AADneg) prior to incubation. After 24 h 
incubation without growth factors or serum, three clearly defined populations were visible, 
79% o f remaining cells were viable, 9% were annexin V+ and 7-AADneg (early apoptotic 
cells), and 11 % were positive for both markers (late apoptotic cells).
These data suggest that annexin V-Cy5 and 7-AAD are able to detect apoptotic 
CD34+ cells, and are able to discriminate between early and late apoptotic populations in 
mixed culture. However, following 24 h incubation without serum or growth factors, a 
large proportion o f the culture was still viable. To maximise any survival difference 
between CD34+ control and CD34+ cells expressing mutant Ras, subsequent experiments 
extended the 24 h incubation to 48 h.
4.3.1.2 H-RasCI2 vpromotes growth factor-independent survival o f  human CD34+
haematopoietic cells
Mutant Ras has been shown to promote growth factor-independent survival in 
several haematopoietic cell lines; including mutant N-Ras and K-Ras in multiple myeloma 
cells (Hoang, B. et al. 2006), mutant H-Ras in murine BaF3 factor-dependent cells 
(Fukuda, S. and Pelus, L.M. 2004) and mutant N-Ras in FDC-P1 factor-dependent cells 
(McGlynn, A.P. et al. 2000). However, the effect of activated Ras on growth 
factor-independent survival of primary human CD34+ cells has not been previously 
investigated.
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Annexin V
Figure 4.1 Detection of apoptosis of CD34+ control cells deprived of growth factors 
and serum for 24 h
CD34+ control cells were labelled with annexin V and 7-AAD to detect apoptotic cells 
prior and after growth factor and serum deprivation. Figure shows bivariate flow 
cytometric plots showing annexin V and 7-AAD staining (A) immediately prior to 
incubation and (B) after 24 h incubation in IMDM without supplements, serum or growth 
factors. Viable cells are found in the lower left quadrant, early apoptotic cells are in the 
lower right quadrant and late apoptotic cells are in the upper right quadrant.
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To establish whether Ras promotes survival o f primary human CD34+ cells, 
CD34+ control and CD34+ H-RasG12V cultures were deprived of growth factors and serum 
for 48 h, and were incubated with annexin V-Cy5 and 7-AAD using the protocol validated 
in section 4.3.1.1. Representative bivariate flow cytometric plots are shown in Figure 4.2. 
As shown in Figure 4.3, CD34+ H-RasG12v cultures showed a significant resistance to 
apoptosis (59±3.3% viable; P<0.05) after 48 h without growth factors when compared to 
CD34+ control (26±3.9% viable) under the same conditions.
_l_ q j 2 Y
4.3.1.3 CD34 H-Ras cells secrete a paracrine pro-survival factor
Whilst performing the experiments described in section 4.3.1.2, it was observed 
that the growth factor-independence o f CD34+ H-RasG12v cells appeared to be dependent 
on cell culture density. To confirm whether cell culture density could affect cell survival, 
the viability o f CD34+ control and CD34+ H-RasG12v cells was determined following 
incubation without serum or growth factors over a range o f starting cell culture densities 
(0.5-3xl05 cells/ml).
I 12^
CD34 H-Ras cells showed a trend o f decreased viability with decreasing 
cell culture density, becoming significant at densities of lx l 05 cells/ml and below 
(P<0.05). CD34+ control cells exhibited a similar (but less pronounced) trend which did 
not reach significance (Figure 4.4).
The data suggest that transduced CD34+ cells secrete a pro-survival factor(s) into 
the extracellular space which may act in a paracrine manner on neighbouring cells. 
Furthermore, the increased dependence o f CD34+ H-RasG12v cells on cell density suggests 
that these cells secrete greater amounts o f these same factors; or secrete different, more 
effective pro-survival factors which contribute to their increased cell survival.
To establish whether these Ras induced putative pro-survival factors could 
augment survival o f neighbouring CD34+ control cells in a paracrine manner, CD34+ 
control cells (expressing a GFP reporter gene) were co-cultured with increasing 
proportions of CD34+ H-RasG12v (expressing a DsRed reporter gene) cells in the absence 
o f serum or growth factors. The use o f different reporter genes enabled independent 
analysis o f both cell populations in mixed culture by flow cytometry. Figure 4.5 shows that 
CD34+ control cells showed a significant increase in viability when cultured with 
increasing numbers o f CD34+ H-RasG12v cells (F^O.Ol).
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Figure 4.2 Flow cytometric analysis of transduced human CD34+ haematopoietic 
cells deprived of serum and growth factors for 48 h
Representative bivariate plots show typical annexin V and 7-AAD labelling of CD34f 
control and CD34+ H-Ras(,l2v cells (A) prior to growth factor and serum deprivation (0 h) 
and (B) following 48 h incubation in IMDM without supplements, serum or growth 
factors. Labelled cells were analysed by flow cytometry (section 2.6).
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Figure 4.3 Summary of flow cytometric data showing viable transduced CD34+ cells 
remaining after growth factor and serum deprivation for 48 h
CD34+ control and CD34+ H-RasG12v cells were deprived of growth factors and serum for 
48 h, and labelled with annexin V and 7-AAD. Bar chart represents mean percentage 
viable cells recovered after 48 h plus 1 S D (n=3). Statistical significance was calculated 
using the Mann-Whitney Test. *P<0.05.
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Figure 4.4 The effect of altering cell culture density on survival of transduced CD34+ 
cells after serum and growth factor deprivation
CD34+ control and CD34+ H-Ras(jl2v cells were incubated without serum or growth factors 
for 48 h at 0.5-3xl05 cells/ml. Data represents mean percentage viable (annexin Vneg and 7- 
AADneg) cells recovered ± 1 S D (n=3). Statistical significance was calculated using by 
one-way ANOVA using Tukey’s Honestly Significant Differences. tPO.OOl, *P<0.05.
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Figure 4.5 Growth factor-independent survival of CD34+ control cells is augmented 
when co-cultured with CD34+ H-RasG,2v cells
CD34+ control cells (expressing a GFP reporter gene) were co-cultured without serum or 
growth factors for 48 h with an increasing proportion of CD34+ H-RasG12v cells 
(expressing a DsRed reporter gene). Data represents mean percentage viable GFP+ cells 
recovered from co-culture after 48 h ± 1 S D (n=3). Statistical significance was calculated 
using by one-way ANOVA using Tukey’s Honestly Significant Differences. **/><0.01, 
*P<0.05.
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Taken together, these data indicate that CD34+ H-RasG12v cells secrete factors 
into the extracellular space which can augment growth factor-independent survival in an 
autocrine manner. Furthermore, these factors appear able to augment growth 
factor-independent survival o f CD34+ control cells in a paracrine manner.
4.3.1.4 Antioxidant treatment improves growth factor-independent survival conferred by
H-RasGI2v on human CD34+ haematopoietic cells
The data presented in section 4.3.1.3 indicate that CD34+ H-RasG12v cells secrete 
a factor which contributes to their growth factor-independent survival. Exposure to high 
concentrations o f ROS can lead to decreased survival via chemical damage to DNA and 
lipid membranes (Valko, M. et al. 2007), however, it has been demonstrated that NADPH 
oxidase-derived ROS (specifically H2O2) can promote survival o f  murine retinal cells 
(Groeger, G. etal. 2009). Given that CD34+ H-RasG12V (and CD34+ N-RasG12D) cells 
produce significantly greater amounts o f ROS than controls (sections 3.3.2.4 and 3.3.5.1), 
we investigated whether ROS may be acting as the paracrine factor suggested from section 
4.3.1.3. To this end, the survival o f CD34+ H-RasG12v cells was assayed using annexin V 
and 7-AAD in the presence o f several antioxidants and ROS inhibitors.
CD34+ control and CD34+ H-RasG12v cells were incubated at an optimal cell 
culture density (3x105 cells/ml; Figure 4.4) for 48 h without growth factors or serum in the 
presence o f either purified catalase (which destroys H2O2), NAC (a precursor o f the 
endogenous antioxidant GSH (Dodd, S. et al. 2008)), DPI or apocynin (NOX family 
oxidase inhibitors). Treatment with DPI and apocynin were well tolerated at low 
concentrations, with no significant change in viability in CD34+ H-RasG12v cells or CD34+ 
control cells. However, the viability o f both CD34+ control and CD34+ H-RasG12v cells 
was reduced at higher concentrations o f DPI, while higher concentrations o f apocynin had 
no significant effects (Figure 4.6A and B). Treatment with catalase or NAC had no 
significant effects on the survival of CD34+ H-RasG12v cells or CD34+ control cells, with 
the exception of a large increase in viability at 75 pM NAC in the control culture. (Figure 
4.6C and D).
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Figure 4.6 The effect of several antioxidants and ROS inhibitors on the survival of 
transduced CD34+ cells
CD34+ control and CD34+ H-RasG12v cells were resuspended at an optimal cell culture 
density (3x105 cells/ml) deprived of growth factors and serum for 48 h in the presence of 
(A) DPI, (B) apocynin, (C) NAC or (D) catalase. After incubation, remaining cells were 
labelled with annexin V and 7-AAD and the percentage of viable cells were counted by 
flow cytometry. Data represents mean ± 1 S D.
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These experiments suggested that at optimal culture density (~ 3x105 cells/ml), 
constitutive ROS production does not significantly influence cell survival, suggesting that 
ROS were not likely to be the paracrine factor suggested in section 4.3.1.3.
4.3.1.5 H2 O2 antagonises growth factor-independent survival o f  human CD34+
haematopoietic cells
Section 4.3.1.4 showed that when CD34+ H-RasG12v cells were cultured at an 
optimal cell culture-density (3xl05 cells/ml, determined by data shown in Figure 4.4), 
antioxidant treatment had no significant effect on cell viability, indicating that ROS do not 
promote survival in this context. However, it is plausible that ROS may impair cell 
viability in this system, an effect that may have been masked by performing the 
experiments at optimal density. Therefore the effect of catalase treatment on CD34+ H- 
Ras cell viability was investigated again, this time at sub-optimal culture densities 
(below lxlO5 cells/ml, as indicated in Figure 4.4). For comparison, CD34+ control cells 
were studied under the same conditions.
CD34+ control and CD34+ H-RasG12v cells were incubated for 48 h without 
growth factors or serum in the presence o f purified catalase at a sub-optimal cell culture 
density (0.5x105 cells/ml; Figure 4.4). Figure 4.7A shows that catalase significantly 
augmented survival o f  CD34 H-Ras cells (but not controls) under these conditions 
(P<0.05), suggesting that H2O2 production by CD34+ H-RasG12v cells impaired cell 
viability in an autocrine manner.
To determine whether H2O2 produced by CD34+ H-RasG12v cells could impair 
CD34+ control cell viability in a paracrine manner, co-culture experiments were conducted 
in the presence o f purified catalase. These experiments showed that the presence of 
catalase increased the viability o f CD34+ control cells beyond that already observed 
(Figure 4.7B).
Since H2O2 derived from CD34+ H-RasG12v cells appeared to impair CD34+ 
control cell viability in a paracrine fashion, this study investigated whether similar 
concentrations of exogenous H2O2 alone could impair viability o f normal cells. However, 
H2 O2 is unstable in cell culture medium (it is cell permeable and catabolised by 
intracellular antioxidants), therefore this study used GOX to continuously generate a low 
level o f H2O2 throughout the assay. GOX (purified from A  niger) generates H2O2 by 
oxidation o f /3-D-glucose and is a useful long-term source o f H2 O2 generation cell culture. 
Figure 4.7C i shows that as expected, increased GOX concentration resulted in increased 
H2 O2 production. As shown in Figure 4.7C ii, CD34+ control cells exhibited a dose-
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dependent decrease in viability in the presence of GOX, but were protected from this effect 
when 500 pg/ml catalase was also present.
Taken together, these data suggest that ROS (specifically H2O2) do not promote 
growth factor independent survival CD34+ H-RasG12v cells, but rather antagonise it in a 
dose-dependent manner. CD34+ control cells only slightly benefited from antioxidant 
treatment, which is consistent with their lower ROS production; however, they still 
exhibited a trend o f improved viability at the highest concentrations o f NAC and catalase, 
and showed a dose-dependent decrease in viability in the presence o f GOX, further 
supporting the notion that H2O2 hinders survival.
These data also show that H2 O2 generated by CD34+ H-RasG12v cells antagonises 
the paracrine effects o f putative secreted factor(s) on control cells. This study has not 
pursued investigations into the identity o f this paracrine factor(s), however a recent study 
has shown that human CD34+ cells expressing mutant N-Ras do upregulate mRNA 
transcripts of several pro-survival factors, including IL-3 and PDGF (Shen, S. et a l 2007).
“F G12 V4.3.1.6 CD34 H-Ras cells show increased activation o f  Akt
p  1 ' ) \ 7
The data presented in this Chapter thus far shows that H-Ras promotes 
growth factor-independent survival o f human CD34+ cells. Since Akt activation is closely 
associated with constitutive Ras signalling in haematopoietic malignancies (Steelman, L.S. 
et a l 2008) this study examined whether altered expression or phosphorylation state o f Akt 
in could explain increased survival observed in CD34+ H-RasG12v cells.
Survivin is a member o f the inhibitor o f apoptosis protein (IAP) family and plays 
an important role in regulating the survival and cell cycle progression of normal 
haematopoietic cells (Fukuda, S. and Pelus, L.M. 2004; Fukuda, S. et al 2002), and is 
over-expressed in a variety of cancers (Sah, N.K. et a l 2006). There is also evidence to 
suggest a link between activation of Akt and subsequent up regulation of Survivin 
(Fukuda, S. et a l 2002). CD34+ control and CD34+ H-RasG12v cells were incubated in 
supplemented serum-replete IMDM without growth factors for 16 h, and Western blot 
analysis o f Survivin and Akt expression was performed.
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Figure 4.7 The effect of catalase and GOX treatment on the survival of transduced 
human CD34+ cells
(A) CD34+ control and CD34+ H-RasGI2v cells were resuspended at a sub-optimal cell 
culture density (5x104 cells/ml) and were deprived of growth factors and serum for 48 h in 
the presence of catalase (n=3). (B) CD34+ control cells expressing GFP were co-cultured 
for 48 h with CD34 H-RasJ cells (expressing DsRed) in the absence of growth factors 
and serum and in the presence of 500 pg/ml catalase (n=3) (C) CD34+ control cells were 
deprived of growth factors and serum for 48 h in the presence of GOX, with or without 500 
pg/ml catalase. i) H2 O2 production by GOX during the incubation was measured in cell- 
free KRPG medium using Amplex Red. 10, 30 and 50 pU/ml GOX generated a final H2O2 
concentration 0.5, 1.1 and 1.5 pM respectively over 48 h (corresponding to an estimated 
mean H2 O2 production rate of 1.5, 3.4 and 5 pmoles/h respectively), ii) After 48 h, 
remaining cells were labelled with annexin V and 7-AAD, and cell viability was analysed 
by flow cytometry (n=2). Data represents mean ± 1 S D. Statistical significance was 
calculated using by one-way ANOVA using Tukey’s Honestly Significant Differences. 
*P<0.05, **P<0.01.
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This study found no consistent evidence of increased Survivin expression in 
transduced CD34+ cultures (Figure 4.8A). Similarly there were no detectable differences in 
expression o f total Akt, however, CD34+ H-RasG12v cells showed phosphorylation o f Akt 
on Serine 473 (suggestive o f increased activation of Akt), while CD34+ controls showed 
little or no detectable phosphorylation on this residue. Finally, CD34+ H-RasG12v cells 
which were incubated in the presence o f DPI showed no change in Akt phosphorylation 
compared with vehicle controls, which is consistent with the observation that DPI (and 
possibly other ROS antagonists) was unable to suppress the survival o f these cells (Figure 
4.8B).
4.3.2 T h e  r o l e  o f  ROS in  p r o l if e r a t io n  o f  h u m a n  CD34+ h a e m a t o p o ie t ic
CELLS
The experiments described in section 4.3.1 used ROS inhibitors and scavengers 
to demonstrate that ROS up regulation antagonises growth-factor independent survival in 
CD34+ H-RasG12v cells. However, it was observed that although antioxidants improved the
I i
viability o f CD34 H-Ras cells, they appeared to suppress the total number o f viable
I i
cells recovered after treatment when compared with CD34 H-Ras cells treated with 
vehicle control, suggesting that antioxidants may act to suppress proliferation in this 
context. These preliminary observations suggested that scavenging o f ROS could suppress 
proliferation; a notion consistent with a study by Sattler et al., which suggested that ROS 
contribute to haematopoietic growth factor signal transduction (Sattler, M. et a l 1999). 
Therefore, this study investigated whether increased production o f ROS played any role in 
the proliferation o f CD34+ H-RasG12v and CD34+ N-RasG12D cells.
4.3.2.1 Activated Ras promotes growth factor-independent proliferation o f  human
CD34+ haematopoietic cells
To establish whether activated Ras promotes growth factor-independent 
proliferation o f human CD34+ cells, a modified version of the survival assay protocol 
(section 4.2.1.3) was used, which was intended to move the emphasis of the assay away 
from survival towards proliferation.
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Figure 4.8 Examination of survivin and Akt expression in transduced human CD34+ 
cells
CD34+ control and CD34+ H-RasG12v cells were incubated in supplemented IMDM 
without growth factors at 4x105 cells/ml for 16 h at 37°C in a 5% CO2 humidified 
atmosphere. Growth-factor withdrawal minimised changes in expression of these proteins 
induced by growth-factor signalling. Following incubation, 3x105 cells were collected by 
centrifugation and expression of key survival molecules was examined by in whole-cell 
extracts by Western blot analysis as described in section 2.4.7. (A) Protein extracts were 
probed with anti-survivin antibody (Cell Signaling). 10 ng/ml anti-/3-actin (Abeam) was 
used as a loading control. Representative of 2 independent experiments. (B) CD34+ control 
and CD34+ H-RasG12v were incubated as in (A), in the presence or absence of 1 pM DPI. 
Protein extracts were incubated with 10 ng/ml anti-phospho-Akt (Ser473) or 16 ng/ml anti­
pan Akt (both from Cell Signaling). 20 ng/ml anti-GAPDH (Santa Cruz) was used as a 
loading control. Data obtained from one experiment.
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CD34+ control, CD34+ N-RasG12D and CD34+ H-RasG12v cells (lxlO4) were 
incubated in supplemented, serum-replete IMDM without growth factors for 48 h (as 
opposed to IMDM without any supplements, serum or growth factors used in survival 
assays). Under these conditions normal CD34+ cells, showed improved viability, but were 
unable to proliferate. Following incubation, viable cells were counted by flow cytometry 
and the number o f cells recovered was used a measure o f proliferation.
Under these conditions, CD34+ N-RasG12D and CD34+ H-RasG12v cells showed a 
significant increase in cell number (H-RasG12v 5.2 fold; N-RasG12D 3.9 fold; F><0.05) over 
48 h whilst CD34+ control cells failed to proliferate (Figure 4.9). To verify that mutant Ras 
was promoting bona fide  proliferation; cell cycle analysis was performed on transduced 
CD34+ cells which had been deprived o f growth-factors for 16 h. As shown in Figure 4.10, 
CD34+ N-RasG12D and CD34+ H-RasG,2v cells exhibited a significant 2 fold increase in the 
proportion o f cells in S+G2/M compared with CD34+ control cells ( /><0.05).
Taken together, these data demonstrate that activated Ras can promote growth 
factor-independent proliferation of human CD34+ haematopoietic cells.
4.3.2.2 ROS play a context-dependent role in proliferation o f human CD34+ cells
To examine whether the proliferation advantage o f CD34+ H-RasG12v and
| 1 2  TA
CD34 N-Ras cells could be partly due to their increased ROS production (sections
3.3.2.4 and 3.3.5.1), transduced human CD34+ cells were deprived o f growth factors for 48 
h (as described in section 4.3.2.1) in the presence o f either DPI, catalase or NAC. 
Interestingly, in the presence o f these antioxidants, CD34+ H-RasG12v and CD34+ N- 
Ras cells exhibited a significant dose-dependent decrease in the number o f cells 
recovered compared with vehicle control (P<0.05), while in contrast, CD34+ control cells 
generally showed an increase in cell numbers under the same conditions (Figure 4.11).
I ^  1
To verify that the decrease in cell numbers observed in CD34 N-Ras and
I 1
CD34 H-Ras cells was not due to reagent toxicity, the viability o f cells recovered
from ROS scavenger-treated cell cultures was determined using annexin V and 7-AAD. 
Figure 4.12 shows that the viability o f all cultures was either unaffected or improved in the 
presence o f these antioxidants, suggesting that the observed decrease in proliferation was 
not due to decreased viability. These data suggest that ROS can augment growth factor- 
independent proliferation of CD34+ cells in the context o f mutant Ras. In contrast, ROS 
appear to have the opposite effect on the proliferation o f normal CD34+ cells.
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Figure 4.9 Examination of the proliferative capacity of transduced human CD34+ 
cells in the absence of growth factors
CD34+ control, CD34+ H-RasG12v and CD34+ N-RasGI2D cells were incubated in serum- 
replete, supplemented IMDM without growth factors for 48 h, after which viable cells 
were counted by flow cytometry as described in section 2.6. Dotted line indicates the 
number of cells at the beginning of the assay. Data represents mean ± 1 S D (n=4). 
Statistical significance was calculated using the Mann-Whitney Test. *P<0.05, **P<0.01.
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Figure 4.10 Cell cycle analysis of transduced human CD34+ cells
Transduced CD34+ cells were deprived of growth factors for 16 h, after which the cells 
were fixed and permeablised, and DNA was labelled with 40 pg/ml PI. PI labelled cells 
were analysed by flow cytometry (section 2.6). Representative flow cytometric histograms 
obtained from (A) CD34+ control, (B) CD34+ H-Rasol2v and (C) CD34+ N-RasGI2D cells 
are shown, together with the mean percentage of cells in S+G2/M ± 1 S D (n=3). Statistical 
significance was calculated using the Mann-Whitney Test. *P<0.05.
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Figure 4.11 The effect of antioxidants and NOX inhibitors on proliferation of 
transduced human CD34+ cells
CD34+ control, CD34+ H-RasG12v and CD34+ N-RasG12D cells were deprived of growth 
factors for 48 h in the presence of either DPI, NAC or catalase. The number of viable cells 
recovered from cultures treated with vehicle control was set at 1 0 0 % (marked with dotted 
line). CD34+ H-RasG12v cells and controls were treated with either (A) 0.05-100 pM NAC 
or (B) 10-500 nM DPI. CD34+ N-RasG12D cells and controls were treated with either (C) 5- 
100 pM NAC, (D) 10-100 nM DPI or (E) 50-100 pg/ml catalase (n=2). Data represents 
mean plus 1 S D. (n >3 unless otherwise stated). Statistical significance was calculated by 
one-way ANOVA using Tukey’s Honestly Significant Differences. *P<0.05; **P<0.01.
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Figure 4.12 The viability of transduced human CD34+ cells treated with antioxidants
To confirm that the suppression of proliferation of CD34+ H-RasG12v and CD34+ N- 
RasG12D cells induced by antioxidants and NOX inhibitors (presented in Figure 4.11) was 
not due to toxicity, the viability o f the recovered cells was examined after treatment at each 
of the concentrations used. Data represents mean ± 1 S D. Statistical significance was 
calculated by one-way ANOVA using Tukey’s Honestly Significant Differences.
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4.3.2.3 The effect o f  NOX-inhibition on CD34+ cell frequency, colony-formation 
capacity and morphology
Next, this study investigated whether activated Ras influenced the self-renewal 
capacity o f human CD34+ haematopoietic cells, and if so, whether ROS production by 
these cells was an important factor. Therefore, this study examined the effect of DPI 
treatment on CD34+ frequency, myeloid lineage colony forming capacity and cellular 
morphology as a measure o f self-renewal capacity (Figure 4.13). CD34+ control and 
CD34 N-Ras cells were cultured in serum-replete medium supplemented with 
cytokines to support myeloid growth (formulation given in section 2.2.3.1) in the presence 
of DPI or vehicle control for 48 h. Subsequently, the effect of DPI on the number o f 
colony-forming cells (CFC) present was assayed by limiting dilution colony assay, and 
CD34+ frequency and morphology were examined.
In the absence o f DPI, CD34+ control cells and N-RasG12D cells behaved 
similarly in all o f the assays -  both cultures showed similar CD34+ frequency (Figure 
4.13A), colony-formation capacity (Figure 4.13B), and morphology (Figure 4.13C). DPI 
treatment had no significant effect on CD34+ frequency and no noticeable effect on 
morphology, but did suppress colony formation capacity in a dose-dependent manner. 
However the effect was similar in both cultures.
These data show Ras does not significantly alter total colony formation capacity 
or CD34+ progenitor frequency, consistent with previously published data (Peam, L. et al. 
2007). In addition, these results suggest that DPI can suppress colony formation capacity, 
but this effect is independent of Ras expression.
4.3.2.4 ROS affects the expression o f  key cell cycle control proteins in human CD34+
haematopoietic cells
To understand the molecular mechanisms by which ROS augments proliferation, 
CD34+ control, CD34+ N-RasG12D and CD34+ H-RasG12v cells were deprived of growth 
factors for 16 h as described in section 4.2.2.2 in the presence or absence o f DPI, and the 
expression and phosphorylation state o f key cell-cycle regulatory proteins was examined 
using Western blot analysis.
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Figure 4.13 Examination of CD34 antigen expression, morphology and colony 
forming capacity of transduced haematopoietic cells in the presence of DPI
(A) CD34+ N-RasG12D and controls (day 4) were incubated for 48 h in serum and growth 
factor-replete medium in the presence of either DPI or vehicle control. After incubation, 
cells (day 6 ) were then labelled with 5 pg/ml anti-CD34 antibody conjugated to PE or 
isotype-matched irrelevant control antibody (both from BD Biosciences) for 30 min at 4°C 
and analysed by flow cytometry as described in section 2.6. Data represents mean CD34+ 
cell frequency plus 1 S.D. (n=2). (B) The number of colony-forming cells present after 
incubation as in (A) was examining using a limiting dilution colony assay (methodology 
described in section 4.2.3). Data represents mean colony forming units scored plus 1 S.D. 
(n=2). (C) Morphological analysis of transduced cells after incubation as in (A). May- 
Griinwald-Giemsa stain; original magnification is x40 in all panels. Scale bars = 10 pm. 
CFC = colony-forming cells
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Consistent with their pro-proliferative role, N-RasG12D and H-RasG12v strongly 
promoted the expression o f D-type cyclins D1 and D3; in each case the influence o f H-
Q12Y G12DRas was greater than N-Ras (a trend also observed in the extent o f ROS induction; 
section 3.4). These oncogenes had no effect on the expression o f the cell cycle inhibitor 
p l5 INK4B, but did upregulate the cell cycle inhibitor p21Cipl, which seemed contrary to their 
pro-proliferative effect (Figure 4.14A). Previously, it has been reported that hematopoietic 
cells express high levels o f  extra-nuclear p21Cipl (Schepers, H. et al. 2003), therefore we 
examined the sub-cellular location o f p21Clpl and found that p21Clpl expression was 
exclusively cytosolic (Figure 4.14B). Recent reports suggest that cytoplasmic p21c,pl plays 
an anti-apoptotic role (Zhou, B.P. et al. 2001), and this is consistent with the increased 
survival o f CD34+ H-RasGI2v cells (described in section 4.3.1.2). The fact that inhibition of 
ROS production promoted p21Clpl levels indicates that ROS normally act to suppress 
p21Cipl expression and (in this context) it’s associated anti-apoptotic function. This notion 
is consistent with previously presented data showing that ROS antagonises the survival o f 
CD34+ H-RasG12v cells (section 4.3.1.4).
To assess whether ROS production contributed to the altered expression o f cell 
cycle regulatory proteins, CD34+ H-RasG12v cells were treated with DPI prior to Western 
blot analysis (Figure 4.14C and D). NOX inhibition resulted in a consistent reduction in 
cyclin D1 (63% of vehicle control) and cyclin D3 expression (80% o f vehicle control), 
indicating that ROS production cooperated with activated Ras in the induction o f these D- 
type cyclins. Activated Ras also upregulated cyclin dependent kinase 4 (CDK4), a binding 
partner of D-type cyclins, however, DPI had no effect on the expression o f this protein or 
CDK6 (Figure 4.14C).
Next, we examined the effect of NOX inhibition on the cell cycle inhibitor 
proteins, p38MAPK, p l6 WK4A, p \5 WK4B, p27Kipl and p21Cipl (Figure 4.14D). ROS normally 
elicit a stress response mediated via phosphorylation of p38MAPK, which leads to the 
induction of the cell cycle inhibitor, p l6 INK4A (Dolado, I. et al. 2007; Macleod, K.F. 2008). 
We therefore examined whether this oxidative stress response was operating in CD34+ H- 
RasG12v cells. H-RasG12v did promote p38MAPK phosphorylation, but not in the presence of 
DPI, demonstrating the specificity o f ROS in the phosphorylation o f p38MAPK (Figure 
4.14D). However, this study did not detect expression o f p l6 INK4A in either CD34+ control 
or CD34+ H-RasG12v cells, despite using a primary antibody that was validated using HeLa 
cell protein extracts (see Appendix 4).
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Figure 4.14 Examination of the effect of DPI on the expression and phosphorylation 
of key cell cycle control proteins
CD34+ control, CD34+ H-RasG12v and CD34+ N-RasG12D cells were incubated for 16 hours 
in supplemented IMDM without growth factors, either in the presence or absence of 1 pM 
DPI. Expression and phosphorylation state of key cell cycle regulatory proteins in whole 
cell or cytosol/nucleus fractionated protein extracts was determined by Western blot 
analysis as described in section 2.4.7. (A) CD34+ control, CD34+ H-RasG12v and CD34+ N- 
Ras 12D whole cell protein extracts were examined using 143 ng/ml anti-cyclin D l, 280 
ng/ml anti-cyclin D3, 7 ng/ml anti-pl5,NK4B (which sequesters CDK4/6) and 418 ng/ml 
anti-p21Cipl (which inhibits CDK/Cyclin complexes) demonstrating that CD34+ N-RasG12D 
cells show a similar trend of proteins expression to CD34+ H-RasCj 2V cells. (B) CD34+ 
control and CD34+ H-RasG12v cytosol/nuclear fractionated protein extracts were probed 
with anti-p21c,pl antibody. Extracts were also probed with 20 ng/ml anti-GAPDH (Santa 
Cruz) and 1 pg/ml anti-Histone HI (BD Biosciences) and which served as loading controls 
and as markers of cytosol/nuclear fraction purity. (C) Expression of key cell cycle 
promoter proteins was examined using anti-cyclin Dl and D3 antibodies as in (A), 346 
ng/ml anti-CDK6 and 64 ng/ml anti-CDK4. (D) Expression and phosphorylation of several 
cell-cycle inhibitors was examined using 8 ng/ml anti-phospho-p38MAPK (Thrl80/182), 2 
ng/ml anti-total p38MAPK 213 ng/ml anti-p27 pl (which has a similar role to p21Clpl), 
p21c,pl and p l5 INK4B antibodies as in (A). All antibodies were from Cell Signaling unless 
otherwise stated. 10 ng/ml anti-/3-actin (Abeam) and 20 ng/ml anti-GAPDH (Santa Cruz) 
served as loading controls. Blots are representative of at least 2 independent experiments.
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This suggests that the p38M K stress-response pathway was uncoupled in these 
cells or that it is not normally linked to p l6 INK4A induction in this context. As expected,
DPI had no effect on p l5 INK4B or p27Kipl, since activated Ras did not alter the expression of 
these proteins (Figure 4.14D). However, DPI augmented p21Clpl levels indicating that ROS 
normally act to suppress p21Cipl expression and (in this context) it’s associated anti- 
apoptotic function (Figure 4.14D).
Finally, the expression and phosphorylation o f the cell cycle checkpoint protein, 
RB was examined. When unphosphorylated, RB proteins bind to E2F transcription factors 
and inhibit their activity. RB phosphorylation by cyclin-dependent kinases leads to release 
o f E2F transcription factors and subsequent transcription o f proteins which promote cell 
cycle progression (Macleod, K.F. 2008).
Surprisingly, we found that H-RasG12v expression induced RB expression (3- 
fold) compared with controls, however a similar increase was observed in the level o f  
phosphorylated RB which is consistent with the increase in cyclin D/CDK4 expression in 
these cells (Macleod, K.F. 2008), suggesting that most of the RB was inactive (Figure 
4.15). Antioxidant treatment caused a consistent decrease in RB expression; however 
concomitant changes in RB phosphorylation level make it difficult to draw any conclusions 
about the significance o f this observation.
r  1 o \ /  p  i
In summary, these data indicate that H-Ras and N-Ras expression 
promotes expression o f the cell cycle promoters cyclin Dl and D3; which provides a 
possible explanation for their increased proliferative capacity. In addition, these results 
suggest that ROS production by CD34+H-RasG12v cells contributes to activation o f CDK4 
(via increased expression o f both CDK4 binding partners, cyclin Dl and D3); which offers 
an explanation for the ability o f ROS to augment proliferation o f these cells. It is likely that 
a similar mechanism also operates in CD34+ N-RasG12D cells but was not formally tested 
herein.
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DPI
p-RB (Ser780) 
p-RB (Ser795) 
p-RB (Ser807/811) 
total RB 
GAPDH
CD34+ CD34+
Control H-RasG12V
Figure 4.15 Examination of expression and phosphorylation of RB in the presence or 
absence of DPI
Whole cell protein extracts were prepared from CD34+ control and CD34+ H-RasG12v cells 
(which had been deprived of growth factors as described in Figure 4.14), and the 
expression and phosphorylation state of the key cell cycle checkpoint regulator Rb was 
examined. Protein extracts were probed with either 13 ng/ml anti-phospho-Rb (Ser780), 5 
ng/ml anti-phospho-Rb (Ser795), 10 ng/ml anti-phospho-Rb (Ser807/811) or 97 ng/ml 
anti-pan Rb, all purchased from Cell Signaling. 20 ng/ml anti-GAPDH (Santa Cruz) served 
as a loading control. Blots are representative of 2 independent experiments.
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4 .4  D i s c u s s i o n
This study investigated the ability o f mutant Ras to promote growth factor- 
independent survival and proliferation in human CD34+ haematopoietic cells, and also 
investigated the effect of ROS on these phenotypes. This study shows for the first time that 
mutant Ras alone can promote the survival o f primary haematopoietic progenitors under 
conditions o f growth factor and serum withdrawal. This supports previous studies in which 
activated Ras has been shown to promote survival o f factor-dependent haematopoietic cell 
lines in the absence o f exogenous growth-factors (Fukuda, S. and Pelus, L.M. 2004; 
McGlynn, A.P. et al. 2000). The most likely explanation for this increased cell survival 
was phosphorylation o f Akt (aka PKB) on Ser473. This is thought to promote survival via 
a number o f mechanisms including phosphorylation and inactivation o f pro-apoptotic 
proteins such as Bad and caspase-9 (Steelman, L.S. et al. 2004). Despite recent evidence 
suggesting that increased survivin expression may contribute to haematopoietic cell 
survival and proliferation in the context of mutant H-Ras (Fukuda, S. and Pelus, L.M. 
2004), this study found no evidence o f altered survivin expression in response to H- 
Ras . However, Fukuda et al. only examined upregulation o f survivin in CD34 cells in 
response to IL-3 receptor activation, which not only activates Ras but also STAT3 and 
STAT5 (Steelman, L.S. et al. 2004). Since the survival assays herein were performed in 
the absence o f growth factors (and therefore ST AT signalling is likely to be minimal) it 
appears that activated H-Ras alone is insufficient to induce survivin upregulation in CD34+ 
cells without cooperation with ST AT signals. Regardless, in the context of the present 
study, survivin upregulation is dispensable for the growth factor-independent survival 
observed in CD34+ H-RasG12v cells.
I 12^
This study also showed that survival o f CD34 H-Ras cells was dependent 
on culture density. Furthermore, CD34+H-RasG12V cells could promote the survival o f 
control cells in paracrine fashion. These data strongly suggested the presence o f a paracrine 
pro-survival factor secreted by CD34+ H-RasG12v cells. Since H2O2 has recently been 
shown to promote cell survival in neuronal cells (Groeger, G. et al. 2009), we examined 
whether ROS may be acting as this putative pro-survival factor. Depletion o f ROS using
I 1 2 ^
catalase, NAC, DPI or apocynin merely promoted the survival o f both CD34 H-Ras 
and control cells, demonstrating that ROS production inhibited cell survival in this context. 
Consistent with the notion that ROS were not supporting survival o f these cells, we found 
that neither DPI nor catalase could suppress Ser473 phosphorylation o f Akt. These results 
were corroborated by experiments showing that GOX-derived H2 O2 caused a
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dose-dependent increase in apoptosis o f control cells. As shown in section 3.3.3, 
production o f H2 O2 can lead to formation o f toxic hydroxyl radicals; which offers an 
explanation for adverse affect o f ROS production on survival. Incidentally, it is worth 
noting that there was a large drop in viability o f CD34+ H-RasG12v cells at high DPI 
concentrations and to a lesser extent, apocynin (Figure 4.5). This effect was not present 
with NAC or catalase treatment. Since low concentrations o f ROS inhibitors caused a mild 
augmentation o f viability (consistent with data observed with NAC and catalase treatment), 
the reduced viability observed at high concentrations is likely due to off-target effects DPI 
and apocynin as opposed to ROS inhibition.
The identity o f the paracrine pro-survival factor remains unknown. CD34+ H- 
Ras cells appear to produce ROS and the pro-survival factor simultaneously and co­
culture experiments conducted in presence o f catalase demonstrate that ROS antagonises 
the actions o f this factor. Since this putative factor is able to promote survival o f control
I 1 2  w
and CD34 H-Ras cells in a paracrine/autocrine manner (section 4.3.1.3), it must be 
assumed that both cell types express the appropriate receptor, which may help 
identification o f this factor in future studies. Recently, a gene array analysis o f  CD34+N- 
RasG13C cells (a Ras mutant with a phenotype similar to N-RasG12D) has revealed that this 
Ras mutant strongly promotes the expression o f a several cytokine genes, including IL-3 
and also both PGDF-A and B and their receptor PDGF-R (Shen, S. et a l  2007). Normal 
CD34+ cells also express the PDGF receptor (Steelman, L.S. et a l 2004; Pantazis, P. et al.
1990). Though speculative, autocrine signalling through PDGFR could explain the 
heightened sensitivity o f CD34+ H-RasG12v to culture density, whilst explaining the ability 
to confer survival on normal cells (which express PDGF receptors). Finally, it should be 
pointed out that this density-dependent survival could be mediated by more than one 
factor; or possibly by another mechanism i.e. promotion o f survival through cell-to-cell 
contact (though the low cell culture densities used in co-culture assays suggest that this is 
less likely). Further insight could be gained by co-culturing transduced CD34+ cells 
separated by permeable barrier (e.g. a transwell insert) or culturing control cells in the 
presence o f CD34+ H-RasG12v cell-conditioned medium (which exclude any cell-cell 
contact mechanism).
In addition to increased cell survival, CD34+H-RasG12v and CD34+ N-RasG12D 
cells (but not controls) were able to proliferate in serum-replete cultures without the 
addition o f growth factor. Previous studies o f the effect o f H-Ras on CD34 cells, 
including studies at Cardiff have all made proliferative comparisons in the presence of 
growth factors (Dorrell, C. et a l 2004; Peam, L. et a l 2007) and under these conditions no
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proliferative advantage is observed; though N-RasG12D has previously been shown to 
promote a growth advantage when CD34+ cells were cultured with the MS5 stromal line 
(Shen, S.W. et a l 2004). Consistent with increased proliferation, H-RasG12v and N-RasG12D 
both induced a strong upregulation o f cyclin Dl and D3, which corroborates previous 
observations (Matsumura, I. et a l 2000). H-RasG12v also upregulated the cyclin D partner 
kinase, CDK4. CDK6 expression was unaltered. This is in contrast to Lazarov et a l , where 
activated Ras has been reported to suppress expression o f CDK4 in primary human 
epidermal cells (Lazarov, M. et a l 2003). Lazarov et a l show that suppression o f CDK4 in 
their study is accompanied by characteristics o f cellular senescence, namely induction of 
CDK inhibitor proteins, and growth arrest. In the present study, CD34+ cells expressing 
mutant Ras appear to avoid Ras-induced senescence (discussed later) and it follows that 
they may also avoid suppression o f CDK4 expression. Forced co-expression o f CDK4 and 
mutant H-Ras results in strong synergy and aggressive melanoma formation (Hacker, E. et 
a l 2006), however, there are no precedents for a similar situation in leukaemias. The cause 
o f differential CDK4 and CDK6 expression in CD34+ H-RasG12v cells is currently 
unknown, however recent work suggests that CDK4 and CDK6 are differentially regulated 
by tyrosine phosphorylation (Bockstaele, L. et a l 2009), which is dysregulated in our 
model (see Chapter 5). An important observation in this study was that ROS production 
appeared to augment the proliferation advantage o f CD34+ H-RasG12v and CD34+ N- 
RasG12D cells, whereas ROS was growth inhibitory for control cells. This suppression o f 
proliferation was not due to changes in cell viability (Figure 4.12). These data also suggest 
that H-RasG12v or N-RasG,2D may not only promote ROS production in haematopoietic 
progenitors, but can simultaneously alter their response to it. Further work is required to 
understand the mechanism underlying this behaviour.
Increased ROS has previously been associated with increased cell proliferation 
in several models. For example, mitogenic signalling in Ras-transformed mouse fibroblasts 
was suppressed with NAC treatment (Irani, K. et a l 1997), while overexpression o f NOX1 
alone (aka Moxl) in mouse fibroblasts resulted in increased ROS production and 
proliferation (Suh, Y.A. et al 1999). Importantly, NOX inhibitor studies revealed that ROS 
contributed to both cyclin Dl and D3 expression in this model, providing a molecular 
explanation for the decreased proliferation observed when CD34+ H-RasG12v and CD34+ 
N-RasGI2D cells were treated with antioxidants. Redox regulation o f cyclin Dl expression 
has been previously reported in murine fibroblasts (MEFs). Menon et a l demonstrated that 
treatment o f MEFs with the antioxidant NAC caused a decrease in cyclin Dl expression, 
and suppressed Gi/S progression. The oxidative modification o f cysteine residues within
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cyclin Dl (presumably affecting cyclin stability) was suggested as a possible mechanism 
(Menon, S.G. et al. 2003). NOX1 derived superoxide has also been reported to delay 
quiescence in murine lung cells after growth factor withdrawal by promoting cyclin Dl 
expression. Ranjan et al. suggest that ROS mediate this effect by prolonging the activity of 
AP-1 transcription factors (which regulate cyclin D gene transcription) after factor- 
withdrawal (Ranjan, P. et a l 2006).
There is similar uncertainty about the redox-regulated expression o f cyclin D3, 
about which less is generally known. However one study shows strong upregulation of 
cyclin D3 in HL60 cells during TPA-induced differentiation, suggesting cyclin D3 may be 
downstream of PKC signalling (Bartkova, J. et al. 1998), which (as discussed in Chapter 
5), PKC signalling is highly sensitive to redox regulation. Interestingly, CDK6-cyclin D3 
complexes (which presumably exist in CD34+ H-RasG,2v and CD34+ N-RasG12D cells) are 
reportedly insensitive to the cyclin-dependent kinase inhibitors p21Cipl and p27Kipl (Lin, J. 
et al. 2001) and this (together with a lack o f p l6 INK4A expression, discussed later) 
reinforces the pro-proliferative milieu in CD34+ expressing mutant Ras. Further work is 
needed to fully establish the role o f redox-regulated cyclin D expression in the 
proliferation o f these cells. In particular, it not currently known whether ROS regulates 
cyclin D expression in normal cells. Experiments which examine the ability o f exogenous 
H2O2 to induce cyclin D expression in normal cells in the presence of AP-1 and/or PKC 
inhibitors might prove informative.
Cell cycle progression is also a function o f cell cycle inhibitor protein activity. 
Whilst, pi 5,NK4B and p27Klpl expression was not significantly affected by mutant Ras 
expression, both mutant Ras iso forms promoted expression of the cell cycle inhibitor 
p21Clpl, which seemed contrary to the proliferative effects o f these oncogenes. However, 
when examined in CD34+ H-RasG12v cells, p21c,pl appeared to have a purely cytosolic 
location, making it unlikely that this change was influencing cell cycle progression. 
Furthermore, constitutive cytoplasmic localisation o f p21Clpl (which is likely driven by 
Akt-dependent phosphorylation of p21Cipl (Zhou, B.P. et al. 2001)) is associated with 
resistance to apoptosis, which is mediated by p21Cipl binding to and suppressing the pro- 
apoptotic functions o f ASK1 (Schepers, H. et al. 2003) and procaspase-3 (Suzuki, A. et al. 
1999). It is worth noting that DPI caused an increase in p21Cipl expression in CD34+ H- 
RasG12v cells, suggesting that ROS normally act to suppress p21Cipl (and its anti-apoptotic 
function) in this context. This may in turn offer further explanation as to why antioxidants 
promote survival in this study.
176
CHAPTER 4: THE ROLE OF ROS IN THE RAS PHENOTYPE
Finally, examination o f phosphorylation o f p38MAPK in CD34+ H-RasG12v cells 
revealed that this was solely a consequence o f ROS production by these cells. In other 
contexts (Dolado, I. et al. 2007), p38MAPK activation provokes cell cycle arrest and cellular 
senescence through induction o f p l6 1NK4A, but we were unable to demonstrate induction o f 
this cell cycle inhibitor in these cells. Indeed, as alluded to earlier, mutant H-Ras or N-Ras 
do not induce senescence in primary human CD34+ haematopoietic cells in this study nor 
in previous studies (Shen, S. et al. 2007; Dorrell, C. et al. 2004; Peam, L. et al. 2007).
In summary, this chapter presents the first report of growth-factor independent 
survival o f primary CD34+ cells expressing activated Ras alone. These data also highlight 
the duality o f ROS effects on proliferation o f these cells, simultaneously promoting 
proliferation whilst hindering survival. The mechanism whereby ROS augment survival o f 
these is most likely to be via increase cyclin D expression, though how this is 
accomplished is unknown.
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The role of ROS in protein 
phosphorylation in human 
CD34+ progenitor cells
Chapter 4 demonstrated that endogenous ROS production has significant effects 
on the proliferation and survival o f human CD34+ haematopoietic progenitor cells 
expressing mutant Ras. Furthermore, the data suggested that ROS promote expression of 
cyclin D1 and D3, which may explain the ability o f ROS to augment proliferation. As 
discussed in section 1.4.3.2, H2 O2 has the ability to inactivate phosphatases by reversible 
oxidation (Rhee, S.G. et al. 2000). Since the transcription and stability o f  cyclin D gene 
products are governed by phosphorylation events (sections 1.3.3.2 and 1.3.4.3); H2 O2 may 
influence cyclin D expression by disturbing the activity o f redox-sensitive phosphatases. 
Phosphatase inactivation results in an increase in phosphorylation o f the target proteins, 
but the consequences o f this are likely to be complex. Protein phosphorylation can cause 
activation, deactivation, increased or decreased stability, and/or sub-cellular targeting. 
Therefore there is scope for considerable complexity for redox-regulation o f signalling in 
kinase cascades, where ROS-sensitive steps may provide an additional layer o f signal 
regulation (Finkel, T. 2003). The downstream effects o f ROS on cell signalling are also 
likely to be dependent on cell context, the quantity and location of ROS production and the 
capacity o f the cell’s intracellular antioxidant pool to cope with ROS generation.
PKC is known to be an important downstream effector o f mutant Ras in human 
haematopoietic cells (together with its important upstream regulator PDK1) (Peam, L. et 
al. 2007), and may directly promote cyclin D3 expression (Yamamoto, D. et al. 2003). 
Redox regulation o f cyclin D3 via PKC and PDK1 could explain redox-sensitive 
proliferation observed in Chapter 4. Given the importance of PKC and PDK1 signalling in 
the mutant Ras phenotype, this study investigated whether PKC and PDK1 
phosphorylation are sensitive to exogenous and endogenous ROS.
The inhibition of redox-sensitive phosphatases by H2O2 is unlikely to be limited 
to a particular pathway, but instead is likely to affect all pathways where redox-sensitive 
phosphatases operate. Therefore, studies o f ‘global’ kinase activity (kinomics) are useful 
for understanding the effects of ROS production on cell signalling as a whole. Kinomic 
studies are facilitated by the recent development o f kinase substrate arrays, which allow the
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kinase activity in complex kinase mixture (e.g. whole cell protein extracts) to be assayed. 
This study used PepChip peptide arrays (described in section 5.2.2) to examine the effects 
o f mutant Ras (and ROS production) on the kinome o f human CD34+ haematopoietic cells.
5.1  A im s
In order to understand whether ROS production driven by activated Ras plays 
any role in protein phosphorylation in CD34+ haematopoietic cells, this Chapter aims to:
• Examine the effects o f exogenous and endogenous ROS on the phosphorylation 
o f the key signalling molecules PKC and PDK1 that mediate dysregulation o f 
haematopoeitic development by activated Ras
O'' 12 V 4“•  Examine the effects o f H-Ras expression on the kinome o f CD34 cells 
using PepChip peptide arrays, and in particular to look for evidence o f changes 
in the kinome due ROS-mediated phosphatase inhibition
5 .2  M a t e r i a l s  a n d  m e t h o d s
5.2.1 In v e s t ig a t in g  t h e  e f f e c t s  o f  ROS o n  e x p r e s s io n  a n d
PHOSPHORYLATION OF PDK1 AND PKC
CD34+ control and CD34+ H-RasG12v cells were recovered from growth medium 
by centrifugation at 180 g for 5 min and resuspended at 3x105 cells/ml in HBSS. HBSS 
with no supplements was used in these experiments to minimise background protein 
phosphorylation. For experiments investigating the effects o f treatment with exogenous 
H2 O2 , CD34+ control and CD34+ H-RasG12v cells were treated with 0.1-50 mM H2O2 for 
0.5-10 min at 37°C in a 5% CO2 humidified atmosphere. In experiments where the time of 
exposure to H2O2 was studied, the duration of exposure was controlled by addition o f 250 
pg catalase. For experiments investigating the effects o f antioxidant treatment, cells were 
resuspended in 1 ml HBSS as above in the presence o f either catalase, DPI, Tempol (a 
SOD mimetic) or SOD and incubated for 10 min under same conditions as above.
To determine the effect o f cell culture density on PKC and PDK1 
phosphorylation, CD34+ control and CD34+ H-RasG12v cells were resuspended in HBSS as 
above at 0.1 -0.6x106 cells/ml and incubated at 37°C in a 5% C 02 humidified atmosphere. 
Some replicates were incubated in the presence o f catalase. After incubation, cells were
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collected by centrifugation at 180 g for 5 min. Cell pellets were washed and whole cell 
protein extracts were prepared for Western blot analysis as described in section 2.4.7.
5.2.2 K in o m ic  a n a l y s i s  u s i n g  P e p C h ip  p e p t id e  a r r a y  t e c h n o l o g y
As well as translocations, AML is characterised by frequent abnormalities o f 
protein kinase signalling such as activation o f FLT3 and c-KIT which drive protein kinase 
signalling upstream o f Ras (Bowen, D.T. et a l 2005; Illmer, T. et a l 2005) and PI3 kinase 
(Doepfiier, K.T. et a l 2007). Downstream signalling elements are subsequently activated 
such as Stat5 (Harir, N. et a l 2007), MAPK (Milella, M. et a l 2001) and Akt (Bardet, V. 
et a l 2006). The high frequency o f kinase hyperactivation in AML makes these attractive 
targets for novel therapeutic approaches. Further, kinases are attractive for drug design 
since, despite a high degree o f conservation in the ATP binding site, highly selective small 
molecules with favourable pharmaceutical properties can be developed (Zhang, J. et a l 
2009). Nevertheless, it has been difficult to emulate the success achieved with Imatinib in 
the treatment o f CML when, for instance, targeting FLT3 in AML (Knapper, S. 2007).
This may reflect the relative importance o f the targeted abnormalities in maintaining 
survival in these diseases (Knapper, S. et a l 2006) or structural factors which reduce their 
druggability. Parallel to the development o f improved kinase inhibitors, efforts have also 
been made to identify new kinases which could be clinical targets in the treatment of AML. 
Recently, the development o f peptide arrays has enabled the study o f global cellular kinase 
activity. This study employed peptide microarray technology to investigate the kinome of 
primary human CD34+ haematopoietic cells.
Peptide microarrays consist o f an array o f peptides mimicking the target motifs 
o f a variety o f kinases which are covalently bonded to a glass slide in duplicate (trial chip) 
or triplicate (full slide) using proprietary surface chemistry. Protein extracts containing 
cellular kinases are introduced to the array in the presence o f y P-ATP, allowing 
phosphorylation o f target peptides on the peptide array to be tracked via incorporation of 
radioactive 33P into the array. Incorporated 33P is detected by exposing the radiolabelled 
microarray to a phosphor-storage screen, which stores the energy o f /3-particles emitted
' X ' Xduring radioactive decay o f P. When stimulated with photons o f the correct wavelength, 
this stored energy is released from the phosphor-storage screen in the form o f photons 
(critically, these emitted photons have a shorter wavelength than the stimulating photons), 
which can be measured using conventional photodetectors. The data obtained from peptide 
arrays can be quantified and analysed using conventional microarray analysis software.
The trial PepChip used for this study has 192 different peptides which are substrates for 30
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known kinases, however, larger arrays exist with 960 different peptides which are the 
substrates o f a broad range o f kinases involved in growth, differentiation and survival (to 
view peptide details, see Chapter 5 PepChip Data.xls on the accompanying CD).
5.2.2.1 Preparation o f  protein extracts fo r  kinomic analysis
CD34+ control and CD34+ H-RasG12v cells (day 5) were harvested from growth 
medium by centrifugation at 180g for 5 min. To reduce background kinase activity due to 
growth factor signalling, all traces o f growth factor were removed by washing the cells 
twice by centrifugation with 25 ml HBSS as described in section 4.2.1.1. Washed cell 
pellets were resuspended at 4x105 cells/ml in serum-replete, supplemented IMDM without 
growth factors and incubated for 16 h at 37°C in a 5% CO2 humidified atmosphere in the 
presence or absence o f 1 pM DPI. After incubation, cells were recovered from the 
incubation medium by centrifugation at 180 g for 5 min and the cell pellet was washed by 
centrifugation with 10 ml ice-cold PBS. Washed cells were counted and sedimented again 
by centrifugation, taking care to remove all supernatant. To encourage cell lysis, cell 
pellets were flash-frozen in liquid N2 , and allowed to thaw on ice in the presence o f 1 pg of 
DNAse I. Cell pellets were then fully resuspended in 50 pl/lxlO6 cells Mammalian Protein 
Extraction Reagent (MPER; Thermo Fisher Scientific) containing 1 complete mini 
protease inhibitor tablet (Roche) per 10 ml MPER. Cell suspensions were incubated on ice 
for 10 min on a rotary shaker (~50 revolutions/min). Detergent-insoluble material was 
sedimented by centrifugation at 16,000 g for 15 min, and supernatants (protein extracts) 
were recovered to fresh tubes. Samples o f protein extracts were diluted 1 in 40 with dH20, 
and protein concentration in diluted samples was determined using Bradford’s assay 
(section 2.5.2).
5.2.2.2 Radiolabelling o f  PepChip microarrays and image acquisition
Experiments which involved the use of y33P-ATP were performed in accordance 
with standard safety guidelines for handling /3-emitters. Geiger-Muller detectors were used 
frequently throughout all radioactive procedures to monitor radioactive contamination, and 
disposal o f  radioactive waste was performed according to university guidelines. Protein 
extracts (prepared in section 5.2.2.1) were diluted to a protein concentration 1.14 fold 
greater than the desired final concentration (final concentrations 0.5-1.5 pg/pl) using 
PepChip dilution buffer (formulation given in section 2.1.2). Diluted extracts (21 pi) were 
mixed (and consequently diluted 1.14 fold) with 3 pi PepChip activation mix (section
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2.1.2) to create the desired final protein concentration. Radioactive extract mixtures were 
centrifuged at 16,000 g for 15 min to sediment debris, and 18 pi o f supernatant was loaded 
onto a PepChip Trial Array slide (PepScan Presto BV, Lelystad, Netherlands) and covered 
with a clean 22x40 mm glass coverslip. PepChips were incubated at 37°C for 2 h at 
saturated humidity, and were then washed once in 30 ml PBS containing 1 % Triton X-100 
(PBS-T) to remove the coverslip, followed by washing in 30 ml 2 M NaCl containing 1 % 
Triton X (NaCl-T). PepChips were washed alternately in 30 ml PBS-T and NaCl-T twice 
more, followed by 3 rinses in 30 ml purified water and drying with compressed air. 
Radioactivity on the PepChips was detected by exposure to a phosphor-storage screen (GE 
Healthcare) for 60 h in a sealed exposure cassette, using a layer o f Saran wrap to prevent 
contamination o f the phosphor-screen. Residual and background radiation signals were 
erased from the phosphor screen prior to use by exposing to a white light source for 16 h. 
After exposure to the radioactive PepChips, the phosphor-storage screen was scanned 
using a Typhoon 9400 Variable Mode Imager (GE Healthcare) at a resolution o f 50 
pm/pixel and digital images were acquired using Typhoon 9400 acquisition software. 
Images were prepared for quantitation and exported to TIF format using ImageJ (W. 
Rasband, National Institute o f Mental Health, USA).
5.2.2.3 A nalysis o f  PepChip microarray data
Phosphorylation intensity (spot intensity minus background intensity) was 
quantified using ImageQuant TL (GE Healthcare). Individual background intensity for 
each spot was determined using ImageQuant's ‘spot edge average’ algorithm. High 
intensity spots overshadowing neighbouring spots were removed from the data set. After 
quantitation, spot intensity data was exported to Microsoft Excel 2007. Bland-Altman 
analysis was used to determine the positive threshold for spot intensity, and to exclude spot 
replicates with poor agreement. Briefly, spot intensity data was log(e)-transformed and a 
Bland-Altman chart was plotted (Bland, J.M. and Altman, D.G. 1986), achieved by 
plotting the mean log(e) intensity (x axis) against the difference in log(e) intensity (y axis) 
for each pair of replicate spots on the array (Figure 5.5). Interpretation o f the graphs is 
simplified by considering that replicates with good agreement will cluster near the x axis, 
while replicates with poor agreement will deviate from the x axis. The positive intensity 
threshold was set as the mean intensity o f the lowest (non-zero) pair o f replicates on the 
array. Replicate pairs (spots) where one or both replicates’ values fell below this intensity 
threshold were discarded (in GeneSpring GX, discarded replicates were called as ‘absent’; 
those that remained were called as ‘present’). Raw intensity data from replicates which
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were not excluded were analysed in GeneSpring GX vl0.2 (Agilent Technologies, 
Stockport, UK). Raw intensity data were log(2)-transformed (to de-skew the data) and 
quantile-normalised (median intensity value set as zero) prior to analysis. Peptide array 
data generated from each sample group (CD34+ control cells, CD34+ H-RasG12v cells or 
CD34+ H-RasG12v cells treated with DPI) were compared using GeneSpring GX. 
Unsupervised and supervised hierarchical clustering was performed on non-averaged 
sample data. Statistical calculations were performed using the averaged data from each 
group. When comparing the two groups, peptides which showed average phosphorylation 
intensity difference o f >2 fold were selected for further study. Significant differences were 
calculated in GeneSpring GX using an unpaired T-test.
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5.3 R e s u l t s
5.3.1 T h e  e f f e c t  o f  H20 2 o r  a n t io x id a n t s  o n  PKC a n d  PDK1
PHOSPHORYLATION IN HUMAN CD34+ HAEMATOPOIETIC CELLS
PKC and PDK1 are important signalling molecules in the context o f human
leukaemia (Peam, L. et al. 2007). PDK1 activity is also associated with increased survival
via activation o f Akt (Introduction section 1.3.3.2 and Results section 4.2.1.3) whilst PKC 
can is closely associated with Phox activation (section 1.4.2.1) and can also promote cyclin 
D3 expression (Yamamoto, D. etal. 2003). H20 2 can oxidise and reversibly inactivate 
cellular phosphatases, which disturbs the dynamic equilibrium between these phosphatases 
and their opposing kinases, resulting in a net increase in phosphorylation. To determine 
whether H20 2 could have this effect on phosphorylation o f PKC and PDK1 in normal 
CD34+ cells, CD34+ control cells were treated with H20 2 in the absence o f growth factors 
(to reduce background protein phosphorylation), and the effects on PKC and PDK1 
phosphorylation was determined by Western blot analysis. PKC phosphorylation on 
Ser660 was monitored using anti-pan phospho-Ser660 PKC antibody. In the case o f PDK1, 
the anti-PDKl antibody used herein recognised an unphosphorylated epitope, however, 
using this antibody it was possible to discriminate several PDK1 protein bands which 
correspond to differentially phosphorylated forms of the protein (Scheid, M.P. et a l 2005) 
(Figure 5.1 A). Incubation of these cells with H20 2 for 10 min was sufficient to induce a 
dose dependent increase in PKC and PDK1 phosphorylation (Figure 5.1 A). Interestingly, 
H20 2-treated CD34+ control cells exhibited a PKC and PDK1 phosphorylation profile 
which appeared similar to untreated CD34+ H-RasG12v cells. A closer examination o f the 
electrophoretic shift o f the 4 main mobility forms of PDK1 visible in CD34+ control cells 
revealed that the changes due to H20 2 treatment were complex, but were consistent with a 
dose-dependent enrichment o f  the slowest-migrating PDK1 mobility form consistent with 
increased phosphorylation.
To establish the time-span over which H20 2 promoted PKC and PDK1 
phosphorylation, H20 2-exposure was terminated at a series o f time points (30 s to 8 min) 
by the addition o f catalase. Figure 5. IB shows that promotion of phosphorylation o f PKC 
and PDK1 in CD34+ control cells occurred within 30 s o f exposure to H20 2, and showed a 
time-dependent increase up to 8 min. In addition, H20 2-treated cells that were allowed to 
recover from H20 2 treatment in the presence o f catalase for 45 min showed reduced PKC 
phosphorylation suggesting that this phosphorylation state was reversible.
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The previous results showed that H2O2 treatment caused control cells to adopt a 
similar pattern o f PKC and PDK1 phosphorylation to untreated CD34+ H-RasG12v cells. To 
establish whether production o f endogenous ROS by CD34+ H-RasG12v cells contributed to 
their high levels o f  PKC and PDK1 phosphorylation, CD34+ H-RasG12v cells were treated 
for 60 min with either DPI, catalase or Tempo 1. As shown in Figure 5.2, antioxidant 
treatment caused a reduction in phosphorylated PKC; and surprisingly appeared to promote 
the degradation o f PDK1 (see Discussion).
Taken together, these results suggest that exogenous high-level H2 O2 can induce 
rapid phosphorylation o f PKC and PDK1 in a dose and time-dependent manner.
5.3.2 H2 O2 IS RESPONSIBLE FOR CELL-CULTURE-DENSITY DEPENDENT INCREASES
IN PHOSPHORYLATION OF PKC
Given that CD34+ H-RasG12v cells generate H2O2 (section 3.3.5.1), the 
concentration o f H2 O2 would be expected to be dependent on the density o f the cell culture. 
Hence, it would be predicted that H2 O2 mediated phosphorylation o f PKC and PDK1 
signalling molecules will be dependent on the cell density. CD34+ control and CD34+ H- 
RasG12v cells were incubated in the absence o f growth factors and the effect o f varying the 
cell-culture density on PKC and PDK1 phosphorylation was examined (Figure 5.3).
Cell-density had no overt effect on PKC phosphorylation in CD34+ control cells, 
while PKC phosphorylation in CD34+ H-RasG12v cells increased in a cell-density 
dependent manner. Catalase treatment suppressed the density-dependent phosphorylation 
of PKC, but was unable to reduce phosphorylation back to control levels. In contrast,
PDK1 remained hypophosphorylated in controls (even at high density), whilst PDK1 was 
consistently hyperphosphorylated in CD34+ H-RasG12v cells, even in the presence o f 
catalase.
These results extend the conclusions o f the previous section suggesting that 
endogenously generated H2O2 can induce phosphorylation o f PKC in CD34+ control and 
CD34+ H-RasG12v cells, but that the endogenous hyperphosphorylation o f PDK1 may arise 
from alternative mechanisms other than ROS.
185
CHAPTER 5: ROLE OF ROS IN PROTEIN PHOSPHORYLATION
A
H2 O2 conc. (mM)
phospho-PKC
(Ser660)
PDK1
Act in 
GAPDH
B
Duration of H2 O2 
treatment (min)
phospho-PKC
(Ser660)
PDK1
Act in 
GAPDH
Figure 5.1 Effect of exogenous H 2O 2 on PKC and PDK1 in control cells
(A) CD34+ control cells were incubated in HBSS with 0-50 mM H2O2 for 10 minutes at 
37°C in a 5% CO2 atmosphere. Protein extracts from these cells and untreated CD34+ H- 
RasGI2v cells were prepared and Western blot analysis was performed as described in 
section 2.4.7. Representative of 3 independent experiments. (B) CD34+ control cells were 
treated with 1 mM H2O2 for 0.5-8 minutes at 37°C in a 5% CO2 atmosphere. Untreated 
cells were included as a negative control. The reaction was terminated at the stated 
timepoint by addition of catalase prior to preparation of protein extracts and Western blot 
analysis. One sample was incubated for 45 min following catalase addition to allow 
recovery. In both cases, Western blots were probed with 2.9 ng/ml pan-phospho PKC 
(Ser660) antibody (Cell Signaling) and 125 ng/ml anti-total PDK1 antibody (mouse 
monoclonal; clone 5; BD Biosciences). 10 ng/ml anti-/5-actin and 20 ng/ml anti-GAPDH 
antibodies were used as loading controls.
CD34+ Control 
0 0.5 5 8  0.5 (+ 45 min recovery)
CD34+ Control
CD34+
0 0.1 1 5 10 20 50 H-RasG12v
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Figure 5.2 Effect of antioxidant treatment on PKC and PDK1 in CD34+ H-RasG12v 
cells
CD34+ H-RasG12v cells (day 7) were treated for 60 minutes at 37°C with 1-1 OmM Tempo 1, 
(a potent SOD mimetic), 10-100pM DPI (a NOX inhibitor) or catalase (which catabolises 
H2O2). Protein extracts from these cells and untreated CD34+ H-RasG,2v cells were 
prepared and Western blot analysis was performed as described in section 2.4.7, and blots 
were probed with anti-pan-phospho PKC (Ser660) antibody (Cell Signaling) anti-total 
PDK1 as described in Figure 5.1.
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Figure 5.3 Effect of cell culture density on PKC and PDK1 phosphorylation in 
transduced CD34+ cells
CD34+ control and CD34+ H-RasGI2v cells were incubated at l-6xl0 5 cells/ml in HBSS for 
60 min at 37°C in a 5% CO2 atmosphere. In addition, one sample of CD34+ H-RasG12v 
cells was incubated at 6x105 cell/ml in the presence of catalase. Protein extracts of these 
cells were prepared and Western blot analysis was perfromed as described in section 2.4.7. 
Western blots were probed with anti-pan-phospho-PKC, anti-PDKl and anti-GAPDH 
antibodies as in Figure 5.1. Representative of 2 experiments.
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5.3.3 K in o m ic  a n a l y s i s  o f  t r a n s d u c e d  h u m a n  CD34+ h a e m a t o p o ie t ic
CELLS EXPRESSING H -R A S G12V
Endogenous H2O2 (e.g. NOX-derived H2O2) and exogenous H2 O2 can promote 
protein phosphorylation in human haematopoietic CD34+ cells (sections 5.3.1 and 5.3.2), 
and given that H2O2 is a freely diffusible molecule, it has the potential to influence protein 
phosphorylation throughout the entire cell. PepChip peptide array technology enables 
examination o f the kinome as a whole; therefore this study used this technique to 
investigate the effects o f activated Ras expression on the kinome o f human CD34+ 
haematopoietic cells. In addition this study used DPI to determine whether the kinome was 
influenced by endogenous ROS production.
5.3.3.1 Acquisition o f  images from radiolabelled PepChips and Bland-Altman analysis
This study used Trial PepChips to assess the feasibility o f  kinomic analysis in 
human CD34+ haematopoietic cells. Figure 5.4A shows the Trial peptide array layout with 
a positional grid which was used to identify 192 individual peptides on the array. In order 
to quantify the intensity o f each spot and relate this to target peptide expression, an image 
of the PepChip was acquired using a storage phosphor-screen and scanner system. An 
example o f the peptide array radiograph is shown in Figure 5.4A. After spot intensities had 
been quantified using ImageQuant TL, data were uploaded into GeneSpring GX vl0.2 
software for analysis.
Prior to data analysis, array data were log(2)-transformed to reduce artefacts due 
to areas o f low or high intensity. Subsequently, the raw sample dataset was quantile- 
normalised and displayed as a box plot. This approach confirmed that each sample showed 
a similar range o f signal intensities (equal in size and shape), that there was no evidence of 
signal saturation and that there were no significant differences between the 9 arrays (Figure 
5.4B). Prior to statistical analysis, the raw data were refined using Bland-Altman analysis. 
Peptides which failed Bland-Altman analysis were called as ‘absent’ and those that 
remained were called ‘present’. The exclusion stringency was set such that any peptide that 
was called absent in 5 or more out o f the total o f 9 samples was excluded from the 
analysis. Out o f 192 peptides on the array, 132 peptides met this criterion. Figure 5.5 
shows an example o f a Bland-Altman plot generated from CD34+ control cell samples.
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Figure 5.4 Quality control of PepChip peptide array data
(A) Peptide array layout diagram showing positional grid used to identify individual 
peptides on the array. An example of the radiograph obtained from one peptide array from 
a typical PepChip is shown. Spot intensity on radiographs was quantified using 
ImageQuant TL (GE Healthcare), and uploaded into GeneSpring GX for analysis. (B) Box- 
whisker plot representing the whole data set (9 peptide arrays). Samples were log(2 )- 
transformed and quantile normalised prior to generation of box-whisker plot in GeneSpring 
GX.
190
CHAPTER 5: ROLE OF ROS IN PROTEIN PHOSPHORYLATION
4
° Present 
+ Absent
*  2
a>•w
a  oa
or -2 o
<u _4
c
2 
i&S  -6 4
-8 Average of Iog(e) replicate intensity
Figure 5.5 Exclusion of replicate spots with poor agreement and determination of 
positive intensity threshold using Bland-Altman analysis
An example of a typical Bland-Altman plot generated from the sample data is shown. For 
each sample in the dataset, the intensity data were log(e)-transformed and mean replicate 
intensity (x axis) was plotted against the difference in replicate intensity (y axis) for each 
replicate pair. The threshold for positivity was set as the x axis value corresponding to the 
trailing datapoint in the x axis cluster (the relevant datapoint in this example dataset is 
marked with an arrow). Replicates where one or both replicates log(e) intensity values fell 
below this threshold were excluded and called as ‘absent’ (red crosses). The remaining 
datapoints were called as ‘present’. These present/absent calls were applied to the raw 
intensity data, which was then uploaded into GeneSpring GX for further analysis. Peptides 
which were called absent in 5 or more samples were excluded from the analysis. 132 out of 
192 peptides met this criterion.
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5.3.3.2 Comparison o f kinomic profiles o f CD34+ control and CD34+ H-RasGI2v cells
In order to detect differences between the kinome o f control CD34+ 
haematopoietic cells and those expressing H-RasGI2v, array signal-intensity data from all 9 
PepChips were analysed using GeneSpring GX vl 0.2. A kinomic profile plot was 
generated summarising the averaged signal intensities o f the 132 peptides remaining after 
Bland-Altman analysis (Figure 5.6); and this plot highlighted a number o f differences in 
the peptide signal intensities between the two groups. To assess whether H-RasG12V 
expression caused any reproducible differences in the kinome o f human CD34+ 
haematopoietic cells, unsupervised hierarchical clustering was performed on the raw 
dataset. The resulting dendrogram showed that the CD34+ H-RasG12v kinome profiles (with 
or without DPI treatment) segregated into a distinct cluster from that o f CD34+ control 
profiles (Figure 5.7). Taken together, these data suggest that when expressed in CD34+ 
cells, H-RasG12v is associated with a distinct kinomic profile compared with controls.
In order to determine which o f the peptides showed significant changes in 
phosphorylation when comparing CD34 H-Ras cells and controls, peptides which 
showed a 2 fold or greater change in phosphorylation between the two groups were 
selected for statistical analysis. Data generated from CD34+ H-RasG12v cells treated with 
DPI were not included in the statistical analysis, since there was only a single sample for 
this condition (this data is discussed in section 5.3.3.3). There were 74 peptides which 
showed a >2-fold change in phosphorylation in the presence o f H-Ras , and o f these, 7 
peptides satisfied the p-value cut-off o f 0.05.
This data is summarised as a volcano plot in Figure 5.8 A. O f the 7 identified 
peptides, 3 were increased in phosphorylation in H-Ras cells, while the remaining 4 
showed decreased phosphorylation in H-RasG12v cells (in Figure 5.8B). Five out o f 7 of 
these peptides were substrates for either PKC (2 peptides) or PKA (3 peptides), both 
members o f the AGC protein kinase family, which are regulated by PDK1 (Mora, A. et al 
2004). However, there was disagreement as to whether the activity o f these proteins was 
upregulated or downregulated; one o f the PKC substrates showed increased 
phosphorylation, while the other showed decreased phosphorylation. A similar conflict was 
observed with PKA, one PKA substrate showed increased phosphorylation while the 
remaining 2 PKA substrates showed decreased phosphorylation (Figure 5.8B).
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Figure 5.6 Kinome profile plot of averaged peptide phosphorylation intensities
Log(2 )-transformed, quantile-normalised CD34+ control and CD34+ H-RasG12v peptide 
array data were used to generate a kinome profile plot, by averaging the data within each 
sample group (CD34+ control or CD34+ H-RasGI2v). Only the peptides which remained 
after Bland-Altman analysis were plotted (132 out of 192 peptides). Profile colours were 
determined by normalised intensity of peptide signal in CD34+ control samples.
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Figure 5.7 Unsupervised hierarchical clustering of non-averaged peptide array data
Unsupervised hierarchical clustering was performed on non-averaged CD34+ control and 
CD34+ H-RasG12v sample data (both with and without DPI treatment) in GeneSpring GX 
using Pearson’s Absolute clustering algorithm with Ward’s Linkage function. CD34+ 
control, CD34+ H-RasG12v and CD34+ H-RasG12V + DPI are marked with green, red, and 
blue branches o f the dendrogram respectively and are marked at the base of the diagram 
with C, H and HD respectively.
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P-Value Substrate ID Peptide
Swissprot Accession 
ID Fold Change Kinase
0.0050 Fructose 1,6-bisphosphatase-l KSRPSLPLP P19112 -306.8 PKA
0.012M Insulin receptor substrate-1 KSLNYIDLD P35570 48.2 INSR
0.0146 Fructose 1,6-bisphosphatase PRRDSTEGF P09201 -26.5___ PKA
0.02.13 Histone 114 VK.RGISGL P02304 -176.6
0.0369 Myelin basic protein_____________________ PKRGSGKDG P02687 48.2 PKA
0.0412 M acrophage-M ARCKS LSGLSFKRN P28667 -149.5 PKC
0.0467 Choline-phosphate cytidylyltransferase A LQAISPKQS PI 9836 44.5 PKC
0.0691 Histone HI KASASPRRK P02256 -61.0 sperm-specific
0.0801 Myelin basic protein PSQRSKYLA P02687 230.0 PKA
0.0882 Trophinin KKASFKAKK -6.7 PKC
0.0919 Myelin basic protein PRTPGGRR P02687 -96.7
Figure 5.8 Statistical analysis of peptides with a >2 fold change in phosphorylation
(A) Volcano plot of 74 peptides which >2 fold change in phosphorylation in CD34+ H- 
RasG12v cells compared with controls. Log(2 ) fold change is plotted on the x axis against -  
log(io) P-value (y axis). Peptides with P<0.05 are marked in red; peptides with .P<0.1 are 
marked in blue; and peptides with P>0.1 and/or < 2 fold change are marked in grey. (B) 
Table showing detailed information associated with the 11 most significant peptides. 
Statistical significance was calculated using an unpaired T-Test. PKA= protein kinase A, 
PKC = protein kinase C, INSR = insulin receptor, MARCKS = myristoylated alanine-rich 
C kinase substrate
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The results o f supervised hierarchical clustering with respect to the 7 peptides 
identified is shown in Figure 5.9. H-RasG12v expression continued to form a distinct
kinomic profile; CD34+ control samples continued to segregate into a separate cluster from 
CD34+ H-RasG12v samples, except for one CD34+ control sample which did not cluster 
with any other o f  the samples. While the differences in phosphorylation o f these 7 peptides 
was not significant when comparing H-RasG12v with controls, taken together these data 
suggest a trend which may become significant with additional experiments.
5.3.3.3 An overview o f  the effect o f  DPI on the kinome o f CD34+ H-RasG 12v cells
An aim o f  this study was to examine the effect o f DPI on the kinome o f CD34+ 
H-RasG,2v cells, however, due to limited time and resources only one replicate o f DPI-
I q  1
treated CD34 H-Ras cells could be assayed, therefore preliminary data is presented to 
this end.
Treatment o f CD34+ H-RasG12v cells with DPI (which inhibits NOX-derived 
ROS) is only expected to affect those pathways where redox-sensitive phosphatases 
operate. Therefore, this study focused on the peptides which demonstrated a change in 
phosphorylation in the presence o f H-RasG12v, and were also sensitive to DPI. Surprisingly, 
o f the 132 peptides that remained after Bland-Altman analysis (shown as a kinome profile 
plot in Figure 5.10A i), there were none that underwent hyperphosphorylation in the 
presence o f H-Ras012 v that could be suppressed by DPI.
However, a subset o f 15 peptides were identified that showed a large decrease in 
phosphorylation in the presence o f H-RasG12v that was rescued by DPI treatment (Figure 
5.10A ii), suggesting that ROS-sensitive phosphatases are responsible for the decreased 
phosphorylation observed in this peptide subset. Interestingly, a second subset o f peptides
G12V •showed a DPI-insensitive increase in phosphorylation in the presence o f H-Ras (Figure 
5.10A iii), suggesting that the mechanisms leading to increased phosphorylation o f this 
subset o f peptides are not ROS-sensitive. Upon examination o f the 7 peptides with the 
most significantly altered phosphorylation (described in section 5.3.3.2), both DPI- 
sensitive and DPI-insensitive peptides were represented (Figure 5.1 OB).
These results do suggest the possibility that the altered activity o f some 
kinase/phosphatase pairs in CD34+ H-RasG12v cells is due to inhibition o f phosphatases by 
NOX-derived ROS.
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Figure 5.9 Supervised hierarchical clustering of peptide array samples
Supervised hierarchical clustering was performed on non-averaged CD34+ control and 
CD34+ H-Ras(jl2v sample data with respect to the 7 most significant peptides identified by 
unpaired T-test (see Figure 5.8). Data was processed in GeneSpring GX using Pearson’s 
Absolute clustering algorithm with Ward’s Linkage function. CD34+ control and CD34+ 
H-RasGI2v samples are marked with green and red branches of the dendrogram respectively 
and are marked at the base of the diagram with C and H respectively.
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Direction 
of change Enzyme Substrate Effect o f  DPI Kinase
Decrease Fructose-1,6-bisphosphatase-l Decrease PKA
Decrease Macrophage-MARCKS Restore PKC
Decrease Fructose-1,6-bisphosphatase Restore PKA
Decrease Histone H4 Restore N.D.
Increase Myelin basic protein None PKA
Increase Insulin receptor substrate-1 None INSR
Increase Choline-phosphate cytidylyltransferase A None PKC
Figure 5.10 Overview of the effect of NOX-inhibition on peptide phosphorylation in 
CD34+ H-RasG12v samples
(A) Kinome profile plots showing samples from CD34+ control, CD34+ H-RasG12v and 
CD34+ H-RasG,2V treated with DPI, i) Profile of peptides which showed decreased 
phosphorylation in CD34+ H-RasG12v samples, and were restored by DPI treatment, ii) 
Profile of peptides which showed increased phosphorylation in CD34+ H-RasGI2v samples, 
and did not respond to DPI treatment. (B) Kinome profile plot showing the effect of DPI 
treatment on the 7 most significant peptides that were altered in CD34+ H-RasG12v samples 
(see Figure 5.8) and table detailing the peptide ID. Direction of change refers to the change 
in phosphorylation of peptide in CD34+ H-RasG12v samples with respect to CD34+ control 
samples. INSR = insulin receptor, MARCKS = myristoylated alanine-rich C kinase 
substrate, N.D. = not determined
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5 .4  D i s c u s s i o n
This study aimed to understand whether ROS could influence the 
phosphorylation o f PKC and PDK1, which may offer an explanation for the ability o f ROS 
to promote the expression o f D-cyclins. Since ROS production is likely to have a global 
effect on protein phosphorylation, this study also aimed to examine the effects o f ROS on 
the kinome o f CD34+ H-RasG12v cells using peptide array analysis.
The data generated in this study suggest that H2O2 promotes phosphorylation of 
PKC in CD34+ cells. Phosphorylation o f PKC induced by H2O2 treatment has been 
reported previously (Abdala-Valencia, H. and Cook-Mills, J.M. 2006), but this effect has 
not been previously studied in primary CD34+ cells. In the present study, CD34+ cells 
treated with H2 O2 exhibited an increase in phosphorylation of PKC on Ser660 and also 
showed a marked increase in PDK1 phosphorylation. Since Ser660 on PKC is only 
autophosphorylated after transphosphorylation by PDK1 (on Ser500 in conventional PKC 
iso forms (Brognard, J. and Newton, A.C. 2008)); it was possible that increased PKC 
phosphorylation was to due increased PDK1 activity. Alternatively, the increased 
phosphorylation o f PKC could have been a result o f phosphatase inhibition by H2 O2 
(section 1.4.3.2). Since CD34+ H-RasG12v exhibit high levels of PKC and PDK1 
phosphorylation, these cells were incubated with several antioxidants to determine whether 
oxidative inhibition of phosphatases contributed to these proteins’ hyperphosphorylation. 
Surprisingly, PDK1 expression in CD34+ H-RasG12v cells appeared to markedly decrease 
after antioxidant treatment. However, given the short time frame o f the experiment, such 
rapid degradation seems unlikely, rather this may be due a degree o f phosphosensitivity of 
the PDK1 -antibody (the binding may be affected by phospho-groups near the antibody 
epitope), or alternatively may reflect the instability and rapid degradation o f PDK1 in the 
unphosphorylated state (Feldman, R.I. et al. 2005; Fujita, N. et al. 2002). While it is likely 
that phosphorylation o f PDK1 is influenced by antioxidants; further investigation (perhaps 
with an alternative antibody) is required to confirm this. In the case o f PKC, each 
antioxidant caused a dose-dependent decrease in Ser660 phosphorylation, suggesting that 
H2O2 strongly contributed toward phosphorylation of PKC by H-RasG12v; and supporting 
the notion that PKC is phosphorylated in these cells partly due to phosphatase inhibition by 
ROS. This study showed that PKC phosphorylation in CD34+ H-RasG12v cells was highly 
dependent on cell culture density, and importantly, this effect was mediated by H2 O2 . 
However, a component o f PKC phosphorylation was refractory to antioxidant treatment, 
which could be explained by the fact that PDK1 remained maximally
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hyperphosphorylated, even in the presence o f catalase. In summary these data support a 
scenario in which PKC phosphorylation (and activation) appears to be driven initially by 
PDK1, and is subsequently amplified by deactivation o f PKC phosphatases mediated by 
H2O2 production.
The hyperphosphorylation o f PDK1 in normal CD34+ control cells treated with 
H2O2 may be explained by the non-physio logical levels o f H2O2 that these cells were 
treated with. Four o f the five phosphorylation sites on PDK1 are dephosphorylated by the 
serine/threonine phosphatases PP1 and PP2A (Casamayor, A. et a l 1999). Importantly, 
PP2A and PP1 are inhibited by H2O2 . Therefore, hyperphosphorylation o f PDK1 in 
response to excessive H2O2 in normal CD34+ cells may be due to oxidative inhibition o f 
PP1 and PP2A.
It was also observed that PDK1 phosphorylation was not efficiently suppressed 
by antioxidants. This is consistent with the notion that activated Ras has an intrinsic ability 
to promote PDK1 phosphorylation. Indeed, PI3K (which is downstream o f activated Ras) 
has been shown to promote PDK1 phosphorylation via Src in HEK293 cells (Yang, K.J. et 
a l 2008; Park, J. et a l 2001). However, an oxidant-insensitive mutant o f Src was unable to 
promote phosphorylation o f PDK1 in Ang Il-stimulated primary rat glomerular cells 
(Block, K. et a l 2008); suggesting that (at least in rats) ROS generation may also be 
required for Src-mediated PDK1 phosphorylation. Conversely, excessive ROS levels may 
lead to hyperactivation o f Src and may offer an additional explanation for 
hyperphosphorylation o f PDK1 in the presence o f H2 O2 .
Hyperphosphorylation o f PDK1 by H2 O2 can lead to its hyperactivation (Prasad,
P  1 9 \ 7
N. et a l 2000), and this implies that H2 O2 could mimic some o f the effects o f H-Ras 
expression. This question could be addressed by examining whether H2O2 treatment alone 
can mimic aspects o f the H-RasG12v phenotype (e.g. monocytic lineage selection) and 
whether this effect could be blocked by PKC inhibitors.
pi^y f
As discussed above, the hyperphosphorylation o f PKC driven by H-Ras is
likely to be a composite o f direct activation o f PKC by Ras via PI3K and PDK1 combined 
with further phosphorylation due to oxidative inhibition o f phosphatases by H2O2 . As 
mentioned above, PP1 and PP2A are serine/threonine phosphatases that are sensitive to 
oxidative inactivation. This is generally undisputed for PP2A (Chen, L. et a l 2009; 
Raghuraman, G. et a l 2009; Foley, T.D. et a l 2007), however there is disagreement with 
regard to PP1 (Rao, R.K. and Clayton, L.W. 2002) and (O’Loghlen, A. et a l 2003). This 
may be resolved by the fact that the sensitivity o f phosphatases to ROS has been shown to 
be highly-context dependent, as discussed by den Hertog et a l (den Hertog, J. et a l 2005).
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Importantly, as well as dephosphorylating residues on PDK1, these phosphatases 
also antagonise the phosphorylation o f PKC by PDK1 (Keranen, L.M. et a l 1995). 
Although the activity of PP1 and PP2A was not formally investigated in this study due to 
time constraints; oxidative inhibition o f these phosphatases offers a plausible explanation 
for our observations, in that inhibition o f these phosphatases by H2 O2 is likely to account 
for a) hyperphosphorylation o f PDK1 in normal CD34+ control cells and b) 
hyperphosphorylation of PKC in the presence of H-RasG12v.
Future studies will endeavour to confirm whether oxidative inhibition o f PP1 
and PP2A is responsible for the increased phosphorylation o f PDK1 and PKC observed in
I 1 2^
CD34 H-Ras cells. Phosphatase activity in the past has been studied by measuring the 
removal o f radioactive ( P) phosphate groups from target substrate (Matsuzawa, S. et al.
1992), however non-radioactive assays are now available in kit form, which measure 
phosphatase activity by dephosphorylating a non-fluorescent substrate, yielding a 
fluorescent product. Activity o f these phosphatases could also be assayed in the presence 
o f ROS inhibitors to confirm that oxidative inhibition is occurring.
PKC signalling is implicated in cyclin D3 upregulation (Yamamoto, D. et a l 
2003; Bartkova, J. et al 1998). Therefore, since ROS contributes to PKC phosphorylation, 
this may explain the contribution o f ROS to cyclin D3 expression (described in section 
4.3.2.4). It may be of interest to see whether treatment o f normal CD34+ cells with H2 O2 
can induce cyclin D3 expression, and if so, whether this can be blocked using PKC 
inhibitors. In addition, since PKC has been shown to be an important mediator o f 
developmental dysregulation by mutant Ras, it would be interesting to see whether a H2O2 
scavenger could block this effect. The mechanisms of cyclin D1 upregulation by ROS are 
still unclear. Cyclin D1 expression is regulated by AP-1 transcription factors, which are 
directly downstream of Ras signalling via the Raf-MEK-ERK pathway. Phosphorylation 
events in this cascade are antagonised by the members o f the MAPK phosphatase family 
(MKP-1 and MKP-3), and also PP1 and PP2A. MKP family members (like PP1 and PP2A) 
are inhibited by H2O2, including MKP-3 which specifically targets ERK (Kim, H.S. et al 
2003). Therefore it is plausible that H2 O2 might also promote cyclin D1 expression through 
amplification of ERK signals. In support o f this notion, H2O2 can promote ERK signalling 
in vascular-derived smooth muscle or endothelial cells, (Yamakawa, T. et a l 2002; Hsu, 
Y.H. et a l 2004), and in murine 32D haematopoietic cells leading to cell cycle progression 
(Iiyama, M. et al 2006). Furthermore, NOX-derived H20 2 has previously been shown to 
directly promote cyclin D1 expression and cell cycle progression via increased AP-1 
transcription factor activity in murine lung epithelial cells (Ranjan, P. et a l 2006).
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Constitutive activation o f ERK is also detected in AML patients (Lunghi, P. et a l 2001), 
but whether this is associated with increased ROS production by these AML blasts is 
unknown; such a study does not appear to have been done. Future studies will investigate 
whether the Raf-MEK-ERK pathway is amplified by H2O2 in CD34+ expressing mutant 
Ras, by analysing the effect o f  antioxidants on ERK phosphorylation in CD34+ H-RasG12v 
(or CD34+ N-RasG12D) cells by Western blot.
This study examined the kinome o f CD34+ cells expressing o f H-RasG12v, to 
look for evidence o f phosphatase inhibition. O f 192 peptides on the array, positive signals 
were consistently detected for 132 o f them. 74 o f these peptides exhibited a 2 fold or 
greater change in phosphorylation in the presence o f H-RasG12v protein extracts compared 
with controls, 7 o f  which were statistically significant. However, when multiple testing 
correction was applied, this significance was lost. This lack o f statistical power is most 
likely due to the low number o f replicate samples. In addition, it should be noted that the 
data generated here was obtained from a protocol that was undergoing optimisation, which 
may also have influenced reproducibility.
However, hierarchical clustering showed that the kinome profiles o f CD34+ 
control and CD34+ H-RasG12v cells were sufficiently different from each other to be 
grouped into separate clusters; confirming expectations that H-Ras expression is 
associated with a distinct kinomic profile to that o f normal CD34+ cells. Interestingly, 
substrates o f AGC kinases (in particular PKC and PKA), were over-represented amongst 
the 7 peptides which were most significant (5 o f these were AGC kinase substrates; 
compared with a total o f 64 (33%) AGC kinase substrates out o f 192 on the array). Indeed, 
when statistical significance was relaxed to P<0.1 to detect any trends in peptides which 
were just short o f  significant, this trend o f over-representation o f PKA and PKC substrates 
continued; 7 out o f  11 peptides were substrates for these kinases. This trend supports the 
data presented here and by others (Peam, L. et al. 2007) that PDK1 (which governs AGC 
kinase activity) is dysregulated in the presence o f H-RasG12v. However, there was
Q12Y
disagreement within the results as to the level of activity o f PKC and PKA in H-Ras 
cells, with some substrates showing an increase in phosphorylation, while other substrates 
o f the same kinase apparently showing down regulation. This could be another example of 
the need for further data, or it could be due to in vitro artefact, since compartmentalised 
signalling is abolished in the protein extract, which may affect substrate specificity.
Unfortunately, due to time constraints this study was unable to fully address the 
question o f  the effect o f NOX inhibition on the kinome o f H-RasG12v cells. Although a 
detailed analysis o f  the results o f DPI treatment is inappropriate given the lack o f statistical
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power; it is o f interest to note, that there appeared to be a subset o f peptides that responded 
to DPI treatment. Interestingly, the phosphorylation of these peptides decreased in the
q 12y  # #
presence o f H-Ras , which suggests increased phosphatase activity (the opposite of the 
expected result). However, this behaviour could be explained by the presence o f a ROS- 
insensitive phosphatase which was itself regulated by a ROS sensitive phosphatase 
(assuming that phosphorylation o f  the ROS-insensitive phosphatase is activating). Taken 
together the results o f  the kinomics assay are encouraging, but require expansion with a 
larger dataset. In future studies, the optimised protocol will improve reproducibility which 
is likely to further improve the statistical significance o f the results.
When considered as a whole, the results o f this chapter suggest that H-RasG12v 
promotes phosphorylation o f  PDK1 and PKC via direct signalling and also through ROS- 
mediated inhibition o f phosphatases. This mechanism may account for the ability o f ROS 
to augment the expression o f  cyclin D3 driven by H-Ras . Although N-Ras was not 
formally examined in this chapter, given that it also promotes ROS production, it is
p  l O r v
plausible that a similar mechanism may operate in the presence o f N-Ras
In closing, it is useful to consider the implications o f the model we propose 
herein. Firstly, since PKC promotes NOX2 activation by direct phosphorylation o f NOX2 
regulatory subunits (Bey, E.A. et al. 2004; Zhao, X. et al. 2005; Bankers-Fulbright, J.L. et 
al. 2 0 0 1 ), this suggests that at high culture-density, a feedback loop may operate which 
boosts NOX2 activation. Furthermore, since H2O2 appears able to phosphorylate (and 
potentially activate) PKC in normal CD34+ cells, PKC activation and NOX2 activation 
may also occur in neighbouring cells in close proximity to a ROS-generating cell. It is 
therefore possible that this H2O2 feedback loop could possibly be established in a HSC 
niche containing a cell expressing activated Ras.
Finally, these results suggest that NOX oxidases may be a relevant therapeutic 
target in AML patients. However, such an approach would have to contend with the 
increased survival o f Ras-mutants that is expected to occur when ROS are scavenged 
(section 4.3.1.4). In addition, ROS generation by blasts from AML patients is highly 
variable (unpublished data) and furthermore, it is not known what role ROS generation 
plays in maintenance o f the disease (see Chapter 6  for further discussion o f this issue).
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General Discussion and 
Further Work
6.1 S u m m a r y  a n d  r e l e v a n c e  o f  d a t a  p r e s e n t e d  i n  t h i s
Activated Ras is closely associated with myeloid neoplasia, with activating 
mutations in Ras detected in 15-25% o f AML cases (Bowen, D.T. et a l 2005) and in 4- 
48% o f patients with MDS (Padua, R.A. et a l 1998; Paquette, RL. et a l 1993). Activating 
mutations o f the Ras pathway are also frequently detected in other myeloid neoplasias, e.g. 
JMML; with up to 60% o f JMML patients harbouring an activating mutation in Ras or 
SHP2; or loss-of-function mutations in NF1 (Tefferi, A. and Gilliland, D.G. 2007). 
Surprisingly, a recent study detected the presence o f novel oncogenic mutations o f Ras in 
AML and JMML patients, suggesting that the frequency o f Ras mutations in myeloid 
neoplasia may be underestimated (Tyner, J.W. et a l 2009). In addition to their role in 
myeloid neoplasia, Ras oncogenes are known to drive generation o f ROS in both human 
cell models and animal models o f disease (Liu, R. et a l 2001; Lee, A.C. et a l  1999; Seru, 
R. et al 2004; Sallmyr, A. et a l 2008; Rassool, F.V. et a l 2007).
Despite the high frequency o f activating Ras mutation found in some human 
myeloid disorders, it has been difficult to elucidate the exact role that activated Ras plays 
in the development o f human myeloid disease. Several studies have concluded that mutant 
Ras does not have prognostic significance in human AML (Kiyoi, H. et a l 1999; Bowen, 
D.T. et a l 2005; Bacher, U. et a l 2006), or, put another way, activated Ras does not 
significantly influence the ‘treatability’ o f the disease. However, it has been shown in 
animal models that activated Ras alone can drive leukaemia-like disease (Braun, B.S. et a l 
2004; Parikh, C. et a l 2007), and this can be augmented by overexpression o f BCL-2 
(Rassool, F.V. et a l 2007). Such studies provide support for the ‘two hit’ hypothesis of 
myeloid neoplasia in mice (Gilliland, D.G. 2001), though the relatively low number of 
lesions required may be due to the relative ease o f murine cell transformation compared 
with human cells (Rangarajan, A. et a l 2004; Rangarajan, A. and Weinberg, R.A. 2003). 
Although a central tenet o f cancer biology is that several genetic ‘hits’ are required to 
subvert major anti-oncogenic systems before tumours can initiate (Hanahan, D. and 
Weinberg, R.A. 2000); it is proposed that more hits are required to transform human cells 
than murine cells, due to more robust anti-oncogenic mechanisms in humans. This
STUDY
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increased complexity o f genetic alteration in human cancers (compared with murine 
models) may partly explain why Ras mutations take a more conservative role in human 
AML, at least when considering prognostic influence -  other mutations may assume the 
role o f activated Ras, relaxing the requirement to maintain mutated Ras expression in the 
malignant clones. Although activated Ras confers increased cell-survival, proliferative 
drive and mediates developmental dysregulation in vitro (Schubbert, S. et a l 2007; Peam, 
L. et a l 2007; Darley, R.L. et al. 2002) and is frequently detected in AML, the reason for 
its lack o f influence on prognosis remains unclear.
However, several studies have provided some understanding o f the 
consequences o f activated Ras expression in haematopoietic progenitors, which provides 
insight into the role o f Ras in AML pathogenesis. It has been demonstrated that mutant Ras 
polarises lineage decisions in human haematopoietic progenitors via hyperactivation o f 
conventional PKC iso forms. Specifically, mutant Ras biases CFU-GM lineage decisions 
towards monocytes, at the expense of granulocytic development (Peam, L. et a l 2007). 
Activated Ras also disturbs erythroid development, resulting in increased proliferation of 
EPO-independent erythroid progenitors followed by a block in terminal erythroid 
development (Darley, R.L. et a l  2002). The combination of erythroid progenitor expansion 
combined with a lack o f terminal erythropoiesis driven by activated Ras bears similarity to 
the most common presenting features of MDS. MDS is a heterogeneous group o f clonal (or 
oligoclonal) haematopoietic disorders, characterised by refractory anaemia in combination 
with a hypercellular bone marrow and uni- or multi-lineage dysplasia (Vardiman, J.W. et 
a l 2009). MDS is distinct from AML, but is considered to be a pre-leukaemic disorder 
with a high probability o f developing overt AML (Nimer, S.D. 2008). Furthermore, Ras 
mutations are closely associated with MDS (Gallagher, A. et a l  1997); though this is not 
true for all MDS subtypes since MDS with deletions in 5q show relatively infrequent Ras 
mutations (Fidler, C. et a l 2004). Interestingly, there appears to be a link between myeloid 
neoplasias (specifically MDS and AML) and oxidative stress (Bowen, D. et al 2003; 
Farquhar, M.J. and Bowen, D.T. 2003). This link has been fiirther reinforced by murine 
model studies conducted by Rassool et a l , which demonstrated that mutant N-Ras co­
operates with BCL-2 overexpression in the myeloid compartment resulting in an MDS-like 
disorder which quickly progressed to AML-like disease (Rassool, F.V. et a l 2007). 
Importantly, disease progression closely correlated with DNA double strand breaks 
(DSBs); attributed to increased NOX-derived ROS production in the primitive myeloid 
progenitors. In their conclusions, these authors propose a model where mutant Ras-derived 
ROS fosters genomic instability which encourages disease progression. The results of the
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present study provide additional evidence o f the link between activated Ras and oxidative 
stress in human haematopoietic cells (section 3.3). Further investigation into a possible 
correlation between Ras mutations and oxidative stress in MDS patients is therefore 
encouraged; at the time o f writing it appears that such an investigation has not been 
performed.
There is also evidence o f oxidative stress amongst some o f the MPNs, including 
CML, which is positive for the BCR-ABL fusion gene (Ahmad, R. et a l 2008). Given that 
BCR-ABL has been shown to activate Ras (Cortez, D. et a l 1996; Sanchez-Garcia, I. and 
Martin-Zanca, D. 1997), it is plausible that Ras-mediated ROS production is responsible 
(or contributes) to the oxidative stress in CML. Some reports have concluded that the 
mitochondria are the sole source o f oxidative stress in CML cells (Kim, J.H. et a l 2005), 
while others have suggested that BCR-ABL generates ROS via NOX oxidases; specifically 
NOX4 (Naughton, R. et a l 2009). While it is possible that mitochondria do indeed 
contribute to ROS generation in CML, it is notable that Kim et a l did not address the 
possibility that NOX oxidases contributed to ROS generated in their model system.
JMML is a form o f MPN which has a striking association with mutations o f the 
Ras pathway (Tefferi, A. and Gilliland, D.G. 2007). In addition to activating mutations o f 
Ras itself, activating mutations in SHP2 and loss-of-function mutations inN Fl have been 
reported in JMML patients. With such a close association with Ras activation, it is 
expected that JMML cells would produce ROS; however, this also does not appear to have 
been investigated.
In contrast to MDS and MPNs, there are few reports o f previous investigations 
into the production of ROS by AML blasts. An early study cited superoxide production in 
leukaemic cells as the probable source o f cutaneous tissue damage (Mazzone, A. et a l 
1986); since then several groups have examined superoxide production in either resting or 
stimulated leukocytes from myeloid and lymphoid leukaemia patient samples. 
Unfortunately, there is a lack o f consensus in the results o f these studies. One study 
examined Ml and M2 patient samples and detected elevated constitutive and stimulated 
superoxide production in apparently mixed preparations o f AML blasts from these patients 
compared with control cell samples (Er, T.K. et a l 2007). Another study examined 
stimulated superoxide production in M1-M4 and M5b AML samples and L1-L3 ALL 
samples, but only found superoxide production in the monocytic leukaemias (M4 and 
M5b), furthermore, stimulated superoxide production was (at best) similar to levels o f 
superoxide generated by leukocytes from healthy patients (Kato, M. et a l 2003). However, 
Kato et a l did not examine constitutive superoxide generation, which is likely to be far
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more relevant to leukaemia pathogenesis than stimulated production. To resolve the 
paucity o f data, constitutive ROS production in AML blasts is currently being examined in 
this Department, and early results suggest that M4 and M5 monocytic AMLs constitutively 
generate more ROS than M l-M3 AMLs (J. Zabkiewicz, unpublished data). This could be 
due to the fact that monocytic AMLs are more developmentally equipped to generate ROS 
than less-differentiated AMLs. Interestingly, activating Ras mutations are also most 
commonly associated with M4 (Bowen, D.T. et al. 2005; Goemans, B.F. et al. 2005) and 
to a lesser extent M5 (Mahgoub, N. et al. 1999); though one report disagrees with this 
trend (Auewarakul, C.U. et al. 2006). Given the results o f the present study, it is possible 
that activating Ras mutations in M4 and M5 AMLs are partly responsible for increased 
constitutive ROS generation in these subtypes; however, examination o f Ras mutation 
status in the patient samples is required to confirm any correlations.
The results o f  this study raise the question as to whether ROS production may be 
a relevant therapeutic target in myeloid leukaemia associated with activated Ras. As 
discussed above, the extent o f oxidative stress in AML blasts is currently being 
determined, therefore the clinical consequences o f ROS production (if any) in AML are 
unknown. If production o f ROS was shown to be associated with poorer treatment 
outcome, this would strengthen the argument for targeting ROS production in AML. 
Although ROS production is not a prerequisite for tumour formation, ROS production does 
alter the properties o f a tumour cell, conferring upon it both advantages and disadvantages. 
The results o f the present study suggest that ROS blockade may partially suppress the 
proliferation of blast cells driven by activated Ras, but would have the undesired side- 
effect o f improving survival (sections 4.3.1 and 4.3.2); though whether this is also the case 
in AML blasts which may have evolved adaptive changes in response to ROS production 
remains to be established. ROS blockade is associated with decreased proliferation in 
HER-2/Neu-transformed rat-1 fibroblasts (Preston, T.J. et al. 2003) and tumourigenicity in 
transformed murine keratinocyte (6M90) cells (Finch, J.S. et al. 2006), while H2O2 can 
drive proliferation in murine lung epithelial cells (Ranjan, P. et al. 2006) and human 
neuroblastoma cells (Havens, C.G. et al. 2006).
ROS could be targeted in AML using two differing strategies; one involves 
reduction o f ROS and oxidative stress using antioxidants, the other involves increasing 
oxidative stress in the malignant cells beyond a critical point resulting in cell death. There 
is support for both strategies; however each strategy also has potential disadvantages.
In the case o f targeting ROS in cancers using antioxidants, one study reported 
that antioxidant supplements may not be beneficial when taken as single agents or in
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combination with other treatments for a range of disorders including cancers (Bjelakovic, 
G. et al. 2007). However, a more recent study conducted by Block et al. concluded that 
antioxidants were generally beneficial for cancer patients, in some cases significantly 
reducing the toxic effects o f  chemotherapy on normal tissues (Block, K.I. et al. 2008). In 
the context o f MDS, the antioxidant molecule amifostine can induce transient recoveries in 
haematopoiesis across all FAB types, and can reduce the requirement for transfusions in 
some MDS patients. However, it ultimately offered no significant reduction o f bone 
marrow blasts by the end o f the treatment (List, A.F. et al. 1997). Targeting ROS using 
antioxidants may indeed be o f  value in AML treatment; however as yet no studies have 
been conducted to establish whether this is the case.
The second strategy involves further increasing ROS stress in tumour cells. This 
strategy proposes that increased ROS stress in tumour cells sensitises them to further ROS 
insult leading to their demise. Interestingly, this potentiation o f stress signals appears to be 
directly mediated by ROS at the molecular level, for example, ASK1 (an upstream 
activator o f p38MAPK) is bound to thioredoxin in an inactive state under normal conditions. 
Oxidation o f thioredoxin by ROS leads to dissociation o f ASK1 from thioredoxin and 
subsequent p38MAPK phosphorylation and activation (Liu, Y. and Min, W. 2002). A similar 
mechanism operates for JNK bound to glutathione-S-transferase it (Adler, V. et al. 1999). 
In addition, it has been discovered that several mainstay cytotoxic drugs are associated 
with a large increase in ROS production inside the malignant cell (Benhar, M. et al. 2002). 
For example, in the context o f  leukaemia, daunorubicin treatment induces ROS 
upregulation possibly by acting as a direct substrate for NADPH oxidase, resulting in 
oxidative damage to the mitochondria and subsequent apoptosis (Laurent, G. and 
Jafffezou, J.P. 2001). Similarly, the cytotoxic effect of the proteasome inhibitor 
Bortezomib is dependent on a transient burst o f ROS production to induce apoptosis (Yu,
C. et al. 2004). In addition, the putative NF-kB inhibitor LC-1 (Jenkins, C. et al. 2008; 
Hewamana, S. et al. 2008) is currently being trialled in a first-in-man study at Cardiff; and 
this agent may also depend on ROS induction to exert its effects (Guzman, M.L. et al. 
2005).
Tumour cells can to adapt to chronic ROS stress. As an example o f this, brief 
exposure to a sub-lethal dose o f oxidant can protect Rat LI cells from toxicity associated 
with a subsequent more aggressive insult (Choi, J. et al. 1997). Similarly, in tumour cells 
where oxidative stress is prevalent, chronic oxidative stress can initiate upregulation of 
antioxidant defences, GSH production and catalase/SODl expression (Trachootham, D. et 
al. 2009). It is also possible that gradual resistance to oxidative stress occurs due to
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selection o f clones with augmented antioxidant capacity, resulting in a more ROS-resistant 
progeny (Bowen, D. et a l 2003) or progeny which acquire the ability to bypass the ROS- 
stress pathways (Dolado, I. et a l 2007). Insensitivity to oxidative stress may also 
contribute to cancer cell drug-resistance by blunting apoptotic mechanisms (Pervaiz, S. and 
Clement, M.V. 2004; Pervaiz, S. 2006).
Tumour cells which have developed such resistance to ROS stress through 
increased anti-oxidant defence may be hyperdependent on maintaining adequate 
antioxidant capacity. Therefore, catastrophic ROS stress may be induced in tumour cells by 
targeting endogenous antioxidants e.g. GSH or SOD. This would be expected to re- 
sensitise these cancer cells to oxidative stress. Indeed, such strategies that target 
antioxidants in cancer cells are proving effective, for example the naturally occurring 
compound beta-phenylethyl isothiocyanate (PEITC), has been shown to effectively induce 
cell death in CLL and CML cells resistant to fludarabine and imatinib respectively; by 
depleting intracellular GSH (Trachootham, D. et al. 2008; Zhang, H. et a l 2008). This 
approach engenders selectivity to the treatment, since normal cells produce little ROS and 
presumably have a large reserve o f intracellular antioxidant capacity. In contrast, tumour 
cells are ‘living life on the edge’ and probably exist on the limits o f their antioxidant 
capacity. Depletion o f intracellular antioxidants is even more effective when combined 
with pro-oxidant compounds, such as arsenic trioxide (AS2 O3). This strategy is in effect, a 
‘double-whammy’, simultaneously lowering antioxidant defences whilst boosting 
oxidative stress. For example, a combination o f the SOD-inhibitor 2-methoxyestradiol (2- 
ME) and AsCb treatment induced cell-death in CLL cells that were resistant to 2-ME alone 
(Zhou, Y. et a l 2003). However, a significant disadvantage o f this general strategy is that 
it is likely to introduce oxidative stress in normal cells, leading to toxicity.
The treatment strategies discussed above could potentially be applied to mutant 
Ras-expressing leukaemias that generate increased ROS. Mutant Ras drives production of 
ROS via NOX oxidases in CD34+ cells, and the results o f experiments examining 
superoxide production induced by TP A revealed that mutant Ras cells are capable of 
generating 50% more ROS than controls, which is probably due to the increased 
availability o f  NOX2 oxidase in the plasma membrane. Interestingly, the synthetic retinoid 
N-(4-hydroxypheny 1) retinamide (4HPR) is reportedly capable o f inducing oxidative stress 
in part through upregulation o f p67phox (Kim, H.J. et a l 2005) (which is abundant in 
CD34+ H-RasG12v cells) and this may occur via stimulation o f PKC activity (Kim, H.J. et 
a l 2006), though the mechanism is not understood. It is important to note however, that 
upregulation o f ROS by cytotoxic drugs usually occurs via the mitochondria (i.e.
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intracellular ROS); whereas the model proposed here would result in activation o f NOX2, 
which would result in extracellular ROS generation, which may result in a loss of 
specificity for the target cell, and simultaneously expose neighbouring cells to excessive 
ROS (since H2O2 can diffuse away from the source). Alternatively, suppression o f ROS 
production in AML using antioxidant compounds may suppress malignant cell 
proliferation, and may also reduce toxicity associated with standard chemotherapy.
6.1.1 C o n c l u s i o n
In conclusion, previous research suggests that Ras mutations are closely 
associated with AML and myeloid dysplasias. This study demonstrated that normal human 
primary CD34+ haematopoietic cells transduced with activated Ras (N-RasG12D and H- 
RasG12v) constitutively generate ROS, attributed to an increase in NOX2-generated 
superoxide. Furthermore, this study is the first to demonstrate that mutant Ras promotes 
growth factor-independent survival and proliferation in primary human CD34+ 
haematopoietic cells. Consistent with their increased cell survival, there was 
phosphorylation o f Akt on Ser473 in CD34+ H-RasG12v cells; which was absent in controls. 
The mechanism underlying growth factor-independent proliferation appeared to be two­
fold: evasion o f p38MAPK-mediated cell-cycle arrest (despite p38MAPK activation); and 
increased expression and/or stability o f cyclin D3 and D l. Whilst endogenous H2O2 
production hindered survival, it significantly contributed to proliferation driven by mutant 
Ras. Inhibition experiments indicated that ROS appear to augment cyclin Dl and D3 
expression. Finally, this study presented evidence that endogenous H2O2 production driven 
by H-RasG12v makes a significant contribution to hyperphosphorylation o f PKC in human 
CD34+ cells (offering an explanation for the ability o f ROS to augment expression o f 
cyclin D3).
6 .2  F u t u r e  w o r k  a n d  p e r s p e c t i v e s
During this study, there were several lines o f investigation which were of 
interest, but were not possible to pursue due to time constraints. For example, while 
precipitous amounts o f ROS were generated by mutant Ras expressing CD34+ cells, the 
effects on DNA integrity were not assessed. This may have been a contributing factor to 
the pro-apoptotic effect o f ROS and could be investigated using markers o f DNA damage, 
for examples y-H2AX or 8 -oxo-guanine can be assayed conveniently by flow cytometry.
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Also, the results o f co-culture experiments strongly suggested the presence of a paracrine 
pro-survival factor(s) secreted by CD34+ H-RasG12v cells. Identification o f this factor(s) 
may also provide further insights into mechanisms o f growth factor-independent 
proliferation o f these cells. Previous studies showing that activated N-Ras upregulates 
several growth-factor mRNAs (Shen, S. et a l 2007) would provide a good starting point 
for studies intending to identify these factors. There are soluble factor identification kits 
sold by several leading reagent manufacturers that would enable detection of factors 
selected for examination. Alternatively, the possibility that this effect is mediated by cell­
cell contact should also be addressed, perhaps by incubating control cells with CD34+ H-
G12 V *Reis -cell conditioned medium. Expansion of the kinomic analysis combined with 
functional analyses o f phosphatase activity will improve the current understanding o f the 
role o f phosphatase inhibition in the phenotype o f mutant Ras in human CD34+ cells. 
Identification o f the phosphatases thus dysregulated (possibly PP1 and PP2A) may shed 
more light on the role o f ROS production in cell cycle control. Finally, this study noted that 
inhibition o f ROS appeared to augment cyclin Dl and D3 expression; however, the 
mechanisms behind these observations are unclear and would be interesting to pursue.
Looking to the future, the results o f  this study provide a rationale for detailed 
investigation o f constitutive ROS production in primary AMLs, as this has not previously 
been investigated in depth. Preliminary work in this area suggests that AML cells do 
indeed generate ROS, but more work is required to establish this. Given that ROS appears 
to play several roles in the Ras phenotype, it may also be o f interest to determine whether 
ROS contributes to the developmental dysregulation caused by activated Ras in CD34+ 
cells. It may be that ROS could partially or completely mimic the effects o f  activated Ras 
and GOX could be used as a source o f consistent H2 O2 production in these experiments. 
Developmental progress in the presence or absence o f ROS can be assayed using flow 
cytometric analysis o f cell-surface markers; these assays have been optimised in Cardiff. 
Finally, since Nox2-deficient mice are available, the role o f ROS in developmental 
dysregulation by Ras could be determined by expressing activated Ras in Sca-1+ cells from 
these mice, and examining whether the developmental dysregulation caused by Ras is 
ameliorated in the absence o f Nox2-derived ROS over-production. Also, since 
overexpression o f activated Ras in murine haematopoietic progenitor cells has previously 
been shown to cause myeloid disease (Parikh, C. et a l 2007), this model system could also 
be used to investigate the role o f ROS in Ras-mediated leukaemogenesis.
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A
N-RasGI2D cDNA
1 GTGTCGCTCC TTGGTGGGGG CTGTTCATGG CGGTTCCGGG GTCTCCAACA TTTTTCCCGG
61  CTGTGGTCCT AAATCTGTCC AAAGCAGAGG CAGTGGAGCT TGAGGTTCTT GCTGGTGTGA
1 2 1  AATGACTGAG TACAAACTGG TGGTGGTTGG AGCAGATGGT GTTGGGAAAA GCGCACTGAC
1 8 1  AATCCAGCTA ATCCAGAACC ACTTTGTAGA TGAATATGAT CCCACCATAG AGGATTCTTA
2 4 1  CAGAAAACAA GTGGTTATAG ATGGTGAAAC CTGTTTGTTG GACATACTGG ATACAGCTGG
3 0 1  ACAAGAAGAG TACAGTGCCA TGAGAGACCA ATACATGAGG ACAGGCGAAG GCTTCCTCTG
3 6 1  TGTATTTGCC ATCAATAATA GCAAGTCATT TGCGGATATT AACCTCTACA GGGAGCAGAT
4 2 1  TAAGCGAGTA AAAGACTCGG ATGATGTACC TATGGTGCTA GTGGGAAACA AGTGTGATTT
4 8 1  GCCAACAAGG ACAGTTGATA CAAAACAAGC CCACGAACTG GCCAAGAGTT ACGGGATTCC
5 4 1  ATTCATTGAA ACCTCAGCCA AGACCAGACA GGGTGTTGAA G ATGCTTTTT ACACACTGGT
6 0 1  AAGAGAAATA CGCCAGTACC GAATGAAAAA ACTCAACAGC AGTGATGATG GGACTCAGGG
6 6 1  TTGTATGGGA TTGCCATGTG TGGTGATGTA ACAAGATACT TTTAAAGTTT TGTCAGAAAA
7 2 1  GAGCCACTTT CAAGCTGCAC TGACACCCTG GTCCTGACTT CCCTGGAGGA GAAGTATTCC
7 8 1  TGTTGCTGTC TTCAGTCTCA CAGAGAAGCT CCTGCTACTT CCCCAGCTCT CAGTAGTTTA
B
H-Rasol2v cDNA
1 CATGACGGAA TATAAGCTGG 
61  CATCCAGCTG ATCCAGAACC 
1 2 1  CCGGAAGCAG GTGGTCATTG 
1 8 1  CCAGGAGGAG TACAGCGCCA 
2 4 1  TGTGTTTGCC ATCAACAACA 
3 0 1  CAAACGGGTG AAGGACTCGG 
3 6 1  GGCTGCACGC ACTGTGGAAT 
4 2 1  CTACATCGAG ACCTCGGCCA 
4 8 1  GCGTGAGATC CGGCAGCACA 
5 4 1  CTGCATGAGC TGCAAGTGTG
TGGTGGTGGG CGCCGTCGGT 
ATTTTGTGGA CGAATACGAC 
ATGGGGAGAC GTGCCTGTTG 
TGCGGGACCA GTACATGCGC 
CCAAGTCTTT TGAGGACATC 
ATGACGTGCC CATGGTGCTG 
CTCGGCAGGC TCAGGACCTC 
AGACCCGGCA GGGAGTGGAG 
AGCTGCGGAA GCTGAACCCT 
TGCTCTCCTG A
GTGGGCAAGA GTGCGCTGAC 
CCCACTATAG AGGATTCCTA 
GACATCCTGG ATACCGCCGG 
ACCGGGGAGG GCTTCCTGTG 
CACCAGTACA GGGAGCAGAT 
GTGGGGAACA AGTGTGACCT 
GCCCGAAGCT ACGGCATCCC 
GATGCCTTCT ACACGTTGGT 
CCTGATGAGA GTGGCCCCGG
cDNA encoding m utant Ras proteins which were subcloned into the PINCO 
retroviral vector
See Chapter 2 (section 2.4.1). cDNAs encoding (A) N-RasG12D and (B) H-RasGI2V protein, 
depicting translated sequences (blue), position of start codon (underlined green), stop 
codon (underlined red) and codon 12 containing a point mutation (underlined purple). N- 
RasG12D, GGT —► GAT mutation encodes a non-silent mutation from glycine to aspartate. 
H-RasG12v, GGC —► GTC encodes a non-silent mutation from glycine to valine.
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Bivariate flow cytometric plots depicting CD34 antigen expression after isolation and 
retroviral transduction
See Chapter 3 Results (section 3.3.1). Primary CD34+ cells were isolated from human cord 
blood and transduced with PINCO as described in chapter 2. To establish the level of 
CD34 antigen expression in the resulting cultures, lxlO4 cells were analysed by flow 
cytomertry as described in section 2.6, using 5 pg/ml mouse anti-human CD34 antibody 
conjugated to PE. An isotype and manufacturer-matched antibody conjugated to PE 
(Isotype control) was used to establish background fluorescence. Figure shows typical 
CD34 expression observed. See Figure 3.3C for a summary of CD34 expression data 
obtained during this study.
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CD34+ CD34+
Control H-RasG12v
Cyt Nuc Cyt Nuc
F0X 03a
GAPDH
Effect of activated Ras on F 0 X 0 3 a  expression in human CD34+ cells
See Chapter 3 Discussion (section 3.4). CD34+ control and CD34+ H-RasG12v cells (3x105) 
were cultured as described in section 4.2.2.1. Cytosol/nuclear fractionated protein lysates 
were prepared as described in section 2.5.1.3, and probed with anti-F0X03a antibody 
(Cell Signaling). GAPDH was used as a loading control. Figure suggests that overall 
expression and nuclear translocation of F0X 03a is increased in CD34+ H-RasGI2v cells, 
which is consistent with the establishment o f a stress response in these cells (perhaps due 
to elevated ROS production), but inconsistent with the apparent hyperactivation o f Akt 
implied by increased phosphorylation o f Akt on Ser473 (depicted in Figure 4.8B).
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Ladder HeLa Control H-RasG12v
40 KDa
30 KDa
20 KDa 
p l6 INK4A '
Validation of p l6 INK4A antibody using Westen blot analysis
See Chapter 4 Results (section 4.3.2.4). CD34+ control and CD34+ H-RasG12v cells (3x105) 
were cultured as described in section 4.2.2.1 and HeLa cells were cultured as described in 
section 2.2.3.6. Whole-cell protein extracts were prepared as described in section 2.5.1.1, 
and were probed with 4 ng/ml anti-pl6,NK4A antibody (Cell signalling). Figure shows that 
antibody is capable of detecting p l6 INK4A, but there is little or no expression in primitive 
CD34+ cells.
246
APPENDICES
Publications
247
MYELOID NEOPLASIA
Ras-induced reactive oxygen species promote growth factor-independent 
proliferation in human CD34+ hematopoietic progenitor cells
Paul S. Hole,1 Lorna Pearn,1 Amanda J. Tonks,2 Philip E. Jam es,3 Alan K. Burnett,1 Richard L. Darley,1 and Alex Tonks1
Departments of ’Haematology, 2Medical Microbiology, and 3Cardiology, School of Medicine, Cardiff University, Cardiff, United Kingdom
Excessive production of reactive oxygen 
species (ROS) is a feature of human malig­
nancy and is often triggered by activation 
of oncogenes such as activated Ras. ROS 
act as second messengers and can influ­
ence a variety of cellular process includ­
ing growth factor responses and cell sur­
vival. We have examined the contribution 
of ROS production to the effects of 
N-RasG12D and H-RasG12V on normal hu­
man CD34+ progenitor cells. Activated 
Ras strongly up-regulated the production 
of both superoxide and hydrogen perox­
ide through the stimulation of NADPH 
oxidase (NOX) activity, without affecting 
the expression of endogenous antioxi­
dants or the production of mitochondri- 
ally derived ROS. Activated Ras also pro­
moted both the survival and the growth 
factor-independent proliferation of CD34+ 
cells. Using oxidase inhibitors and antioxi­
dants, we found that excessive ROS pro­
duction by these cells did not contribute 
to their enhanced survival; rather, ROS 
promoted their growth factor-indepen­
dent proliferation. Although Ras-induced
ROS production specifically activated the 
p38MAPK oxidative stress response, this 
failed to induce expression of the cell- 
cycle inhibitor, p i6 INK4A; instead, ROS pro­
moted the expression of D cyclins. These 
data are the first to show that excessive 
ROS production in the context of onco­
gene activation can promote proliferative 
responses in normal human hematopoi­
etic progenitor cells. (Blood. 2010;115: 
1238-1246)
Introduction
Reactive oxygen species (ROS) are a heterogeneous group of 
inorganic molecules and free radicals, with a wide spectrum of life 
span and reactivity. In physiologic systems, ROS formation begins 
with the univalent reduction o f diatomic oxygen to produce 
superoxide radicals. There are 2 main sources o f cellular superox­
ide; the first is the mitochondrial electron transport chain, where 
incomplete reduction of oxygen to water can result in superoxide 
formation. The other major source of superoxide is professional 
oxidases (exemplified by the NADPH oxidase [NOX] protein 
family),1 which are expressed and functional throughout hematopoi­
etic development.2 These proteins form part of a membrane-bound 
complex that transfers single electrons from cytosolic nicotinamide 
adenine dinucleotide phosphate via flavin adenine dinucleotide to 
extracellular oxygen, producing superoxide. Superoxide is a short­
lived radical but can dismutate forming hydrogen peroxide (H20 2), 
a relatively long-lived species that lies at the hub of a variety of 
potential chemical reactions and is the main molecule from which 
all other physiologic ROS molecules are derived. ROS levels are 
regulated by a complex network of antioxidant molecules and 
enzymes that detoxify ROS.3 For example, superoxide generation 
is balanced by the actions o f superoxide dismutases (SO Ds), which 
convert superoxide to H20 2. Subsequently, H20 2 is destroyed 
during oxidation reactions involving glutathione or members o f the 
peroxiredoxin family.
Although ROS production can have adverse consequences 
causing lipid peroxidation and DNA damage, it is also clear that 
ROS act as cell-signaling molecules. In recent years, it has become 
clear that H20 2 reacts with a variety o f proteins sensitive to thiol 
oxidation.4 In particular, H20 2 can inhibit phosphatases via oxida­
tion o f cysteine at the active site and may consolidate growth factor 
signaling by preventing futile cycles o f phosphorylation and 
dephosphorylation o f proteins and phosphoinositides.5 The fact 
that H20 2 is freely membrane-permeable also has the consequence 
that its production affects not only the cells generating it but also 
neighboring cells. This applies particularly to transmembrane- 
bound NOX oxidases that release ROS into the extracellular 
environment. Rapid increases in ROS are observed after growth 
factor stimulation and inhibition o f ROS production can lead to 
abolition o f signaling.5'7 Other reports indicate that ROS may also 
directly promote G r to-S progression, perhaps by direct modifica­
tion o f cell-cycle regulatory proteins.6,8
Excessive production o f ROS (comprising mainly superoxide 
and H20 2) is a common feature of malignant disease including 
leukemia.9,10 Common leukemia-associated abnormalities such as 
activated Ras,9,11 activated FMS-like tyrosine kinase 3 ,12 and 
BCR-ABL13 are associated particularly with overproduction of 
ROS. One consequence of this is an increase in DN A damage,14 
which may thereby contribute to leukemogenesis; however, its role 
in cell signaling suggests that overproduction o f ROS may have 
more direct consequences. On the one hand, ROS overproduction 
may act as a tumor suppressor15 by promoting a stress response that 
leads to cell-cycle arrest,16 senescence, or apoptosis9; conversely, it 
is clear that cancer cells can evolve to evade this stress response,9 
and several models indicate that sustained ROS overproduction is 
essential to maintain the transformed phenotype.11,13,17,18 Little is 
known o f the consequences o f ROS overproduction in leukemia.
Mutational activation o f Ras is observed in 15% to 25% of acute 
myeloid leukem ias.19 Using a model system based on normal
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human C D 34+ hematopoietic progenitor cells, we have therefore 
examined the impact of this oncogene in terms of its capacity to 
promote ROS production in these cells and also the contribution 
that ROS make to the phenotype exhibited by activated R as- 
expressing progenitor cells. Here we show that constitutively active 
Ras strongly promotes superoxide and H20 2 production in human 
C D 34+ cells through activation o f NOX oxidases. Ras also 
strongly promoted both survival and growth factor-independent 
proliferation of C D 34+ cells in a culture density-dependent 
manner. We found that ROS overproduction did not contribute to 
the prosurvival phenotype, but did contribute to growth factor- 
independent proliferation by augmenting the expression o f cyclins 
D1 and D3.
Methods
Generation of human CD34+ and murine Sca-1+ hematopoietic 
progenitor cells expressing activated Ras
Murine bone marrow was extracted from wild-type and Nox2~/_C57BL/6 
littermates (kindly provided by Professor A. Shah, King’s College Hospital) 
as described elsewhere.20 Human neonatal cord blood was obtained from 
healthy full-term pregnancies at the University Hospital Wales. These 
specimens were obtained with informed consent and with approval from the 
South East Wales Research Ethics Committee in accordance with the 1964 
Declaration of Helsinki. Murine Sca-1 + and human CD34+ hematopoietic 
progenitor cells were positively selected using the MiniMACS Sca-1 + or 
CD34+ cell isolation kits, respectively, according to the manufacturer’s 
instructions (Miltenyi Biotec). Ectopic expression of H-RasG12V orN-RasG12D 
and reporter genes (green fluorescent protein [GFP] or DsRed) was 
achieved using the PINCO retroviral vector. Retroviral transduction was 
carried out over 2 subsequent days as previously described.21 Transduced 
human CD34+ and murine Sca-1 + hematopoietic progenitor cells were 
cultured in supplemented Iscove modified Dulbecco medium (IMDM), as 
previously described,22 containing 20% fetal calf serum, supplemented with 
either 5 ng/mL human interleukin-3, human granulocyte colony-stimulating 
factor (CSF), human granulocyte-macrophage CSF, and 20 ng/mL human 
stem cell factor (for CD34+ cells), or with the same concentrations of 
murine interleukin-3, murine granulocyte-macrophage CSF, murine stem cell 
factor, and human granulocyte CSF (for Sca-1+ cells), unless otherwise stated.
Detection of superoxide using the chemiluminescent probe 
Diogenes
Superoxide measurement was carried out using the chemiluminescent 
probe Diogenes (National Diagnostics). Transduced human C D 34+ cells 
or murine Sca-1 + cells were washed in phosphate-buffered saline (PBS) 
and resuspended in standard buffer (KH2P 0 4 4.6mM, Na2H P04 8.0mM, 
NaCl 13mM, KC1 0.44mM, glucose 5.5mM, bovine serum albumin (low 
lipopolysaccharide] 0.1%, MgCl2 0.5mM, CaCl2 0.45mM dissolved in 
lipopolysaccharide-low water, pH 7.3) at 1 X 106 cells/mL. Cell 
suspensions (150 |xL) were assayed in triplicate in FluoroNunc Maxi- 
sorp 96-well plates (Thermo-Fisher Scientific). Diogenes (50 p.L) was 
added immediately before recording chemiluminescence (Dynex MLX 
Luminometer; Jencons). Some experiments were carried out in the 
presence of either 5 p.g/mL superoxide dismutase (SOD), 100 p.g/mL 
catalase, 50p.M diphenyleneiodonium (DPI), ImM apocynin, or 5p,M 
rotenone (Sigma). Human peripheral blood monocytes stimulated with 
opsonised zymosan21 were used for comparative purposes.
Detection of superoxide using electron paramagnetic 
resonance spectroscopy
To confirm the presence of the superoxide radical, the spin-trap probe 
5-(diethoxyphosphory l)-5-methyl-1 -pyrroline-/V-oxide (DEPMPO; Axxora) 
was used. Transduced cells were washed in PBS and resuspended at
1 X 107 cells/mL in standard buffer. DEPMPO (60mM) was added 
immediately before measurement. Electron paramagnetic resonance (EPR) 
spectra were detected in 10 scans of 60 seconds at 37°C using a Varian 104 
EPR spectrometer (Varian Inc) at X-band (9.5 GHz). Typical recording 
conditions were field center, 3378 Gauss; gain, 2 X 105; modulation 
amplitude, 2.0; time constant, 0.25; microwave power, 10 raW; and field 
range, 160 Gauss. Addition of 5 p.g/mL SOD served as a negative control. 
Background was established using DEPMPO probe alone.
Determination of mitochondrial superoxide production using 
MitoSOX
Mitochondrial superoxide was measured using MitoSOX (Invitrogen). 
Transduced CD34+ cells (days 5 to 7) were washed in warm PBS and then 
incubated with 5|xM MitoSOX for 15 minutes at 37°C and washed in 
FACSFlow (BD Biosciences) before flow cytometric analysis (“Flow 
cytometric analysis”). For some experiments, cells were incubated for
15 minutes at 37°C before MitoSOX treatment with either 50p.M rotenone 
(Sigma) or5p.M iron (111)5, 10, 15, 20-tetrakis-4-carboxyphenyl porphyrin 
(FeTCPP; Frontier Scientific Inc) as a positive or negative control, 
respectively.
Detection of hydrogen peroxide using Amplex Red
Amplex Red (Invitrogen), a H20 2-sensitive fluorescent probe, was prepared 
according to the manufacturer’s instructions. Transduced CD34+ cells 
(days 4 to 5; 2 X 105) were resuspended at 1 X 106 cells/mL in Krebs- 
Ringer phosphate buffer containing 5.50mM glucose, pH 7.35, for 4 hours 
at 37°C. After centrifugation (180g for 5 minutes), the conditioned medium 
(supernatant) was harvested and 50 p,L was assayed (in triplicate) in 
96-well fluorescent assay plates (Thermo Fisher Scientific) containing 
50 p.L/well Amplex Red solution. Fluorescence was recorded using a FluoStar 
Optima instalment (excitation, 540 nm; emission, 590 nm; BMG Labtech). The 
concentration of H20 2 was determined using a standard curve.
Western blotting
Western blotting was performed using the NuPage Bis-Tris (bis(2- 
hydroxyethyl)iminotris(hydroxymethyl)methane-tris(hydroxymethyl)ami- 
nomethane) gel system (Invitrogen) using whole-cell lysates prepared as 
previously described.24 In some cases, transduced CD34+ cells (day 5) were 
incubated at 37°C in supplemented IMDM without growth factors for
16 hours before lysate preparation. For cell fractionation experiments, 
plasma membrane and cytosol fractions were prepared by 2 freeze-thaw 
cycles in the presence of homogenization buffer (sucrose 0.25M, N-2- 
hydroxyethylpiperazine-/V'-2-ethanesulfonic acid-KOH lOmM, magne­
sium acetate 1 mM, ethylenediaminetetraacetic acid 0.5mM, ethyleneglycol- 
tetraacetic acid 0.5mM, (3-mercaptoethanol lOmM, 20 jxg/mL DNase, pH 
7.2). Homogenate (100 p,L) was centrifuged at 16 OOOg for 1 hour at 4°C. 
Cytosolic proteins (supernatant) were aspirated and the membrane pellet 
was solubilized in homogenization buffer containing 1% Triton X-100. 
Nuclear and cytosol fractions were prepared using a cell fractionation kit 
(PerkinElmer) according to the manufacturer’s instructions. Protein concen­
tration was determined using the Bradford method, or by the DC Protein 
Assay Kit (Bio-Rad) according to the manufacturer’s instructions. Subcellu- 
lar fractions or whole-cell lysates (2-5 X 104 cell equivalents/lane) were 
loaded onto a 4% to 12% Bis-Tris gel and electroblotting was performed as 
previously described.24 Electroblotted membranes were probed overnight at 
4°C using antibodies recognizing p67pho* (clone H-300), p47phox (A-7), 
p4 Qph°x (D-8; all from Santa Cruz Biotechnology), pan Rac, cyclin D3, 
cyclin-dependent kinase 4 (CDK4), CDK6, anti-pl6INK4A, p l5 1NK4B, p21Cipl, 
p27Kipl, total p38MAPK, phospho-p38MAPK (Thrl 80/182), total Akt, phospho- 
Akt (Ser473), SOD 1, anti-phospho-Rb (Ser780), anti-phospho-Rb (Ser795), 
anti-phospho-Rb (Ser807/811), anti-pan Rb, pan Ras (all from Cell 
Signaling Technology), catalase (Abeam), pan RasV12 (DWP; Calbiochem), 
and peroxiredoxin I (Lab Frontier). Anti-glyceraldehyde-3-phosphate dehy­
drogenase (GAPDH; 6C5; Santa Cruz Biotechnology), anti-0-actin (mAb- 
cam 8226; Abeam) or anti-a-tubulin (DMA1; Calbiochem) was used to 
confirm equal loading. Purity of plasma membrane and nuclear or cytosolic
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Figure 1. Measurement of ROS production by human hemato­
poietic progenitor cells expressing N-RasG12D or H-RasG12V.
(A) Representative chemiluminescence trace of superoxide pro­
duction measured using Diogenes. In some replicates (inset), 
superoxide production was quenched by addition of SOD at 
50 minutes. (B) Summary of fold increase of total light emission 
due to expression of activated Ras over controls during early 
hematopoietic development. (C) Using Diogenes, superoxide 
production in H-RasG12V-transduced cells was measured, with 
either 5 pg/mL SOD or 100 pg/mL catalase present from the start 
of the assay (n = 3). Bar chart represents total superoxide 
produced (area under chemiluminescence trace). (D) Using 
Amplex Red, H2 O2  production rate was determined over 4 hours. 
Data represent mean + 1 SD (n >  3). Statistical significance was 
calculated by ANOVA using Tukey honestly significant differ­
ences, Mann-Whitney test, or Student paired t test. iP <  .001; 
'P <  .05.
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fractions was verified using anti-CD45 (69; BD Biosciences), anti Histone 
HI (AE4; AbD Serotec), and anti-GAPDH. Target proteins were visualized 
using the ECL Advance Detection Kit (GE Healthcare) according to the 
manufacturer's instructions. Chemiluminescence was recorded using a 
LAS-3000 image analyser (Fujifilm UK Ltd), and analyzed using AIDA 
Image Analyser Version 4.19 (Fujifilm UK Ltd).
Cell survival, proliferation, and cell-cycle analysis assays
After gene transduction (day 3) and 2 washes in Hanks balanced salt 
solution (Invitrogen), 0.5 to 4 X 105 transduced CD34+ cells/mL were 
cultured in 96-well U-bottom microplates (Thermo Fisher Scientific) at 
37°C for 48 hours in cither IMDM without supplements, serum, or growth 
factors (for survival assay), or supplemented IMDM without growth factors 
(for proliferation assay). In some experiments, cells were incubated with 
either highly purified catalase (no. C100), DPI, or Af-acetylcysteine (NAC; 
Sigma). After incubation, cells were washed in PBS, 1% bovine serum 
albumin and stained with an annexin V-cyanin 5 conjugate (BioVision) 
according to the manufacturer’s instructions in the presence of 1 pig/mL 
7-amino-actinomycin D (7-AAD) to discriminate membrane-permeable 
cells. Viable cells were counted by flow cytometry as described below using 
5 X 101 allophycocyanin microbeads (BD Biosciences) to control for cell 
recovery. For cell-cycle analysis, 0.5 to 1 X 105 human CD34+ cells (day 5) 
were quiesced for 16 hours as in “Western blotting." before fixation and 
determination of DNA content as previously described.25 The threshold for 
inclusion of apoptotic bodies was set at 25% of the fluorescence peak 
representing cells in G0. Proportion of cells in Go and S + G 2/M was 
determined using Cylchred Version 1.0 (T. Hoy, Cardiff University). All 
data were acquired by flow cytometry as described in “Flow cytometric 
analysis.”
Flow cytometric analysis
Transduced CD344 cells were stained for cytometric analysis with unconju­
gated mouse anti-NOX2 antibody (7D5; Caltag Medsystems) or anti-
CD 34“ phycoerylhrin (PE) antibody (BD Biosciences). Unconjugated 
anti-NOX2 antibody was detected using secondary rat anti-mouse immuno­
globulin G|-PE (BD). Background fluorescence was established by isotype- 
matched controls; autofluorescence of mock-infected cultures defined the 
threshold for GFP or DsRed positivity. Data were acquired using a BD 
FACSCalibur and analyzed using FCS Express Version 3 (De Novo 
Software).
Statistical analysis
Significance of difference was determined using one-way analysis of variance 
(ANOVA) with Tukey honestly significant differences test, Mann-Whitney test, 
or Student t test using Minitab Version 13.0 (Minitab Ltd).
R esults
Expression of N-RasG12D or H-RasG12V in human CD34+ 
hematopoietic progenitor cells promotes ROS production
To establish whether expression o f activated Ras promoted ROS 
production in normal hematopoietic progenitor cells, we trans­
duced human C D 34+ hematopoietic cells using the retroviral 
vector PINCO, encoding N-RasG12D or H-Ras0l2V and a reporter 
gene (GFP), or reporter gene alone. The resultant cell cultures are 
referred to hereafter as C D 34+ N-RasGI2D, CD34+ H-RasGI2V, or 
control, respectively, and typically 50% to 80% of the cells were 
GFP+ after transduction (supplemental Figure I, available on the 
Blood  website; see the Supplemental Materials link at the top o f the 
online article). Superoxide was assayed using the superoxide- 
sensitive chemiluminescent probe, Diogenes. A low level of 
constitutive superoxide production was observed in normal cells, 
and was strongly augmented by activated Ras (Figure 1A). As
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Figure 2. Mutant Ras promotes ROS production via activation of 
NOX family oxidases. (A) Superoxide production by N-RasGI2D-  
transduced murine Sca-1+ cells from either wild-type (Nox2+/+) or 
Nox2-deficient (Nox2"'‘ ) mice was measured using Diogenes. Bar 
chart represents total superoxide produced during assay. (B) Mitochon­
drial superoxide was measured using MitoSOX. Figure depicts percent­
age of control or H-RasG,2v cells positive for MitoSOX fluorescence 
after labeling. A PBS control was used to define positive threshold. 
(C) Representative histograms depict MitoSOX fluorescence in con­
trol and H-RasG,2V cells labeled with MitoSOX (i) alone or (ii) in the 
presence of 5p.M FeTCPP or 50p.M rotenone. (D) Using Diogenes, 
superoxide production by CD34+ H-RasG12V cells was measured in 
the presence of 50p.M DPI, 50p.M apocynin, or 5|xM rotenone (n = 3). 
Bar chart represents total superoxide produced. (E) Transduced 
CD34+ cells were incubated with anti-NOX2-PE and analyzed by flow 
cytometry. Typical histogram showing anti-NOX2-PE expression; bar 
chart (inset) indicates percentage of fluorescent cells after incubation 
with anti-NOX2-PE. Isotype control antibody was used to define 
positive threshold (n = 5). (F) Cytosol/membrane fractionated lysates 
were analyzed by Western blot using antibodies recognizing p67pho\  
p40phox, or Rac. Tubulin acted as a loading control and cytosolic 
marker. CD45 was used a membrane marker. C indicates cytosoi; and 
M, membrane. Data represent mean + 1 SD. Statistical significance 
was calculated by ANOVA using Tukey honestly significant differences 
or Mann-Whitney test. tP  < .001; ‘ P <  .05.
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shown in Figure IB, superoxide induction was typically more 
efficient with H-RasGI2v ( ~  4-fold increase compared with con­
trols) than with N-RasG12D ( ~  2-fold increase), though maximal 
superoxide induction was only a tenth of that generated by 
activated phagocytes (supplemental Figure 2B). SOD quenched 
chemiluminescence, whereas treatment with catalase (which decom­
poses H20 2 but not superoxide) did not, demonstrating the 
specificity o f the probe and confirming superoxide as the major 
source of ROS in this assay (Figure 1C).
Because H20 2 rather than superoxide has been implicated as a 
second messenger, we measured levels of H20 2 in medium 
conditioned by N-RasG,2D-a n d  H-RasG12v-expressing cells. Hydro­
gen peroxide (which can be generated from superoxide via a 
dismutation reaction26) was assayed using the H20 2-sensitive 
fluorescent probe, Amplex Red. C D 34+ H-RasGI2V cells showed 
significantly higher rates o f H20 2 production compared with 
controls (P  <  .05), whereas CD34+ N-RasG12D cells showed a 
similar trend, which did not reach significance (Figure ID).
Aberrant Ras signaling affects transcription of a variety of 
genes27 and could potentially perturb the expression of endogenous 
antioxidant molecules resulting in an apparent increase in ROS
production. However, no differences in the levels o f common 
antioxidants were observed compared with control cultures (supple­
mental Figure 2D). Taken together, these data demonstrate that 
activated Ras stimulates significant overproduction o f  superoxide 
as well as the more stable and membrane-permeable putative 
second messenger, H20 2, in hematopoietic progenitor cells.
Ras-induced ROS are mediated via NOX family oxidase activity
ROS can be generated by several mechanisms, the major sources 
being oxidase activity (eg, NOX family oxidases) or the mitochon­
drial electron transport chain.28 The NOX family oxidase Phox is a 
transmembrane multimeric complex consisting of the NOX2 (aka, 
gp9 lphox) catalytic subunit and several regulatory subunits. When 
N-RasG12D was expressed in Nox2 wild-type Sca-1+ murine 
hematopoietic cells, a 1.5-fold increase in superoxide production 
was observed compared with controls, whereas superoxide produc­
tion was absent in Sca-1+ cells from N ox2_/“ mice, suggesting that 
in murine hematopoietic cells, Nox2 is the major source of ROS in 
the context o f activated Ras (Figure 2A). To establish whether this
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Figure 3. Survival of human CD34+ hematopoietic cells express­
ing mutant Ras. CD34+ cells expressing mutant Ras or GFP control 
were incubated in serum-free, growth factor-free medium for 48 hours 
and stained with annexin V and 7-AAD. Annexin V~ and 7-AAD~ cells 
were defined as viable. (Ai) Typical flow cytometric plots obtained at 
start of incubation and after 48-hour incubation with percentage of 
viable cells indicated. (Aii) Bar chart representing survival averaged 
over 3 experiments. (B) Viability of CD34+ cells expressing H-RasG12V 
or GFP control while decreasing cell-culture density. (C) Normal 
(control) CD34* cells were cocultured with an increasing proportion of 
CD34+ H-Ras6,2V cells coexpressing DsRed, enabling analysis of 
CD34+ control cell viability in mixed culture by flow cytometry. Some 
experiments were carried out in the presence of catalase. (D) CD34+ 
cells expressing mutant Ras or GFP were cultured at a cell density of 
5 x 10* cells/mL in the presence of purified catalase. (E) Whole-cell 
lysates were analyzed by Western blot, using antibodies recognizing 
phospho-Akt (S473) or total Akt protein. GAPDH was used as a 
loading control. Data represent mean ± 1 SD (n = 3). Statistical 
significance was calculated by ANOVA using Tukey honestly signifi­
cant differences or Mann-Whitney test. -fP  <  .001; *P < .05; **P < .01.
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was also the case in human cells, we first used the mitochondria- 
specific superoxide-sensitive probe MitoSOX to determine whether 
activated Ras promoted ROS production from this source. No 
significant differences in mitochondrial ROS were observed in 
CD34 1 H-RasGI2v cells (which produced the highest levels of 
ROS) compared with controls (Figure 2B). The sensitivity o f  
MitoSOX for mitochondrial superoxide was confirmed using the 
antioxidant FeTCPP or the mitochondrial poison rotenone, which 
reduce or increase mitochondrial superoxide, respectively (Figure 
2C). These data indicated that excess superoxide production 
detected by Diogenes did not arise from the mitochondria. To 
determine whether NOX oxidases were the source of increased 
superoxide production, we used the NOX oxidase inhibitors DPI 
and apocynin. Superoxide production (measured using Diogenes) 
was completely blocked by these inhibitors in both CD34 + 
H-Ras0,2v cells and control cells, whereas the mitochondrial 
poison rotenone had no effect (Figure 2D). These data, together 
with the data from N ox2_/~ mice (Figure 2A), indicate that the 
major source of increased superoxide production in human CD34 + 
cells expressing activated Ras is the NOX family oxidase, Phox.
During Phox activation, Phox regulatory subunits translocate 
from the cytosol to form a complex with NOX2 at the plasma
membrane.26 Therefore, the ability o f activated Ras to alter the 
expression and localization o f Phox components was investigated. 
Flow cytometric analysis showed that activated Ras significantly 
increased in the expression of NO X2 compared with controls 
(P  <  .05; Figure 2E). In addition, Figure 2F shows that activated 
Ras also promoted the membrane translocation/expression o f the 
Phox activators p67phox and p40phox. Taken together, these data 
support the observations that activated Ras promotes ROS produc­
tion by increasing Phox activity in human C D 34+ cells.
Activated Ras promotes survival in human CD34+ cells but 
Ras-induced ROS antagonize survival
Constitutively active Ras is associated with increased cell sur­
vival.29 Consistent with this, C D 34+ N-RasG,2D and C D 34+ 
H-RasG,2v cells were resistant to apoptosis when incubated in 
serum-free, growth factor-free medium for 48 hours compared 
with controls ( P  <  .05; Figure 3A). Interestingly, the strength of 
the survival phenotype correlated with the level o f ROS produc­
tion. Excessive H20 2 exposure leads to oxidative stress and cell 
death, however low levels o f H20 2 can promote cell survival.30 
Therefore the role o f H20 2 in the survival o f C D 34+ cells
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Figure 4. Proliferation of hematopoietic cells expressing mutant 
Ras in the presence of antioxidants. (A) CD34 • cells (1 x 104) 
expressing mutant Ras or GFP control were incubated in serum- 
replete, growth factor-free medium for 48 hours, and viable cells 
(7-AAD-, annexin V ) were counted by flow cytometry. (B) Represen­
tative histograms showing cell-cycle distribution of CD34+ cells 
expressing N-RasG12D or GFP control after 16 hours in serum-replete, 
growth factor-free medium. The percentage of cells in S+G 2/M is 
indicated. (C) CD344 cells expressing N-RasG12D or GFP control were 
incubated as in panel A in the presence of (i) DPI or (ii) NAC. Data 
represent number of viable cells remaining as a percentage of that 
recovered from cells treated with vehicle control, set at 100%. Data 
are mean * 1 SD; n a  3. Statistical significance was calculated by 
ANOVA using Tukey honestly significant differences or Mann-Whitney 
test. " P <  ,01;*P< .05.
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expressing H-RasGI2v was investigated (because this oncogene 
induced the strongest survival phenotype). C D 34+ H-RasG,2v cells 
showed a significant decrease in cell survival with decreasing cell 
culture density (P <  .001; Figure 3B). Furthermore, C D 34+ con­
trol cells showed a significant increase in cell survival when 
cocultured with increasing numbers of C D 34+ H-RasGI2V cells 
( P < . 0 1 ;  Figure 3C). Given that H7O2 generated by CD34 + 
H-RasGI2V cells is extracellular and membrane permeable, these 
data suggest that H2O2 may be acting as a paracrine prosurvival 
factor. To establish whether H20 2 was responsible for this effect, 
additional coculture experiments were carried out in the presence 
of catalase. The presence of catalase did not suppress control cell 
survival, but instead augmented it further, indicating that the 
prosurvival influence was not mediated by H20 2, which in fact 
antagonized the survival o f control cells (Figure 3C). Indeed, 
catalase treatment also further promoted the survival of C D 34+ 
H-RasGI2V cells themselves, indicating that H20 2 production also 
antagonized the survival of these cells (Figure 3D). A similar trend 
was seen upon treatment with the antioxidant NAC or the NOX 
inhibitor DPI (data not shown). As expected, catalase treatment had 
a modest effect on control cells cultured alone because these cells 
produced very low levels o f H2O2 (Figure 3D). Taken together, 
these data suggest that C D 34+ H-RasG12v cells secrete factors that 
promote survival, but ROS production appears to antagonize the 
prosurvival effects of these factors.
In further demonstration of this, we examined the phosphoryla­
tion of the prosurvival protein, Akt. H-RasG,2V increased the 
phosphorylation of Akt, which probably contributed to the in­
creased survival of these cells (Figure 3E). However, incubation 
with the NOX inhibitor DPI (Figure 3E) or catalase (data not 
shown) did not reduce the phosphorylation of Akt, supporting our 
observations that ROS were not contributing to the enhanced
survival o f C D 34+ H-RasG12v cells. Increased expression of the 
antiapoptotic protein Survivin has also been reported as an 
explanation for Ras-induced survival31; however, our study found 
no evidence o f increased Survivin expression as a consequence of 
activated Ras expression (data not shown).
ROS production augments activated RAS-induced growth 
factor-independent proliferation
We observed that control cells were better able to survive in 
serum-replete medium but were unable to proliferate without the 
addition of growth factors, whereas C D 34+ cells expressing 
N-RasG12D or H-RasG12v were able to proliferate under these 
conditions and showed a significant approximately 4-fold increase 
in cell numbers after 48 hours compared with controls ( P  <  .05; 
Figure 4A). Cell-cycle analysis confirmed that C D 34+ N-RasGI2D 
cells exhibited a significant approximately 2-fold increase in the 
proportion of cells in cycle (S + G 2/M) compared with controls 
( P  <  .05; Figure 4B). To determine whether ROS production 
played a role in the growth factor-independent proliferation, 
C D 34+ N-RasG12D cells were incubated in serum-replete, growth 
factor-free medium for 48 hours in the presence of the antioxidants 
DPI and NAC. Both DPI and NAC suppressed proliferation of 
these cells, whereas control cells showed increased proliferation 
(Figure 4C). Similar effects were observed with CD34 + H-RasG12V 
cells (supplemental Figure 3). We also examined whether ROS 
production could influence progenitor frequency. In accordance 
with previously published work,32 we found no significant differ­
ence in progenitor frequency either in terms of CD34 positivity, 
morphology, or colony-forming ability. Treatment with DPI had no 
differential effect in each case, indicating that under these condi­
tions excessive production of ROS (stimulated by Ras) does not
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Figure 5. Determination of cell-cycle regulatory protein status by Western blot 
in CD34+ hematopoietic progenitors transduced with mutant Ras. CD34+ 
control, CD34+ N-RasG12D, or CD34+ H-RasG12V cells were incubated for 16 hours in 
seium-replete, growth factor-free medium in the presence or absence of 1 p.M DPI. 
Expression and phosphorylation state of key cell-cycle regulatory proteins in 
whole-cell lysates were determined by Western blot. In all cases, GAPDH was used 
as a loading control. (A) The endogenous expression of cell-cycle promoters cyclin 
D3 and cyclin D1 and cell-cycle inhibitors p15INK4B and p21cip' was determined. 
(B) Cytosol/nuclear fractionated lysates were probed with antibody recognizing the 
cell-cycle inhibitor p21cip1. (C) Whole-cell lysates derived from both CD34+ control 
and CD34+ H-RasG12v cells (treated with either DPI or vehicle control) were probed 
with antibodies recognizing the cell-cycle promoters CDK6, CDK4, cyclin D1, and 
cyclin D3. (D) Whole-cell lysates as in panel C were probed with antibodies 
recognizing the following cell-cycle inhibitory proteins; p21Cip1 (which inhibits CDK/ 
cyclin complexes); p15,NK4B (which sequesters CDK4/6); p27Kip1 (which has a similar 
role to p21Cip1) and p38MAPK, both total and phosphorylated (T180/T182).
(Figure 5D). ROS normally elicit a stress response mediated via 
phosphorylation o f p38MAPK, which leads to the induction of the 
cell-cycle inhibitor, p i6 ,NK4A.9’15 We therefore examined whether 
this oxidative stress response was operating in C D 34+ H-RasG12v 
cells. We found that H-RasG12V did promote p38MAPK phosphoryla­
tion, but not in the presence o f DPI, demonstrating the specificity o f 
ROS in the phosphorylation of p38MAPK (Figure 5D). However, we 
were unable to detect expression o f p l6 INK4A in these cells (not 
shown), indicating either that the p38MAPK stress-response pathway 
was uncoupled in these cells or that it is not normally linked to 
plgiNK4A induction in this context. A s expected, DPI had no effect 
on p l5 1NK4B or p27Kipl, because activated Ras did not alter the 
expression o f these proteins (Figure 5D). However, DPI augmented 
p21c‘P' levels, indicating that ROS normally act to suppress p21c’P1 
expression and (in this context) its associated antiapoptotic func­
tion (Figure 5D).
Finally, we examined the expression of the cell-cycle inhibitor, 
RB. H-RasG12v expression induced RB expression (3-fold), how­
ever, a similar increase was observed in the level o f phosphorylated 
RB (consistent with the increase in cyclin D/CDK4 expression in 
these cells15), suggesting most o f the RB was inactive (supplemen­
tal Figure 3C). Antioxidant treatment caused a consistent decrease 
in RB expression, however concomitant changes in RB phosphory­
lation level make it difficult to draw any inference from this 
observation.
In summary, these data indicate that ROS production by CD34 + 
N-RasGI2D and C D 34+ H-RasG,2v cells contributes to cyclin 
D induction, which is consistent with these oncogenes’ proprolifera- 
tive influence.
significantly influence progenitor frequency (supplemental Figure 
4). Taken together, these data suggest that Ras signaling strongly 
drives factor-independent growth, and indicate that Ras-induced ROS 
production plays a role in augmenting this proliferative signal.
ROS production modulates key cell-cycle regulatory proteins
Consistent with their proproliferative role, N-RasGI2D and H-RasGI2v 
strongly promoted the expression of D-type cyclins D1 and D3; in 
each case the influence o f H-RasG,2V was greater than N-RasG,2D. 
These oncogenes had no effect on the expression of the cell-cycle 
inhibitor p !5 INK4B, but did up-regulate the cell-cycle inhibitor 
p21ciP| , which seemed contrary to their proproliferative effect 
(Figure 5A). Previously, it has been reported that hematopoietic 
cells express high levels o f extranuclear p21ciP1,33 therefore we 
examined the subcellular location of p21CiP' and found that p21ciP| 
expression was exclusively cytosolic (Figure 5B). This suggests 
that induction of p 21ciP1 in these cells is concerned with its 
antiapoptotic cytoplasmic function rather than its nuclear cell-cycle 
inhibitory role.34
To assess whether ROS production contributed to the altered 
expression of cell-cycle regulatory proteins, C D 34+ H-RasG12v 
cells were treated with DPI before Western blot analysis (Figure 
5C-D). NOX inhibition resulted in a consistent reduction in cyclin 
D1 and cyclin D3 expression, indicating that ROS production 
cooperated with activated Ras in the induction of these D-type 
cyclins. Activated Ras also up-regulated cyclin-dependent kinase 
4 (CDK4), a binding partner o f D-type cyclins, however, DPI had 
no effect on the expression o f this protein or CDK6 (Figure 5C). 
Next, we examined the effect o f NOX inhibition on the cell-cycle 
inhibitor proteins p38MAPK, p l6 INK4A, p l5 INK4B, p27KiP1, and p21CiP1
D iscu ssion
In agreement with previous research,2 we found that normal human 
C D 34+ hematopoietic progenitors constitutively produce low lev­
els o f both superoxide and its derivative, H20 2. Expression of 
N-RasG12D and H-RasGI2V strongly augmented constitutive produc­
tion of superoxide and H20 2 (though the extent o f production could 
also have been influenced by the concomitant overexpression of 
Ras in these cells). Activated Ras has been shown to promote ROS 
production in a variety of human cell types including transformed 
embryonic lung cells,35 fibroblasts,36 neuroblastoma cells,37 as well 
as in hematopoietic cells in vivo, indicating the potential for ROS 
to act as a proproliferative stimulus in an N-Ras leukemic 
context.1214 Although untested in this study, activated K-Ras is not 
usually associated with increased ROS production, possibly due to 
isoform-specific cellular localization and signaling preferences.38 
Cellular ROS production is balanced by expression of endogenous 
antioxidants. For example, Ras activity can decrease the activity of 
peroxiredoxins, leading to an increase in intracellular ROS.39 In 
this study, however, Ras expression did not affect levels o f  the 
major antioxidant enzymes, peroxiredoxin I catalase, and SOD 1, 
suggesting that altered antioxidant expression was unlikely to 
account for the increased ROS detected.
ROS can be produced via oxidase activity (eg, NOX family) or 
via the mitochondrial electron transport chain.26 In this study, the 
use o f a series o f probes and inhibitors demonstrated that the source 
of excess ROS production was derived from NOX oxidases. This is 
consistent with other reports o f Ras-induced ROS production in a 
variety of cell types.14’37,40,41 Specifically, we observed NOX2 
overexpression and increased membrane translocation of NOX2 
regulatory subunits and N-RasGI2D was unable to induce ROS in
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mice deficient in Nox2. Taken together, these data suggest NOX2 is  
the major source o f Ras-induced ROS in primitive hematopoietic 
cells. NOX1 may also contribute, because it is also expressed in 
human C D 34+ progenitors2 and contributes to ROS production 
driven by activated Ras in rat fibroblasts.17
Activated Ras can promote survival o f hematopoietic cell 
lines,31 but this is the first report that Ras can promote the survival 
of primary hematopoietic progenitors when deprived of growth 
factors and serum. Consistent with this, H-RasG,2v strongly pro­
moted the phosphorylation o f Akt. Observations that survival of 
C D 34+ cells expressing activated Ras was dependent on culture 
density and that these cells could promote the survival o f control 
cells in paracrine fashion led us to examine whether ROS may be 
acting as a prosurvival factor (particularly as H20 2 has recently 
been shown to promote cell survival in neuronal cells30). Depletion 
of exogenous H20 2 (using catalase) merely promoted the survival 
of both C D 34+ H-RasG12v and control cells, demonstrating that 
ROS production inhibited the survival o f  these cells. Correspond­
ingly, neither catalase nor NOX inhibition suppressed the phosphor­
ylation of Akt in C D 34+ H-RasG12V cells. These data indicate that 
Ras provokes the secretion of prosurvival factors in C D 34+ cells, 
but that their effects are antagonized by ROS. We have not 
investigated the nature of these prosurvival factors, however, a 
gene array analysis of C D 34+ N-RasG12D cells has revealed that Ras 
strongly promotes the expression of several cytokine genes with 
this potential.42
In addition to promoting survival, we were surprised to observe 
that C D 34+ N-RasG12D and C D 34+ H-RasG12v cells were able to 
proliferate in serum-replete cultures without growth factors. Previ­
ous studies o f the effect o f activated Ras on CD34 + cells, including 
our own, have all made proliferative comparisons in the presence 
of growth factors,32,43 and under these conditions no proliferative 
advantage is observed; though N-RasG12D has previously been 
shown to promote a growth advantage when C D 34+ cells were 
cultured with the MS5 stromal line.44 This increased proliferation is 
likely driven by the same secreted factors that promoted cell 
survival. However, unlike the cell survival experiments, we found 
that ROS production appeared to augment the proliferation of 
C D 34+ N-RasG12Dand C D 34+ H-RasG12v cells, whereas ROS were 
growth inhibitory for control cells. These data suggest that 
activated Ras may not only promote ROS production in hematopoi­
etic progenitors, but can simultaneously alter their response to it. 
Increased ROSs have previously been associated with increased 
cell proliferation in several models. For example, mitogenic 
signaling in Ras-transformed mouse fibroblasts was suppressed 
with NAC treatment,11 whereas overexpression of NOX1 alone 
(aka, M oxl) in mouse fibroblasts resulted in increased ROS 
production and proliferation.45
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We also examined the changes in cell-cycle control proteins that 
may have mediated the proliferative changes elicited by activated 
Ras and ROS in these cells. Activated Ras induced strong 
up-regulation o f cyclins D1 and D3, which has been reported 
previously,46 and also up-regulated their partner kinase, CDK4. In 
this study, ROS were shown to contribute to cyclin D  expression, 
which is consistent with previous observations made in mouse 
embryo fibroblasts where ROS production was also associated with 
up-regulation o f cyclin D expression and cell-cycle progression 47 
Surprisingly, both isoforms of Ras also promoted expression of 
p 2 1 c ,p 1 ; though this appeared to have a purely cytosolic location 
making it unlikely that increased p21c,i’1 was influencing cell-cycle  
progression. Finally, C D 34+ H-RasG12V cells exhibited substantial 
phosphorylation o f p38MAPK, which was solely a consequence of 
ROS production by these cells. In other contexts,9 this provokes 
cell-cycle arrest through induction of p l6 INK4A, but we were unable 
to demonstrate induction o f this protein in these cells.
In conclusion, these data show that activated Ras strongly 
promotes the expression o f ROS in early human progenitor cells, 
through a NOX-dependent process. A range o f ROS was detected 
including H20 2, which has the capacity to affect a wide range of 
cell signaling processes. This species is membrane permeable, 
meaning its production can also influence neighboring cells. Our 
data therefore suggest that production o f ROS may confer a 
competitive advantage on premalignant/malignant cells by promot­
ing the proliferation o f these cells, while at the same time inhibiting 
the proliferative capacity o f  normal cells in the surrounding 
microenvironment.
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